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Abstract 
This thesis is concerned with the question of whether developing countries such 
as the People‘s Republic of China (PRC) are well prepared for the ethical and 
legal conduct of human population genetic research (HPGR) with specific regard 
to  vulnerable  target  group  protection.  It  highlights  important  issues  such  as 
whether  the current frameworks  of  Western  developed  countries  can  provide 
adequate protections for target groups in human population genetic research. 
One fundamental question is who may suffer harm in this kind of research. Most 
bioethical scholars focus on individual participants but it is argued here that the 
interests of target groups are also seriously implicated in this kind of research. 
Since  the  target  groups  of  HPGR  are  almost  always  vulnerable  groups  from 
isolated  and  rural  areas  of  developing  countries,  the  ethical  and  legal 
frameworks for human subject protection may need to be reconsidered in order 
to eliminate, or at least reduce, the vulnerability of those groups. Accordingly, 
given the dominance of the current ideology of Western developed countries, a 
critical  study  of  vulnerable  population  protection  is  necessary  to  identify 
whether this ideology is appropriate in this context. This thesis aims to propose 
recommendations on the ethical and legal frameworks of biomedical research in 
developing countries with specific consideration of vulnerable group protection 
and cultural sensitivity. The PRC is used as an example to investigate current 
regulations  for  both  human  subject  protection  and  group  protection  in 
developing  countries.  The  thesis  argues  for  an  alternative  model  for  group 
protection in the context of human population genetic research in developing 
countries.  
Translations of titles, authors, and publishers from Chinese works are unofficial, 
and the laws in this thesis are up to date at April 2011. iii 
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 Chapter 1 – Introduction 
The Human Population Genetic Research Project (HPGR) seeks to identify the 
diversity and variation of the human genome and how human group and 
individual genetic diversity has developed. Since HPGR targets specific groups to 
discover variation, it also raises many pressing ethical and legal concerns. This 
thesis focuses on concerns raised by the application of the current dominant 
Western ethical and legal frameworks on human research subject protection to 
HPGR. It discusses target group protection in HPGR and examines it in the 
context of developing countries, specifically, the People‘s Republic of China. It 
argues that the current understanding of universal values on human research 
subject protection needs to be modified to take account of the particular 
challenges presented by HPGR in developing countries. 
1.1 Introduction  to  Human  Genes  and  Genetic 
Information 
On 25 April 1953, the article, Molecular Structure of Nucleic Acids - A Structure 
of Deoxyribose Nucleic Acid, was published in the well-known British scientific 
journal Nature by a young pair of scientists, James D. Watson and Francis H. C. 
Crick.
1  It has been said  that their names have  ‗joined Darwin and Copernicus 
among the immortals,‘
2 and the new era of biology began. Their discovery of the 
DNA double helix is thought to be the greatest single scientific achievement of 
the 20th century and a new milestone of human history. 
It has been a dream to explore the secrets of life, to solve the puzzles of death, 
growing old and sickness; to eradicate disease, to improve living standards and 
prolong human life. For a long time, people have been seeking to solve these 
puzzles,  but  although  a  great  deal  of  financial  and  personal  effort  has  been 
expended,  and  despite  quite  significant  progress  having  been  made  in  some 
                                         
1 Watson, J. D. & Crick, F. H. C. 1953, " Molecular Structure of Nucleic Acids - A Structure of 
Deoxyribose Nucleic Acid ", Nature, vol. 171, no. 4356, pp. 737-738. 
2 Hunt-Grubbe, C. The Elementary DNA of Dr Watson. Times. 10-14-2007.  Chapter 1 
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areas, until recently no great progress had been made in many others.
3 However, 
the discovery of the importance of genes and the development of genetic 
technology has enabled human beings to study the secrets of life at the 
molecular level, and to see glimpses of hope of making greater progress. 
Formerly, the understanding of the constitution of human beings was limited 
largely to what could be seen. However, when science and technology entered 
the molecular era, the understanding of the constitution of human beings at the 
level of DNA opened scientific possibil ities while at the same time raising some 
problematic issues.  
1.1.1 What is a Human Gene? 
At the outset, there are some terms which need to be clarified. The official 
document of the Human Genome Project (HGP) defined these terms as following: 
Cells are the fundamental working units of every living system. All the 
instructions needed to direct their activities are contained within the 
chemical DNA (deoxyribonucleic acid).  
DNA from all organisms is made up of the same chemical and physical 
components.  The  DNA  sequence  is  the  particular  side-by-side 
arrangement of bases along the DNA strand (e.g., ATTCCGGA). This 
order spells out the exact instructions required to create a particular 
organism with its own unique traits.  
The  genome  is  an  organism‘s  complete  set  of  DNA.  Genomes  vary 
widely in size: the smallest known genome for a free-living organism 
(a bacterium) contains about 600,000 DNA base pairs, while human 
and mouse genomes have some 3 billion. Except for mature red blood 
cells, all human cells contain a complete genome.
4 
As ‗Nature‘ magazine‘s reporter Helen Pearson said: 
                                         
3 Although ‗Today, global life expectancy at birth is about 67 years; two centuries ago it was 30 
years or less.‘ (Riley, J. C. 2001, Rising Life Expectancy: A Global History, Cambridge 
University Press, New York), we still cannot say that we have mastered all the secrets of human 
life. 
4 Genomics and Its Impact on Science and Society, full text can be seen on the official website of 
HGP, available on 
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/primer2001/primer11.pdf, last 
visit on 2010-04-19. Chapter 1 
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In  classical  genetics,  a  gene  was  an  abstract  concept  —  a  unit  of 
inheritance  that  ferried  a  characteristic  from  parent  to  child.  As 
biochemistry came into its own, those characteristics were associated 
with enzymes or proteins, one for each gene. And with the advent of 
molecular biology, genes became real, physical things — sequences of 
DNA which when converted into strands of so-called messenger RNA 
could be used as the basis for building their associated protein piece 
by piece. 
5 
Every cell in a human body containing DNA has the full set of instructions 
necessary to create that particular individual.
6 These instructions are encoded in 
twenty-three pairs of individual DNA strands which are  called chromosomes.
7 
These chromosomes carry over 30,000 encoded genes.
8 Each gene performs a 
specific function, some may perform several, but the functions of only a small 
amount of genes are currently understood.
9  
In general terms, a gene is unit of her edity,  ‗a  union  of  genomic  sequences 
encoding a coherent set of potentially overlapping functional products‘.
10  There 
are three basic features of a gene:  
a)  It is a relatively independent unit of heredity. As an information unit, a 
gene can refresh combinations of the genetic make-up of both parents by 
transferring  them  to  offspring.  What  is  more,  a  gene  can  instruct, 
influence and even decide creatures‘ traits, such as body structure and 
living habits. 
                                         
5 Pearson, H. 2006, "What is a Gene?", Nature, vol. 441, pp. 399-401, at 399. 
6 Mehlman, M. J. & Botkin, J. R. 1998, Access to the Genome: The Challenge to Equality, 
Georgetown University Press, Washington, D.C. 
7 Ibid. 
8 The International Human Genome Sequencing Consortium has estimated, based on the rough 
draft of the genome published in February 2001, that there are approximately 30,000 human 
genes. However, this number may be incorrect, as complex cellular processing of genes and 
gene products may result in several possible products from a single gene sequence. See 
International Human Genome Sequencing Consortium 2001, "Initial Sequencing and Analysis of 
the Human Genome", Nature, vol. 409, no. 6822, pp. 860-921. 
9 See Online Mendelian Inheritance in Man, the full text can be seen on the official website of the 
National Center for Biotechnology Information of the US, available on www.ncbi.nlm.nih.gov, 
last visited on 2008-10-27. 
10 Gerstein, M. B., Bruce, C., Rozowsky, J. S., Zheng, D., Du, J., Korbel, J. O., Emanuelsson, O., 
Zhang, Z. D., Weissman, S., & Snyder, M. 2007, "What Is a Gene, Post-ENCODE? History and 
Updated Definition", Genome Research, vol. 17, no. 6, pp. 669-681. Chapter 1 
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b)  At  a  molecular  level,  a  gene  is  a  segment  of  a  DNA  molecule,  the 
sequences of nucleotides (or bases) in genes represent the heredity of 
human beings and other creatures. The information in a gene is encoded 
in the sequence of base groups of DNA. 
c)  Genes are specific sequences of bases that encode instructions on how to 
make proteins.
11 Gene sequences of DNA, when transferred into strands 
of messenger RNA, could be used as the basis for building their related 
protein piece by piece. The  gene  could not only transmit all of this 
information through replication, but al so could dominate the organism‘s 
character  by  controlling  the  process  of  synthesizing  protein,  which  is 
called  ‗gene  expression‘.  In  other  words,  a  gene  exerts  its  physical 
function through directing the production of proteins and RNA molecules. 
1.1.2 What is Genetic Information? 
According  to  Article 2  (i)  of  the  UNESCO  International  Declaration  on  Human 
Genetic  Data,  human  genetic  data  is  ‗the  information  about  heritable 
characteristics of individuals obtained by analysis of nucleic acids or by other 
scientific analysis.‘
12 Although the intention of this definition is merely to set out 
the relationship between human genetic information and scientific research, it 
suggests that the real value of the gene is not its physical substance but the 
information carried in it. 
In general, genetic information is the information for making all of the proteins 
required by all organisms. These proteins determine, among other things, how 
the organism looks, how well its body metabolizes food or fights infection, and 
sometimes even how it behaves.
13 
Genetic information, as Laurie summarized, has  the  following features and 
functions: it 
                                         
11 See supra note 4.  
12 The International Declaration on Human Genetic Data which was adopted unanimously and by 
acclamation at UNESCO's 32nd General Conference on 16 October 2003.   
13 ‗About the Human Genome Project‘, it can be seen on the official website of Human Genome 
Project, available on http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml, 
last visited on 2009-02-19. Chapter 1 
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…relates to families and not just individuals; can offer a degree of 
certainty  in  determining  which  of  those  persons  is  likely  to  be 
affected by genetic disease; can provide a measure of predictability in 
the assessment of likelihood of ill health in particular individuals from 
an affected group; can reveal secrets about future ill health, even in 
those who are currently well; can help to determine future risks in 
future person.
14  
In fact, genetic information is the real  research target of all genetic research, 
while the gene is the material carrier of genetic information . Hence, genes and 
genetic information have a close relationship with each other. Since most human 
cells contain two sets of chromosomes
15 which come from both father and 
mother and each chromosome contains an integrated human genome,
16 in theory, 
almost every human cell is able to express all human genetic information  (one 
example of an exception to the general rule is that of mature red blood cells). 
It has been argued  that a gene is ‗a packet of information encoded within the 
DNA  molecule‘.
17  However,  this  argument  confuses  the  gene  and  genetic 
information. The relationship between genes and genetic information is similar 
to that of a book and the knowledge it contains. The book is the material carrier 
of  its  knowledge.  Therefore,  while  a  gene  contains  genetic  information,  this 
does not mean that genetic information is the same thing as the gene itself; the 
gene is matter, but genetic information is intangible. Matter and information are 
different concepts, and this is the fundamental difference between these two 
terms.  
1.1.3 Three Types of Human Genetic Information 
There is a wide range of debate on whether or not human genetic information 
should be a special subject of research and needs to be treated separately from 
                                         
14 Laurie, G. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, Cambridge University 
Press, at 104. 
15 Chromosomes are long strands of DNA containing many genes and are packaged in structures. 
There are approximately 25000 genes in human genome. 
16 A genome is the entire DNA contained in one cell. The hereditary material in nearly all living 
organisms is deoxyribonucleic acid or DNA. DNA is held in a cellular structure called the 
nucleus. 
17 Silver, L. M. 1999, "Meaning of Genes and "Genetic Rights"", Jurimetrics, vol. 40, pp. 9-20, at 
11-12. Chapter 1 
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other types of medical information.
18 It seems that both sides have their own 
reasonable points, in favour and against doing so.  This debate results from the  
fact that human genetic information collected from an individual has  abundant 
applications. Different  applications  would influence the interests of different 
parties, such as individual participants, certain groups or communities, even all 
human beings.
 19 It has been argued that the human genetic information carried 
by  an  individual  can  be  divided  into  three  different  types:  non-differential 
human  genetic  information,  individual  human  genetic  information  and 
community or group/collective human genetic information.
20 Each of these three 
types of human genetic information has its own attributes and merits distinctive 
treatment.  
a) Non-differential human genetic information 
Non-differential  human  genetic  information  describes  the  genetic  information 
shared by each human being. It has been shown that nearly 60% of human genes 
are isogenies with the fruit fly.
21 In addition, the chimpanzee genome is 95% 
identical to the human genome. On average, a typical human protein -coding 
gene differs from its chimpanzee ortholog
22 by only two amino acid substitutions; 
nearly one third of human genes have exactly the same protein translation as 
their chimpanzee orthologs. A major difference between the two genomes is 
human chromosome 2, which is equivalen t to a fusion product of chimpanzee 
chromosomes 12 and 13.
23 The working draft of the Human Genome Project (HGP) 
which was released in 2000 and the complete version published in 2003 reveal 
that these non-differential genes are present in each human individ ual. In this 
sense,  non-differential  human genetic information could be viewed as a new 
type of common heritage of mankind.  
                                         
18 More details of this debate can be seen in Chapter 2. 
19 Zhou, Q. 2006, "The Legal Status of Human Gene and Genetic Information (Lun Renlei Jiyin ji 
Jiyinxinxi de Falvdiwei)", Science-Technology and Law (in Chinese), vol. 63, pp. 113-117. 
20 See supra note 19. 
21 ‗Fruit Fly Gene Success‘, it can be seen on BBC News website, available on 
http://news.bbc.co.uk/1/hi/sci/tech/647139.stm, last visited on 2009-02-19. 
22 Orthology describes genes in different species that derive from a common ancestor.  
23 "Human chromosome 2 resulted from a fusion of two ancestral chromosomes that remained 
separate in the chimpanzee lineage" The Chimpanzee Sequencing and Analysis Consortium 
2005, "Initial sequence of the chimpanzee genome and comparison with the human genome", 
Nature, vol. 437, no. 7055, pp. 69-87. Chapter 1 
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The view that a resource can be the common heritage of mankind originated 
from the United Nations Convention on the Law of the Sea and was one of its 
fundamental principles.
24 The tenet was established in Articles 136 and 137: 
Article136 Common heritage of mankind: The Area and its resources 
are the common heritage of mankind. 
Article137 Legal status of the Area and its resources: 
1. No State shall claim or exercise sovereignty or sovereign rights over 
any part of the Area or its resources, nor shall any State or natural or 
juridical  person  appropriate  any  part  thereof.  No  such  claim  or 
exercise of sovereignty or sovereign rights nor such appropriation shall 
be recognized. 
2. All rights in the resources of the Area are vested in mankind as a 
whole, on whose behalf the Authority shall act. These resources are 
not subject to alienation. The minerals recovered from the Area, 
however, may only be alienated in accordance with this Part and the 
rules, regulations and procedures of the Authority. 
3. No State or natural or juridical person shall claim, acquire or 
exercise rights with respect to the minerals recovered from the Area 
except  in  accor dance  with  this  Part.  Otherwise,  no  such  claim, 
acquisition or exercise of such rights shall be recognized.
25 
At present, the scope of this principle has gone beyond the ocean and extended 
to particular areas and related natural resource s, such as outer spa ce and the 
Antarctic.
26 
Each human being only has one genome which contains about 25,000 genes, and 
99.8% of human genetic information is entirely uniform. It has been selected and 
                                         
24 The United Nations Convention on the Law of the Sea (UNCLOS), also called the Law of the Sea 
Convention or the Law of the Sea Treaty is the international agreement that resulted from the 
third United Nations Conference on the Law of the Sea (UNCLOS III), which took place from 
1973 through 1982. The Law of the Sea Convention defines the rights and responsibilities of 
nations in their use of the world's oceans, establishing guidelines for businesses, the 
environment, and the management of marine natural resources. The Convention concluded in 
1982 replaced four 1958 treaties. UNCLOS came into force in 1994; a year after Guyana 
became the 60th state to sign the treaty. To date 157 countries and the European Community 
have joined in the Convention. However, it is now regarded as a codification of the customary 
international law on the issue. 
25 United Nations Convention on the Law of the Sea, it can be seen on the official website of UN, 
available on http://www.un.org/Depts/los/convention_agreements/texts/unclos/unclos_e.pdf, 
Article136 and 137, last visited 2009-03-26. 
26 Porras, D. A. 2006, "The "Common Heritage" of Outer Space: Equal Benefits for Most of 
Mankind", California Western International Law Journal, vol. 37, no. 1, pp. 143-176. Chapter 1 
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evolved for thousands of years; hence, it is a gift from nature, like the natural 
resources of particular areas, such as outer space and the Antarctic. Thus, it is 
suggested that non-differential human genetic information should be a new type 
of common heritage of mankind.  Neither states nor individuals could claim a 
proprietary right or sovereignty over non-differential human genetic information. 
Although enormous sums of human, financial and material resources have been 
spent on attempting to understand the 99.8% of non-differential human genetic 
information, and this research is potentially of great medical and commercial 
value, all mankind has a right to use it in peace and share benefit from its use.  
b) Individual human genetic information 
0.2% of human genetic information dominates the diversity of approximately 6 
billion  human  beings,  such  as  height,  weight,  colour  of  eyes,  hair  and  skin, 
appearance, character and even the possibility of suffering from certain diseases. 
This  kind  of  information  is  individual  in  nature.  It  can  be  used  in  forensic 
databases, relationship testing and genetic research on certain diseases.
27 Some 
biobanks, for example those established in Estonia (Estonian Genome Project)
28, 
Iceland (Iceland Health Centre Database)
29 and the UK (U.K. Biobank)
30 aim to 
collect this kind of genetic information.  
Individual human genetic information which contains high specificity has one to 
one  correspondence  to  a  specific  human  being ,  except   identical  siblings. 
Accordingly,  except  for such siblings ,  individual human genetic information 
directly  decides  each  individual‘s  unique  existence  in  the  world.  Although 
individual human genetic information has huge economic and social value, since 
it can be used in genetic diagnosis and therapy as well as to identify individuals, 
it is a type of crucial personal information. In some countries, such as the US, 
                                         
27 Richards, M. 2001, "How Distinctive is Genetic Information?", Studies in History and Philosophy 
of Science Part C: Biological and Biomedical Sciences, vol. 32, no. 4, pp. 663-687, at 674-677. 
28 Tzortzis, A., ―Estonia Looks to Make Mark with DNA Data,‖ Boston Globe, August 19, 2003 at E1. 
29 Adalsteinsson, R. 2004, "Human Genetic Databases and Liberty", The Juridical Review, no. 1, 
pp. 65-74. 
30 Winikoff, D., ―Partnership in U.K. Biobank: A Third Way For Genomic Property?‖ Journal of Law, 
Medicine & Ethics 35, no. 3 (2007): 440-456. Chapter 1 
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personal  information  is  undoubtedly  the  subject  of  the  right  of  privacy.
31 
Accordingly,  the  subject  has  the  right  to  access,  collect  and  obtain  the 
information, keep the information strictly confidential, as well as decide on the 
use of the information. Identification of individual human genetic information 
may lead to violations of privacy, especially in the context of the possibility of 
suffering from certain diseases. For example, if susceptibility becomes known to 
employers or in surance companies, it may lead to discrimination.
32 Thus, the 
effective protection of individual human genetic information has become a new 
challenge in the regulation of privacy. 
If individual human genetic information is regarded as being subject to the right 
of privacy, individual human genetic information ‗belongs‘ to the individual who 
is the source of the information and as a result, access to it should be controlled 
by that individual.  
c) Community or Group/Collective Human Genetic Information 
Community or group/collective human genetic information is a useful research 
tool to explore variations that could lead to knowledge about genetic disorders 
and possible cures, as well as the origin and migration patterns of peoples.
33 A 
group of people who live tog ether for a long period of time in a certain area 
seem more likely to have a similar genetic make-up, especially in isolated areas, 
because of a number of factors, such as sharing the same habitat, similar life 
style and inter -marriage. Moreover, the possi bility of recessive traits in such 
groups would be greater than in other populations. For instance, 
Laken and colleagues…. used anonymized samples from a Tay-Sachs 
data bank in their search for the frequency in Ashkenazi Jews of a 
particular mutation in a gene predisposing to colon cancer (I1307K in 
the APC gene). They found that the mutation was present in 6.1% of 
                                         
31 Annas, G. J. 1999, "Genetic Privacy: There Ought to be a Law", Texas Review of Law and 
Politics, vol. 4, pp. 7-15. 
32 See Spaak, T. 2006, "Genetic Discrimination", Minnesota Journal of Law, Science & Technology, 
vol. 7, pp. 639-655. Also see Hellman, D. 2003, "What Make Genetic Discrimination 
exceptional?", American Journal of Law and Medicine, vol. 29, pp. 77-116. Also see Jungreis, R. 
2007, "Fearing the Fear Itself: The Proposed Genetic Information Nondiscrimination Act of 2005 
and Public Fears about Genetic Information", Journal of Law and Policy, vol. 15, pp. 221-247. 
33 McGregor, J. L. 2007, "Population Genomics and Research Ethics with Socially Identifiable 
Groups", Journal of Law, Medicine and Ethics, vol. 35, pp. 356-370. Chapter 1 
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the Jews in the sample and none of the non-Jews. The authors noted 
with understandable excitement that this is the commonest cancer-
associated mutation in a specific population yet described.
34 
Community or group/collective human genetic information reflects the influence 
of a long period of history, nature and lifestyle. This kind of genetic information, 
which is common to certain  populations, communities or groups of people and 
contains information about heritability, can be studied and analyzed using a 
large number of samples from these communities and groups.
35  It can be 
suggested that in the same way that  all human beings have collective interes ts 
in  n on-differential  human  genetic  information,  although  it  is  carried  by 
individuals, certain communities or groups also could have collective interests in 
community or group collective human genetic information . Since  collective 
human genetic information is the research target of human population genetic 
research,  I will argue that  the  interests  of groups or communities   should be 
considered carefully in HPGR. 
1.2 Human Population Genetic Research (HPGR) 
With the development of genetic science and technology, research on the human 
genome and genetic information is the new  ‗hotspot‘ of biomedical research. 
However, it also leads to ethical and legal concerns concerning human subject 
protection. 
1.2.1 The Significance of Human Population Genetic Research 
HPGR  focuses  on  human  genetic  information  at  a  group  level.  It  is  also 
sometimes  called  ‗population-based  genetic  research/study‘  or  ‗population 
genomic research/study‘. There are two different definitions of HPGR: a general 
one and a narrow one.  
                                         
34 Weijer, C. 1999, "Protecting Communities in Research: Philosophical and Pragmatic Challenges", 
Cambridge Quarterly of Healthcare Ethics, vol. 8, pp. 501-513, at 502. 
35 There was an existing example that Harvard‘s School of Public Health has selected over 6 
millions of people and brought back 16400 blood samples of asthma patients in name of 
therapy. ‗Harvard Gene Study in China Is Questioned‘ can be seen on the website of Los 
Angeles Times, available on http://articles.latimes.com/2002/mar/30/news/mn-35514, last 
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General HPGR  is defined as ‗….a study which aims at understanding the nature 
and extent of genetic variation among a population or individuals within a group 
or between individuals across different groups.‘
36 To  be precise, the research 
object of general HPGR is the first type of genetic information mentioned above, 
which is non-differential human genetic information that is shared by all human 
beings.  
At present, the most influential general human population genetic research is 
the Human Genome Project (HGP), which ‗refers to the international 13-year 
effort, formally begun in October 1990 and completed in 2003, to discover all 
the estimated 20,000-25,000 human genes and make them accessible for further 
biological study. Another project goal was to determine the complete sequence 
of the 3 billion DNA subunits (bases in the human genome).‘
37 The UK House of 
Commons  Science  and  Technology  Committee  Report  on  Human  Genetics 
outlined the Project‘s possible outcomes in the following way: 
-  better  understanding  of  human  illness  and  the  role  of  genetic 
influences  in  a  great  many  conditions  including  psychiatric  and 
neurological disorders; 
-  quicker and cheaper diagnoses of common diseases; 
-  better  understanding  of  the  biochemical  or  physiological 
mechanisms involved in genetic disease: focusing on the mechanism 
involved may bring; 
-  improved techniques in the design of drugs to produce chemicals 
that  can  fit  precisely  with  molecules  implicated  in  disease 
(pharmacogenomics); 
-  gene therapy; 
-  germ-line therapy.
38 
                                         
36 This definition stems from United Nations Educational, Scientific and Cultural Organization‘s 
―Bioethics and Human Population Genetics Research (1995)‖. 
37 See supra note 13. 
38 UK House of Commons Science and Technology Committee, Human Genetics: The Science and 
its Consequences, Third Report (London, HMSO, 6 July 1995), pp. 31-51, paras. 65-124. 
Quoted from Laurie, G. T. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, 
Cambridge University Press, at 87.  Chapter 1 
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Hence,  the  potential  benefits  of  the  HGP  are  numerous  and  significant. 
Connecting the DNA sequences of individual genes within the human genome to 
the various diseases and traits for which they encode will require thousands, 
even millions, of individual research subjects. Therefore, this research relies on 
the large-scale collection of genetic, genealogical and medical data from many 
individuals.
39 Meanwhile, the research spawned a range of concerns, regarding 
human dignity,
40 privacy,
41 autonomy,
42 patent,
43 and discrimination.
44 
The narrow definition of HPGR focuses on community or group/collective human 
genetic information, such as  the  Human Genome Diversity Project   (HGDP).
45 
According  to  international  consensus,  population  genetic  research  aims  to 
understand the nature and extent of genetic varia tion among a population or 
individuals within a group or between individuals across different groups .
46  This 
is the common understanding o f human population genetic research and is  the 
aspect that will be considered  in this thesis. Th is type of HPGR focuses on a 
certain population, normally an isolated one. Studies such as the Human Genome 
Diversity Project belong to this type of HPGR. The research object of this kind of 
                                         
39  Greely, H. T. 1999, "Iceland's Plan for Genomics Research: Facts and Implications", Jurimetrics, 
vol. 40, no. 2, pp. 153-192, at 157. 
40 See Brownsword, R. 2003, "An Interest in Human Dignity as the Basis for Genomic Torts", 
Washburn Law Journal, vol. 42, pp. 413-487. Also see Caulfield, T. & Brownsword, R. 2006, 
"Human Dignity: A Guide to Policy Making in the Biotechnology Era?", Nature Reviews: 
Genetics, vol. 7, pp. 72-76. 
41 See Ginsburg, D. H. 1999, "Genetics and Privacy", Texas Review of Law and Politics, vol. 4, pp. 
17-23. Also See Laurie, G. T. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, 
Cambridge University Press. 
42 See Smith, M. J. 2001, "Population-based Genetic Studies: Informed Consent and 
Confidentiality", Santa Clara Computer and High Technology Law Journal, vol. 18, pp. 57-93. 
Also see Lawton, A. 1997, "Regulating Genetic Destiny: A Comparative Study of Legal 
Constraints in Europe and the United States", Emory International Law Review, vol. 11, pp. 365-
418. 
43 See Gold, E. R. & Caulfield, T. A. 2003, Human Genetic Inventions, Patenting and Human Rights, 
Health Law Institute of University of Alberta.  
44 See Spaak, T. 2006, "Genetic Discrimination", Minnesota Journal of Law, Science & Technology, 
vol. 7, pp. 639-655. Also see Hellman, D. 2003, "What Make Genetic Discrimination 
exceptional?", American Journal of Law and Medicine, vol. 29, pp. 77-116. Also see Jungreis, R. 
2007, "Fearing the Fear Itself: The Proposed Genetic Information Nondiscrimination Act of 2005 
and Public Fears about Genetic Information", Journal of Law and Policy, vol. 15, pp. 221-247. 
45 The Human Genome Diversity Project (HGDP) was started by Stanford University's Morrison 
Institute and a collaboration of scientists around the world. It is an international project that 
seeks to understand the diversity and unity of the entire human species. The official website of 
HDGP is http://hsblogs.stanford.edu/morrison/human-genome-diversity-project/.  
46 This definition stems from United Nations Educational, Scientific and Cultural Organization‘s 
―Bioethics and Human Population Genetics Research (1995)‖. It sometimes also is called 
‗population-based genetic research/study‘ or ‗population genomic research/study‘. Chapter 1 
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HPGR  is  the  third  type  of  genetic  information  referred  to  above;  that  is, 
community  or  group  collective  human  genetic  information  that  is  able  to 
determine variation that could lead to knowledge about genetic disorders and 
possible cures, as well as the origin and migration patterns of peoples. In other 
word,  unlike  general  HPGR,  which  emphasises  the  basic  genetic  equality  of 
humans, the narrow HPGR project is directed at discovering DNA polymorphisms, 
emphasizing the genetic difference between human groups.
47  
For example,  the Human Genome Diversity Project,  proposed in 1991 , is a 
collaborative research project that is being developed on a global basis under 
the auspices of the Human Genome Organisation . The  ‗Summary Document of 
the Human Genome Diversity Project‘, which is the official report of the HGDP 
International Planning Workshop, describes the project as follows: 
The overall goal of the project is to arrive at a much more precise 
definition of the origins of different world populations by integrating 
genetic  knowledge,  derived  by  applying  the  new  techniques  for 
studying genes, with knowledge of history, anthropology and language. 
More specifically the aims are: To investigate the variation occurring 
in the human genome by studying samples collected from populations 
that are representative of all of the world‘s peoples, and, ultimately, 
to  create  a  resource  for  the  benefit  of  all  humanity  and  for  the 
scientific  community  worldwide.  The  resource  will  exist  as  a 
collection of biological samples that represents the genetic variation 
in  human  populations  worldwide  and  also  as  an  open,  long-term, 
genetic  and  statistical  database  on  variation  in  the  human  species 
that  will  accumulate  as  the  biological  samples  are  studied  by 
scientists from around the world. 
48 
The HGDP, which targets genes from certain populations, especially isolated and 
indigenous ones  which are unusually homogenous, made genetic and medical 
research easier and genes from such populations were  considered valuable. In 
1991, one of HGDP's initiators, Cavalli -Sforza, highlighted the importance of 
genetic research on these populations: 
                                         
47 Sleeboom-Faulkner, M. 2006, "How to Define a Population: Cultural Politics and Population 
Genetics in the People's Republic of China and the Republic of China", BioSocieties, vol. 1, pp. 
399-419, at 401-402. 
48 Summary Document of Human Genome Diversity Project, full text can be seen on the official 
website of HGDP, available on http://www.stanford.edu/group/morrinst/hgdp/summary93.html, 
last visited on 2010-06-02. Chapter 1 
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Isolated  human  populations  contain  much  more  informative  genetic 
records  than  more  recent,  urban  ones.  Such  isolated  human 
populations are being rapidly merged with their neighbors, however, 
destroying  irrevocably  the  information  needed  to  reconstruct  our 
evolutionary  history.  Population  growth,  famine,  war,  and 
improvements in transportation and communication are encroaching 
on once stable populations. It would be tragically ironic if, during the 
same decade that biological tools for understanding our species were 
created, major opportunities for applying them were squandered.49 
The  ‗Summary  Document  of  Human  Genome  Diversity  Project‘  describes  the 
values of the HGDP as follows: 
1 The main value of the HGD Project lies in its enormous potential for 
illuminating our understanding of human history and identity. 2 The 
resource  created  by  the  HGD  Project  will  also  provide  valuable 
information on the role played by genetic factors in the predisposition 
or resistance to disease. 3 The HGD Project will bring together people 
from many countries and disciplines. The work of geneticists will be 
linked  in  an  unprecedented  way  with  that  of  anthropologists, 
archaeologists, biologists, linguists and historians, creating a unique 
bridge between science and the humanities. 4 By leading to a greater 
understanding of the nature of differences between individuals and 
between human populations, the HGD Project will help to combat the 
widespread  popular  fear  and  ignorance  of  human  genetics  and  will 
make a significant contribution to the elimination of racism.
50 
Therefore, the HGDP has become an important  type of human genetic research 
which may result in great benefits.  
1.2.2 Concerns about Human Population Genetic Research 
HPGR on target groups on the one hand ‗can generate valuable knowledge about 
genetic  disorders,  possible  cures,  and  the  origin  and  migration  patterns  of 
distinctive peoples‘.
51 On the other hand, it also may ‗pose distinctive risks and 
                                         
49  Cavalli-Sforza, L., Wilson, A. C., Cantor, C. R., Cook-Deegan, R. M., & King, M. C. 1991, "Call 
for a Worldwide Survey of Human Genetic Diversity: A Vanishing Opportunity for the Human 
Genome Project", Genomics, vol. 11, pp. 490. 
50 See supra note 48. 
51  Tsosie, R. & McGregor, J. L. 2007, "Genome Justice: Genetics and Group Rights", Journal of 
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disadvantages  for  targeted  groups  and  may  even  resurrect  now-discredited 
―scientific‖ theories of race and human capacity‘
52. 
It has therefore inspired a debate between proponents who argue that research 
on certain groups, especially isolated groups, should be vigorously advocated to 
gain more knowledge about the origins of human life,
53 and opponents of such 
research, who argue that results of such research could be seen as  ‗scientific‘ 
proof to support several types of discrimination and which may pose significant 
risks for the target groups.
54 
In the context of human population genetic research, the real research target is 
not individual human genetic information, but community  or group collective 
human genetic information. Nevertheless, this type of genetic information  must 
be sourced from individual members of a particular group/community. Not only 
does a member of the group/community ha ve a personal interest in the use of 
the  information  resulting  from  his  or  her  involvement ,  so  too  does  the 
group/community as a whole .  This is entirely different from the traditional 
Western approach to  the control of information, which  generally vests in  the 
person to whom the information belongs, or to whom it relates.
55 The traditional 
core value of Western ethics and law has been  ‗the rights of the individual to 
determine  for  herself  the  course  of  her  life,  with  minimal  interference  by 
others.‘
56 However, community or group collective human genetic information 
relates not only to the person from whom it is derived, but also to the whole 
community/group.  
As  McGregor  has  said,  ‗given the public‘s  view  about  the  power  of  genetics, 
genetic  research  has  many  risks  associated  with  it‘.
57 She  argued  that  the 
disclosure of negative information or research results of HPGR could lead to risks 
                                         
52 See supra note 51. 
53 See supra note 49. 
54 See supra note 34. 
55 Laurie, G. 2002, Genetic Privacy: a Challenge to Medico-Legal Norms, Cambridge University 
Press, at 93. 
56 Ibid. 
57 See supra note 33, at 362. Chapter 1 
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of harm to the group as a whole both externally and internally.
58 While these 
concepts of external and internal harm will be explored in greater detail later in 
this work, for the moment it can be noted that external harms may arise where 
there is the possibility of exposing a community or group to stereotyping and/or 
stigmatization,  including  damaging  effects  on  employment  and  insurance 
opportunities. It has been argued that HPGR may also lead to potential internal 
harms to target group ,  which  would  include  effects  upon  group  members‘ 
perceptions of the group. For example, Tsosie identified ‗cultural harms‘ as the 
violation of groups‘ rights to their own culture in the context of HPGR.
59  
Genetic research which focuses on population groups  in the Western World has 
raised concerns about protection of group rights or community rights. In 1990s, a 
research project on the genetics of cancer in Ashkenazi Jews illustrated the 
problem well: 
Streuwing and colleagues reported work on the frequency in Ashkenazi 
Jews  of  one  particular  mutation  (185delAG)  in  the  BRCA1  gene 
associated with a high risk of developing breast and ovarian cancer. 
Samples for the project were collected from databanks established for 
Tay-Sachs  disease  and  cystic  fibrosis  screening.  Since  identifying 
information was removed from all samples, the NIH Office of Human 
Subjects Review did not require individual informed consent. The 
investigators found that 0.9% of Ashkenazi Jews carry the mutation, a 
much higher rate than in the general population.
60 
In this project, all  of  the DNA samples   were collected without any   personal 
identifying information, which is to say that the DNA samples w ere  analyzed 
anonymously. Thus, except for any physical harm which might be caused by the 
collection procedures, there were no direct risks to individuals who participated 
in these projects, even in respect of discrimination or stigmatization.  However, 
the community may be put at risk. The results of these studies could generate a 
substantial negative influence on the whole community of Ashkenazi Jews, and 
have repercussions not only for individ uals whose genetic information was used 
                                         
58 Ibid. 
59 Tsosie, R. 2007, "Cultural Challenges to Biotechnology: Native American Genetic Resources 
and the Concept of Cultural Harm", Journal of Law, Medicine & Ethics, vol. 35, no. 3, pp. 396-
411. 
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but also for those whose personal information was not used. As Lehrman noted 
with concern: 
Such findings, which have already led to Jewish groups being targeted 
as a potential market for commercial genetic tests, could create the 
perception  that  Jewish  people  are  unusually  susceptible  to 
disease. . . . As a result . . . anyone with a Jewish-sounding name 
could face discrimination in insurance and employment as companies 
struggle to keep down health-care costs.
61 
Due to the possibility of discrimination, US  Jewish leaders asked the National 
Human Genome Research Institute to discuss developing guidelines for the 
conduct of genetic research on Ashkenazi Jews.
62 Another example is that the 
Nuu-chah-nulth people of Vancouver Island, Canada, were shocked to learn that 
the genetic samples they had given to a researcher in the early 1980s to discover 
the genetic cause of rheumatoid arthritis were shared with many researchers 
and used for purposes beyond those to which the tribe  had consented.
63 The 
research uncovered the spread of lymphotropic viruses by intravenous drug use. 
That discovery imposed risks on the group as a whole, stigmatizing the group and 
altering the perception of the group about itself.  
Thus, although human gen etic information is not entirely different from other 
types of information in respect of human beings,  in the context of HPGR, 
community or group/collective human genetic informatio n is arguably unique, 
and the interests of  the  community/group  require special consideration  in 
bioethics and legal regulation. The uniqueness of community or group collective 
human genetic information is that it can be gained from individual members, but 
in conjunction with results obtained from others may reveal information about a 
particular group/community. The idea of the uniqueness of genetic information, 
whether it can be regarded as ‗exceptional‘ and requiring special consideration 
as  opposed  to  other kinds  of  information that  can be acquired  from  medical 
history or tests, will be explored in more detail later in the thesis. 
                                         
61 Lehrman, S. 1997, ―Jewish leaders seek genetic guidelines‖. Nature, vol. 389, at 322. 
62 See supra note 61, at 322. 
63 R. Dalton, ―Tribe Blasts ‗Exploitation‘ of Blood Samples,‖ available at 
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1.2.3 The  Inadequacy  of  Applying  Current  Western  Dominant 
Research  Ethics  to  Human  Population  Genetic  Research 
(HPGR) 
In general terms, the fundamental aims of ethics are to achieve two objectives: 
to tell us how we ought to act in a given situation, and to provide us with strong 
reasons for doing so.
64 Research ethics is ‗basically about means of ensuring that 
vulnerable people are protected from exploitation and other forms of harm.‘
65 
The contemporary focus on ethics in research came about because of the human 
experiments on prisoners of war and its own citizens conducted by Nazi Germany 
and Japan during World War II.
66 Following World War II, the Nuremberg Code 
required  that  ‗the  voluntary  consent  of  the  human  subject  is  absolutely 
essential.‘
67 The World Medical Association‘s Declaration of Helsinki noted that 
clinical research could be conducted only when the ‗risks involved have been 
adequately  assessed  and  can  be  satisfactorily  managed.  Physicians  must 
immediately stop a study when the risks are found to outweigh the potential 
benefits or when there is conclusive proof of positive and beneficial results.‘
68 
Further, in the US, the Ethical Principles and Guidelines for the Protection of 
                                         
64 Schuklenk, U. 2005, "Module One: Introduction to Research Ethics", Developing World Bioethics, 
vol. 5, no. 1, pp. 3. 
65  Ibid.  
66 United States of America v. Karl Brandt et al, which is also known as Doctors', was the first of 12 
trials for war crimes that the United States authorities held in their occupation zone in 
Nuremberg, Germany after the end of World War II. The record of this trail can be seen on the 
official website of the US, available on http://www.archives.gov/research/captured-german-
records/microfilm/m889.pdf, last visited on 2010-10-11. Unit 731 was a covert biological and 
chemical warfare research and development unit of the Imperial Japanese Army that undertook 
lethal human experimentation during the Second Sino-Japanese War (1937–1945) and World 
War II. However, because of political reasons, Japan Unit 731 avoided a procedure like the 
Nuremberg Doctors Trial. 
67 Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 
10, vol. 2 (Washington, D.C.: US Government Printing Office, 1949): 181-182.  
68 WMA Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects 
was adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended 
by the: 29th WMA General Assembly, Tokyo, Japan, October 1975, 35th WMA General 
Assembly, Venice, Italy, October 1983, 41st WMA General Assembly, Hong Kong, September 
1989, 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000, 53rd WMA General 
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added), 55th WMA General 
Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added), 59th WMA General 
Assembly, Seoul, October 2008. The full text of Helsinki Declaration can be seen on the official 
website of World Medical Association (WMA) on 
http://www.wma.net/en/30publications/10policies/b3/index.html, last visited on 2010-07-27. 
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Human Subjects of Research (Belmont Report)
69 articulate guidelines for human 
subject research. The basic principles, such as respect for persons, beneficence, 
and justice, have been established and widely accepted in Western countries. 
However, as McGregor has said: 
These regulations and codes based their ethical principles on respect 
for persons, beneficence, and justice. The principle of respect for 
persons translates into respect for individual autonomy (determining 
one's life plan in terms of one's own values and beliefs), res pect for 
privacy  (access  to  a  person's  private  sphere),  and  respect  for 
confidentiality  (not  divulging  such  privileged  knowledge).  The 
principle of respect also protects persons with diminished autonomy 
due to age, illness, mental disability, or particular circumstances that 
affect  one's  autonomy.  The  most  direct  implementation  of  the 
principle seeks and secures informed consent to conduct research. 
The principle of beneficence focuses on whether the benefits of the 
research  outweigh  the  risks.  Questions  of   risks  are  traditionally 
directed to risks to the individual research participant and the benefit 
for humanity generally. And the principle of justice requires at least 
that the selection of subjects is equitable, and questions, for example, 
why a certain  group or population is being targeted for research. 
Questions of justice should also include that the benefits of research 
flow to those who take the risks of research, that is, that there be 
equitable benefit sharing.
70 
At a practical level, ‗respect for persons‘ is secured through the requirement for 
individual informed consent. The most concise definition of informed consent to 
take  part  in  research  is  ‗a  decision  to  participate  in  research  made  by  a 
competent  individual  who  has  received  the  necessary  information;  has 
adequately understood the information; and after considering the information, 
has  arrived  at  a  decision  without  having  been  subjected  to  coercion,  undue 
influence,  inducement  or  intimidation.‘
71 There  are  four  basic  elements  of 
informed  consent  that  have  been  developed  since  the  Nuremberg  trials:  a) 
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Capacity  to  consent;  b)  Full  disclosure  of  relevant  information;  c)  Adequate 
comprehension of the information by the participant; d) A voluntary decision to 
participate and the right to withdraw from participation at any stage without 
prejudice  to  the  participant.  Participant  withdrawal  should  be  accepted  and 
withdrawing participants should not be expected to give any reasons for their 
decision.
72 
However, HPGR seems to potentially demand an exception   to the common 
reliance on the sufficiency of  individual informed consent. Genetic information 
not only discloses information about the human subjects concerned, but also 
discloses genetic information about her/his relatives, and even certain groups  
and their members. Thus, the impact of genetic research is complicated by the 
fact that genetic information may be shared among members of families, ethnic 
or racial communities, and other groups with a distinctive genetic inheritance.  
This not only creates spec ial risks for individuals but also widens the  scope of 
people who may be exposed to risk and who must be considered as involved in 
the research. The complication will be more serious in HPGR, because HPGR may 
also lead to potential risks of harm to  specific groups. It seems reasonable to 
believe that an individualistic autonomy model, focused on direct risks to the 
subject of research, is ill-suited to the shared nature of group collective genetic 
information, which is the research target of HPGR. Instead i t will be suggested 
that  another  approach  to  the  understanding  of  autonomy:  the  relational 
autonomy  model   is  more  appropriate.  This  model   highlights  the  need  to 
recognise that an individual exists in a social context, and his or her choices may 
thus be affected by concerns other than personal ones. It will be explored in 
more detail later in the thesis. 
Therefore, it is necessary to go on to consider the extent to which the  target 
groups/communities of HPGR and  their members are exposed to risks of harm 
from participation in this type of research, and the  kind of risks  needs to be 
identified. There will  also  be an evaluation of whether the current  Western 
ethical and legal framework s on research involving human subjects, which  are 
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dominated  by  individualism,  can  provide  adequate  protections  for  target 
groups/communities in HPGR.  
1.3 HPGR in Developing Countries 
HPGR, like the HGDP, is interested in sampling populations to study how human 
groups  and  individual  genetic  diversity  have  grown  and  aims  to  identify  the 
diversity of the human genome. Ethnic minorities and isolated groups in rural 
areas of developing countries, such as the PRC, would be the ideal target groups 
in  HPGR,  for  following  reasons:  (1)  members  of  these  groups  are  relatively 
homogeneous with respect to ethnic background, environment, and lifestyle; (2) 
the groups have existed for several thousands of years with a stable resident 
population; (3)  the population is large enough  to ensure the availability of a 
sufficient number of potential research participants.  
However, ethnic minorities and isolated rural groups in developing countries also 
have features which may lead to concerns  about protecting their interests in 
HPGR. For example, On 20 December 2000, Washington Post staff writers John 
Pomfret  and  Deborah  Nelson  published  an  article  ‗In  Rural  China,  a  Genetic 
Mother  Lode.‘
 73 It  was  a  story  that  reported  that  a  drug  company-supported 
research  program  involving  Harvard  University  researchers  and  six  Chinese 
medical centres were intending to sample the blood and genes of 200 million 
Chinese people in rural isolated areas to conduct genetic research; in addition, 
these resources would be incorporated into foreign  products without bringing 
any benefit to the Chinese people who furnished the genetic resources. Harvard 
Provost Fineberg said that ‗[w]e were very mindful of having the same [ethical] 
standards applied to them as in the US every effort was made to assure that was 
the case.‘
74 However, this example highlights a question increasingly asked by 
legal professionals and medical ethicists as developed countries‘ academic and 
corporate  researchers  turn  to  developing  countries  to  find  large  amounts  of 
human  research  materials  to  conduct  HPGR:  do  these  standards  provide 
adequate protections for participants and groups in HPGR? 
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Target groups of HPGR may be vulnerable because of their members‘ frequently 
low  educational  level,  lack  of  economic  and  social  resources,  difficulties  in 
correct  understanding  of  the  risks  of  HPGR  or  the  possibility  of  undue 
inducement  to  take  part  in  research.  These  common  characteristics  arguably 
make  them  more  likely  to  accept  risks  that  are  either  not  understood  or 
appreciated,  or  that  are  unjust.  Meanwhile,  the  researchers  or  research 
institutions involved in HPGR, who are mostly research institutions or companies 
from developed countries, have the potential to take unfair advantage of their 
superior economic and social resources by offering target groups unfair benefits 
in exchanging for their participation. Furthermore, the absence of effective and 
adequate legal regulations and ethical guidelines in most developing countries, 
as well as poor law enforcement, also exacerbates the vulnerability of target 
groups in HPGR.  
Therefore, the vulnerability of target groups in HPGR in  developing countries 
should be addressed in more detail and depth. In particular, it is essential to 
evaluate whether or not the dominant (Western) underpinnings of the ethics of 
research  are  sufficient to eliminate or reasonably reduce  the vulnerability of 
target groups and provide adequate protections for them in HPGR in developing 
countries, such as the PRC. In addition, some target groups from rural areas of 
developing countries have their own cultural sensitivities  concerning decision-
making patterns which will also be relevant to this evaluation.  This too may 
mandate a reconsideration of the applicability and practice of HPGR projects 
and processes. 
The People‘s Republic of China is a good model on which to base an analysis of 
whether  or  not  target  populations  in  HPGR  are  adequately  protected  by 
contemporary  legal  and  ethical  regulations  of  human  subject  research.  The 
Chinese  population  comprises  one-fifth  of  the  human  species.  The  Chinese 
government  officially  recognizes  56  ethnic  groups,  one  of  which  is  the  Han 
majority  (1  billion  and  100  million  people),  and  the  other  55  are  ethnic 
minorities (totalling about 100 million).
75 China contains rich genetic resources in 
isolated areas which have idiographic cultures. At the same time, the PRC is the 
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only  developing  country  participating  in  the  HGP.  Accordingly,  a  number  of 
developed  countries  and  their  research  organizations  desire  to  do  genomics 
research  in  China  or  undertake  collaborative  research  with  Chinese  research 
organizations in this area. In 1996, experts warned that China faces the prospect 
that the genes of hundreds of millions of its people may become the priceless 
resources of foreign pharmaceutical companies.
76  
As mentioned above in the reference to the Harvard case, these researchers will 
generally be expected to have met the ethical and legal requirements for 
conducting  their  research  in  their  country  of  origin  (generally  developed 
countries).  However,  the  PRC,  has a thoroughly different legal and cultural 
background from those developed countries, which leads to the need to consider 
whether or not existing developed world legal and ethical frameworks provide 
these research participants with adequate levels of protection and are sensitive 
to cultural concerns . The legal regulation of HPGR in C hina, such as it is, 
including ‗Interim Measures for the Administration of Human Genetic Resources 
1998‘
77 and ‗Ethical guidelines for human embryonic stem cell research 2003‘,
78 
is – as will be seen - copied almost word for word from Western legal and ethical 
frameworks, which means that these regulations are neither designed to provide 
protection to target groups in biomedical research, nor consider the particular 
position and cultural sensitivities of the populations concerned.  
The PRC has a unique cultural and historical tradition. China is a country with a 
history as long as the history of human beings themselves, and is also a country 
with strong cultural traditions. The largest group, the Han, make up over 92% of 
China‘s vast population, and the Han civilization is the dominant culture in China. 
                                         
76  Sleeboom, M. 2005, "The Harvard case of Xu Xiping: exploitation of the people, scientific 
advance, or genetic theft?‖, New Genetics and Society, vol. 24, no. 1, pp. 60. 
77 Ren Lei Yi Chuan Zi Yuan Guan Li Zhan Xing Ban Fa [Interim Measures for the Administration of 
Human Genetic Resources 1998] (in Chinese), available on the official website of the Ministry of 
Science and Technology of the PRC: 
http://www.most.gov.cn/fggw/xzfg/200811/t20081106_64877.htm, last visited on 2010-05-06. 
78 Ren Pei Tai Gan Xi Bao Yan Jiu Lun Li Zhi Dao Yuan Ze [Guidelines for the Moral Principles in 
Human Embryonic Stem Cell Research 2003] (in Chinese), available on the official website of 
the Ministry of Science and Technology of the PRC: 
http://www.most.gov.cn/fggw/zfwj/zfwj2003/200512/t20051214_54948.htm, last visited on 2010-
05-06. Chapter 1 
Introduction    24 
 
Meanwhile, the other 55 ethnic minorities maintain their own rich traditions and 
customs.  It has been said that:  
From the dawn of time, China‘s history is a story of an immense land 
with several diverse tribes. It is also one of migrations and conflict, 
and  separation  and  fusion  of  cultures.  The  product  of  the 
intermingling of many tribes, the Han people were among the first to 
settle  down  and  develop  an  agrarian  society…  Over  a  2,000  year 
period,  a  large  number  of  invaders  breached  the  Great  Wall  and 
poured  into  the  Chinese  heartland.  The  Huns,  the  Mongols,  and 
Manchurians  all  came  --  and  unlike  the  plunder  and  destruction 
characterized  by  the  barbarian  invasions  of  Rome,  these  peoples 
admired what they saw, leading them to stay and assimilate.
79 
The fact that the PRC has its own range of cultural and ethical traditions makes 
it more difficult to adopt Western individualised ethical and legal frameworks in 
HPGR. For example, in China‘s traditional culture, the notion of respect for an 
individual‘s right to self-determination is not prominent. In fact, the Confucian 
concept  of  relational  personhood  challenges  the  assumption  that  the  patient 
alone should be given the diagnosis and prognosis and the opportunity to make 
his  or  her  own  medical  decisions.  Social  and  moral  meaning  rests  in 
interdependence,  which  overrides  self-determination.  Consequently,  many 
Chinese  people  may  give  the  family  or  community  the  right  to  receive  and 
disclose information, to make decisions and to co-ordinate patient care, even 
when they themselves are competent.
80 In contrast, privacy rights and individual 
autonomy are the starting points of the protection system of Western countries.  
In an article on Chinese genetics and ethics by Qiu Ren -zong, one of the most 
well-known bioethicists in China, it is claimed that in traditional medicine in 
general, medicine is taken as the art of humaneness (yi ben ren shu). This means 
that the doctor loves people, cares for people and does well for people. In  his 
view, the essential core relationship between patient and doctor is not the same 
as in Western countries; rather, it is based in  absolute trust. For example, Qiu 
says: 
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Doctors who practice medicine in China have the capacity to decide 
the life or death of a patient, so they bear a very heavy responsibility. 
Traditional China is a patriarchal society in which paternalism is very 
strong in social life. …In the encounter between physician and patient, 
medical decisions are made by the physician, and the doctor‘s opinion 
is directive. Although there has been a great change in modern China, 
and the paternalism in medicine has been considerably weakened, it 
still prevails.
81 
However,  most  international  conventions  and   ethical  guidelines  for  human 
subject  resea rch  are  based  on  the  principles  of  individual  autonomy, 
beneficence, and justice. Considering the special situation in China, patients‘ 
undoubted trust in doctors and the emphasis on  family and group/community 
over individual interests can cause problems in terms of medical research which 
may extend to HPGR.  
In addition, in the PRC, 25% of the population is illiterate or semi-literate. The 
majority of these people are distributed in the isolated rural areas which are 
attractive targets of HPGR.
82 As was reported in the Harvard story, those target 
people, whose lives were extremely poor and who had scarcely any medical care, 
were told that if they participated there would be free medical care  - so of 
course most people volunteered to participate.
83  Even had th ere been an 
introduction to the aims and anticipated achievements of this research, which 
‗adhered to the principle of informed consent‘, this would be of arguable value 
in such cases since ‗many couldn‘t read, and few could have guessed at the 
tangle of scientific and business dreams that lay behind the project.‘
84  
For these reasons, this thesis will use the PRC as an example to analyze how to 
build new legal and ethical frameworks on biomedical research involving human 
subjects, with special reference to the protection of vulnerable target groups 
and  consideration  of  the  specific  Chinese  bioethical  background  and  cultural 
sensitivities. 
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The proposed alternative ethical and legal frameworks for biomedical research 
will  be  designed  to  allow  the  ethical  conduct  of  human  population  genetic 
research  which  does  not  harm  the  interests  of  vulnerable  target  groups  and 
individual participants, based on the specific bioethical background and cultural 
sensitivity of a developing country.  
In summary, human genetic research has come a long way, but some aspects of 
it remain controversial. During the past 20 years, alongside the exploration of 
human genetic information, debates have focused on how to regulate genetic 
research  and  use  genetic  technology.
85  Human population  genetic research 
creates additional  dilemmas that are also significant  and urgent, especially in 
developing countries.  
1.4 Hypothesis of the Thesis 
Target groups of HPGR are almost always ethnic minorities or isolated groups in 
rural  areas  of  developing  countries.  These  groups  have  not  only  objective 
characteristics  which  distinguish  them  from  other  groups,  such  as  history, 
geography,  ethnicity,  economics,  language  and  religion,  but  also  may  have 
inherent  values  which  lead  to  the  group  and  its  members  having  a  self-
perception of the group‘s distinctiveness.  Further, individual members of the 
group may strongly identify themselves with the group, and particularly with its 
common spiritual tradition, historical narratives, or traditional beliefs. They may 
also have their own well-developed cultural traditions, such as group collective 
decision-making. Meanwhile, the researchers  in HPGR are almost always from 
Western developed countries, who are outsiders of target groups.  The personal 
and  cultural  forces  that  link  members  of  groups  to  each  other  and  to  their 
traditions, are of great importance to both the individual and to the group itself.  
These traditions are worthy of respect and protection, yet risk being overlooked, 
ignored or disrespected by researchers from a different tradition. 
This thesis intends to examine current ethical and legal frameworks for research 
involving human subjects in HPGR, particularly HPGR in developing countries, 
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specifically in China. Therefore, it will argue that the interests of group in this 
kind of research should be recognised as being worthy of protection and that this 
is  not  available  using  the  Western  ethical  and  legal  regulations  already  in 
existence. It aims to propose a model that will offer additional protections to 
groups in HPGR. 
This thesis is concerned with two aspects of ethical and legal regulations on 
HPGR. The first relates to an explanation as to why current ethical and legal 
regulations on human subject protection cannot provide adequate protection to 
target  groups  and  their  members  in  HPGR.  The  second  element  is  the 
vulnerability of target groups in HPGR in developing countries and the additional 
protections they need. This will require consideration of how and why HPGR may 
pose risks of harm to both target groups and their members. Having examined 
these  issues,  I  will  then  consider  how  ethical  and  legal  frameworks  can  be 
proposed in developing countries, such as the PRC, in terms of HPGR. 
This thesis consists of five chapters, including an Introduction and Conclusion. In 
Chapter 2 of this thesis, the risks of harm of human population genetic research 
(HPGR)  will  be  identified  and  an  analysis  of  the  deficiencies  of  the  current 
ethical  and  legal  approaches  to  human  subject  protection  for  HPGR  will  be 
undertaken. This chapter will address the role and general rules of consent in 
the medical context, as well as the specific rules of consent to medical research 
involving human subjects, including ethical and professional guidance and legal 
principles. It will then address the risk-benefit distinctions between therapeutic 
research and non-therapeutic research, and introduce the legal regulations and 
cases  on  the  protection  of  the  well-being  of  human  subjects  from  an 
international  perspective.  Subsequently,  it  will  argue  that  genetic  research 
raises its own concerns in respect of research ethics and explain the uniqueness 
of the types of harm caused by genetic research.  It will clarify that in HPGR it is 
not only an individual but also a population/group that may be at risk of harm, 
such as psychological harms including shame or humiliation; loss of opportunities 
and  other  economic  setbacks  or  loss  of  insurance  or  insurability  (possibly 
resulting from stereotyping or stigmatising a group as a whole). Further, this 
chapter will point out that group/community members may suffer harm without 
the opportunity of knowing the risks of harm in advance and being able to make Chapter 1 
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decisions  as  to  whether  or  not  to  accept  them.  In  addition,  contemporary 
Western legal systems and regulations depend on philosophical statements that 
identify  individual  rights  as  the  appropriate  foundation  for  the  protection  of 
human  beings.  For  instance,  in  the  context  of  medical  law,  one  prevalent 
principle  is  ‗respect  for  persons‘,  which  aims  to  protect  an  individual‘s 
autonomy  through  practical  measures  like  the  requirement  for  legally  valid 
consent  to  treatment.
86  Furthermore,  traditional  investigators,  Institutional 
Review  Boards  (IRBs)  or  Research Ethics  Committees   (RECs)  ordinarily  pay 
attention to the risks of harm to the individual participant. The ethical basis of 
this framework is concern for the individual rather than for groups or particular 
populations.
87 Thus, some scholars suggest that since the  current Western legal 
system  is  ‗rooted  in  natural  rights  theories,  social  contract  theories,  Kantian 
notions of the individual, and other philosophical antecedents, it is generally 
assumed by liberal democratic governments that legally cognizable human rights 
are individual rights, which stand against the potential tyranny of government‘.
88 
Therefore,  it  will  be  argued  that  at  least  some  of  the  traditional  Western 
approaches to research are unsuited to this specific kind of research and are 
particularly inadequate in developing countries, such as China, although some 
essential  rules  need  to  be  followed,  such  as  the  provision  of  adequate 
information when seeking consent. 
Chapter  3  will  make  the  case  for  the  protection  of  groups  as  potentially 
vulnerable populations in HPGR. Since HPGR aims to identify specific aspects of 
the diversity of the human genome, target groups are mostly ethnic minorities or 
isolated groups in rural areas of developing countries. This chapter will suggest 
that these groups are vulnerable to three types of vulnerability: consent-based, 
risk-based,  and  justice-based.  According  to  these  concerns,  target  groups  in 
HPGR may be vulnerable by virtue of a low education level, lack of economic 
and social resources, failure to recognise cultural sensitivities and the absence 
of  effective  and  adequate  legal  regulations  and  ethical  guidelines  in  most 
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developing countries. Although in respect of international law, there has been 
some  discussion  of  group  rights  and  some  attempts  to  recognise  and  protect 
them, such as The Convention on the Prevention and Punishment of the Crime of 
Genocide,
89 these declarations  are usually aimed at civil and political rights . 
Group/community protection in the area of  biomedical research has not been 
given much attention in general, beyond the protection of such groups as 
children and mentally incapacitated adults.
90 However, it will be argued that the 
target group and its members need to be protected by specific legal and ethical 
regulations. Thereafter, it will analyze current regulations on vulnerable group 
protection and a ttempt to  provide  revised  guidelines to protect groups in 
population genetic research. 
Chapter  4  will focus on issues specifically in  the PRC.  It  begins with  a  brief 
introduction  to  the   Chinese  legal  system.  It  will  then  explore  the 
implementation of the c urrent legal framework in respect of human subject 
research protections in HPGR. This is critically reviewed since it is necessary to 
explain the  problems of existing  Chinese  regulation in this area.   It will then 
explain the  current practices of HPGR in th e PRC, while also exploring the 
bioethical background of the PRC and identif ying  its  special characteristics. 
Finally, this chapter will address the specific situation of ethnic minorities and 
isolated groups in rural areas in the PRC, including their cultural sensitivities and 
contemporary legal protections. It will be argued that in order to protect target 
group in HPGR in the PRC, neither can Western standards be merely transplanted 
into China directly, nor are current Chinese legal regulations adequate. Rather, 
a new construct which considers  both group vulnerability and specific cultural 
sensitivities is needed. 
In Chapter 5, it will be  concluded that the only way of adequately  protecting 
target groups in HPGR in developing countries is to  construct a tailored ethical 
                                         
89 The Convention on the Prevention and Punishment of the Crime of Genocide, it was adopted by 
the United Nations General Assembly in December 1948 as General Assembly Resolution 260, 
the full text can be seen on the official website of the United Nations, available on 
http://www.hrweb.org/legal/genocide.html, last visited on 2010-10-24. 
90 Almost all the international declarations and ethical guidelines on research involving human 
subject have specific regulations on vulnerable population protection, including the Declaration 
of Helsinki and the International Ethical Guidelines for Biomedical Research Involving Human 
Subjects (CIOMS Guidelines). Chapter 1 
Introduction    30 
 
and legal framework. The proposals that will be put forward for regulation of 
HPGR in the PRC will highlight the issues of group protection, with reference to 
international  ethical  guidelines  and  the  legal  regulations  of  other  countries, 
taking into account the specific cultural sensitivities of the PRC. The proposed 
solution will be helpful in improving the ethical conduct of biomedical research 
involving human subjects, as well as vulnerable group protection in the PRC. This 
alternative model could also be a valuable guide as to how to provide adequate 
protections for target groups in HPGR in other developing countries, which have 
similar issues to those that will be highlighted in the PRC. Recommendations will 
be made as how such a construct might be developed. I will suggest that group 
protection should be highlighted in ethical and legal frameworks on biomedical 
research, specifically in terms of HPGR. The main bases for this derive from (1) 
the  need  to  take  group  interests  and  cultural  sensitivities  into  account,  by 
adopting a model of relational autonomy, enhancing researchers‘ responsibilities 
and requiring ethical review of group interests; (2) the need to respect the role 
of developing countries and their own legal and ethical regulations which fit into 
their specific social, economic and cultural context.  Chapter  2  Harms  of  Human  Population  Genetic 
Research 
2.1 Consent and Human Subject Protection 
While most discussions about the ethics of biomedical research involving human 
subjects agree that there is a need for it to take place, they also accept the 
significance of protection for human subjects to ensure their well-being and to 
avoid  abuse  and  exploitation.
1 The requirements of consent, based on   the 
principle  of  respect for  autonomy,  have  become central measures for the 
protection of human subjects in Western bioethics and law. These requirements 
have been developed in the medical treatment context and subsequently applied 
to  medical  research,  although  their  application   even  here  is  n ot  always 
straightforward. Their applicability to genetic research, and more specifically 
HPGR, raises additional problems which will be explored in this and subsequent 
chapters. However, before turning to this particular situation it is necessary to 
consider how the role  of autonomy  and the general rules of consent in the 
Western medical context have been approached. This chapter will also introduce 
the concept of relational autonomy as a challenge to a highly individualised 
concept of autonomy. The signif icance of this challenge is in its invitation to 
consider the social context of even individual decision-making.  This will become 
relevant when discussing the potential for collective harm to target groups in 
HPGR, highlighting the need for an enriched un derstanding of the requirements 
for individual decision -making when people are asked to participate in such 
research. 
2.1.1 Individual Autonomy and Relational Autonomy  
I  wish  my  life  and  decisions  to  depend  on  myself,  not  on  external 
forces of whatever kind. I wish to be the instrument of my own, not of 
other men‘s acts of will. I wish to be a subject, not an object; to be 
moved by reasons, by conscious purposes, which are my own, not by 
causes  which  affect  me,  as  it  were,  from  outside.  I  wish  to  be 
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somebody, not anybody; a doer – deciding not being decided for, self-
directed and not acted upon by external nature or by other men … I 
wish, above all, to be conscious of myself as a thinking, willing, active 
being, bearing responsibility for his choices and able to explain them 
by reference to his own ideas and purposes.
2 
Such statements are at the core of Western moral and ethical history,  and 
emphasize and justify the  concepts  of free choice, self -determination and 
individual autonomy. For example, Mill argued  that the individuality of human 
beings should be respected by allowing them to make free choices, unless their 
actions would cause significant harm to others.
3 Kant highlighted the significance 
of free choice and personal autonomy by stating that a person should be an end 
in himself and should never be used  solely as a means to an end.
4 Dworkin also 
emphasized the importance of individual  autonomy: ‗What makes an individual 
the particular person he is his life-plan, his projects. In pursuing his autonomy, 
one shapes one‘s life, one constructs its meaning. The autonomous person gives 
meaning to his life.‘
5 Of particular interest to this thesis is that in the context of 
research on human subjects, he further argued for the importance of individual 
autonomy: ‗one‘s body is irreplaceable and inescapable … In addition because 
my body is me, failure to respect my wishes concerning my body is a particularly 
insulting denial of autonomy.‘
6  
Consequently, in both Western medical and research ethics, there exists a strong 
moral  conviction,  grounded  on  notions  of  human  dignity  and  respect  for 
individual  autonomy,  that  every  individual  has  a  prima  facie  right  to  self-
determination with respect to his or her body. Thus, in the context of medical 
ethics, autonomy and consent are central concepts.
7 
                                         
2 Berlin, I. 1969, Two Concepts of Liberty, Oxford: Clarendon Press, at 123. 
3 Mill, J. S. 1989, On Liberty, S Collini edn, Cambridge University Press, at 13. 
4 Sedgwick, S. 2008, Kant's Groundwork of the Metaphysics of Morals: An Introduction, Cambridge 
University Press. 
5 Dworkin, G. 1988, The Theory and Practice of Autonomy, Cambridge University Press, at 31. 
6 Ibid., at 113. 
7 Childress, J. F. & Fletcher, J. C. 1994, "Respect for Autonomy", Hastings Centre Report, vol. 24, 
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The term ‗autonomy‘, stems from the Greek words autos (self) and nomos (rule), 
literally meaning is self-rule or self-governance.
8 The original use of the concept 
of  autonomy  was  to describe the self -rule or self-governance of  independent 
city-states.
9 Since then its use has been expanded to cover the individual. There 
are, however,  various definitions of personal autonomy, as well as  different 
senses in which autonomy may be used. For example, autonomy can be seen as 
‗the capacity to think, decide, and act on the basis of such thought and decision 
freely and independently and without… let or hindrance,‘
10 and be employed to 
refer  to  an  individual‘s  capacity  to  ‗think,  decide  and  act.‘
11 Autonomy  may 
further refer to a way of living one‘s life, with autonomy being seen as a virtue 
rather  than  a  simple  ability.
12 Alternatively,  according to  two of the  main 
proponents of  the dominant conception of   autonomy  in a medical context,  
Beauchamp and Childress, autonomy is the ‗personal rule of the self that is free 
from both controlling interferences by others and from personal limitations that 
prevent  meaningful  choice.‘
13 On  this  view,  the  subject  of  autonomy  is  an 
individual person who ‗freely acts in accordance with a self-chosen plan,‘
14 and 
to respect the autonomy of individuals is to ‗acknowledge their right to hold 
views, to make choices, and to take actions based on their personal values and 
beliefs.‘
15 This principle has been seen as the moral and ethical basis of the need 
for consent to medical treatment and is also widely accepted as the dominant 
rule to prevent harms to human subjects of research.
16  
                                         
8 Beauchamp, T. L. & Childress, J. F. 2009, Principles of Biomedical Ethics, Sixth edn, Oxford 
University Press, at 99. 
9 Ibid. 
10 Gillon, R. 1985, "Autonomy and the Principle of Respect for Autonomy", British Medical Journal, 
vol. 290, pp. 1806-1808, at 1806. 
11 Ibid.  
12 Maclean, A. 2009, Autonomy, Informed Consent and Medical Law, Cambridge University Press, 
at 12. 
13 See supra note 8, at 99. 
14 Ibid. 
15 Ibid., at 103. 
16 For example, Beasley, A. D. & Graber, G. C. 1984, "The Range of Autonomy: Informed Consent 
in Medicine", Theoretical Medicine and Bioethics, vol. 5, no. 1, pp. 31-41. In this article, the 
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However, from the late 1980s, some communitarian philosophers and feminists 
began to criticize the dominance of an over-individualised concept of autonomy, 
and especially Beauchamp‘s and Childress‘s approach to the principle of respect 
for personal autonomy in bioethics.  
This  criticism  argues  that  autonomy  described  in  this  way  presupposes  an 
individual with no social context. It also overstates the presumption about the 
way  in  which  the  individual  makes  his  or  her  own  decisions,  as  being 
uninfluenced by others. For example, communitarian philosophers argued that 
‗self-determination presupposes the existence of a community from which an 
individual derives many of his or her values.‘
17 They stress that the principle of 
respect for persons must reflect the fact that the individual is situated within a 
particular community. Miller summarizes this argument as follows: 
First, the socialization process determines, or shapes, the values and 
preferences of individuals; hence, the idea of autonomously chosen 
values is factually incorrect. Second, an individual‘s actions, desires, 
and objectives are comprehensible only within the context of social 
conventions  and  institutions.…  Third,  the  view  that  an  autonomous 
individual  chooses  his  or  her  own  values,  preferences,  and  desires 
presupposes a self that does the choosing. This self will have to have a 
core of values with which to choose, in which case either there are 
values not autonomously chosen, or it is inexplicable how individuals 
come to have a set of values.
18 
In  addition,  f eminist  theorists  have  challenged  the  concept  of  individual 
autonomy  because of its lack of attention to human relationships; to the  
‗relational  nature  of  human  life.‘
19 There  are  two  major  concerns  which  are 
raised  by  feminists:  (1)  the  conception  of  persons  which  is  dominant  in  the 
theory  of  autonomy,  is  typically  believed  to  be  false;  they  charge  that  the 
theory overemphasizes people‘s independence and deference to rationality in 
decision making. They argue that people sometimes act contrary to their best 
interests,  which  undermines  the  liberal  understanding  of  an  autonomous 
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18 Miller, B. 1995, Autonomy. In: Reich WT, ed. Encyclopedia of Bioethics, Rev. ed. New York: 
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person.
20 (2) The kind of autonomy espoused  by the dominant theory  has also 
been questioned, especially since it relies on an ideal   of personhood that 
feminists  generally  believe  to  be  ‗both  unrealistic  and  pernicious.‘
21  They 
believe  that  people  can  be  harmed  by  demands  to  meet  the  ideal  of 
independence  and  the  implicit  definition  of  persons  in  medical  practice.  For 
example, Wendell argues that this view of personhood could ‗turn against people 
with  disabilities  as  unrealistic  demands  that  they  achieve  goals  deemed 
appropriate by others or as excuses for refusing to provide necessary services.‘
22 
Beauchamp and Childress have responded to this criticism in their most recent 
edition of Principle of Biomedical Ethics as follows: 
Some  feminists  have sought  to affirm autonomy  but to  interpret  it 
through  relationship.  These  conceptions  of  ‗relational  autonomy‘ 
derive from the conviction that persons‘ identities are shaped though 
social  relationships  and  complex  intersecting  social  determinants, 
such as race, class, gender, ethnicity, and authority structures. These 
accounts see persons as interdependent, but they also caution that 
‗oppressive  socialization  and  oppressive  social  relationships‘  can 
impair  autonomy…  Such  a  relational  conception  of  autonomy  is 
illuminating and defensible as long as it does not neglect or obscure 
the main features of autonomy that we analyze in this chapter.
23 
Hence,  Beauchamp  and  Childress  believe  that  feminist   writers  have 
misunderstood their theory, but  arguably they have  failed to appreciate the 
nature of this critic ism. Feminists‘ real criticism focuses on the foundation of 
their theoretical position, which is the presupposed definition of a person. Ells 
explained this as follows: 
B&C's  [Beauchamp  and  Childress‘s]  feminist  critics  believe  that  the 
liberal view of personhood is unacceptable as an ‗ideal‘ on at least 
two grounds. First, the factual ground: persons simply are not, and 
cannot  be,  the  sort  of  beings  that  the  ideal  in  the  dominant 
conception  of  autonomy  requires…  Second,  the  consequentialist 
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Philosophy, vol. 26, no. 4, pp. 417-430, at 422. 
21 Ibid, at 418. 
22 Wendell, S., 1996, The Rejected Body: Feminist Philosophical Reflections on Disability, New 
York: Routledge, at 145. 
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ground: the imposition of such an ideal by the dominant conception of 
autonomy can be harmful.
24 
Thus, the feminists cited believe that persons are always and necessarily socially 
situated, which means that they are always and necessarily in relationships with 
others.  Their  alternative  conception  of  autonom y,  which  emphasizes  the 
limitations  of Beauchamp and  Childress ‘s  conception,  is  ‗grounded  on  this 
relational conception of persons as involving the competent exercising of skills, 
derived and constrained by social circumstances, that facilitate self-direction.‘
25  
Although  the  feminists‘  accounts  of  relational  autonomy  are  varying,
26 these 
alternative conceptions  of autonomy  have several advantages. Firstly, they 
provide a richer and more socially contextualised conception of persons. In some 
situations  of  me dical  treatment   it  is  not  likely  that  people  can  make 
independent and autonomous decisions. For example, a patient may suffer from 
a  serious  disease  which  influences  her/his  capability  to  make  decision s 
independently. Even if the disease is not so serious  as  to influence her/his 
capacity to exercise independent decision making, she/he might also be scared 
by the disease, and be  vulnerable, weak and not in control of the situation . In 
these situations, individualistic autonomy often leaves the patient in a h elpless 
situation  when her/his social  relationships are excluded, and as a result the 
patient  often  cannot  actually  make independent and rational decisions  and 
                                         
24 See supra note 21, at 422. 
25 Ibid., at 423. 
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mother-child relations are far closer and tighter than ties among friends, and mothering has 
historically offered women the opportunity to exercise agency more fully than other relationships 
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possessed of a robust sense of self, and a striving for the full use of one‘s powers;  while 
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would  be  more  likely  to  ‗fall  prey  to  the  implicit  manipulation  of  medical 
professionals.‘
27 Dodds  even  argued  that  individualistic  autonomy  in  medical 
decisions is inapplicable, since ‗many of the important, but by no means unusual, 
health-care  decisions  that  individuals,  friends,  and  families  make  are  far 
removed  from  the  cool,  reflective,  clear-headed  decision  making  that  is  the 
paradigm of this view of autonomy.‘
28  
Secondly,  they  extend  the  responsibility  for  choices  to  society,  since  society 
contributes  to  the  development  of  the  necessary  skills  for  choice.  Autonomy 
should be understood on the basis of an institutional and cultural background. So 
an account of autonomy cannot be totally individualistic but should recognize 
that  the  individual  is  situated  in  a  large  number  of  social  practices, 
commitments and relations to other people. In practice, there may be certain 
cultural norms that make it likely that individuals would wish to seek or rely on 
family or even community views in their decision-making process. For example, 
in  traditional  Chinese  society,  ‗the  family  is  based  on  an  extended  or  clan 
structure and plays a central role in an individual‘s life… Consequently, many 
Chinese  patients  may  give  the  family  or  community  the  right  to  receive  and 
disclose information, to make decisions, and to co-ordinate patient care, even 
when  they  themselves  are  competent.‘
29  Under  a  model  of  individualistic 
autonomy, reliance on family or community views may be considered to place a 
person at the mercy of undue influence, which would hamper the exercise of 
individual  autonomy.  Under  a  model  of  relational  autonomy,  this  seeking  or 
relying on outside opinion is not viewed as undue influence, but as reasonable 
involvement of relevant parties and also permits consideration of the interests 
of other people who might be influenced by the decision.  
Thirdly,  feminists  make  it  clear  that  a  new  understanding  of  respect  for 
autonomy requires ‗anticipation by others of what is needed to make the choice 
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in question and facilitating that choice accordingly.‘
30 Individualistic autonomy is 
the result of an abstract universalism that does not take into account the daily 
reality of human life. However, in daily reality, the individual is always situated 
in a multiplicity of contexts and life situations where dependency on others is 
very  important.  The  narrative  structure  of  personal  identity  and  of  the 
experiences of the individual,  which are  based on relational autonomy, show 
that decision-making should always be regarded as the result of the interactions 
of the individual with the social context.  
Therefore, the critiques made by communitarian philosophers and feminists of 
individual autonomy are positive challenges to the dominant  interpretation of 
the  principle  of  respect  for  individual  autonomy.  No  matter  what  kind  of 
relationship they suggest as a model, they recognize that the individual is not an 
entirely  independent  entity,  but  a  person  who  is  grounded  in  important  and 
close social relationships. In other words, when individuals make decisions, they 
are  not  in  a  vacuum,  but  are  always  influenced  by  interactions  between 
themselves and others, and make decisions not only based on their own interests 
but  also  how  this  decision  will  affect  other  people  relevant  to  them.  An 
individual may wish to take into account information on how  her/his decision 
may  affect  others  who  are  important  to  her/him.  Just  as  individualistic 
autonomy  cannot  account  for  the  interests  of  other  relevant  parties,  it  also 
cannot adequately take account of context. Indeed, in certain contexts, such as 
HPGR, simply to ensure that the individual research participant has been able to 
exercise autonomy based on their own interests would fail to take into account 
the interests  of other group members.  The shared nature of  group collective 
genetic information means that HPGR on some members of the group potentially 
affects other members of the group who did not consent to participating in the 
research, even the whole target group/community. In addition, in some cultures, 
when the decision would be relevant to the interests of both the group and the 
individual,  individuals  may  wish  to  consider  and  respect  the  interests  of  the 
group as having priority, rather than making the decision only based on  their 
personal interests. Therefore, I argue that in the context of HPGR, the relational 
autonomy  model  would  be  more  appropriate.  Before  making  a  decision  to 
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participate,  an  individual  would  need  to  be  enabled  to  take  into  account 
information on the potential influence of her/his decision on others relevant to 
him  who  might  be  affected  by  the  decision.  The  exact  concerns  raised  by 
adopting an individualised informed consent model, rather than the proposed 
relational autonomy model, will be discussed in more detail in following sections.  
2.1.2 The Role of Autonomy and Consent in the Western Medical 
Context 
While there are some challenges to the meaning of the principle of autonomy 
from the philosophical or ethical perspective, the core concept of respect for 
individual autonomy is still dominant in the Western medical context. Respect 
for  individual  autonomy  indicates  that  an  individual  who  has  the  capacity  to 
make  the  decision  for  him  or  herself  should  be  permitted  to  do  so  without 
inappropriate  external  pressure,  and  that  this  decision  should  be  respected. 
Meanwhile,  it  also  implies  that  no-one  has  the  authority  to  conduct  any 
intervention  upon  such  people‘s  bodies  without  their  consent.  Under  this 
principle, when considered in a medical context, consent can be defined as the 
‗autonomous  authorization  of  a  medical  intervention  or  of  participation  in 
research.‘
31 Ideally,  patients  or  research  participants  have  the  right  to  make 
choices about their medical care or research participation and to be provided 
with all available information relevant to such decisions. A person must do more 
than express agreement or comply with a proposal. He or she must authorize it 
through an act of informed and voluntary consent. Consent occurs if and only if a 
patient or research subject, with substantial understanding, and in the absence 
of  substantial  control  by  others,  intentionally  authorizes  a  physician  or 
researcher to do something.
32 
The consent discussed above is  being described at the ethical level. There is 
another way of looking at consent – one that refers to the rules of consent that 
determine legally or institutionally valid consent. A legally valid consent may not 
be exactly the same as autonomous authorization within an ethical framework; 
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rather,  it  is  a  valid  authorization  within  the  framework  of  legal  regulations. 
Sometimes, a morally or ethically valid consent is not a legally valid one. For 
example, different countries have various legal ages of consent to surgery. If the 
legal  age  of  consent  is  twenty  in  a  certain  country,  although  an  average 
individual, aged nineteen is capable of understanding relevant information and 
making an autonomous choice to agree to it, this choice cannot be seen as a 
legally  valid  consent.  Nonetheless,  it  could  be  argued  to  be  a  substantially 
autonomous  authorization.  Thus,  a  legally  valid  consent  is  a  sufficiently 
autonomous authorization under the operative legal regulations. Current legal 
rules  and  ethical  guidelines  concerning  medical  treatment  and  biomedical 
research  are  all  based  on  this  meaning  of  consent;  that  is,  a  legally  valid 
autonomous  authorization  from  a  patient  or  a  participant  to  certain  medical 
interventions or research. Consent, when discussed further in this thesis, refers 
to legally valid consent. 
The principles of autonomy and consent are inherent in the civil and political 
rights and freedoms protected by international human rights law, such as the 
European  Convention  for  the  Protection  of  Human  Rights  and  Fundamental 
Freedoms (ECHR)
33 and the International Covenant on Civil and Political Rights  
(ICCPR),
34 domestic law, such as the Human Rights Act 1998
35 and pre-existing 
common law in the UK.  
At the level of international human rights law, these principles are expressed in 
both implicit and explicit ways. The ECHR protects a person ‘s  freedom  to 
determine how to live her/his own life through a number of articles including 
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freedom of expression and religion, the right to life and liberty of the person 
and  respect  for  private  life,  which  all  provide  for  respect  for  individual 
autonomy.  In addition, although Article 3 of the ECHR which prohibits ‗torture 
or inhuman or degrading treatment or punishment‘
36 does not directly refer to 
medical treatment, the European Commission of Human Rights pointed out in X v 
Denmark that ‗medical treatment of an experimental character and without the 
consent of the person involved may under certain circumstances be regarded as 
prohibited by Article 3.‘
37 What is more, Article 7 of the ICCPR, which is the 
equivalent article of Article 3 of the ECHR, noted specifically that ‗In particular, 
no-one  shall  be  subjected  without  his  free  consent  to  medical  or  scientific 
experimentation.‘
38 
At the level of UK domestic law, common law also explicitly includes the need 
for consent in the medical context. For example, in the case of Re T, all three 
judges in the Court of Appeal supported patient autonomy. They noted that: 
[Lord Donaldson MR]: An adult patient who, like Miss T., suffers from 
no  mental  incapacity  has  an  absolute  right  to  choose  whether  to 
consent to medical treatment, to refuse it or to choose one rather 
than another of the treatments being offered.… This right of choice is 
not  limited  to  decisions  which  others  might  regard  as  sensible.  It 
exists  notwithstanding  that  the  reasons  for  making  the  choice  are 
rational, irrational, unknown or even non-existent.
39 
[Butler-Sloss LJ]: A man or woman of full age and sound understanding 
may  choose  to  reject  medical  advice  and  medical  or  surgical 
treatment either partially or in its entirety. A decision to refuse 
medical treatment by a patient capable of making the decision does 
not have to be sensible, rational or well-considered…
40 
[Staughton LJ]: An adult whose mental capacity is unimpaired has the 
right to decide for herself whether she will or will not receive medical 
or surgical treatment, even in circumstances where she is likely or 
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even certain to die in the absence of treatment. Thus far the law is 
clear.
41 
Furthermore, in t he case of  Airedale  NHS  Trust  v  Bland,  the House of Lords 
affirmed the principles of autonomy and consent as following: 
… it is established that the principle of self-determination requires 
that respect must be given to the wishes of the patient, so that if an 
adult  patient  of  sound  mind  refuses,  however  unreasonably,  to 
consent  to  treatment  or  care  by  which  his  life  would  or  might  be 
prolonged, the doctors responsible for his care must give effect to his 
wishes, even though they do not consider it to be in his best interests 
to do so…
42 
In the case of St George’s Healthcare NHS Trust v SR. v Collins Ex p. S, the Court 
of Appeal considered and re-stated the principle as follows: 
…how can a forced invasion of a competent adult‘s body against her 
will even for the most laudable of motives (the preservation of life) 
be  ordered  without  irremediably  damaging  the  principle  of  self-
determination? When human life is at stake the pressure to provide an 
affirmative answer authorising unwanted medical intervention is very 
powerful.  Nevertheless  the  autonomy  of  each  individual  requires 
continuing protection even, perhaps particularly, when the motive for 
interfering  with  it  is  readily  understandable,  and  indeed  to  many 
would appear commendable…
43 
These statements clearly addressed the significance of individual autonomy in 
the  medical  context  and  illustrated  recognition  of  the  need  for  consent  by 
English courts. Since the rules of consent in relation to medical research are 
similar to those regulating medical treatment, in the next section, the general 
rules of legally valid consent to treatment will be addressed in more detail. 
2.1.3 General Rules of Medical Consent 
Aside from the ethical need for consent, there is also a need to consider the 
legal purpose of consent. Generally speaking, most forms of medical treatments 
involve physical interventions on the patient, even if only an initial examination 
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and tests. A legally valid consent relieves healthcare professionals of liability for 
battery, trespass or assault under the laws of both crime and tort.
44 However, in 
the criminal setting, victims  generally  cannot  give a legally valid   consent to 
bodily harm. This was made clear in the case  of R v Brown, in which the court 
held  that  the  consent  of  men  to  sado-masochistic  sexual  activities  was  not 
capable  of  obviating  the  criminal  liability  of  the  actors.
45  Therefore,  if  a 
patient‘s  consent  is  capable  of  protecting  healthcare  professionals  from 
prosecutions  for  medical  interventions  involving  actual  bodily  harm,  medical 
interventions must be seen as an exception to the general criminal law. This has 
been accepted by UK courts. For example, in R v Brown, Lord Templeman noted 
that  ‗[S]urgery  involves  intentional  violence  resulting  in  actual  or  sometimes 
serious bodily harm but surgery is a lawful activity.‘
46 In Airedale NHS Trust v 
Bland Lord Mustill said that:  
…bodily  invasions  in  the  course  of  proper  medical  treatment  stand 
completely outside the criminal law. The reason why the consent of 
the patient is so important is not that it furnishes a defence in itself, 
but  because  it  is  usually  essential  to  the  propriety  of  medical 
treatment.
47 
These statements point out that appropriate surgery has its own justification as 
an exception to the general crimin al law.  This  means  that  normal  medical 
procedures performed to an appropriate standard with the patient‘s consent will 
not be criminal offences. 
In the non-criminal setting, medical intervention without legally valid consent 
can be seen as battery (assault in Scotland) or negligence. A battery occurs when 
there is any touching without a legally valid consent. Early case law in the US, 
such as Mohr v. Williams,
48 accepted that no matter whether or not the touching 
is  hostile,  a  battery  has  been  constituted  by  touching  without  legally  valid 
consent from the patient. In this case, an ear specialist, Williams, performed 
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surgery on Mohr‘s right ear with her consent. After Williams began performing 
the operation he decided that Mohr‘s left ear rather than her right ear required 
surgery.  Although  the  condition  was  not  life  threatening.  Williams  operated 
successfully on the left ear without having received permission from Mohr. Mohr 
sued in battery and was successful. The court  held that the physician should 
have obtained the consent of the patient before operating on the  other ear. 
However, in the case of Wilson v Pringle
49 in the UK, the Court of Appeal held 
that in order to constitute a battery, the touching must be ‗hostile‘. The main 
consideration is that there is generally acceptable physical touching in ordinary 
life, such as physical touching in crowded stores. In the medical context, since 
healthcare  professionals‘  intention  in  providing  medical  treatment  is  almost 
always  to  benefit  their  patients,  it  could  be  argued  that  healthcare 
professionals‘  actions  cannot  be  seen  as  battery  under  the  ‗hostile‘  touching 
condition, although this point has not been considered by UK courts. In some 
cases where health care professionals have been successfully sued for battery, 
they  had  conducted  unnecessary  treatment.  For  example,  in  the  UK  case, 
Appleton v Garrett,
50 the judge held that the dentist , Garrett, in order to gain 
personal profit,  deliberately  conducted  unnecessary  treatment  on Appleton, 
while deliberately misleading Appleton that the treatment was necessary, since 
he knew that otherwise  Appleton would not have consented to  it. The consent 
Appleton had provided was not, therefore, based on  the truth about the need 
for treatment and was accordingly not a legally valid consent. The court found 
Garrett liable in battery. 
However, there are some medical treatments which do not require physical 
touching, such as when a doctor prescribes a drug. Given that the essence of 
battery is physical touching, battery is not an appropriate legal action in these 
cases if they take place without legally valid consent. In addition, there are 
some cases where the patient has given her/his consent to a certain medical 
intervention, but the process of obtaining consent is flawed to some extent, 
such as where the risks of this medical intervention have not been disclosed 
completely or adequately. In these cases, negligence would be the only available 
legal avenue for redress. The differences between the actions of battery and 
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negligence were stated clearly in the UK case of Chatterton v Gerson
51 which 
will be considered further below. Generally, if a person is competent and 
consent is given voluntarily, then once a person has given consent in the 
knowledge of the broad nature of the intervention, they have given a legally 
valid consent. Thus, if there has been inadequate information disclosure about 
risks, the consent is still legally valid, so there can be no action for battery, but 
the person performing the intervention may be able to be sued for negligence. 
The essential elements of a legally valid consent that will avoid liability for both 
battery and negligence on the part of the person performing medical procedures 
can be summarized as follows: competence, adequate information disclosure 
and voluntariness. 
(1) Competence: this term means the ability to perform a task. In the context 
of  medical  decisions,  competence  is  the  capacity  that  a  patient  must 
understand  both  the  information  presented  and  its  relevance,  and  the 
reasonably foreseeable consequences of  her/his  decision, as well as  to 
make a choice on this decision. Faden and Beauchamp argued that the 
function of a competence judgement is to ‗distinguish persons from whom 
consent should be solicited from those from whom consent need not or 
should not be solicited.‘
52 
There  are  two  requirements  for  competence:  1)  the  capacity  to 
understand relevant information and the potential risks of harm; 2) the 
capacity to make the decision as to whether or not to authorize a certain 
medical intervention. This capacity includes physical, psychological and 
legal  requirements.  Thus,  consent  must  be  given  by  a  person  who  is 
deemed  to  be  legally  capable  of  consenting.  The  Mental  Capacity  Act 
2005,
53 which applies in England and Wales, noted that a person cannot be 
seen as competent to make decisions for herself/himself if s/he is unable: 
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(a) to understand the information relevant to the decision, 
(b) to retain that information, 
(c) to use or weigh that information as part of the process of 
making the decision, or 
(d)  to  communicate  his  decision  (whether  by  talking,  using 
sign language or any other means).
54 
Although there is a presumption that an adult is competent,
55 in practice, 
most judgements on competence can only be  made in specific situations. 
A person can  be capable of performing some tasks at one time,  such as 
making decisions about proposed medical treatment, while not capable of 
accomplishing the same tasks at another time.
56 For example, in a UK case, 
Re  T,  Lord  Donaldson  MR  highlighted  the  complexity  of  making  a 
judgement on capacity as follows: 
Doctors  faced  with  a  refusal  of  consent  have  to  give  very 
careful and detailed consideration to the patient's capacity to 
decide at the time when the decision was made. It may not be 
the simple case of the patient having no capacity because, for 
example, at that time he had hallucinations. It may be the 
more difficult case of a temporarily reduced capacity at the 
time when his decision was made. What matters is that the 
doctors  should  consider  whether  at  that  time  he  had  a 
capacity  which  was  commensurate  with  the  gravity  of  the 
decision which he purported to make. The more serious the 
decision, the greater the capacity required.
57 
Thus, competence cannot be evaluated without  knowledge of  the exact 
situation. Generally,  in  respect of medical interventions, the  following 
requirements are essential to competence: capa city  to understand  the 
proposed  interventions; capacity  to weigh its risks and benefits;  and 
                                                                                                                             
Convention on the International Protection of Adults signed at the Hague on 13th January 2000. 
It aims to provide a comprehensive framework for decision-making on behalf of adults aged 16 
and over who lack capacity to make decisions on their own behalf in England and Wales. The 
full text of Mental Capacity Act 2005 can be seen on the official website of UK government, 
available on http://www.legislation.gov.uk/ukpga/2005/9/contents, last visited 2010-11-10.   
54 Ibid., S 3(1). 
55 Re MB (Medical Treatment) (Court of Appeal) [1997] 2 FLR 426, at 436. 
56 Ibid., at 289-290. 
57 See supra note 39, at 113. Chapter 2 
Harms in Human Population Genetic Research    47 
 
capacity to make an autonomous decision based on relevant knowledge 
and information.
58 
(2) Adequate Information Disclosure: this refers to the duty of the clinician to 
inform the patient of the nature of the proposed procedures and provide 
information relevant to the medical intervention, before seeking consent. 
The  European  Convention  on  Human  Rights  and  Biomedicine  (ECHRB)
59 
highlights that a patient should be given  ‗appropriate information as to 
the purpose and nature of the intervention as well as on its consequences 
and risks.‘
60 The Explanatory Report on the ECHRB
61 emphasized that the 
information provided: 
…must be sufficiently clear and suitably worded for the person 
who is to undergo the intervention. The patient must be put 
in  a  position,  through  the  use  of  terms  he  or  she  can 
understand, to weigh up the necessity or usefulness of the aim 
and  methods  of  the  intervention  against  its  risks  and  the 
discomfort or pain it will cause.
 62 
The disclosure of relevant information is essential to the rules of consent, 
because  adequate  relevant  information  is  the  basis  for  the  patient  to 
make autonomous choices.
63 Ethically, if patients have a right to make 
decisions about proposed procedures, they must also have  the right to be 
told what they need to know in  order to make an informed assessment 
before deciding what to do. Thus, if they do not know all of the relevant 
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information,  their  decision  to  give  or  refuse  consent  is  problematic. 
Therefore, information disclosure is vital in the medical consent. 
Having noted the significance of information disclosure to consent, it is 
necessary to address the legal standard for information disclosure. The 
general  principle  of  information  disclosure  in  UK  law  was  set  out  in 
Chatterton v Gerson by Bristow J who said that  
In my judgment once the patient is informed in broad terms of 
the nature of the procedure which is intended, and gives her 
consent, that consent is real, and the cause of the action on 
which  to  base  a  claim  for  failure  to  go  into  risks  and 
implications  is  negligence,  not  trespass.  Of  course  if 
information  is  withheld  in  bad  faith,  the  consent  will  be 
vitiated by fraud. Of course if by some accident, as in a case 
in the 1940‘s in the Salford Hundred Court where a boy was 
admitted  to  hospital  for  tonsilectomy  and  due  to 
administrative error was circumcised instead, trespass would 
be the appropriate cause of action against the doctor, though 
he was as much the victim of the error as the boy. But in my 
judgment  it  would  be  very  much  against  the  interests  of 
justice if actions which are really based on a failure by the 
doctor to perform his duty adequately to inform were pleaded 
in trespass.
 64 
This principle was approved by a further two cases: Hills v Potter
65 and 
Sidaway v Bethlem Royal Hospital Governors.
66 It creates two different 
levels of information disclosure   one to avoid liability for b attery, the 
other to avoid liability for negligence.   This approach has been criticized 
for several reasons, such as that it ‗reduces the role of battery in English 
law,‘
67  it  ‗excludes  other  relevant  information  such  as  alternative 
treatment,  benefits  of  the  proposed  treatment  and  advice  on  the 
underlying ailment‘,
68 and that there is ‗no inherent difference between 
information as to the nature of a procedure and the information as to its 
risks and consequences.‘
69 Nevertheless, the current law is that once the 
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broad  nature  of  the  procedure  has  been  disclosed  to  the  patient, 
negligence  is  the  only  possible  legal  claim.  Thus,  the  specific  level  of 
information disclosure under the current law of negligence needs to be 
explored. There are several options that could be considered when setting 
a legal standard.  
The  subjective  standard  of  disclosure  focuses  on  what  is  of  specific 
interest to a particular individual. The justification for this standard was 
provided by Justice Stanley Mosk in the US case Cobb v Grant
70: 
A  medical  doctor,  being  the  expert,  appreciates  the  risks 
inherent  in  the  procedure  he  is  prescribing,  the  risks  of  a 
decision not to undergo the treatment, and the probability of 
a  successful  outcome  of  the  treatment.  But  once  this 
information has been  disclosed, that aspect of the doctor‘s 
expert function has been performed. The weighing of these 
risks against the individual subjective fears and hopes of the 
patient is not an expert skill. Such evaluation and decision is a 
non-medical judgment reserved to the patient alone.
71 
The subjective standard requires the discovery of the interests of  each 
particular patient and the use of this information as a part of disclosure, 
so it  is potentially time -consuming.  Given the limited time in medical 
practice available to make disclosure,  although this approach is probably 
the standard which can provide  a person with  the maximum information 
s/he  needs  to  make  an  autonomous  choice,  it  would  be  extremely 
difficult to meet. Therefore, generally, there are two  further alternative 
standards of information disclosure regarding medical interventions that 
could be required by law: a prudent patient standard (reasonable patient 
standard) and a prudent doctor (professional practice) standard. 
Under the prudent patient standard , which is applied in some States in 
the US, the law would require doctors to disclose all  of the information 
which would be considered relevant by a reasonable patient.  This was 
proposed in the  US  case of  Salgo  v  Leland  Stanford  Jr.  Univ.  Bd.  of 
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Trustees.
72 In this case,  a patient, Martin Salgo, awoke paralyzed after 
aortography, having never been informed that such a risk existed. He sued 
the physician for negligence in performance  of the procedure and failing 
to warn of the risk of paralysis. The court noted that the physician has the 
duty to disclose  ‗any facts which are necessary to form the basis of an 
intelligent consent by the patient to proposed treatment,‘ but that ‗in 
discussing  the  element  of  risk  a  certain  amount  of  discretion  must  be 
employed  consistent  with  the  full  disclosure  of  facts  necessary  to  an 
informed consent.‘
73 Thereafter, the standard was developed in another 
influential  case,  Canterbury  v  Spence.
74  In  this  case,  the  patient 
underwent a laminectomy for serious back pain. After this ope ration, he 
fell off his hospital bed and then suffered major paralysis. He sued the 
physician claiming that he had  not informed him  that there was  about a 
1% risk of paralysis after a laminectomy. The court said as follows: 
True consent to what happens  to one‘s self is the informed 
exercise  of  a  choice,  and  that  entails  an  opportunity  to 
evaluate  knowledgeably  the  options  available  and  the  risks 
attendant  upon  each.  The  average  patient  has  little  or  no 
understanding of the medical arts, and ordinarily has only his 
physician to whom he can look for enlightenment with which 
to reach an intelligent decision. From these almost axiomatic 
considerations springs the need, and in turn the requirement, 
of a reasonable divulgence by physician to patient to make 
such a decision possible.
75 
This statement made it clear that since the aim of information disclosure 
is to provide relevant information to patient s to enable them to  make 
decisions about their medical treatment, the disclosure should be able to 
be  understood  by  an  average  patient  who  has  little  or  no  medical 
knowledge. After this case, the reasonable patient standard has gradually 
been  accepted  by courts in a number of countries.
76   In the UK ,  this 
standard was also accepted by Lord Scarman in the landmark UK case  of 
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Sidaway v Bethlem Royal Hospital Governors. In this case, Lord Scarman 
noted as follows: 
The  doctor‘s  duty  arises  from  his  patient‘s  rights.  If  one 
considers the scope of the doctor‘s duty by beginning with the 
right of the patient to make his own decision whether he will 
or will not undergo the treatment proposed, the right to be 
informed  of  significant  risk  and  the  doctor‘s  corresponding 
duty are easy to understand: for the proper implementation of 
the right requires that the doctor be under a duty to inform 
his patient of the material risks inherent in the treatment.
77 
Despite  this,  however,  the  other  Law  Lords   held  that  the  question 
whether an omission to warn a patient of inherent risks of proposed 
treatment  constituted  a  breach  of  a  doctor‘s  duty  of  care  was  to  be 
determined by applying the Bolam principle, which is also known as the 
prudent  doctor,  or  professional  practice,  standard.  This  principle  was 
established  in  the  case  of  Bolam  v  Friern  Hospital  Management 
Committee.
78 In this case, the judge set out the principle that a doctor is 
‗not guilty of negligence if he has acted in accordance with a practice 
accepted as proper by a responsible body of medical men skilled in that 
particular  art.‘
79  Thus,  in  Sidaway  the  majority  did  not  share  Lord 
Scarman‘s view and did not support it. However, it has been considered 
more  favourably  in  Commonwealth  jurisdictions.  For  example,  in  an 
Australian case, Rogers v Whittaker,
80 Whittaker did not disclose to Rogers 
that an operation to correct the sight of  her almost blind right eye ha d 
the potential risk to cause her left eye to lose sight, which would lead to 
total blindness. The High Court of Australia considered both  the Sidaway 
case
81 and  Canterbury  v.  Spence,
82 then applied the reasonable patient 
standard and explained the reasons for doing so as follows: 
The law should recognise that a doctor has a duty to warn a 
patient of a material risk inherent in the proposed treatment; 
                                         
77 See supra note 66, at 888. 
78 Bolam v Friern Hospital Management Committee [1957] 1 W.L.R. 582. 
79 Ibid., at 587. 
80 Rogers v Whittaker (1992) 175 CLR 479. 
81 See supra note 66. 
82 See supra note 74. Chapter 2 
Harms in Human Population Genetic Research    52 
 
a  risk  is  material  if,  in  the  circumstances  of  the  particular 
case, a reasonable person in the patient‘s position, if warned 
of the risk, would be likely to attach significance to it or if 
the medical practitioner is or should reasonably be aware that 
the particular patient, if warned of the risk, would be likely 
to  attach  significance  to  it.  This  duty  is  subject  to  the 
therapeutic privilege.
 83 
In the UK, however, in the Sidaway case, Lord Diplock gave the Bolam 
principle a wide application as follows: 
…no convincing reason has in my view been advanced before 
your Lordships that would justify treating the Bolam test as 
doing anything less than laying down a principle of English law 
that is comprehensive and applicable to every aspect of the 
duty of care owed by a doctor to his patient in the exercise of 
his healing functions as respects that patient.
84 
In addition,  Lord Bridge,  Lord Keith and Lord Templeman,  although 
accepting  that  the  risks  of  certain  medical  intervention s  should  be 
evaluated  with  reference  to  the  specific  situation  of  the  patient ‘s 
subjective beliefs, fears and hopes, not expert skill, still held that the 
level of disclosure should be decided based on medical evidence, unless ‗a 
patient‘s  right  to  decide  whether  to  consent  to  the  treatment  was  so 
obvious that no prudent medical man could fail to warn of the risk save in 
emergency or some other sound clinical reason for non-disclosure.‘
85 Thus, 
the  English  courts  applied  a  medical  professional  practice  principle  to 
information  disclosure.  This  requires  disclosure  of  information  that  the 
medical  professional,  supported  by  other  medical  opinion,  considers 
relevant. 
However, since Sidaway, the Bolam test has been refined. In the case of 
Bolitho v City and Hackney HA,
86 the House of Lords modified the  Bolam 
test, although not in the context of information disclosure. Lord Browne-
Wilkinson held: 
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…in my view, the court is not bound to hold that a defendant 
doctor escapes liability for negligent treatment or diagnosis 
just  because  he  leads  evidence  from  a  number  of  medical 
experts  who  are  genuinely  of  opinion  that  the  defendant's 
treatment  or  diagnosis  accorded  with  sound  medical 
practice.…the court has to be satisfied that the exponents of 
the body of opinion relied upon can demonstrate that such 
opinion has a logical basis. In particular in cases involving, as 
they so often do, the weighing of risks against benefits, the 
judge before accepting a body of opinion as being responsible, 
reasonable or respectable, will need to be satisfied that, in 
forming their views, the experts have directed their minds to 
the  question  of  comparative  risks  and  benefits  and  have 
reached a defensible conclusion on the matter.
87 
This statement showed that the courts still have the right and the duty to 
critically analyse  the basis of the expert witnesses‘ evidence to ensure 
that the opinion itself is reasonable, not just that the experts are suitably 
qualified and credible, although Lord Browne-Wilkinson emphasised that 
‗it will very seldom be right for a judge to reach the conclusion that views 
genuinely held by a competent medical expert are unreasonable.‘
88  
In  addition,  in  Pearce  v  United  Bristol  Healthcare  NHS  Trust,
89  the 
standard of risk disclosure required to enable   the  patient  to decide 
whether to accept the  doctor‘s  advice  was  considered.  The  consultant 
obstetrician in this case suggested to the patient, who was pregnant and 
had  gone  past  the  expected  date  of  delivery  and  was  extremely 
concerned for the safety of her fetus, that the safest course was to allow 
labour to begin naturally, but did not disclose that there was a small (0.1–
0.2 per cent) risk of stillbirth. The risk unfortunately materialised. The 
woman sued the doctor for failure to disclose the risk. Although her claim 
was rejected both at first instance and by the Court of Appeal, Lord Woolf 
MR‘s judgment did argue that: 
…if there is a significant risk which would affect the judgment 
of a reasonable patient, then in the normal course it is the 
responsibility  of  a  doctor  to  inform  the  patient  of  that 
significant  risk,  if  the  information  is  needed  so  that  the 
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patient can determine for him or herself as to what course he 
or she should adopt.
90 
This statement  appeared  to advance the cause of the  prudent  patient 
standard. This more patient-centred trend has been continued in more 
recent cases. For example, in  Wyatt v Curtis,
91 Sedley LJ suggested that 
Lord  Woolf‘s  explanation  on  Lord  Bridge‘s  statement  in  Sidaway  on 
whether or not a risk is ‗substantial‘ or ‗grave‘ should be considered from 
the prospective of the patient not the doctor. He noted that 
Lord  Woolf‘s  formulation  refines  Lord  Bridge‘s  test  by 
recognising  that  what  is  substantial  and  what  is  grave  are 
questions on which the doctor‘s and the patient‘s perception 
may differ, and in relation to which the doctor must therefore 
have regard to what may be the patient‘s perception. To the 
doctor, a chance in a hundred that the patient‘s chickenpox 
may  produce  an  abnormality  in  the  foetus  may  well  be  an 
insubstantial chance, and an abnormality may in any case not 
be  grave.  To  the  patient,  a  new  risk  which  (as  I  read  the 
judge‘s appraisal of the expert evidence) doubles, or at least 
enhances,  the  background  risk  of  a  potentially  catastrophic 
abnormality  may  well  be  both  substantial  and  grave,  or  at 
least sufficiently real for her to want to make an informed 
decision about it.
92 
In another case, Chester v Afshar,
93 Lord Steyn explicitly rejected medical 
paternalism as follows: 
A surgeon owes a legal duty to a patient to warn him or her in 
general  terms  of  possible  serious  risks  involved  in  the 
procedure. The only qualification is that there may be wholly 
exceptional cases where objectively in the best interests of 
the patient the surgeon may be excused from giving a warning. 
This is, however, irrelevant in the present case. In modern 
law medical paternalism no longer rules and a patient has a 
prima facie right to be informed by a surgeon of a small, but 
well established, risk of serious injury as a result of surgery.
94 
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Although  Lord  Steyn‘s  statement  did  not  clearly  indicate  whether  the 
issue of determining if a risk is significant should be decided by the view 
of the patient, his rejection of medical paternalism could be viewed as 
evidence of the trend towards acceptance of a prudent patient standard 
in the UK. In another more recent case, Birch v University College London 
Hospital NHS Foundation Trust,
95 the patient, had been warned of the 1% 
risk of stroke of undertaking catheter angiography,  but was not informed 
that there was an alternative procedure, a MRI scan, which has no risk of 
stroke. According to expert witnesses  on behalf of the defendants , the 
doctor‘s  duty  was  merely  to  disclose  the  risks  relevant  to  catheter 
angiography,  which  had  been  done  properly.  However,  Mr  Justice 
Cranston agreed with Mrs Birch that the prudent doctor standard was not 
logically reasonable in this case. He firmly agreed with Lord Woolf MR‘s 
statement that the doctor‘s duty to inform of ‗significant risks‘ would not 
be discharged until the patient was made aware that fewer or no risks 
were associated with another available treatment. He then argued that 
although  expert  witnesses  insisted  the  doctor  has  fulfilled  the  duty  of 
disclosure, the  failure to discuss these  comparative risks ‗could not be 
described  in  law  as  reasonable,  responsible  or  logical.‘
96  Therefore, 
although  the  judgment  of  Sidaway  is  still  not  directly  overruled,  this 
(albeit limited) movement towards the acceptance of a prudent patient 
standard is, therefore, a continuing trend in English law, which may be 
welcomed in its potentially greater respect for patient autonomy. 
(3) Voluntariness:  this  refers  to  the  patient‘s  right  to  come  to  a  decision 
freely,  without  undue  influence,  such  as  force,  coercion  or 
manipulation.
97 In general, coercion means  that ‗one party intentionally 
and  successfully  influences  another  by  presenting  a  credible  threat  of 
unwanted and avoidable harm so severe that the person is unable to resist 
acting  to  avoid  it.‘
98  Manipulation  refers  to  several  forms  of  undue 
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influence  that  are  neither  coercion  nor  reasonable persuasion.
99 At  the 
ethical  level,  voluntariness  indicates  that  an  individual  can  make 
decisions regarding his or her treatment free from overwhelming external 
pressure  and is exercising   the right to self -determination. However, in 
medical interventions, external influence by those performing them may 
be  a  factor  in  the  person‘s  decision  to  give  consent.  For  example,  a 
patient may refuse to undergo certain medical procedures for reasons of 
fear  or  false  belief,  but  s/he  may  agree  to  undergo  this  medical 
intervention following persuasion from the physician. In this case, it may 
well be the case that the patient‘s consent is given voluntarily, if this 
influence is not seen as improper, although the physician has externally 
influenced  the  patient‘s  decision.  Thus,  the  boundary  of  ‗undue 
influence‘  is  a  significant  issue  in  the  evaluation  of  valid  consent  and 
should be considered carefully. 
In UK case law, the voluntariness of patient involvement was considered 
in the case of Re T (Adult: Refusal of Medical Treatment).
100 In this case, 
Miss T a woman injured in a car accident when 34 weeks pregnant,  told 
medical staff that she refused to consent  blood transfusion which might 
be  necessary  following a  Caesarean  section. She refused blood , after 
being alone with her  mother, who was a Jehovah‘s Witness. This faith 
does not accept blood transfusions. After Miss T became unconscious, her 
father and boyfriend applied to the court for assistance. The English Court 
of  Appeal  held  that  Miss  T‘s  mother  had  apparently  influenced  the 
decision of the daughter, who was not a Jehovah‘s Witness. The court 
denied the effectiveness of the Miss T‘s refusal of treatment as follows 
…although an adult patient was entitled to refuse consent to 
treatment irrespective of the wisdom of his decision, for such 
a refusal to be effective his doctors had to be satisfied that at 
the time of his refusal his capacity to decide had not been 
diminished by illness or medication or by false assumptions or 
misinformation,  that  his  will  had  not  been  overborne  by 
another‘s influence and that his decision had been directed to 
the situation in which it had become relevant; that where a 
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patient‘s refusal was not effective the doctors were free to 
treat  him in accordance  with  their  clinical  judgment of  his 
best interests…
101 
Although the judge in this case failed to define undue influence in any 
detailed manner, this case illustrates the requirement of voluntariness in 
medical consent in English law. 
In summary, if the decision is made by a patient who meets the requirement of 
competence,  with  adequate  information  disclosure  from  her/his  medical 
professionals and without any form of undue influence, this consent would be 
seen as a legally valid consent. If people have difficulties in providing voluntary, 
informed  consent  arising  from  limitations  of  decision-making  capacity  (e.g. 
children),  or  situational  circumstances  (e.g.  prisoners),  or  because  they  are 
especially  at  risk  of  exploitation  (e.g.  some  under-valued  ethnic  minorities), 
they should be seen as vulnerable and additional scrutiny of their decisions or 
other  protections  would  be  required.
102  Generally,  t he  requirements  and 
standards of medical consent discussed above can be applied to human subjects 
in  biomedical  research;  however,  given the existence  of  some  differences 
between medical treatment and research, there are  additional  specific rules 
concerning consent to take part in research. In the next section, these rules will 
be addressed.  
2.1.4 General Rules of Consent in Medical Research 
It  is  self-evident  that,  from the  standpoint  of promoting  the development  of 
biomedical science and technology, as well as contributing to human knowledge, 
there  is  a  need  for  research  involving  human  subjects.  In  order  to  translate 
biomedical discoveries into practical medical treatment procedures or products, 
research involving human subjects is a necessary step, which offers the prospect 
of better lives for many people.
103 To take this further, some have argued that it 
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is a moral obligation to undertake, support and even to participate in serious 
scientific research.
104 For example, Harris proposes that: 
The argument concerning   the obligation to participate in research  
should  be  compelling  for  anyone  who   believes  there  is  a moral 
obligation to help others, and/or a moral obligation to be just and do 
one‘s  share.  Little  can  be  said  to  those  whose  morality  is  so 
impoverished  that  they  do  not  accept  either  of  these  two 
obligations.
105 
Research involving human subjects is helpful to scientific development,  to the 
benefit of society in general and future patients in particular, so as a member of 
society, Harris considers that every individual should support and participate in 
biomedical research,  at least  if the  research is directed   toward preventing 
serious harm or   providing significant benefits . Although  it  is too extreme   to 
argue that research is a bigger priority than concern for the welfare and rights of 
human subjects, his argument has identified one important distinction between 
biomedical  r esearch  and  medical  treatment.  In  medical  treatment ,  the 
healthcare professional has a number of clear obligations: to seek to  cure the 
patient; to alleviate his or her symptoms and to prevent illness or injury. This  
means  that  medical treatment is  targeted  to benefit the patient   himself or 
herself. However, in the research context, promoting the human subject‘s well-
being is not the primary focus, which is instead the improvement of the well-
being of society and future patients by the creation of generalizable knowledge. 
Research  focuses  on  benefiting  the  public  as  a  whole,  although  it  may  also 
provide benefits to the research participant. The researcher has an obligation to 
ensure  that  the  research  findings  are  valid  and  replicable,  and  this  has 
implications for the design and execution of the research.  
Medical research on human subjects in the UK is currently regulated through a 
combination  of  the  principles  enunciated  in  international  agreements  and 
professional  rules  and  guidance.  There  is  a  general  assumption  that  the 
principles of consent to medical treatment form the foundation of consideration 
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of consent to medical research in the UK, but there is little case law on medical 
research. 
There is no legal definition of medical research in the UK,
106 (although there is a 
definition of a clinical trial) .
107 The ‗Supplementary Guidance Good Practice in 
Research and Consent to Research‘,
108 the professional guidance provided by the 
General Medical Council (GMC),
109 defined medical research as follows:  
Research…  refers  to  an  attempt  to  derive  generalisable  new 
knowledge.  Research  aims  to  find  out  what  is  best  practice  by 
addressing  clearly  defined  questions  with  systematic  and  rigorous 
methods. It includes studies that aim to generate hypotheses as well 
as those that aim to test them.
110  
This definition indicates that a medical researcher‘s primary aim is to benefit a 
broader  population  by  producing  reliable,  statistically  significant  information 
through their medical research, while medical treatment is designed to benefit a 
specific individual, aims to restore the patient‘s health or prevent deterioration. 
The Helsinki Declaration also does not provide an explicit definition of medical 
research, but instead describes it by reference to the purpose of the research:  
The primary purpose of medical research involving human subjects is 
to understand the causes, development and effects of diseases and 
improve  preventive,  diagnostic  and  therapeutic  interventions 
(methods,  procedures  and  treatments).  Even  the  best  current 
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interventions must be evaluated continually through research for their 
safety, effectiveness, efficiency, accessibility and quality.
 111 
Similarly, in the US, the Ethical Principles and Guidelines for the Protection of 
Human  Subjects  of  Research  (the  Belmont  Report)
112 also pointed out  that 
medical treatment, which aims to  provide diagnosis, preventive treatment or 
therapy to particular individuals, encompasses ‗interventions that are designed 
solely to enhance the well-being of an individual patient or client and that have 
a reasonable expectation of success;‘,
113 while medical research, which is usually 
described  in  a  formal  protocol  that  sets  forth  an  objective  and  a  set  of 
procedures designed to reach that objective, is ‗designed to test a hypothesis, 
permit  conclusions  to  be  drawn,  and  thereby  to  develop  or  contribute  to 
generalizable knowledge (expressed, for example, in theories, principles, and 
statements of relationships).‘
114 
The main consideration of a biomedical research design must be to include a 
research question which should be able to be answered reliably and efficiently, 
sufficient numbers of human subjects must be enrolled in a reasonable period, 
and human subjects must comply with their allocated treatment. In theory then, 
the welfare of individual human subjects may be sacrificed to complete these 
targets when there is conflict. However, if researchers ignore the interests and 
well-being of human subjects, it may lead to unacceptable results, such as the 
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medical  experiments  conducted  by  Nazi  doctors  in  German  concentration 
camps
115 during the Third Reich,  and the egregious experimentation undertaken 
in Unit 713
116 in China.  Therefore, the first b asic principle of  the  Nuremberg 
Code
117 highlighted the  importance  of human subjects ‘  voluntariness;  ‗[T]he 
voluntary consent of the human subject is absolutely essential.‘
118 The potential 
research participant ‗should be so situated as to be able to exercise free power 
of  choice,  without  the  intervention  of  any  element  of  force,  fraud,  deceit, 
duress, over-reaching, or other ulterior form of constraint or coercion‘.
119 The 
first principle  placed  the well-being and protection of the individual at the 
centre of research ethics, and highlighted that neither the progress of medical 
science and technology nor potential benefit for society as a whole should be 
the determining factor of the ethics of research involving human beings.  
In addition, compared to medical tre atment, biomedical research  may expose 
human subjects to a degree of additional risk to that inherent in proven medical 
treatment. In the medical treatment setting, the patient takes the treatment for 
his or her health benefit . In the context of biomedical  research, although such 
research  could lead to  potential  benefits to biomedical science and human 
knowledge as a whole, as well as potential benefits to future patients, the direct 
and immediate benefits to participants in biomedical research may be less clear-
cut. In contrast, human subjects may be exposed to a broad array of  risks as a 
result of research participation.  
Moreover, uncertainty is one of  the main features of biomedical research. No 
matter how  much  animal and laboratory research has been con ducted, the 
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effect of biomedical research on human subjects cannot be known. Mason and 
Laurie identify the aim of randomized clinical trials (RCTs) as being ‗to decide 
whether a new drug or other treatment is better than an existing one, or is 
preferable to none at all, the new treatment is given to a group of patients or 
healthy  volunteers  and  not  given  to  a  group  as  similar  a  group  as  can  be 
obtained.‘
120  
Therefore, it may be concluded that since biomedical research involving human 
subjects is a necessary step which may lead to benefits to society as a whole, 
even  though  it  may  cause  uncertain  and  additional  risks  of  harm  to  its 
participants, we should allow it to be conducted.  Nevertheless, we also bear 
responsibility for ensuring that the interests of those who participate in research 
are  understood  and  protected.  In  other  words,  it  could  be  suggested  that 
biomedical research involving human subjects deserves specific rules, distinct 
from those that apply to medical treatment. 
Currently, there are several international declarations and ethical guidelines on 
research  involving  human  subjects,  including:  the  World  Medical  Association 
(WMA)  Declaration  of  Helsinki  (Helsinki  Declaration)
121  which  is  the  most 
important  statement  of  the   principles  guiding  medical  research;  the 
International  Ethical  Guidelines  for  Biomedical   Research  Involving  Human 
Subjects
122  (CIOMS  Guidelines)  drawn  up  by  the  Council  for  International  
Organisation for Medical Sciences (CIOMS) in collaboration with the World Health 
Organisation  (WHO), which sets general standards for the ethical conduct of 
research in countries around world;  the Universal Declaration on Bioethics and 
Human Rights
123, and  the Universal Declaration   on  the  Human Genome and 
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Human  Rights, 
124 both  adopted by  United Nations Ed ucational, Scientific and 
Cultural Organization (UNESCO). In addition, the European regional convention, 
the Convention for the Protection of Human Rights and Dignity of the Human 
Being with Regard to the Application of Biology and Medicine: Convention on 
Human Rights and Biomedicine (Convention on Human Rights and Biomedicine)
125, 
is also an influential document on research involving human subjects. 
According to these international declarations and ethical guidelines, there are 
two basic values  that are central to current ethical and legal frameworks on 
biomedical research: the autonomy of the human subject and the well-being of 
the human subject. In order to protect the autonomy  and well-being of human 
subjects,  t here  are  two  critical  steps  in  determining   whether  biomedical 
research  involving them can be conducted in an ethical   manner: obtaining 
potential subjects‘  valid consent and assessing risks and potential benefits to 
them. These two steps work  at two different levels.  At one level,  individual 
research subjects should be fully informed about the nature, scope, and risks of 
the research, and consent to participation should be voluntary. At another level, 
existing  regulations  require  researchers  to  submit  proposals  for  research 
involving  human  subjects  to  expert  committees,  which  must  judge  those 
proposals  based  on  their  adherence  to  current  legal  regulations  and  ethical 
guidelines for the protection of human subjects, as well as ensuring the validity 
of the process of information disclosure and consent. 
Similar to the rules of consent in medical treatment, in the biomedical research 
context  competence  is  a  precondition  of  valid  consent.  However,  all  of  the 
current international declarations and ethical guidelines provide additional rules 
designed to provide protection for vulnerable populations, for example, human 
subjects who are incompetent to give a valid consent. CIOMS Guideline 9 noted 
that  
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When there is ethical and scientific justification to conduct research 
with individuals incapable of giving informed consent, the risk from 
research  interventions  that  do  not  hold  out  the  prospect  of  direct 
benefit for the individual subject should be no more likely and not 
greater  than  the  risk  attached  to  routine  medical  or  psychological 
examination of such persons. Slight or minor increases above such risk 
may be permitted when there is an overriding scientific or medical 
rationale for such increases and when an ethical review committee 
has approved them.
126 
According to the  Helsinki  Declaration there are three rules   that need to be 
obeyed. Firstly, ‗if the research subject is legally incompetent, then the consent 
has to be given by the legally authorised representative.‘
127 Secondly, there are 
other special protections for these vulnerable people, which are that minors and 
incompetents should not be included in research unless the research is necessary 
to promote the health of the population to which they belong, and the research 
could not be performed on legally competent persons instead. If the minor is 
able to understand the research, his or her assent is necessary in addition to the 
consent of the parents.
128 Thirdly, if the patient is not able to give consent, for 
example because s/he is unconscious, and in the absence of proxy consent, the 
research should be done onl y if the condition that prevents the obtaining of 
informed consent is a necessary characteristic of the research population.
129 
In  the  context  of  biomedical  research  on  competen t  human  subject s, 
voluntariness  is another  fundamental  requirement. As  has been  pointed out 
above, the first principle of  the Nuremberg Code highlighted  that the human 
subjects‘  voluntary  consent  is  an  essential  and  absolute  requirement  for 
biomedical  research.  It  placed  the  individual  human  subject  as  the  decisive 
entity in biomedical research. However, this absolute requirement of individual 
informed  consent  would  mean  that  individuals  who  cannot  provide  consent 
would be excluded from participation, which may lead to some negative effects. 
For  example,  excluding  individuals  from  participation  in  biomedical  research 
might result in losing the opportunity to test new drugs and medical treatments 
which might be relevant to a particular population, such as babies and young 
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children.  What  is  more,  these  individuals  may  also  be  excluded  from  some 
clinical research which might benefit them as individuals.
130 Thus, the absolute 
requirement  of  consent  has  been  reconsidered  by  all  other  i nternational 
declarations and ethical  guidelines for  biomedical research involving human 
subjects. These declarations all highlight the importance of freedom of choice 
and personal  decision-making  in  informed consent, while allow ing  individuals 
who  are not competent  to  be included  in biomedical research under specific 
strict rules to seek to ensure their well-being is not compromised. 
The main distinction between the general rules of consent for medical treatment 
and medical  research is consideration of  the  extent of necessary  information 
disclosure. In comparison with the  legal requirements of information disclosure  
in medical treatment,
131 ethical declarations,  guidelines and  limited  case law 
indicate that in the context of biomedical research involving human subject s, a 
higher  standard  of  information  disclosure  is  required.  Most  international 
declarations and conventions on biomedical research have attempted to describe 
the information  that  needs  to be disclosed by researchers. For example, t he 
Helsinki Declaration noted that: 
In  medical  research  involving  competent  human  subjects,  each 
potential subject must be adequately informed of the aims, methods, 
sources of funding, any possible conflicts of   interest, institutional 
affiliations of the researcher, the anticipated benefits and potential  
risks of the study and the discomfort it may entail, and any other 
relevant aspects of the study…. Special attention should be given to 
the specific information needs of individual potential subjects as well 
as to the methods used to deliver the information.
132 
The UNESCO Universal Declaration on Bioethics and Human Rights noted the duty 
of disclosure as the following:  
Scientific research should only be carried out with the prior, free  and 
informed consent of the person concerned. The information should be 
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adequate,  provided  in  a  comprehensible  form  and  should  include 
modalities for withdrawal of consent.
133 
Similarly,  the  CIOMS  Guidelines,  which  defined  informed  consent  in  the 
biomedical research context as ‗a decision to participate in research, taken by a 
competent  individual  who  has  received  the  necessary  information;  who  has 
adequately  understood  the  information;  and  who,  after  considering  the 
information, has arrived at a decision without having been subjected to coercion, 
undue influence or inducement, or intimidation,‘
134 listed 27 pieces of essential 
information  that  need  to  be  disclosed  to  inform  the  research  subject  ‗in 
language  or  another  form  of  communication  that  the  individual  can 
understand.‘
135  
In addition, the need for a higher standard of information disclosure for medical 
research involving human subjects has also been pointed out in court judgments 
in some countries. For example, in the Canadian case of Halushka v University of 
Saskatchewan,
136 the judge noted the requirement of full  information disclosure 
in biomedical research and explained this as follows 
The duty imposed upon those engaged in medical research to those 
who offer themselves as subjects for experimentation  is at least as 
great as, if not greater than, the duty owed by the ordinary physician 
or surgeon to his patient. The  subject of medical experimentation is  
entitled to a full and frank disclosure of all the facts, probabilities 
and opinions which a reasonable man might be expected to consider 
before giving his consent... Failure to make full disclosure may vitiate 
any consent whether impliedly or expressly g iven; the undisclosed or 
misrepresented facts need not concern matters which directly cause 
the ultimate damage if they are of a nature which might influence the 
judgment upon which the consent is based.
137 
Similarly, in another Canadian case ,  Weiss  v  Solomon,
138 the judge of the 
Superior Court of Quebec noted  that ‗The court must thus conclude that in a 
purely experimental research programme, the doctor must disclose all known 
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risks, including those which are very rare or remote and a fortiori those whose 
consequences would be grave.‘
139 However, in the UK, although medical research 
involving human subjects has been addressed by law in the Medicines for Human 
Use  (Clinical  Trials)  Regulations  2004  and  the  EU  Clinical  Trials  Directive 
2001/20/EC
140 through the requirement to inform clinical trial subjects of ‗its 
nature,  significance,  implications  and  risks  and  appropriately  documented,‘
141 
there  is  no  specific  obligation  set  out  concerning  the  degree  or  standard  of 
information disclosure on the part of researchers. Whether a higher standard of 
information disclosure is required for potential research participants compared 
with patients is therefore uncertain. 
It must also be noted that medical research involving human subjects is a broad 
term  that  encompasses  a  wide  variety  of  research.  It  has  been  described  as 
having  two  categories:  therapeutic  research  and  non-  therapeutic  research. 
Therapeutic research, which includes most clinical trials, can be distinguished 
from non-therapeutic research in that the former has a possibility of immediate 
benefit to the subjects, whereas the latter has no such intended potential.
142 
This distinction has an historical basis, emerging after World War II in order to 
prevent future medical treatment and biomedical research abuses such as those 
committed during the war, under the assumption that research combined with 
patient care could be considered   more ethical, as the patient benefited and 
physicians were  guided  by  the  patient‘s  interests.  Therapeutic  research  may 
benefit the participants as it not only aims to provide scientific knowledge, but 
also aims at healing or improving the participant‘s condition. Non-therapeutic 
research, which can be carried out on both patients and healthy subjects, will in 
all  likelihood  not  be  for  the  benefit  of  the  research  participant  but  for  the 
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benefit of others, such as future patients. The participant would need to accept 
the possibility of adverse effects and health risks, but the potential benefits, 
such as findings in connection with a new treatment, will be for others. While 
the  Helsinki  Declaration  dropped  the  therapeutic/non-therapeutic  research 
distinction in its 2008 version,  it nonetheless  provided separate principles on 
‗clinical  research  combined  with  professional  care.‘  Section  31  of  the 
Declaration  states  that  ‗the  physician  may  combine  medical  research  with 
medical care only to the extent that the research is justified by its potential 
preventive, diagnostic or therapeutic value and if the physician has good reason 
to believe that participation in the research study will not adversely affect the 
health of the patients who serve as research subjects.‘
143 As has already been 
pointed out, there may be reasons to require a higher standard of information 
disclosure  for  medical  research  than  for  medical  treatment.  However,  a 
distinction  may  also  be  made  between  therapeutic  and  non  –therapeutic 
research. For example, in the US case of Whitlock v Duke University,
144 the court 
took  the  view  that  the  standard  of  information  disclosure  in  non-therapeutic 
research is stricter than in therapeutic research. Since the considerations and 
balance  of  interests  are  different,  the  court  concluded  that  the  standard  of 
consent adopted by the Nuremberg Code required a greater degree of disclosure 
where research is considered non-therapeutic, and found the standard of care 
required  for  informed  consent  relating  to  medical  treatment  inapplicable  to 
determine the responsibility for obtaining consent in a non-therapeutic context. 
In non-therapeutic research, the researcher is under a duty to disclose all risks 
which may reasonably be anticipated and not just the ‗usual and most frequent‘ 
risks.
145  The  standard  of  disclosure  in  non -therapeutic  research  requires 
disclosure of ‗the possible effects upon the health and person of the subject.‘
146  
In the current medical ethical and legal frameworks, if these general rules of 
consent to medical research are met, any consent offered would be seen as valid 
and  respectful  of  the  autonomy  of  the  individual.  Apart  from  the  issue  of 
consent to participation, the other main concern of ethical and legal frameworks 
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governing  medical  research  is  that  of  an  assessment  of  the  risks  involved 
compared with the potential benefits. 
2.2 Harms of Research Involving Human Subjects 
2.2.1 Risks of Harm in Medical Research 
A  ‗risk-benefit  assessment‘  or  ‗risk-benefit  ratio‘  is  a  common  expression  in 
biomedical  research  involving  human  subjects.
147  Risk  involv es  both  the 
probability and the magnitude of harms to human research subjects, and cannot 
be  equated simply with the m agnitude of  negative  outcome, such as  serious 
physical injury or death. Under this approach, a proper analysis of risk requires 
consideration of its probability of harm occurring, since a one-in-a-million risk of 
death is likely to be regarded differently to a one-in-ten risk of death.  However, 
magnitude of risk is also significant, so that  a risk of death  would be  viewed 
differently from  a  risk of minimal physical harm.  Human subjects may be 
exposed to a wide spectrum of   risks as a result of participation   in medical 
research.  Weijer  divided  such risks  of harm  into four categories: physical,  
psychological, social, and economic.
148 He described each type of risk briefly as 
follows: 
Physical risks: The research subject may suffer bodily harm - minor or 
serious, temporary or permanent, immediate or delayed  - as a result 
of his or her participation in the study. 
Psychological  risks:  Study  participation  may  affect   the  research 
subject‘s perception of self, cause emotional suffering (e.g., anxiety 
or shame), or may induce aberrations in thought or behaviour. 
Social risks: Research findings, or even study participation itself may 
expose  subjects  to  the  possibility  of  insurance  or  employment 
discrimination, or other forms of social stigmatization. 
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Economic  risks:  Research  subjects  may  directly  or  indirectly  bear 
financial costs related to research participation.
149 
More than one  type of risk may occur in a  single biomedical research protocol 
involving human subject s.  An example provided by Weijer can illustrate this 
clearly. In research  into a new drug for   people with acutely symptomatic 
schizophrenia, although there are  effective  drugs for  this disease at present , 
patients  are  randomly  assigned  to  take  various  types  of  drug:  a  new 
antipsychotic  drug, a standard drug or a  placebo.  These human subjects   are 
treated in a hospital for a period of time, where they are assessed with a variety 
of psychometric scales.
150 In this medical research, since the new drug may have 
serious adverse effects, some of which may even be irreversible, human subjects 
who  take  the  new  drug  may  suffer  physical  harms,  such  as  continuing 
hallucinations or paranoia, and they may be at increased risk of suicide. Human 
subjects who are assigned to the placebo will be deprived of needed treatment  
for a  period of time,  which  may lead to the  deterioration of the  disease. 
Meanwhile,  although  this  is  rare,  participating   in  this  p lacebo-controlled 
research may also lead to psychological harm, such as  emotional suffering 
caused by exacerbation of the ir disease because of the absence of treatment, 
since human subjects may sometimes believe that they are taking a placebo, no 
matter whether they are in fact taking a real medicine.  Due to the existence of 
potential risks of harm caused by randomized trials involving pl acebos, the 
Helsinki Declaration (as amended) required that placebos should only be used in 
very limited circumstances. It noted in Article 32 that: 
The benefits, risks, burdens and effectiveness of a new intervention 
must be tested against those of the best current proven intervention, 
except in the following circumstances: 
The use of placebo, or no treatment, is acceptable in studies where 
no current proven intervention exists; or 
Where for compelling and scientifically sound methodological reasons 
the use of placebo is necessary to determine the efficacy or safety of 
an intervention and the patients who receive placebo or no treatment 
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will not be subject to any risk of serious or irreversible harm. Extreme 
care must be taken to avoid abuse of this option.
151 
Realizing  the  risks of harm  for  human  subjects in biomedical research, a ll 
international declarations and conventions, without exception, declare that the 
welfare of human subjects is the first priority. For example, the Helsinki 
Declaration emphasizes this principle several times in the introduction.  Article 3 
states that ‗[I]t is the duty of the physician to promote and safeguard the health 
of  patients,  including  those  who  are  involved  in  medical  research.  The 
physician‘s knowledge and conscience are dedicated to the fulfilment of this 
duty.‘
152 The Universal Declaration on Bioethics and Human Rights also declares 
the welfare of human subjects as the first priority, and set it as a basic principle 
which  has  to  be  respected.  In  Article  3,  it  states  that  ‗[T]he  interests  and 
welfare of the individual should have priority over the sole interest of science or 
society.‘
153 The  Convention  on  Human  Rights  and  Biomedicine  in  Article  2, 
similarly declares that ‗[T]he interests and welfare of the human being shall 
prevail over the sole interest of society or science.‘
154 In order to ensure the 
welfare  of  human  subjects,  these  international  declarations  and  conventions 
require  the  harm/benefit  assessment  to  weigh  the  merits  of  proposed 
biomedical research and the potential impact on the rights, safety, and welfare 
of  participants.  They  clearly  state  that  the  risk  to  participants  should  be 
justified  by  the  anticipated  benefits  to  them  and/or  society,  through 
risk/benefit  assessments  which  are  concerned  with  the  probabilities  and 
intensity of possible harm balanced against anticipated benefits. The research 
should be designed so that the researcher or research institution ensures that 
the  potential  benefits  and  risks  are  reasonably  evaluated,  and  risks  are 
minimised.  The  assessment  of  risks  and  potential  benefits  requires  a  careful 
appraisal of all available relevant data including, in some cases, alternative ways 
of obtaining the benefits sought in the research. For example, Article 16 of the 
Convention on Human Rights and Biomedicine, which provides special regulations 
for the protection of human subjects in scientific research, urges that it should 
be ensured that: 
                                         
151 See supra note 111. 
152 Ibid, Article 3. 
153 See supra note 123. 
154 See supra note 125. Chapter 2 
Harms in Human Population Genetic Research    72 
 
The  risks  which  may  be  incurred  by  that  person  are  not 
disproportionate  to  the  potential  benefits  of  the  research;  the 
research  project  has  been  approved  by  the  competent  body  after 
independent examination of its scientific merit, including assessment 
of the importance of the aim of the research, and multidisciplinary 
review of its ethical acceptability.
155 
In addition, the first guideline of  the CIOMS Guidelines relates to  risk-benefit 
assessment and risk management. It points out that  
The  ethical  justification  of  biomedical  research  involving  human 
subjects  is  the   prospect  of  discovering  new  ways  of  benefiting 
people‘s health. Such research can be ethically justifiable only if it is 
carried  out  in  ways  that  respect  and  protect,  and  are  fair  to,  the 
subjects  of  that  research  and  are  morally  acceptable  within  the 
communities in which the research is carried out. Moreover, because 
scientifically invalid research is unethical in that it exposes research 
subjects to risks without possible benefit, investigators and sponsors 
must ensure that proposed studies involving human subjects conform 
to generally accepted scientific principles and are based on adequate 
knowledge of the pertinent scientific literature.
156 
This  means that when ,  and only when ,  biomedical research involving human 
subjects provides adequate respect and protection  for their welfare, can it be 
seen  as  ethically  justifiable.   Thus,  providing  adequate  respect   for,  and 
protection  of  the welfare of,  human subjects is also the first priority of  the 
CIOMS Guidelines. Guideline 8  also refers to  risk-benefit assessment and risk 
management. In general, the guideline req uires  that  the  researchers  must 
ensure that potential benefits and risks are reasonably balanced and that risks 
are minimized.
157 In respect to the different aims of therapeutic research and 
non-therapeutic  research,  CIOMS  Guideline  8  sets  distinctive  standa rds  on 
benefit-risk assessment in therapeutic research and non-therapeutic research.
158 
In therapeutic research, since participants are involved in the expectation that 
it will be at least as advantageous to the individuals concerned as normal 
treatment, the risk must be justified ‗in relation to expected benefits to the 
individual  subject.‘
159  This  means  that  the  risks  should  be  less  than,  or 
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approximately  equal  to,  the  risks  of  existing  treatment,  while  the  benefits 
should be better than existing treatment. On the other hand, in non-therapeutic 
research,  which  aims  to  gain  generalizable  knowledge  expected  to  benefit 
society as a whole, risks must be ‗reasonable in relation to the importance of 
the knowledge to be gained.‘
160 
Risk assessment also has a legal basis in some countries. For example, the US 
Common  Rule
161 requires  that  risks to  human  subjects  should be  minimized. 
Furthermore, risks associated  with non-therapeutic  research  as well as being 
minimized must be ‗reasonable in relation  to anticipated benefits, if any, to 
subjects, and the importance of the knowledge that may reasonably be expected 
to result.‘
162 Risks associated with therapeutic research must be in relation to 
the ‗benefits of therapies subjects would receive even if not participating in the 
research.‘
163 
The  example  of  new  drug  research  for  people  with  acutely  symptomatic 
schizophrenia  provided  above  also  indicated  another  type  of  risk:  these 
schizophrenic  patients  may  pose  risks  to  third  parties,  for  instance  if  their 
behaviour is affected leading them to act violently toward others, such as their 
family. If this research is conducted while they are living in their homes, more 
third parties‘ interests could be exposed to risk of harm, such as neighbours, or 
people who may have daily contact with them.  Despite the possibility that there 
may be third parties who could be adversely affected by the research, under the 
current ethical and legal frameworks of biomedical research, only the consent of 
the  human  subject  is  required.  The  interests  of  third  parties  cannot  be 
protected by the rule of consent, which is the core principle in both legal and 
ethical frameworks on medical research. Another legal and ethical requirement 
for  medical  research  is  protecting  the  well-being  of  human  subjects,  which 
through the assessment of the risks and potential benefits of certain medical 
research is the overriding criterion for deciding whether or not certain research 
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should be conducted. Nevertheless, the interests of third parties  may not be 
sufficiently protected by this requirement either. 
Kimmelman  analyzed  the  Tuskegee  Syphilis  case,
164  in  which  a  study   was 
designed to document the natural history of the disease by preventing about 400 
men from obtaining treatment for their late stage syphilis. The men in question 
were told that they were being treated for ‗bad blood‘. Kimmelman illustrated 
that third parties‘ interests were at risk of harm as follows: 
Normally,  late-stage  syphilis  is  not  contagious.  However,  two 
circumstances  surrounding  this  study  suggest  that  family  members, 
children, and the sexual partners of the male subjects may have been 
at  risk  of  contracting  syphilis.  First,  medical  historians  have 
speculated that some of the men in the study might not have been in 
the  late  stage  of  syphilis.  If  so,  they  would  have  been  contagious. 
Second, persons in the early phases of the late stage syphilis are also 
contagious.
165 
In this research, relevant information was not provided to the research subjects, 
but it was  also not provided to their family members or sexual p artners, who 
could  have  been  adversely affected by this research. Under current research 
guidelines, since this   type of  research  would  neither  collect any information  
from or about persons other than the patients, nor would any other persons be 
asked to undergo any interventions relevant to the research, the researcher does 
not need to obtain consent from or provide any relevant information to persons 
other than the research subjects. 
Furthermore, Resnik and Sharp also list some examples of research that ma y 
expose third parties to risks of harm as follows: 
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Vaccine research in which subjects are exposed to a biological agent 
that may pose a health hazard to others who come in contact with 
research  subjects;  studies  that  involve  research  interventions  in 
settings occupied by multiple individuals such as a home, a school, or 
a  community  centre;  research  in  settings  in  which  third-party 
occupants may assume privacy, such as a home; research on mental 
illnesses  associated  with  violent  behaviour  in  which  changes  to 
ongoing treatment programs may present risks to persons living nearby; 
research  on  a  localized  environmental  hazard  that  may  impact  all 
community  residents;  studies  in  which  lactating  women  receive 
experimental medication that may be transmissible through nursing. 
166 
In all of these types of research, certain third parties may suffer harm caused by 
the research, but their opinions would not be sought. Although the risks to third 
parties might be considered as  part of the review of the effects of the study  in 
general, current guidelines and regulations do not explicitly require IRBs/RECs to 
address such risks, and many IRBs/RECs tend to limit their deliberations to issues 
and concerns related to the  guidelines and  regulations.
167 Since IRBs/RECs may 
not have sufficient time or appropriate expertise to assess risks to third parties 
in research, especially given the many demands and pressures of ethical review 
work, without such a requirement, it would be rare to  conduct a risk-benefit 
assessment on the interests of third parties. Thus, the interests of third parties 
cannot be protected adequately under current research guidelines and legal 
requirements.  
In summary, expanding knowledge on human health and  the causes of disease, 
as well as promoting the developmen t of biomedical science ,  is important. 
Obtaining the valid consent of human subjects and the assessment of risk s and 
potential  benefits  of  research  are  the  two  main  measures  that  provide 
protection to human subjects. Nevertheless, some types of biomedical research 
may  lead to new challenge s  to the legal and ethical frameworks o f  human 
subject protection, a problem that is particularly acute in the case of genetic 
research, which will be considered in the next section. 
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2.2.2 Concerns Raised by Genetic Research 
According to John Harris: 
It is [human] genetics that is beginning to create a new generation of 
acute and subtle dilemmas that will in the new millennium transform 
the ways in which we think of ourselves and of society. It is genetics, 
bringing both a new understanding of what we are and almost daily 
developing new ways of enabling us to influence what we are, that is 
creating a revolution in thought, and not least in ethics.
168  
The main  thrust of this statement reflect s contrasting thinking on the  genetic 
revolution.  On the one hand, there is the possibility of  benefits that will arise 
from the development of  genetic technology. For example, the Guidelines for 
Human Biobanks and Genetic Research Databases (HBGRDs)
169 of the Organisation 
for Economic Co-operation and Development (OECD) noted that human genetic 
research ‗analysed in conjunction with personal or health data is particularly 
promising  and  will  be  critical  to  improvements  in  the  prevention,  detection, 
diagnosis,  treatment,  and  cure  of  disease  and  for  the  development  of  new 
products and services.‘
170 Another example is the Human Genome Project (HGP), 
which is the most influential genetic research project designed to ‗determine 
the complete sequence of the 3 billion DNA subunits (bases), identify all human 
genes, and make them accessible for further biological study.‘
171 The potential 
benefits of the project have been described as follows: 
Technology and resources generated by the Human Genome Project 
and other genomics research are already having a major impact on 
research  across  the  life  sciences.  The  potential  for  commercial 
development of genomics research presents US industry with a wealth 
of opportunities, and sales of DNA-based products and technologies in 
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the  biotechnology  industry  are  projected  to  exceed  $45  billion  by 
2009.
172 
Given these factors, some public medias asserted that  biology has been widely 
predicted to be the foremost science of the 21st century.
173 Some current and 
potential applications of  genetic research include molecular medicine, energy 
sources  and  environmental  applications ,  r isk  assessment,   bioarchaeology, 
anthropology, evolution, and human migration ,  DNA forensics (identification) , 
agriculture,  livestock  breeding,  and  bioprocessing.
174  This  view  of  genetics 
reflects an optimistic and positive view of human genetic research; namely, that 
it should be promoted and conducted because human genetic research may help 
to unfold the secrets of many human diseases, discover the cures and therapies 
for human suffering, and enrich our knowledge of human origins and evolution.  
On the other hand, there are challenges that may result from human genetic 
research.  Genetic  science  and  technology  have  invoked  significant  debate  on 
ethical and legal concerns. In order to understand the particular concerns raised 
by genetic research, we need to consider the genetic exceptionalism debate and 
its application to the alleged uniqueness of genetic research. 
(1)  The Genetic Exceptionalism Debate 
In 1995, Annas, Glantz and Roche published the article ‗Drafting the Genetic 
Privacy  Act:  Science,  Policy  and  Practical  Considerations‘.
175  This  article 
generated a huge debate on what has been described as genetic exceptionalism. 
Murray, amongst others, has used this term, borrowing from the earlier term 
‗HIV  exceptionalism.‘
176 In  this  debate,  the  target  topic  is  whether  genetic 
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information  is  different  in  kind  from  other  medical  information;  and,  if  so, 
whether this means that genetic information deserves special legal protection. 
Proponents  of  the  special  nature  of  genetic  information  provide  several 
arguments to illustrate it. In an article on genetic privacy, for example, Gostin 
indicated that the analysis of genetic information can identify the most sensitive 
and  personal  attributes  of  an  individual‘s  life.
177  Annas,  Glantz  and  Roche 
maintained  that  genetic  information  is  unique,  and  concluded  that  ‗[t]o  the 
extent that we accord special status to our genes and what they reveal, genetic 
information is uniquely powerful and uniquely personal, and thus merits unique 
privacy protection.‘
178 They provided three reasons why genetic information is 
‗uniquely private or personal information‘:  
(1)  Human  genetic  information  can  be  seen  as  the  ‗future  diary‘  of  human 
beings.
179 This means that genetic information can predict a human being‘s 
probable health future.  In addition,  they argued that genetic information 
describes an important proportion of an individual‘s future and may even 
affect the individual‘s view on the possibility of having a future. Moreover, 
genetic information is written in ‗code‘ and in most situations it remains 
stable and can be stored for a long period of time. As molecular biological 
technology  advances,  more  of  the  code  can  be  uncovered.    As  a  result, 
sensitive information concerning future health probabilities may be learned 
from gene fragments and genetic information that were stored in the past, 
without the permission of the individual who is, or was, its originator. In 
addition, it has been argued that genetic information not only can predict 
future disease, but also human behaviour. There is, for example, an existing 
area of research concerning behavioural genetics which seeks to understand 
both the genetic and environmental contributions to individual variations in 
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human  behaviours.
180 According to this research, genes m ay influence the  
personality  and  behavioural  characteristics  of  human  being s.  This  may 
suggest that genetic information is different from other medical information.  
(2)  Genetic  information  ‗divulges  personal  information  about  one‘s  parents, 
siblings and children.‘
181 An individual inherits half of his or her  genes from 
each of his or her biological parents, and passes half of  these genes to each 
of  his/her  biological  children.  It  means  that  genetic  information  provides 
information about others in addition to the individual from whom samples 
were taken. This does not stop at the door of the family but extends to those 
larger  groups  of  peoples,  such  as  indigenous  people,  minority  people,  or 
people in isolated areas, who share a specific genetic heritage. Thus, they 
argued that the ‗key feature about genetic information is that it is typically 
information about a family, or even … about a larger community not just 
about an individual patient.‘
182 Besides, unlike the use of physical material, 
information can be used at the same time by a great many people for various 
purposes  without  any  loss  or  wastage.  The  comparison  of  knowledge 
contained in a book and genetic information contained in a gene was made 
previously and is relevant here also. For example, if I send a book to a friend 
as a gift, I no longer own the book or have any rights to control it again; 
however, if I have read this book, I can still make use of the knowledge 
gained  from  information  within  it.  In  addition,  my  use  of  this  knowledge 
does not prevent the use of this information by my friend who now owns this 
book.  
(3)  Genetic  information  could  be  a  new  basis  for  discrimination:  ‗…  genetic 
information  and  misinformation  has  been  used  by  governments  …  to 
discriminate viciously against those perceived as genetically unfit to restrict 
their reproductive decisions.‘
183  Genetic discrimination has been defined as 
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‗discrimination against an individual or against members of that individual‘s 
family solely because of real or perceived differences from the  ―normal‖ 
genome in the genetic constitution of that individual.‘
184 It has been argued 
that  individuals  and  their  family  members  might  encounter  genetic 
discrimination  during  any  interaction  with  other  social  institution  that 
provides a benefit or a service, especially in two areas: employment and 
insurance.
185 From the discovery of DNA ‘s double-helix structure in 1951 to 
the completion of the Human Genome Project in 2003, the development of 
genetic  science  and  technology  has  been  given  wide  publicity,  and  the 
potentially  powerful  effects  of  genetic  science  and  technology  have  also 
been predicted, sometimes even overstated. For example,  Francis Collins, 
director of the US National Institutes of Health (NIH) Genome Project, called 
the  Human  Genome  Project  (HGP)  the  ‗Book  of  Life.‘
186  This  kind  of 
expression  could  lead  to  fears  that  scientists  involved  in  this  area  are 
‗playing God‘, with all the negative connotations of that phrase.
187  Resulting 
from the influence of this terminology, and media commentary, the public 
may be concer ned  that  genetic  testing  will  certainly  predict  a  person‘s 
future  diseases,  even  future  behaviours,  such  as  criminal  behaviour.  This 
may  lead  to  or  aggravate  the  potential  risks  of  harms  caused  by  genetic 
research, such as discrimination and stigmatization. 
From the arguments above, we can summarize that the supporters of genetic 
exceptionalism rely on two main considerations.  Firstly, the ability of genetic 
information to predict a person‘s future health status is presumed to be more 
precise than other forms of health information. Secondly, genetic information is 
unique when compared with other health information, in the sense that certain 
types  of  genetic  information  can  be  obtained  from  any  individual,  but  may 
reveal the collective information of a certain family, even a group/community. 
Furthermore, the inappropriate disclosure or misuse of an individual‘s genetic 
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information  could  violate  the  interests  of  his/her  family  members  or 
group/community members.  
Despite this, the opponents of the uniqueness of genetic information argue that 
this  is  an  over-dramatic  view  of  the  significance  of  genes  and  genetic 
information in human life. They suggest that although there is something to be 
said for each of the above arguments, on reflection they are unpersuasive.  
(1) First, they argue, genetic information is ‗neither unique nor distinctive in its 
ability to offer probabilistic peeks into human‘s future health‘.
188 They have 
explained that some other medical information or family history also could 
be used to predict the current and future health status of an individual and 
even his/her kin. For example, Murray argued as follows: 
Many  other  things  afford  equally  interesting  predictions  … 
examples include asymptomatic hepatitis B infections, early 
HIV infection, and even one‘s cholesterol level. These have 
implications for future health that are every bit as cogent and 
sensitive as genetic predispositions.
189 
(2)  Second, Ross has argued that there being a difference between genetic and 
other  medical  information  should  be  ‗rejected  on  the  grounds  that  other 
types  of  health  information  also  have  significant  implications  for  family 
members.‘
190 For example, the fact that a family member or another person 
with very intimate relationships is HIV+ is certainly relevant to other family 
members, some of whom are possibly open to infection, as may be those 
who come into intimate contact with the infected individual.  
(3)  Third, Ross concludes that ‗threats of discrimination and stigmatization will 
exist as long as there are differences and that these differences need not 
have  a  genetic  basis,  as  current  international  conflicts  illustrate‘.
191  In 
addition, Murray argues that the genetic discrimination argument is not a 
convincing one, because: 
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Institutions  and  individuals  can  and  have  used  all  sorts  of 
information,  both  visible  and  occult,  as  the  basis  for 
discrimination…. But it is difficult to make the argument that 
it is fair to discriminate on non-genetic factors but unfair to 
discriminate on genetic ones.
192 
(2)  The Concerns that Arise from Genetic Research 
Despite the differing arguments discussed above, there are several facts that are 
accepted  by  both  sides.  Firstly,  genetic  information  not  only  discloses 
information about a human subject, but also discloses genetic information about 
her/his relatives, and even certain groups and their members. Secondly, genetic 
information not only shows the present situation of human subjects, but also, 
potentially, future information about her/him and her/his relatives, and even 
group members associated with the individual. Thirdly, this future information 
may  be  reasonably  predictable,  although  it  discloses  possibilities  rather  than 
certainties.  It  could,  of  course,  be  argued,  as  above,  that  these  are  not 
characteristics  unique  to  genetic  information,  since  some  types  of  medical 
information,  such  as  family  histories,  also  have  similar  characteristics  and 
potential.
193 In the clinical context, it can be accepted that there is no essential 
difference between genetic information and some other medical information , 
such as family history. This is because, in the clinical context, the analysis o f 
both genetic information and other health information, including family history, 
aims to contribute to an accurate diagnosis for this specific patient. However, in 
the context of genetic research, the situation is different. In fact, family history, 
which refers to the  recollections of illness/disease by family members ,  is 
abstract knowledge, which is not  necessarily accompanied by a   confirmed 
medical diagnosis, thus may be lacking in accurate knowledge about why  these 
members have become ill or died in the absence of a true understanding about 
the pattern of disease in  this family.
194 In contrast, genetic  research in clinical 
care is targeted on identifying the origin and causes of certain diseases. Genetic 
information, which is the object of genetic research, can offer a high degree of 
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specificity in predicting the likelihood of disease in other family members, even 
certain group/community members. 
Therefore, in the context of research, I would contend that genetic information 
does  have  a  uniqueness  which  distinguishes  it  from  other  forms  of  heath 
information, including family history. Under the current individualistic rules of 
consent, if an individual decides to participate in genetic research, the potential 
risks of harm, such as discrimination and stigmatizations based on its negative 
results,  may  be  suffered  by  participants,  her/his  family  members,  even  the 
fellow group members of the participants. Except for the human subject, the 
other family members and group/community members have no chance to make a 
decision about the implications of discoveries about their genetic information, 
and lack protection for their interests.  
Although expressions like ‗coded probabilistic future diary‘ and ‗likely medical 
future‘ can be seen as overstated, some of the views of Annas, Glantz and Roche 
are  valuable;  for  example,  when  they  say  that  compared  to  other  health 
information,  genetic  information  may  have  more  significant  unwanted 
consequences  for  families  and  population  groups.  In  the  context  of  genetic 
research,  compared  to  other  types  of  biomedical  research  involving  human 
subjects, the real risk of harm to the subject of research is the inappropriate 
disclosure or use of negative genetic information, not the risks of harm to the 
physical body of the human subject. There are two problems which arise from 
this distinction. 
Firstly, in the past any harm that arose in biomedical research would almost 
certainly  be  physical harm  to  the participant  and  as  such  would  not  directly 
harm third parties‘ interests or public interests. The samples taken for genetic 
research  usually  are  blood  samples  which  are  no  different  from  the  blood 
samples taken in routine medical examinations, so the physical harms of genetic 
research are slight. However, the potential harms of genetic research appear to 
be associated with the use of, and access to, information. The risks associated 
with the information-rich nature of genetic research have long been apparent, 
such as anxiety, distress, and other psychological harms to subjects who learn Chapter 2 
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that they carry genes that may predispose them to serious medical problems.
195 
The risks of harm caused by genetic research  may also include employment and 
insurance  discrimination,  discov eries  of  mis -attributed  paternity,   altered 
relationships between family members, and   changes in self-perception.  Thus, 
since  these  concerns  had  not  been  the  main  ones  in  traditional  ethical 
frameworks,  beginning in the early 1990s there   emerged an importan t new 
theme in the ethics of biomedical research: namely, that genetic research posed 
the threat of genetic discrimination.
196 
In consideration of  the risks of harm  that may be caused by the discovery and 
use of genetic information, since the Human Genome Project began in 1990 a 
number of national and international   regulations and treaties have emerged 
aiming to  prohibit genetic  discrimination. These policy documents  highlighted 
the fact that genetic information is in need of specific strict regulation, given its 
sensitive and distinctive  properties  which may lead to   a  high  potential for 
discrimination. For example, in the Universal Declaration on the Human Genome 
and Human Rights,
197 UNESCO devised special regulations for the human genome  
and for research subje cts participating in research on it . In addition, some 
countries  also have  enacted legislation prohibiting genetic discrimination   in 
health  insurance .  Two-thirds  of  the   states  in  the  US  have  enacted  laws 
prohibiting genetic discrimination   in employment, an d other states  also  have 
legislation  to  regulate  genetic  discrimination  in  insurance ,  protect  genetic 
privacy,  and  govern  genetic  testing.
198  In  2008,  the  federal  legislation  on 
prohibiting  genetic  discrimination  in  the  US,  t he  Genetic  Information 
Nondiscrimination Act of 2008 (GINA),
199 was signed. Its aim is to prohibit genetic 
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discrimination in employment and health insurance. These regulations show that 
the concerns of legislators have turned to the risks of psychological and social 
harm  in  genetic  research,  in  contrast  to  previous  concerns  about  medical 
research which concentrated on the physical harms to human subjects. 
Secondly, since the genetic information carried by an individual participant is 
shared by her/his blood family, even groups/communities, these potential harms 
could be suffered by the whole family, group/community of  the subject. Any 
harm is not, therefore, limited to the participating individuals. This means that 
the other parties‘ interests and potentially the public interest could be at risk. 
Traditionally, the control of information is exercised by the person to whom the 
information belongs, or to whom it relates. It is widely accepted that health 
care professionals owe an obligation of confidentiality to their patients and that 
only  rarely  should  disclosure  without  a  patient‘s  consent  be  made.  While 
exceptions to the duty exist, in practice no breach should be made lightly or 
without good cause.
200 Similarly, in the context of biomedical research, all of the 
international declarations and   ethical guidelines  highlight the significance of 
maintaining  the  confidentiality and privacy  of  human  subjects  by researchers 
and research institutions. For example, the Helsinki Declaration noted in its first 
principle  that  it  is  the  duty  of  physicians  to  protection  the  privacy  and 
confidentiality of personal   information of research subjects .
201   In addition, 
Guideline 19 of  CIOMS Guidelines is entitled ‗Safeguarding Confidentiality‘. It 
notes that  
The  investigator  must  establish  secure  safeguards  of  the 
confidentiality of subjects‘ research data. Subjects should be told the 
limits,  legal  or  other,  to  the  investigators‘  ability  to  safeguard 
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confidentiality  and  the  possible  consequences  of  breaches  of 
confidentiality.
202  
Medical records are subject to confident iality or privacy laws that, save in 
exceptional circumstances, require permission from the person whose records 
they  are  for  them  to  be  disseminated .
203  All  of  these  regulations  on 
confidentiality and privacy are rooted  in the protection  of the  informational 
security of  the individual who provides the information , as traditionally this is 
the person who would be harmed by unauthorised disclosure.  However, in the 
context of genetic information, control of  the information is more complicated 
because genetic information collected from an individual participant is shared by 
her/his blood relatives,  or sometimes  members of  a particular  group. For 
example, when one family member  decides to participate in genetic research 
and tests positive for a disease-related gene, that person‘s parents, siblings and 
children all have a chance of carrying that same version of the gene. In addition, 
close community members may also carry this disease-related gene. Because of 
this, if research results are revealed in a manner enabling the participant or a 
group to be identified, not only the participant herself/himself, but also her/his 
family members and  members of his or her community  might suffer negative 
effects, such as an insurance company refusing to underwrite a life insurance 
policy unless they agree to be tested and are found not to have this disease-
related  gene.  Nevertheless,  as  I  have  mentioned  above,
204  under  current 
research  guidelines  on  research  involving  human  subject s,  although  family 
members and community/group membe rs may  be exposed to  risks of harm 
caused by genetic research, they have no  opportunity  to be  given  relevant 
information about  it  or  to decide  whether or not  to  participate, unless the 
subject volunteers this information .  What  is more,  current guidelines d o not 
clearly require IRBs/RECs to provide the risk and potential benefits assessment 
on  the  interests  of  family  members  and  community/group  members  of 
participants.  
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In summary, as distinct from the physical harm oriented traditional assessments 
of risks, the main risks of harm in genetic research are primarily related to the 
disclosure of information and research results that could lead to discrimination 
social stigmatization, familial disruption, or psychological distress to the human 
subject and her/his family members.
 205 Other risks of harm that may be caused 
by genetic research include ‗inadvertent disclosure of painful facts about family 
relationships  (such  as  non-paternity);  stigmatization  associated  with  having  a 
genetic  abnormality;  and  intra-familial  discord.‘
 206 Although  the  possibility  of 
the  occurrence  of  these  risks  might  be  quite  low,  these  harms  can  be 
devastating for individuals and communities if they occur. 
2.2.3 Concerns  Raised  by  Human  Population  Genetic  Research 
(HPGR) 
According to the discussion of genetic research above, we can conclude that the 
real  risks  of  harm  caused  by  genetic  research  mainly  stem  from  the 
inappropriate  disclosure  of  negative  genetic  information,  in  contrast  to  the 
physical harm that may be caused by other biomedical research. In the context 
of research, compared to other medical information, genetic information can be 
particularly sensitive. While some countries, such as the US,
207 currently have 
laws  prohibiting  genetic  discrimination  in  employment   or  insurance,  these 
regulations have paid specific attention to the protection of the individual. This 
means that the subjects that these regulations try to protect are still individual 
human beings. However, human population genetic research (HPGR) focuses on 
the  group/community   collective  genetic  information  of  specific  target 
groups/communities, not  individual human subjects. Thus, some scholars  have 
argued that research on human genetic variation can present  collective risks to 
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all  members  of  a  socially  identifiable  group.
208  However,  current  research 
guidelines adopt  the requirement for  individual  informed  consent. This  may 
provide  some  protection to human subject s,  but  the potential interests of  a 
group/community  as  a  whole  ha ve  not  been   specifically  addressed .  This 
deficiency in current ethical and legal frameworks is more pronounced in HPGR. 
This section will argue that HPGR may lead to some additional, specific potential 
risks of harm to human subjects, as well as challenging existing legal regulations 
and ethical guidelines on research involving human subjects. 
(1)  Potential Risks of Harm of HPGR 
Many of the risks of harm that may be caused by HPGR seem to be similar to 
those  raised  by  general  genetic  research,  since  they  are  also  related  to  the 
disclosure of negative information or research results rather than physical harms. 
However, the issues arising from HPGR have some differences too. HPGR, as with 
the  Human  Genome  Diversity  Project  (HGDP),  ‗provides  no  information  on 
individual phenotypes — the only information provided about each sample is the 
population name, its geographical location in degrees of latitude and longitude, 
and the sex of each individual.‘
209 This means that the information collected by 
HPGR will not lead to risks of harm to individual participants in exactly the same 
way as other types of genetic research might, since the information sought in 
HPGR  is  not  individual,  subject-identifiable  information.  The  target  genetic 
information of HPGR is group/community collective genetic information, which 
is carried by individuals in the  target group.  However, the collective genetic 
information of the target group is the result of thousands of years of evolution; 
thus, the interests affected by research on it cannot be seen as a matter relating 
solely  to  individuals,  even  though  it  relies  on  samples  taken  from  individual 
members. Rather, some scholars have argued that group/community collective 
genetic information relates to the interests of the whole group. For example, 
McGregor has pointed out that there are two types of harms that may be caused 
by research: tangible harms and dignitary harms. Both of them can be suffered 
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by either the individual or the group.
210 According to her, tangible harms to ‗a 
group  include  stereotyping  or  stigmatizing  which  can  result  in  loss  of  social, 
political,  or  economic  opportunities‘,
211  while  dignitary  harms  to  a  group  
‗undermine the value and worth of the group in the eyes of others and the group 
itself‘,
212 which may include ‗disrespectful or humiliating treatment of the group 
or community, or treating them as less than or subordinate to others.‘
213 The 
disclosure of negative information or research results of HPGR could lead to risks 
of harm to the group as a whole, both externally and internally. Some examples 
of external and internal harms were briefly noted in the introduction but this 
issue will be explored further here.  
(1) External harms:  
Abuse of group/community genetic information might threaten national 
security  and  the  survival  of  certain  groups/communities.  For  example, 
there  was  a  theory  that  severe  acute  respiratory  syndrome  (SARS),  of 
which there was an outbreak in China in the spring of 2003, might have 
been a man-made biological weapon, because ‗there is no vaccine for this 
virus, its make-up is unclear, it has not been very widespread and the 
population is not immune to it.‘
214 Although there was no clear evidence 
to  support  this  view,  it  raised  the  issue  of  concerns  about  population 
targeted bio-weapons based on population genetic research. In developing 
this type of bio-weapon, scientists would try to exploit medical advances 
by identifying distinctive genes carried by the target population, and then 
create a genetically modified bacterium or virus. The  distinctive genes 
carried by certain populations is the exact research target of HPGR; thus, 
the  abuse  of  genetic  samples  collected  by  HPGR  or  the  inappropriate 
disclosure of HPGR results could perhaps lead to this kind of devastating 
consequence. Imagine that there is a HPGR project involving a Chinese 
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ethnic minority - Miao Nationality - which has a population of more than 7 
million currently. The group‘s collective genetic information is disclosed 
to  scientists  who  use  that  information  to  produce  a  kind  of  virus  or 
bacterium  which  is  more  likely  to  infect  and  harm  Miao  people.  The 
development of this biological profile is based on HPGR, which revealed 
the  unique  predisposition  of  Miao  people.    If  this  kind  of  virus  or 
bacterium is hard to destroy or protect against and the effects cannot 
easily be treated, the survival of the Miao Nationality would be seriously 
threatened. The risk of harm, which might  be  caused by abuse of  the 
research  results  of  HPGR  or  inappropriate  disclosure  of  the  group‘s 
collective genetic information, is relevant to the interests of the whole 
group, even the security of a whole country. Thus, the concerns about the 
risk of harms that may be caused by HPGR cannot simply be equated to 
those  that  may  arise  in  other  biomedical  research  involving  individual 
human subjects. Although this type of bio-weapon targeted to a certain 
population  is  alarming,  some  would  argue  that  this  is  an  unrealistic 
scenario. However, there have been reports that this type of bio-weapon 
may become a reality. For example, in a front-page report in the London 
Sunday Times, November 15, 1998, the newspaper stated that  
Israel  is  working  on  a  biological  weapon  that  would  harm 
Arabs but not Jews, according to Israeli military and Western 
intelligence sources. The weapon, targeting victims by ethnic 
origin, is seen as Israel‘s response to Iraq‘s threat of chemical 
and biological attacks.
215  
According  to  this  article,  t his  secret  Israeli  program  was  based  on 
research targeted on a small town southeast of Tel Aviv, conducted by the 
Institute for Biological Research in Nes Tsiona, which is the main research 
facility  for  Israel's  clandestine  arsenal  of  chemical  and  biological 
weapons.
216  Despite  this,  there  is  no clear  evidence  to  support  the 
existence of genetic based types of bio-weapons at present. However, if 
they were to be developed , this type of bio -weapon could be  a serious 
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threat to national security and national population survival, since it would 
kill or harm some parts of the population but not others. 
Perhaps  more  likely  though  is  the  possibility  that  HPGR  can  expose  a 
whole  community/group  and  all  of  its  members  to  stigmatization. 
Stigmatization  of  certain  groups  could  include  claims  that  a  certain 
population  is  prone  to  particular  diseases,  such  as  schizophrenia,  or 
behavioural problems, such as alcoholism.  The public‘s views of genetic 
determinism and reductionism could exacerbate this discrimination. If a 
HPGR  result  revealed  that  Miao  Nationality  people  have  a  genetic 
disposition for alcoholism, for example, each member of the Miao might 
face the risk of higher automobile liability insurance premiums than other 
people, based on the perceived risk of higher numbers of car accidents as 
a  result of  the  misuse  of alcohol.  As  opposed  to  genetic testing  of  an 
individual in medical research which may have a negative effect on the 
individual,  and  possibly  her/his  family  members,  the  potential  risks  of 
harm  in  HPGR  could  affect  a  broader  range  of  people.  Further,  the 
discrimination caused by individual genetic research is often relevant to 
inappropriate disclosure of or access to the individual‘s and her/his family 
member‘s personal information or privacy. These risks of harm in this kind 
of  research  can  be  regulated  by  personal  data  protection  regulations 
which  protect  the  confidentiality  and  privacy  of  individual  genetic 
information.  What  is  more,  some  kinds  of  genetic  research  can  be 
conducted anonymously and disclosure of genetic research results could 
also  avoid  the  disclosure  of  personal  identities  of  human  subjects. 
However,  HPGR  aims  to  identify  information  about  a  specific  human 
population; thus, it cannot avoid disclosing information about a specific 
group/community and the HPGR result may lead to negative effects for 
the target group. This disclosure would be likely to be a part of any report 
of  the  scientific  research  findings,  which  is  the  normal  outcome  of 
scientific research, even though these research findings could be the basis 
of discrimination against a whole group. 
There are other derivative negative effects on the group as a whole that 
may  be  caused  by  HPGR.  For  example,  negative  effects  could  include Chapter 2 
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economic ones: ‗downgrading the group/community‘s bond rating, making 
it more expensive to borrow money.‘
217 Legal and political claims can be 
threatened, too. In the PRC, for example, there are some special benefit 
policies  and  special  legislation  for  ethnic  minorities,  which  might  be 
threatened if, for instance, HPGR proves that the target group is not in 
fact related historically or geographically. One could also imagine claims 
that ethnic minorities are not really ethnic minorities at all, since their 
origins can be traced to alternative ancestries than those that had been 
previously believed to be the case. 
(2) Internal harms: 
Internal harms are the potential risks of harm which may occur inside the 
target  groups  of  HPGR.  They  include  the  group‘s  self-conception  of 
genetic determinism and self-stigmatization, for example, ‗we Jews are 
defective  because  our  genes  make  us  prone  to  cancer‘  and/or  ‗we 
American  Indians  are  defective  because  our  genes  make  us  prone  to 
alcoholism.‘
218  Given that psychosocial stress and the disruption of family 
life are recognized and widely accepted by researchers as harms
219 and 
are regarded as legitimate risks to be considered and minimized by IRBs in 
some countries,
220 consistency dictates that community /group stress and 
the disruption of a group/community‘s constitution or core culture should 
also be treated as significant research-related harms in the context of 
HPGR, since target groups of HPGR almost always have their own unique 
cultural sensitivities.  The powerful identification of individual members 
with  their  group  also  means  that  group  harms  can  have  significant 
individual effects. 
In order to discuss group internal harms, it is significant at the outset to 
make  clear  what  a  group  is.  What  constitutes  a  group  is  not  only 
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problematic in the context of HPGR, but also in the recognition of group 
entities  and  interests  by  law.  Although  conceptually  uncertain,  it  is 
evident that local, state, and national political entities, religious groups, 
cultural groups, corporate groups, minority groups, indigenous and tribal 
groups, and a myriad of others have distinctly recognized and protected 
interests in law.
221 
‗Group‘ is a common term that occurs frequently in legal publications. In 
fact, like the other most common terms, such as dignity and rights, there 
is  no  consensus  on  what  constitute  a  group  even  in  the  context  of 
international law, although several studies have attempted to define it 
and  use  various  terms  to  describe  it,  such  as  ‗people‘,  ‗community‘, 
‗communality‘, ‗social group‘ and the most prevalent one ‗minority.‘
222 
There is a related definition of what constitutes a ‗people‘. The following 
definition  was  provided  by  experts  of  the  United  Nation  Education, 
Scientific and Cultural Organization (UNESCO) in 1990: 
A  group  for  the  rights  of  peoples  in  international  law, 
including  the  right  to  self-determination,  has  the  following 
characteristics: 
1.  A group of individual human beings who enjoy some or all of 
the  following  common  features:  (a)  a  common  historical 
tradition;  (b)  racial  or  ethnical  identity;  (c)  cultural 
homogeneity; (d) linguistic unity; (e) religious or ideological 
affinity; (f) territorial connection; (g) common economic life. 
2.  The group must be of a certain number who need not be large 
(e.g., the people of micro state), but must be more than a 
mere association of individuals within a state. 
3.  The group as a whole must have the will to be identified as a 
people or the consciousness of being a people—allowing that 
groups or some members of such group, though sharing the 
foregoing  characteristics,  may  not  have  the  will  or 
consciousness. 
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4.  Possibly, the group must have institutions or other means of 
expressing its common characteristics and will for identity.
223 
Another related concept is  ‗minority group‘. The most widely accepted 
definition of a minority group is ‗a group which is numerically inferior to 
the  rest  of  the  population  of  a  state  and  in  a  non-dominant  position, 
whose  members  possess  ethnic,  religious  or  linguistic  characteristics 
which differ from those of the rest of the population and who, if only 
implicitly,  maintain  a  sense  of  solidarity,  directed  towards  preserving 
their culture, traditions, religion or language.‘
224  
Although the terms ‗people‘ and ‗minority‘ are closely related to group, 
‗minority‘  emphasizes  their  political  situation,  while  ‗people‘  focuses 
more on the social situation of a group.  
Other  theorists  also  provide  explanations  as  to  what  is  a  group  in 
particular contexts.  For example,  Thomas Pogge  argued that an ethnic 
group has the following three features: the members of this group must 
identify themselves as descendants of members of a historical society, 
which is a board concept of society, including tribes, principalities, and 
others; this group has a unified culture, or partial culture, among which 
its  members  can  be  connected,  through  a  continuous  history;  and  the 
group must contain most of the persons who, within the relevant state, 
are taken to share the group‘s descent and culture.
225 Natan Lerner, in an 
analysis of group recognition in international law, stressed the purposes 
and  goals  of  the  group,  the  connections  and  distinctions  between  the 
group and other relative groups, the history and permanence of the group, 
the  naturalness  or  spontaneity  of  the  group,  and  the  voluntariness  of 
group membership.
226 There are other definitions of  a group, too, which 
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focus on shared normative understandings, the importance of the group to 
personal  identity,  and  whether  the  well-being  of  group  members  is  at 
least in part determined by group well-being.
227   
These definitions all reflect some features of  a group, but none of them 
has been universally accepted as an explanation to make it clear what a 
group  is.  However,  through  all  those  efforts,  scholars  and  legal 
practitioners have developed two  widely accepted criteria for defining a 
group;  one of which is subjective  while  the other is objective. The 
subjective criterion is the group and its  member‘s self-perception of the 
group‘s distinctiveness, and the desire of the individual members of the 
group to identify themselves as a group. The objective criterion is the 
existence  of  objective  characteristics  which  distinguish  the  group  from 
the remainder of the population, such as history, geography, ethnicity, 
economics, language and religion. It is important to keep in mind that 
neither of these two criteria is sufficient on its own to constitute a group. 
Only if a group fulfils both of these two  criteria can it  be seen as an 
independent group.
228  
If something leads to negative effects on members of a group, this could 
also cause harm to  the constitution of the group itself. In this situation, 
the interest of group as a whole would also be harmed, not only  its 
individual members. Some scholars  have argued that ‗the most common 
and damaging risk of harm to communities is community disruption,‘ and 
in respect of genetic research, that ‗the disruption is usually at the stage 
of  publication  and  release  of  the  research  results  or  secondary  use  of 
existing specimens.‘
229 HPGR is just this kind of research which may cause 
intra-group harms to the target group. For example, HPGR specific to an 
ethnic  minority  in  China  might  prove  that  this  group  has  no  genetic 
difference  to  other  Chinese  people.  This  result  may  lead  the  group 
members to reassess their origins and relationships to one another. This 
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may threaten ‗group members‘ self-identity and the identity of the group 
as a whole, as well as causing cultural harms to spiritual traditions and to 
their sense of who they are and where they are from, all of which upset 
their  historical  narrative.‘
230  Some  HPGR,  such  as  that  looking  into 
migration  pattern  research,  can  also  challenge  or  disrupt  a  group‘s 
cultural or spiritual values. For example, the cultural narratives of Miao 
Nationality  people  in  China  say  that  they  are  the  descendants  of  a 
butterfly and a bubble; thus Miao people believe that they are distinct 
from other people.  The  HPGR‘s result  might,  however,  show that they 
have no essential biologically based distinction from other people. Under 
current research guidelines, this type of risk of harm would not even need 
to  be  disclosed  to the  individual  human  subjects.  This  means  that  the 
target group and its members could suffer risks of harm which they have 
not consented to; indeed, the risk has not even been disclosed to them. 
Since HPGR aims to discover variation that could lead to knowledge about 
genetic disorders, possible cures, and the origin and migration patterns of 
target  groups,  the  results  of  HPGR  may  challenge  or  disparage  target 
groups‘  spiritual  traditions,  historical  narratives,  or  traditional  beliefs, 
which can be defined as cultural harms. Rebecca Tsosie, as noted earlier, 
defined ‗cultural harms‘ as the violation of groups‘ rights to their own 
culture.
231 Her definition was based on the theory of  Avishai Margalit and 
Moshe Halbertal
232 on culture, which defined  culture  as  the  ‗material, 
spiritual,  and  artistic  expression  of  a  group  that  defines  itself‘,
233 and 
maintains that ‗human beings have a right to culture – not just any culture, 
but  their  own.‘
234  The  target  groups  of  HPGR  are  almost  all  ethnic 
minorities or isolated groups in rural areas of developing countries. Their 
rights  to  their  own  culture,  including  a  comprehensive  way  of  life  by 
which a group defines itself, have been accepted in international human 
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rights law. For example, Article 27 of the International Covenant on Civil 
and Political Rights (ICCPR) reads as follows: 
In  those  States  in  which  ethnic,  religious  or  linguistic 
minorities exist, persons belonging to such minorities shall not 
be  denied  the  right,  in  community  with  other  members  of 
their  group,  to enjoy  their culture,  to  profess  and  practice 
their own religion, or to use their own language.
235 
HPGR results, for example, those that provide evidence that  an historical 
spiritual leader  of  a  certain  group  does not genetically   belong to  that 
group, could lead to cultural harms . In addition, the result of HPGR as 
scientific proof  to  challenge  group  identity  and  group  members‘  self-
understanding could also be defined as causing cultural harms. The group 
members‘  self-consciousness  is  crucial  to  a  group‘s  coherence.  HPGR 
results which question the historical narratives of the target group, may 
decrease  group  members‘  belief  and  pride  in  the  group  tradition  and 
culture, which can also lead to negative effects on the group‘s cultural 
rights. 
Some  scholars  have  argued  that  cultural  harm,  such  as  undermining  a 
group‘s  beliefs  about  its  origins,  is  not  a  real  risk  which  needs  to  be 
disclosed in the research protocol and when seeking consent; therefore, 
the risks of cultural harms caused by HPGR should equally not be taken 
into account. For example, Reilly said that  
Should  a  potential  subject  be  warned  that  one  or  more 
findings may challenge his religious beliefs? This strikes me as 
beyond the appropriate boundaries of the duty to warn, for it 
suggests  that  scientists  must  censor  their  inquiries  if 
conducted in the shadow of religion. When Galileo trained his 
telescope on the heavens and saw four moons orbiting Jupiter, 
he set in motion forces that would destroy the narratives built 
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around a geocentric universe— no doubt upsetting the world 
views of a lot people.
236 
This  example  is  inappropriate ,  however,   in  the  context  of  HPGR. 
Admittedly, in general,  scientific  research does not need to  take into 
account  existing ideology and public  beliefs. However, this argument 
cannot apply to HPGR, which is  specifically conducted on certain groups. 
HPGR needs the target group and its members to participate voluntarily. 
If the research results may cause one of the potential risks  that could 
challenge the common group belief, such as the  narrative origins of the 
group, I would argue that the group and its members do have the right to 
be informed of that risk before deciding on whether or not to participate. 
If  the  target group and  its members decide  not  to participate in this 
research, this potential risk, which is specific to them, would not arise.  
In summary, HPGR could lead to additional risks of harm other than those raised 
by  other  genetic  research.  All  of  the international de clarations and ethical 
guidelines on research involving human subjects have noted that the welfare of 
the individual research subject must take precedence over all other interests . It 
needs to be highlighted that the welfare of target groups in HPGR should also be 
considered. 
(2)  The Application of Consent to HPGR 
In 1914, in the US, Justice Cardozo argued that ‗[e]very human being of adult 
years and sound mind has a right to determine what shall be done with his [or 
her] own body.‘
237 This influential statement paved the way for the development 
of the importance of individual autonomy and consent in the medical setting. As 
has been discussed,
238 the primary legal and ethical considerations in biomedical 
research have traditionally revolved around the individual subject, ranging from 
issues as to how a piece of  research will affect a human subject to whether the 
human subject will have the opportunity to provide voluntary and sufficiently 
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informed consent. In brief, given the competence of human subject to give a 
valid  consent,  consent  is  a  two  step  process  in  biomedical  research:  first, 
researchers  present  appropriate  information  to  the  human  subject.  Secondly, 
the human subject is free to either agree or refuse to participate in a given 
biomedical research project, based upon this information disclosure. 
As  we  have  seen,  HPGR  is  research  on  specific  groups  which  can  generate 
valuable  knowledge.  As  has  been  discussed  above,  the  acceptability  of  non-
therapeutic research without direct and immediate benefits to participants has 
historically been based on a requirement that the research subject consents to 
exposure  to  risks  of  harm  which  may  be  caused  by  the  research,  with  full 
disclosure of relevant information to enable him or her to make a decision on 
whether or not to participate. Consent is also important in HPGR. However, the 
application of  the current approach to consent to participation in biomedical 
research to the specific context of HPGR is problematic.  
Under  the  ethical  justification  of  respect  for  individual  autonomy,  in  non-
therapeutic research the subject who may suffer harm caused by the research 
should make  the  decision  as to  whether or not  to  participate. In most other 
biomedical  research,  the  potential  risks  of  harm  would  be  posed  to  the 
individual human subject, so again the human subject would make the decision 
on research participation, based on the consideration of her/his own interests. 
Thus, in these types of research, under current research guidelines, the simple 
consent of individual human subjects based on the consideration of their own 
interests is ethically and legally justifiable. 
As discussed above,
239 in HPGR, the research objective is obtaining the collective 
genetic information shared by members of a target group. Therefore, it could be 
argued that the  target group/community of HPGR is the research subject of 
HPGR, and it is the group which  should make  the decision on whether or not 
participate.  However,  the  current dominant ethical principle  of  ‗respect  for 
persons‘ is secured through individual consent. The moral basis of consent as 
currently understood in law is an individualised model of autonomy. This means 
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that  current  research  protections  are  not  aimed  at  protecting  populations, 
communities, groups, or other possible third-party victims.  
In addition, the uniqueness of genetic information is that the genetic samples 
obtained from human genetic research subjects contain not only her/his genetic 
information,  but  also  genetic  information  about  her/his  blood  relatives,  and 
even potentially genetic information about the group of which s/he is a member. 
However,  HPGR,  which  targets  specific  groups,  can  be  conducted  with  the 
participation  of  only  some  of  the  members  of  the  group.  Nonetheless,  the 
potential risk of harm could be created for every member of the target group, 
and even the group itself.  
Thus,  the  individual  human  subject  has  no  overwhelming  superior  moral 
justification to give consent to participate in HPGR than any other member of 
the group who may be affected, other than the fact that s/he must undergo the 
procedure upon his or her body to allow a blood sample to be taken. Individuals 
have no superior rights to consider issues concerning the welfare of the group, 
though they may wish to take them into account for themselves as part of the 
information  process  before  giving  consent  to  participate.  The  issue  of 
information  disclosure  will  be  returned  to  later.  However,  for  the  moment, 
current ethical and legal frameworks of consent help support autonomy and self-
determination, protect the vulnerable, and promote the welfare and equality of 
human beings; but this focuses primarily on individual rights and does not always 
see individuals as part of wider social orders and community.
240 The application 
of current individualistic ethical  frameworks of consent for medical research to 
HPGR is problematic.  
This chapter has discussed the concept of relational autonomy as part of a 
reconsideration of the individualised Western idea of autonomy.
241 It examined 
the  idea  that  individual‘s  decision  making  depended  on  their  position  within 
social networks. It argued that individuals may wish to take account not only of 
personal  interests,  but  also  the  welfare  of  her/his  group  which  could  be 
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influenced by the decision. Applying this relational autonomy model to HPGR 
would provide one means of greater protection of the interests of target group, 
as well as recognising the need for such issues to be considered as part of an 
individual‘s decision-making process. Based on the relational autonomy model, I 
will suggest that ways to incorporate this model might include two important 
developments:  adding  the  risks  of  harm  to  the  target  group/community  as  a 
whole as one aspect of ethical review of the project, before seeking participants, 
and  adding  the  risks  of  harm  to  the  target  group  as  a  whole  as  relevant 
information  that  needs  to  be  disclosed  to  potential  participants.  One  further 
issue that arises is the need for cultural sensitivity. 
(1) Adequacy of Information disclosure 
As  I  have  considered  above,
242 the  rule of  consent in the  medical treatment 
context has a different purpose than in the  biomedical  research context.  In 
general, because there  might be  a greater potential for harm in  biomedical 
research, it may be considered that there must be  more relevant information 
disclosed to  the research subject than to a patient.  Thus, many international 
declarations, ethical guidelines and national legislation on biomedical research 
provide a list of items  of information that must be  disclosed to the  potential 
human subject. For example,  the following are those elements  of information 
considered relevant to the vast   majority of research projects   in US federal 
legislation: 
(I) A statement that the study involves research, an explanation of the 
purposes of the research, and the  expected duration of the subject‘s 
participation,  a  description  of  the  procedures  to  be  followed,  and 
identification  of  any  procedures  which  are  experimental;  (2)  A 
description of any reasonably foreseeable risks or discomforts to the 
subject; (3) A description of any benefits to the subject or to others 
which may reasonably be expected from the research; (4) A disclosure 
of appropriate alternative procedures or courses of treatment, if any, 
that might be advantageous to the subject; (5)A statement describing 
the extent, if any, to which confidentiality of records identifying the 
subject  will  be  maintained;  (6)  For  research  involving  more  than 
minimal risk, an explanation as to whether any compensation and an 
explanation  as  to  whether  any  medical  treatments  are  available  if 
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injury occurs and, if so, what they may consist of, or where further 
information may be obtained; (7) An explanation of whom to contact 
for  answers  to  pertinent  questions  about  the  research  and  the 
research  subject‘s  rights,  and  whom  to  contact  in  the  event  of  a 
research  related  injury  to  the  subject;  and  (8)  A  statement  that 
participation  is  voluntary,  refusal  to  participate  will  involve  no 
penalty or loss of benefits to which the subject is otherwise entitled, 
and  the  subject  may  discontinue  participation  at  any  time  without 
penalty  or  loss  of  benefits  to  which  the  subject  is  otherwise 
entitled.
243 
From this list of information  that needs to be disclosed, it can be shown that 
existing legal regulations and ethical guidelines concentrate on imm ediate risks 
to individual  research participants and do not explicitly require researchers to 
consider potential harms to non-participants.  
Nonetheless,  HPGR  is a good example of the argument that when research  
involving  human  subject s  places  non -participating  members  of  specific 
groups/communities  at risk, these potential harms should be considered by 
persons conducting, reviewing, and participating in  the research. Compared to 
other types of harm  that research may cause, the risks of harm from HPGR are 
collective and c ould be suffered by all members of  the  group, not  simply 
individual participants. For this reason, I would argue that potential researchers 
should demonstrate respect for the diverse social and cultural traditions of many 
communities  and  ack nowledge  that  research  findings  can  disrupt  social 
relationships within and between communities. These considerations suggest 
that in order to protect  certain groups/communities from  HPGR related harm, 
the scope of information disclosure should be expanded  to risks at group level, 
not  limited  to  the  immediate  risks  to  individual  participants.  Thus,  the 
information disclosure  requirements in existing legal regulations and ethical 
guidelines  are  inadequate  in  HPGR,  since  only  potential  risks  of  harm  to 
individual participants would normally be disclosed, while risks of harm that may 
potentially be  suffered by  the target group as a whole  are not required to be 
disclosed. 
In fact, there are rare examples in Western genetic research which indicate that 
information  disclosure  concerning  wider  risks  than  those  to  participants 
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themselves, under what might be considered a relational model of autonomy, 
would be appropriate. For example, a study of 30 women on  the breast cancer 
BRCA1/2 mutation  showed that the dilemma relevant to information disclosure 
on issues which may affect others, in this case female relatives, was not whether 
or not to inform participants of these kinds of factors, but how to tell them.
244 In 
this  study,  over  90%  of  participants‘  intention  to  participate  was  in  order  to 
obtain information for their relatives. Hence, the authors concluded  that ‗we 
need to ground consent upon an ethic that takes into account the social nature 
of human beings.‘
245 This example indicated that individual benefits or risks of 
harm  are  not  the  only  factors  which  influence  individual  decision-making, 
especially  in  the  context  of  genetic  research.  The  interests  of  relatives  or 
families may also be essential. In  such cases, the potential interests of their 
relatives  would  be  the  determinative  factor  influencing  their  decision  on 
whether or not to participate in certain kinds of genetic research. Although this 
example  related  to  the  issues  of  families  in  genetic  research,  it  may  be 
reasonable to require researchers to provide information about potential effects 
on a group of other people as well as the participants, it would enable potential 
participants to consider such issues as part of their own risk/benefit analysis 
before they are asked to consent. 
(2) The interests which should be considered in consent 
Since  the  research  target  groups/populations  of  HPGR  are  usually  ethnic 
minorities or isolated groups in rural areas in developing countries, in some of 
these groups/populations, such as in the PRC, the understanding of the nature of 
a person may be in line ‗with more relational definitions of the person found in 
other societies … which stress the embeddedness of the individual within society 
and define a person by his or her relations to others.‘
246 In these areas, where 
the  notion  of  persons  as  individuals  is  not  dominant,  the  individual  consent 
process may not be suitable, and there may be a need to widen the focus from 
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the  individual  to  the  family  or  to  the  community,  and  to  accept  that  their 
involvement  may  be  a  cultural  expectation.  For  example,  in  India  and  West 
Africa,  great  respect  and  deference  may  be  given  to  clinicians,  healers  and 
elders.
247 Clinton also indicates that: 
…Indians and many non-Westerners, often have a very different view 
of the nature of their rights and legal relationships... human beings 
are  born  into  a  closely  linked  and  integrated  network  of  family, 
kinship, social and political relations. One‘s clan, kinship, and family 
identities  are  part  of  one‘s  personal  identity  and  one‘s  rights  and 
responsibilities exist only within the framework of such…networks.
248 
The model of relational autonomy also concluded that individual decisions might 
be  influenced  by  external  considerations,  without  such  influences  necessarily 
amounting  to  improper,  or  undue,  influence.  In  addition,  the  cultural 
sensitivities of some developing countries are also conducive to the adoption of 
relational  autonomy.  HPGR  projects  are  almost  always  conducted  on  target 
groups  from  isolated  rural  areas  of  developing  countries,  where  cultural 
ideologies  are  different  from  Western  ones.  For  example,  in  a  traditional 
Chinese group/community, the group/community is the background to personal 
acts  and  decisions.  When  facing  decision-making  issues  relevant  to  group 
collective interests, it may be a cultural expectation that individual members of 
target group for HPGR would wish to rely on the opinion of group/community 
leaders,  or  group/community  leaders  would  make  the  final  decision  directly. 
Although it is not argued in this thesis that a group member should be compelled 
to participate in HPGR if approval of the research was given by a group leader, 
or that individual consent should not be sought from potential participants, what 
is at issue here is the need for respect for cultural sensitivity to enable the 
involvement of others than participants in decision-making and consideration of 
the  welfare  of  those  in  the  group  who are  not actively  participating.  In  this 
respect, HPGR participation would be considered as a group collective affair or a 
collective interest. Thus, cultural sensitivities would also be an important factor 
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to be considered in HPGR. The issue of cultural sensitivities in HPGR will be 
discussed in more detail in Chapters 3 and 4.  
In HPGR, adopting a relational autonomy model would be even more appropriate. 
In HPGR,  unlike the situation of most medical treatment which primarily has 
consequences for the individual, since the research target is group collective 
genetic information, the main risks of harm would be group harms which may 
affect  the  group  as  a  whole  as  well  as  each  group  member.  A  relational 
autonomy model, as has been discussed above,
249  requires that the interests of 
all  relevant  parties  should  be  considered  in  the  decision -making  process. 
Applying a r elational autonomy model in HPG R would require researchers  to 
disclose information about both about individual risks and potential group harms 
posed by HPGR, because the interests of  the group could be  affected by the 
decision  whether to participate, and whether or not target groups and  other 
group members would be negatively affected could be a determinative factor to 
the decision makers. 
Accordingly, the  current  Western research  ethical  and legal  frameworks of 
consent have not sufficiently addressed the harms that may be suffered by the 
target groups of HPGR. The individualistic frameworks can neither fit into the 
cultural sensitivities of target groups in HPGR from some developing countries, 
nor properly provide for disclosure of the main risks of harm that may be posed 
by HPGR. In HPGR, the relational autonomy-based consent model is superior to 
the  highly  individualised  autonomy   based  consent  model,  particularly  in 
developing  countries  like  China  where  collective  decision -making  is  not 
uncommon. 
Recently,  some  scholars  have  discussed  group  protection  measures  as 
supplements  to  individual  informed  consent.
250  They  have  argued  that  a 
group/community/population ought to have moral status in  HPGR, especially in 
respect of research in developing countries, for the following reasons: (1) people 
do  not  view  themselves  atomistically,  but  as  members  of  one  or  more 
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communities that constitute their values and self-understanding; (2) a variety of 
communities are already given the authority to make binding decisions on behalf 
of individual members on certain issues; (3) the primacy of the individual versus 
the community varies from one community to the next.
251 Yet, although there is 
a clear need for alternative model which include group consideration,  it could 
be argued that there are concerns with models which take the group as the unit 
of ethical concern. It is arguable that it might be problematic to determine the 
boundaries of the group/community and to find a mechanism for balancing 
interests within a group. The most essential ethical issue here is whether or not 
‗individuals and their claims of right will be crushed beneath the greater weight 
of groups and their claims of right.‘
252 Other scholars have argued that group 
consent is hard to obtain in practice. There are three main difficulties: (1) the 
extent  of  the  affected  parties‘  participation  in  decision-making;  (2)  the 
identification of the parties whose consent should be sought if collective consent 
procedures were adopted; (3) the veto power problem: the possibility of a group 
veto power over individual decisions to participate or not would make collective 
consent extremely difficult to support.
253 The alternative to the ethical principle 
and rule of individualistic consent, such as  ‗respect for community‘ or ‗group 
consent‘,  will  be  discussed  in  detail  in  the  next  chapter.  However,  while 
supporting group and community involvement in reviewing HPGR, it needs to be 
emphasized  that  this  thesis  does  not  intend  to  substitute  group  consent  for 
individual  consent,  but  to  supplement  individual  consent  with  additional 
considerations concerning the interests of target group, based on the relational 
autonomy model. 
(3)  The Application of Risk- benefit Assessment to HPGR  
Compared to clinical research, in most cases genetic research cannot produce 
direct and immediate benefits to human subjects.  This characteristic is  even 
more apparent in HPGR. Thus, in the risk-benefit analysis of HPGR, the risks of 
harm should be considered more carefully. It should not only consider the risks 
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and potential harms to each member of the target group, but also the risks and 
potential harms to the group/community as a whole and all of its members. 
Recognizing that additional protections are needed in the research context, all 
of  the  international  declarations  and  conventions,  such  as  the  Helsinki 
Declaration,
254 the CIOMS Guidelines,
255 as well as some national legislation, such 
as those in the US, require institutional review boards (IRBs)  or research ethics 
committees (RECs) to ensure that research is conducted ethically and with the 
fully informed consent of the participants.   IRBs  or RECs  provide the initial 
approval of the proposed research and then conduct a continuing review of the 
research to ensure ongoing compliance with institutional policies and procedures. 
Under the terms of the  Helsinki Declaration, ethical review committees must  
‗take into consideration the laws and regulations of the country or countries in 
which the research is to be performed as well as applicable international norms 
and standards but these must not be allowed to reduce or eliminate any of the 
protections for research subjects set forth in this Declaration.‘
256 Ethical review 
committees are responsible for reducing unnecessary risks for the participants in 
research and for guarding against the exploitation of those subjects. US federal 
common  law  also  notes  that  the  specific  role  of  the  IRBs  is  to  assure  the 
protection of research subjects and ‗to ascertain the acceptability of proposed 
research in terms of institutional commitments and regulations, applicable law, 
and standards of professional conduct and practice.‘
257  Thus, one of the core 
functions of RECs or IRBs is to review the potential risks of harm that may be 
caused by research to ensure that the interests of human subjects are protected. 
However,  considering  the  criteria  for  IRB‘s  or  REC‘s  approval  of  biomedical 
research  involving  human  subjects,  the  essential  risks  of  harm  that  may  be 
caused by HPGR may not be identified by them. For example, the US Common 
Rule noted that IRBs must ensure that: 
Risks to subjects are reasonable in relation to anticipated benefits, if 
any,  to  subjects,  and  the  importance  of  the  knowledge  that  may 
                                         
254 See supra note 121. 
255 See supra note 122. 
256 See supra note 254. 
257 45 C.F.R. § 46. 107(a) (2005). Chapter 2 
Harms in Human Population Genetic Research    108 
 
reasonably be expected to result. In evaluating risks and benefits, the 
IRB should consider only those risks and benefits that may result from 
the  research  (as  distinguished  from  risks  and  benefits  of  therapies 
subjects would receive even if not participating in the research). The 
IRB  should  not  consider  possible  long-range  effects  of  applying 
knowledge  gained  in  the  research  (for  example,  the  possible 
effects of the research on public policy) as among those research 
risks that fall within the purview of its responsibility.
258 (emphasis 
added) 
According to these criteria, IRBs are only requested to consider the risks of harm 
which can be clearly foreseen, and these are focused on individual participants. 
These types of risks might befall anyone: physical harms,  hurts or injuries and 
psychological harms including pain and suffering. It might be suggested that IRB 
members will tend to identify the risks of harm they themselves might expect to 
experience if they were to take part in the proposed research . However, the 
target groups of HPGR are ethnic minorities and isolated groups in rural areas of 
developing countries. IRB members almost  always are at a  social and cultural 
distance from them; thus, they are not likely to have a cultural awareness of the 
target groups. Consequently, they are not likely to recognize  the circumstances 
and traditions of these groups, so they may not be able to appropriately identify 
the possible and potential harms that may occur to certain groups correctly , 
especially internal or cultural harms.  
Similar  to  the  focus  on  individual  autonomy  in  current  ethical  and  legal 
guidelines on informed consent,  with regard  to welfare,  the basic ethical 
principle of ‗respect for persons‘ results in the concentration of IRBs and ethical 
review  committees  on  individual  human  subjects.  For  example,  the  human 
subject in the US Common Rule is defined as ‗a living individual about whom an 
investigator (whether professional or student) conducting research obtains data 
through intervention or interaction with the individual, or identifiable private 
information.‘
259 Thus, according to this definition, the risks of harm IRBs need to 
consider are the risks of harm  that individual participants may suffer. In the 
context of HPGR, existing ethical guidelines do not require an assessment of 
risks of group harm in to be addressed in the ethical review process.  
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In  fact,  it  is  worth  noting  that  a  number  of  scholars  have  indicated  their 
concerns about the interests of groups and communities in research ethics. For 
example, as far back as the  National Bioethics Advisory Commission‘s (NBAC) 
first meeting, Emanuel argued that the three principles, ‗respect for persons, 
beneficence,  and  justice,‘  and  their  related  guidelines  do  not  adequately 
address  the  interests  of  communities.
260 Levine  also argued  that the  Belmont 
Report overemphasized individual rights and failed to talk about the community. 
He noted:  
In each of its publications, it [the National Commission] seems to  
embrace an atomistic view of the person. The person is seen as a  
highly individualistic bearer of duties and rights; among his or her  
rights, some of the most important are to be left a lone, not to be  
harmed, and to be treated with fairness. Except, perhaps, in its 
report on research involving children, there is little or no reference to 
persons in relationship to others or as members of communities.
261 
On the other hand, the consumerist movement swept America in the early 1970s 
and concern for individual rights was very much a part of the zeitgeist . The 
Belmont Report was undoubtedly also influenced by these larger societal forces. 
Nonetheless, the failure of the Belmont Report to deal adequately with families 
and communities does not, Levine argues, render it useless: ‗Having said this, I 
do not think the Commission‘s recommendations are obsolete. . . . [I]t is usually 
quite  appropriate  to  view  investigator-subject  relationships  as  relationships 
between strangers. Thus, in general an individualistic ethics is appropriate.‘
262 
Along with the development of biomedical science and technology, especially 
the prevalence of population genetics, the NBAC came to realize the need to 
protect groups/communities. For example, the NBAC‘s specific recommendation 
on stored human biological materials indicated that: 
Research  using  stored  human  biological  materials,  even  when  not 
potentially harmful to individuals from whom the samples are taken, 
may be potentially harmful to groups associated with the individual. 
To the extent such potential harms can be anticipated, investigators 
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should to the extent possible plan their research so as to minimize 
such harm and should consult, when appropriate, representatives of 
the relevant groups regarding study design. In addition, when research 
on unlinked samples that poses a significant risk of group harms is 
otherwise  eligible  for  exemption  from  IRB  review,  the  exemption 
should  not  be  granted  if  IRB  review  might  help  the investigator  to 
design the study in such a way as to avoid those harms.
263 
This recommendation seems to indicate the NBAC‘s awareness of the possibility 
of specific research protocols posing a risk to a specific group, and its concern 
that, if this risk can be anticipated it should be disclosed during the informed 
consent  process.  However,  this  has  not  been  reflected  in  current  ethical 
guidelines,  such  as  the  Declaration  of  Helsinki,  nor  in  legal  regulation. 
Nevertheless, HPGR may pose some risks of internal group harm, which are hard 
to  recognise  or  identify  by  people  who  are  outside  the  group.  Thus,  under 
current  frameworks,  similar  risks  posed  to  target  groups  in  HPGR  would  very 
probably not be taken into account in the risk-benefit analysis of IRBs/RECs. 
In  summary,  HPGR  may  lead  to  specific  risks  of  harm  to  the  target 
groups/communities. However, existing legal and ethical frameworks on human 
subject protection, such as consent and risk-benefit assessment, are ill-equipped 
to provide a comprehensive solution to avoid the potential risks of harm posed 
by HPGR.  
In addition to these concerns, the target groups/communities in HPGR are also 
distinguished from participants in many other types of biomedical research. They 
are almost always deliberately selected as target groups because they are in 
isolated groups/communities in rural areas of developing countries, which may 
lead  to  the  potential  for  vulnerability  in  HPGR  participation.  Thus,  the  next 
chapter  will  go  on  to  consider  the  issues  of  protecting  target 
groups/communities as potentially vulnerable populations in HPGR. 
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As discussed in Chapter 2, since HPGR aims to identify specific aspects of the 
diversity  of  the  human  genome,  target  groups  are  often  ethnic  minorities  or 
isolated  groups  in  rural  areas  of  developing  countries,  whose  members  are 
believed  to  share  the  same  community  or  group  collective  human  genetic 
information.  This  chapter  will  suggest  that  these  target  groups  should  be 
considered to be vulnerable in respect of HPGR, and need specific protections. 
3.1 The Vulnerability of Target Groups in HPGR 
Vulnerability  itself  is  a  complex  and  ambiguous  concept.  Although  several 
influential  national  laws  and  international  declarations  concern  special 
protection for vulnerable groups, such as racial minorities, ethnic minorities, or 
groups with disadvantaged economic and social resources,
1 the specific aims of 
these  documents  did  not  focus  on  HPGR,  so  the  definition  and  scope  of 
vulnerability of these groups in this context has not been addressed.
2 Despite the 
available codes of research ethics and regulations describing certain individuals 
and groups as vulnerable, little consensus exists on what this actually  means, 
even in the context of human subject protection in medical research. 
The World Medical Association‘s Declaration of Helsinki (Helsinki Declaration),
3 
for example, noted that ‗[s]ome research populations are particularly vulnerable 
and  need  special  protection.  These  include  those  who  cannot  give  or  refuse 
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consent for themselves and those who may be vulnerable to coercion or undue 
influence.‘
4 It also points out that ‗the particular needs of the economically and 
medically  disadvantaged  must  be  recognized.‘
5 According  to  this  explanation, 
the target groups of HPGR, ethnic minorities and isolated groups in developing 
countries, which often go hand in hand with limited social resources, poverty, 
low  level  of  education,  little  familiarity  with  genetic  research,  and  lack  of 
access to health care, should be seen as vulnerable.  
Guideline 13 of the International Ethical Guidelines published by the Council of 
International  Organizations  of  Medical  Sciences  (CIOMS)  entitled  ‗Research 
Involving Vulnerable Persons‘ noted that: ‗[s]pecial justification is required for 
inviting  vulnerable  individuals  to  serve  as  research  subjects  and,  if  they  are 
selected,  the  means  of  protecting  their  rights  and  welfare  must  be  strictly 
applied.‘
  6  The  meaning  of  vulnerable  people  was  also  addressed  in  the 
commentary on this guideline as follows: ‗[v]ulnerable persons are those who are 
relatively  (or  absolutely)  incapable  of  protecting  their  own  interests.  More 
formally, they may have insufficient power, intelligence, education, resources, 
strength,  or  other  needed  attributes  to  protect  their  own  interests.‘
7 It  also 
listed  several  types  of  populations  and  individuals  who  could  be  seen  as 
constituting  vulnerable  groups,  including  ‗some  ethnic  and  racial  minority 
groups‘.
8 In addition, in the reference and commentary  on Guideline 12 it was 
noted that: 
Not only may certain groups within a society be inappropriately 
overused  as  research   subjects,  but  also  entire  communities  or 
societies may be overused. This has been particularly likely to occur in 
countries or communities with insufficiently well  developed systems 
for the protection of the rights and welfare of human research  
subjects.  Such  overuse  is  especially  questionable  when  the 
                                         
4 Ibid, Article 9. 
5 Ibid. 
6 International Ethical Guidelines for Biomedical Research Involving Human Subjects was prepared 
by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with 
the WHO, Geneva, 2002. The full text of CIOMS Guidelines can be seen on the official website 
of World Health Organization (WHO) on 
http://www.cioms.ch/publications/guidelines/guidelines_nov_2002_blurb.htm, last visited on 
2010-07-27. 
7 Ibid. 
8 Ibid. Chapter 3 
Group Protection in Human Population Genetic Research  113 
 
populations  or  communities  concerned  bear  the  burdens  of 
participation in research but are extremely unlikely ever to enjoy the 
benefits of new knowledge and products developed as a result of the 
research.
9 
Article 8 of the Universal Declaration on Bioethics and Human Rights ,
10 adopted 
by the United Nations Educational, Scientific and Cultural Organization (UNESCO), 
is entitled ‗Respect for human vulnerability and personal integrity‘. This article 
noted that:  
[I]n  applying  and  advancing  scientific  knowledge,  medical  practice 
and associated technologies, human vulnerability should be taken into 
account.  Individuals  and  groups  of  special  vulnerability  should  be 
protected and the personal integrity of such individuals respected.
11  
It can be seen from this  Article that this declaration made a claim  as to the 
necessity  of  special  protection  for  vulnerable  individuals  and  groups  in 
biomedical research, but  it did not explain the meaning and scope of human 
vulnerability.  
In addition to the international declarations and ethical guidelines above, some 
national  laws  or ethical guidelines also mention t he vulnerability of  certain 
groups. For example, t he US National Commission‘s Belmont Report
12 includes 
‗racial  minorities,  the  economically  disadvantaged,  the  very  sick,  and  the 
institutionalized‘
13 in their list of vulnerable populations. The Common Rule, the 
core of the US human subject protection regulation, did not define vulnerability, 
but  it  mentioned  ‗economically  or  educationally  disadvantaged  persons‘
14 as 
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10 The Universal Declaration on the Bioethics and Human Rights was adopted by UNESCO's 
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and Human Rights can be seen on the official website of UNESCO on 
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vulnerable  populations,  which  is  a  general  characteristic  of  target  groups  of 
HPGR in developing countries. 
From  the  above,  it  can  be  seen  that  despite  broad  agreement  that  the 
vulnerable  have  a  claim  to  special  protection,  the  definition  and  scope  of 
vulnerable  persons  or  populations  are  not  clear.  In  addition,  the  pattern  of 
defining  vulnerability  in  international  declarations  and  ethical  guidelines,  or 
national  legal  regulations  and  ethical  guidelines,  is  to  focus  on  particular 
populations, for example prisoners, children, or ethnic minorities. This pattern 
has been criticized as it may lead to the implication that individuals who are 
members  of  these  populations  are  inherently  vulnerable  in  all  types  of 
biomedical research. For example, the National Bioethics Advisory Commission 
(NBAC) argued that ‗vulnerability is sensitive to context and individuals may be 
vulnerable  in  one  situation  but  not  in  another.‘
15 Thus,  NBAC  suggested  that 
vulnerability should be defined in terms of situations in which individuals might 
be considered vulnerable, rather than in terms of groups or populations. The 
situation  of  the  vulnerability  of  target  groups  in  HPGR  is  similar.  Ethnic 
minorities or groups which live in poverty or with fewer social resources may be 
categorized in international declarations and ethical guidelines as ‗vulnerable 
groups‘, but this does not prove that these groups are necessarily vulnerable in 
HPGR.  The  concept  of  the  vulnerability  of  target  groups  in  HPGR  has  been 
defined so broadly and inconsistently
16 that it is tempting to conclude  that it is 
incapable of providing any meaningful ethical guidance.  
Coleman has pointed out  that the core of fully understanding  vulnerability is 
determining the nature of the human subject‘s vulnerability  — i.e., what are 
vulnerable human subjects actually vulnerable to?
17 He argued that vulnerability 
should be lin ked to the basic principles  that underlie  society‘s  regulation  of 
human subject research, as reflected in regulatory standards and internationally 
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agreed-upon  ethical  guidelines.
18 According to this framework,  a vulnerable 
person or group can be seen as an individual or a group at risk of being enrolled 
in research in violation of one or more of the  interests defined by regulations 
and ethical guidelines. Vulnerability should be examined   from  three distinct 
perspectives  —  consent-based,  risk-based,  and  justice-based.
19 Consent-based 
and  risk -based  vulnerabilities  make   more  sense  when  conceptualized  as 
individual issues, but   justice-based vulnerabilities are hard to understand   as 
anything other than a population-based concern.
20 
There are several reasons to agre e with this understanding of vulnerability in 
human subject research. Firstly, avoiding these three kinds of vulnerability is the 
baseline of permitting researchers and research institution s  to invite human 
subjects to participate in their research, since their research may cause risks of 
harm  to  the  participants  without  any   compensating  benefits,  medical  or 
otherwise. According to principles such as ‗respect for autonomy‘, ‗beneficence‘, 
and  ‗justice‘,  the  following  conditions  should  be  fulfilled  before  conducting 
research: the IRB‘s or ethical REC‘s determination that the risks of the study are 
reasonable in relation to its total anticipated benefits (both direct benefits to 
subjects and potential long-term benefits to society), that the risks have been 
minimized to the extent reasonably possible, and that the subjects will be able 
to provide voluntary, informed consent. If an individual or a certain group  is 
identified  as  vulnerable,  their  interests  will  be  more  susceptible  to  violation 
than those of other individuals or groups. Thus, in order to clarify the nature of 
vulnerability of target groups in HPGR, we should explore what are these groups 
vulnerable to from these three distinct aspects: consent-based, risk-based and 
justice-based.  Secondly,  the  division  of  authority  and  responsibility  between 
IRBs or RECs, research subjects and legislators within this framework is clear. It 
can be  seen  that the  conditions  mentioned  above  require  human  subjects  to 
determine whether or not  to participate in the  research; meanwhile, IRBs or 
RECs  should  decide  whether  or  not  the  risks  of  the  study  are  reasonable  in 
relation to its total anticipated benefits, as well as whether the risks have been 
minimized to the extent reasonably possible; then, the legislators stipulate the 
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legal requirements for the implementation of research subject‘s consent and the 
ethical review conducted by IRBs or RECs. Coleman has argued that the roles of 
individuals and IRBs or RECs are not well-balanced: 
At  one  extreme,  we  could  let  competent  adults  participate  in  any 
type of research, regardless of the study‘s objective risk-benefit ratio, 
on  the  theory  that  autonomous  individuals  have  the  right  to  take 
whatever risks they find personally acceptable. We do not have such a 
system: if the study does not offer a net social benefit, then the IRB is 
not supposed to approve it, even if a fully informed subject would be 
willing to participate. At the other extreme, we could require IRBs to 
determine that participating in research would be in the individual 
best interests of all the subjects in a study….
21 
Neither of these two extreme  situations is acceptable. As Coleman continues: 
‗we defer to individuals‘ choices to take research-related risks for idiosyncratic 
reasons — but only if they are genuinely capable of acting autonomously, and 
only if the risks are ―worth it‖ from a societal point of view.‘
22  
As a result, a reasonable division of authority between ethical review agents and 
research participants should respect competent individual participants‘ decisions 
to participate in research, but only if the risks of harm are deemed reasonable in 
relation to the importance of the knowledge to be gained from a societal point 
of view. 
According to this framework, the risks to vulnerable individuals or groups can 
arise from different sources. First, consent-based vulnerabilities can create or 
exacerbate  barriers  to  obtaining  sufficiently  informed  consent  to  research, 
potentially  violating  the  requirement  that  consent  to  the  research  risks  be 
voluntary.  Second,  risk-based  vulnerabilities  may  enhance  the  level  of  risks 
associated  with  subjects‘  participation  in  human  subject  research,  thereby 
calling into question the study‘s underlying risk-benefit ratio. Finally, justice-
based vulnerabilities can raise concerns about the distribution of the benefits 
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and  burdens  of  the  research,  and  these  distributional  concerns  may  also  be 
relevant to the risk-benefit analysis.
23  
According to these concerns, it can be suggested that target groups of HPGR are 
vulnerable  in  respect   of  consent,  benefit -risk  assessment  or  exploitation, 
because  of a low education al  level, lack of economic and social resources , 
cultural sensitivities and an absence of effective and adequate legal regulations 
and ethical guidelines in most developing countries.  
3.1.1 Consent-based Vulnerability of Target Groups in HPGR 
Consent-based vulnerability refers to the diminished ability to protect one‘s own 
interests,  leading to  a  compromised  capacity  to  give  sufficiently  informed  or 
voluntary consent. This diminished ability may render a particular individual or 
group  more  susceptible  to  impaired  decision  making,  coercion  or  undue 
influence in research.  
In the context of HPGR, there are several factors which may lead to the consent-
based vulnerability of target groups. Target groups and their members may have 
difficulty giving valid consent and protecting their own interests and could thus 
be classed as vulnerable. 
HPGR aims to study isolated populations to find out the impact of their history 
on their genetic makeup, so target groups of HPGR are often located in isolated 
areas, where transportation is inconvenient; the members of target groups are 
relatively homogeneous with respect to ethnic group, environment, occupation, 
and diet, and the  groups will have existed for several thousand years with a 
stable  population.  For  example,  Arizona  State  University  (ASU)  conducted 
several  research  projects  on  the  Havasupai  tribe,  which  is  a  small  tribe 
numbering  in  the  few  hundred  living  in  an  isolated  community  in  the  Grand 
Canyon, accessible only by foot, mule, or helicopter.
24 The Harvard  University 
research in the Anhui province of the PRC was also conducted on isolated groups 
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in rural areas.
25 It is quite normal that the members of target groups in HPGR are 
less-educated than the majority population and unfamiliar with the implications 
and possible consequences of  genetic research. For instance, according to the  
Second National Agricultural Census by the National Bureau of Statistics of the 
PRC,
26 at the end of 2006, the total o f the rural labour force numbered 478,520 
persons, occupying 90.1 percent of the total  labour force resources; however, 
among these rural labour ers, 6.8% had no formal education , 49.5% had junior 
middle school education level and  32.7%  had primary school e ducation.
27 It 
showed that 89% of the population in the rural areas in the PRC have less than 9 
years  of  education.  This  low -educational  situation  might  have  a  negative 
influence on their understanding of information disclosed and their evaluation of 
the potential risks of harm in HPGR.  
These groups or individuals  may have limited health   literacy and may  not 
appropriately understand the exact meaning of sample collect ion procedures or 
the possible outcomes of the research project.   For example, in 1984, a US  
physician,  Dr. Arthur Bosley, who conducted medical research in developing 
countries, told of the dilemma he faced in the application of informed consent.
28 
According to his report, in most developing countries,  ‗the  germ  theory  of 
disease causation is yet to be accepted, particularly among the not so-educated 
members  of  the  population.‘
29 What  is  more,  most  of  the  people  in  these 
countries thought that a blood test was a good thing, because ‗if your blood is 
good,  then  you  are  all  right‘.  Thus,  if  Dr.  Bosley  wished  to  invite  patients 
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attending the clinic to undergo a blood test, they would consent readily.
30 In 
addition, information about HPGR, including the risks involved, may be difficult 
to understand. The majority of members of target groups in HPGR may n ot be 
able to read and write.  Even those who can read may not understand  all the 
medical terms that such information is bound to contain. If the consent form is 
in a normal Western style, which  often lists possible risks over multiple pages, 
but does not e xplain  them in common terms or spell out the seriousness,  
probability, or consequences of each possible risk in simple terms, the difficulty 
can be  exacerbated.  If  the target groups are in developing countries,   whose 
members are not aware of the potential risks of harm  of biomedical research, 
even if they agree to participate in it,
31 these difficulties increase even further.  
Any decision whether or not to participate in scientific research that is based on 
incomplete understanding or misunderstanding of research information or on an 
inaccurate assessment of potential risks of harm is ethically and may be legally 
problematic.  In fact, normal competent  people  sometimes  do participate  in 
research studies without a good understanding  of the study purpose and ri sks, 
even in non-HPGR projects. Competent individuals may sometimes consent to 
research  without  fully  understanding  each  sentence  of  the  consent  form; 
however, these  individuals often have  background knowledge on research, can 
realize the scope of risks ro ughly and are capable  of making an  appropriate 
evaluation  o f  potential  risks.  Thus,  they  may  be  deemed   capable  of 
understanding the research information sufficiently. It could therefore be argued 
that understanding may be correlated with educational level
32 but the person‘s 
social and cultural context will also play an important role.  
The members of target groups of HPGR may be less capable of understanding, 
and hence more vulnerable to impaired decision making, because of their lack of 
education,  cultural  orientation,  or  limited  health  and  medical  knowledge.  In 
other  words,  target  groups  do  not  have  the  experience  to  weigh  up  the 
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advantages  and  disadvantages  as  they  are  unused  to  making  these  kinds  of 
decisions.  Target  groups  of  HPGR  and  their  members  who  do not  understand 
what the purpose of HPGR is may not know what they are actually consenting to 
and may misunderstand or not realize the risks of participation. Thus, they are 
vulnerable when making a decision on whether or not to participate in HPGR. 
Therefore,  explanations  with  adequate  accuracy  and  articulation,  easily 
understood by people with a low level of education, are essential requirements 
both for the ethical conduct of this type of biomedical research and for the 
protection  of  subjects‘  interests.  In  the  context  of  HPGR,  as  in  any  other 
research, the burden is on the researchers and research institutions to inform 
individuals in a way that ensures that the target groups and their members can 
appreciate  the  risks  and  requirements  of  participation  while  minimizing  the 
possible  impact  of  educational  or  cultural  barriers  that  may  distort 
understanding.  
The  second  possible  type  of  consent-based  vulnerability  is  that  if  medical 
services, or other goods are offered in connection with participating in an HPGR, 
these  may  be  so  attractive  that  members  of  target  groups,  especially  with 
limited economic and social resources, will irrationally disregard the risks and 
requirements of the research. These attractive offers are referred to as ‗undue 
inducements‘  in  biomedical  research.  According  to  Emanuel,  there  are  four 
elements to undue inducement, and each of these four elements is necessary for 
undue inducement to exist:  
(1)  An  Offered  Good—Individuals  are  offered  something  that  is 
valuable or desirable in order to do something. (2) Excessive Offer—
The offered good must be so large or in excess that it is irresistible in 
the  context.  (3)  Poor  Judgment—The  offer  leads  individuals  to 
exercise poor judgment in an important decision. (4) Risk of Serious 
Harm—The  individual‘s  poor  judgment  leads  to  sufficiently  high 
probability  that  he  or  she  will  experience  a  harm  that  seriously 
contravenes his or her interests.
33 
According to this account, it could be argued that HPGR may  only offer some 
free common medicine or access to limited primary healthcare treatment, which 
can be seen as normal compensation  for research participation and  would not 
                                         
33 Emanuel, E. J. 2005, " Undue Inducement: Nonsense on Stilts? ", The American Journal of 
Bioethics, vol. 5, no. 5, pp. 9-13, at 9. Chapter 3 
Group Protection in Human Population Genetic Research  121 
 
lead to the undue influence of potential participants. In fact, just as happened 
in the Harvard project in China, in order to recruit participants from rural areas 
of  developing  countries,  researchers  might  seek  to  provide  some  medical 
services or standing drugs for free. In 2001, Outlook Weekly published a survey 
on the Harvard case, describing one of the participants, Chu Mianzhai, whose 
whole family had twice taken these kind of free ‗physical examinations‘, given 
blood samples and received a little money as compensation for loss of working 
time, as well as two packages of instant noodles.
34 The first time, on 5 November 
1996, the family gave a blood sample for which they were given 10 Yuan each as 
compensation. The second time, on 10 March 1997, they gave more blood and 
were given 20 Yuan each. Chu also received a bottle of medicine for his high 
blood pressure. A similar situation  also arose in the case of  Havasupai. In this 
case, taking part in  the research would result in access to  some free summer 
school for students from the Tribe.
35 Thus, the question arises whether  target 
groups of HPGR  should be  considered vulnerable to undue i nducement if such 
benefits were offered. 
An example, provided by McGregor, of an impecunious mother with a very  sick 
child and a lecherous millionaire can illustrate that whether or not something is 
an undue inducement should be decided by the specific situation of the subject, 
although the example is not in the context of research: 
The millionaire proposes to the impecunious mother that he will pay 
for the medical treatment that her child needs if she will become  his 
mistress.
36 
This hypothetical situation satisfies the first element of undue inducement : an 
irresistible offer. The offer to fund the treatment of a very sick child is not an 
excessive one for a millionaire, but it is an irresistible one for the child‘s mother, 
given her inability to pay for the treatment. Poor judgement is  less obvious, 
because  from  the  perspective  of  the  child‘s  welfare,  accepting  the  offer  is 
reasonable,  but  on  the  other  hand,  accepting  unwanted  sexual  interactions 
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would generally not be seen as reasonable. To some extent, whether or not this 
leads to a serious harm would be decided by the subject‘s circumstances and 
values (for example, if the mother here was a prostitute, she might think this 
exchange is not a serious harm).
37 Thus, undue inducement would occur where 
an attractive offer distorts the individual‘s ability to make rational decisions for 
himself or herself, according to their own values and preferences. Such offers 
may be especially irresistible to those individuals who lack economic and social 
resources.  That  is  to  say,  the  main  concern  of  undue  inducement  is  that 
individuals are offered some good that, effectively without reference to their 
better  judgement,  makes  them  assume  risks  of  harm  that  compromise  their 
welfare.
38 
In the context of HPGR, considering  the level of economic development   and 
actual living conditions of most target groups, their members may be vulnerable 
in the face of what may appear to others to be small and reasonable offers.  
Indeed, HPGR conducted in some developing countries may  offer payments or 
primary  healthcare  service   to  the  Western  standard  as  part  of  research 
participation, such as free health care or other benefits such as free housing, etc.  
However, these offers could be enticing enough to impair decision making, such 
that  members of  target groups  participate in  HPGR  disregarding risks or not 
giving risks appropriate weight in the decision -making process. In the Harvard 
case,  an  individual  participant  Chu  and  his  family  lived  in  Toutuo,  an 
impoverished village in Yuexi district with a n average yearly wage of less than 
2,000 yuan.
39 Thus, although 10 Yuan or 20 Yuan can be seen as  a small sum and 
normal compensation in medical research, compared to the low annual wages of 
target group members in  HPGR, the compensation offered might amoun t to an 
undue influence. 
From the above case, we can appreciate that seemingly simple offers could be a 
decision-impairing inducement rendering   members of target groups in HPGR  
incapable of appropriately considering research risks. In this situation, they have 
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fulfilled the definition of CIOMS that they are ‗relatively or absolutely incapable 
of protecting their own interests.‘
40 
In addition, there are also other concerns about the potential vulnerability of 
target groups of HPGR, especially in developing countries, such as the PRC. In 
China, medical care in each county is administered through a three-tier (county, 
township, village) service network, which was established a quarter of a century 
ago to provide medical services for all residents.
41 It is quite  convenient and 
efficient to conduct biomedical research through collaboration with this medical 
care service network. Meanwhile, in pursuing a better future for their personal 
career, some physicians  in developing countries   like to conduct collaborative 
HPGR  with Western research institutions . In these  HPGRs, they may dispatch 
personnel to be trained in foreign research institutions, experience how foreign 
researchers conduct HPGR and even publish co -authored journal articles.
42 
However, these physicians are also practitioners in the health service network of 
the country; thus, they are reli ed on by the local people. HPGR conducted by 
these local physicians may provide a misconception to members of target groups 
of HPGR  that the project is  risk-free and might  be good for their health. This 
situation would  exacerbate the consent-based vulnerability of target groups of 
HPGR and there might be a risk of undue influence if local doctors encourage 
participation.  
3.1.2 Risk-based Vulnerability of Target Groups in HPGR 
Risk-based vulnerability refers to a situation where the risks to subjects are not 
reasonable, compared to the potential benefits of the research. According to 
Coleman, risk-based vulnerability may be ‗jeopardized if some subjects are at 
risk of greater than usual harms from participating in research.‘
43 For example, if 
the primary risk of an HPGR is the potential disclosure of the genetic evidence of 
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the  origin  of  ethnic  or  isolated  group,  the  target  group  can  be  considered 
vulnerable if it has its own narrative origin stories which have been believed to 
be the foundation of its collective identity.  
In  general,  IRBs  or  RECs  should  address  risk-based  vulnerability  and  require 
additional safeguards to protect the subjects‘ interests. In the context of HPGR, 
however,  the  situation  is  more  complicated.  As  discussed  in  Chapter  2,  the 
potential risks of harm caused by HPGR include external harms, such as group 
discrimination and group stigmatizations as well as internal harms, such as group 
self-conception of genetic determinism and self-stigmatization. External harms 
might  perhaps  be  assessed  by  IRBs  or  RECs,  although  they  are  not  usually 
required to do so, but internal harms, which are specific to an ethnic or isolated 
group, are  difficult to identify  correctly by any agent outside  of the specific 
group. Foster, Sharp et al provided an example from the Indian Health Service 
(IHS) Headquarters IRB, which can illustrate this point. 
… the Indian Health Service (IHS) Headquarters IRB has 28 members, 
20  of  whom  are  Native  Americans  (including  MD-  and  PhD-level 
researchers,  health  professionals,  and  laypersons  from  Native 
communities). Despite its unique composition, however, the IHS IRB 
sometimes  is  unable  to  predict  what  a  specific  Native  community 
views  as  the  primary  risks  to  itself.  Two  recent  examples  include 
worries about the use of genetic research into migration history to 
attack tribal sovereignty and concerns about the use of mitochondrial 
DNA  and  Y  chromosome  research  in  claims  about  who  is  or  is  not 
‗Indian.‘ These risks were identified only by community review, not by 
any IRB.
44 
In this case,  the HIS IRB included  many American Indian and American Native 
(AI/AN)  members,  which  reflected  the  IRB‘s  regard  for  the  sensitivity  of 
indigenous communities. However, even here there have been instances where 
the IHS IRB has failed to identify potential risks of internal group harms that 
were of concern to members of the target population, such as culturally specific 
harms. The reason why the IHS IRB, with its unique composition and wide range 
of experiences with AI/AN communities, failed to identify such potential risks 
may  include  following  two  aspects:  firstly,  the  members  from  certain  target 
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groups often fully understand their socio-cultural traditions, but they may lack 
sufficient  knowledge  on  biomedical  research  and  sufficient  training  on  the 
proper conduct of ethical review. Secondly, ordinary IRBs or RECs members, due 
to deficiency in knowledge of cultural background of target groups, could not 
correctly identify potential the potential risks of internal group harms or give 
them  sufficient  weight.  Therefore,  unless  IRBs  include  target  group 
representatives  with  appropriate  training  on  ethical  review,  and  there  is 
sufficient community consultation and investigation of group cultural sensitivity, 
IRBs may be unable to assess these potential risks correctly. 
The absence of  sufficient  understanding  of the cultural sensitivities of target 
groups by researchers may also lead to a failure to address these risks of harm in 
their  research  protocol  or  not  providing  adequate  information  disclosure  on 
these risks. For example, in the Havasupai Indian Tribe case,
45 ASU researchers 
collected  more than 200 blood samples   from tribe members   for research on 
diabetes  and genetics in 1990. Th e consent  form described the project   as 
studying ‗the causes of behavioural/medical disorders,‘
 46 but in the pre-research 
communications with tribal leaders, it was agreed that the samples should be 
used  in  research  focused  on  diabetes.  However,  the  researchers  used  the 
samples in several other research projects unrelated to diabetes, sharing them 
with other researchers, and publishing several articles based on data from tribal 
members‘  blood  samples.
47 Among  these  research  publications,  ‗some  of  the 
papers generated from the blood samples dealt with schizophrenia, inbreeding 
and  theories  about  ancient  human  population  migrations  from  Asia  to  North 
America.‘
48 The focus on schizophrenia raised stigmatization issues for the tribe 
along with concerns related to a cultural belief that inbreeding brings harm to 
one‘s  family.  Furthermore,  evolutionary-genetics  research  suggested  that, 
contrary to the tribe‘s own origin story, its ancestors migrated across the Bering 
Sea, creating the possibility of cultural harms.
49 Although the core legal question 
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of the Havasupai case was whether the downstream uses  of the samples fell 
within the scope of the donors‘ informed consent, it also illustrates that the 
unique cultural beliefs of a target group might be a barrier to researchers and 
IRBs or RECs actually identifying potential risks of harm that may be caused by 
research to target groups and their members. It also implied the responsibility of 
researchers to ensure that the study population‘s perspectives are understood 
and considered. Thus, isolation and specific cultural sensitivities can increase 
the risk-based vulnerability of target groups in HPGR. 
3.1.3 Justice-based Vulnerability of Target Groups in HPGR 
This kind of vulnerability concerns the violation of the principle of justice in 
research  ethics.  The  concern  that  target  groups  of  HPGR  are  particularly 
vulnerable to exploitation is a consideration of justice-based vulnerability. 
Exploitation is a complex concept which has been explained in several different 
ways.  Generally,  there  are  two  elements  considered  to  be  essential  to 
exploitation: (1) using people as mere means for the ends of others (a Kantian 
sense  of  exploitation)
 50 and/or  (2)  taking  unfair  advantage  of  people.
51 Thus, 
exploitation usually occurs ‗when wealthy or  powerful individuals or agencies 
take advantage of the poverty, powerlessness, or dependency of others by using 
the latter to serve their own ends (those of the wealthy or powerful) without 
adequate  compensating  benefits  for  the  less  powerful  or  disadvantaged 
individuals or groups.‘
52 
In the context of HPGR, target groups who are usually poor, less-educated and 
lacking social and economic resources, may not understand that they might be 
used as means to others‘ ends, or might agree to participate in an exchange 
without  realizing  its  inherent  unfairness.  As  noted  previously,  researchers  or 
research institutions may provide some free primary drugs or simple treatment 
in exchange for the genetic samples and consent forms signed by participants. 
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These participants may not even realize that the outcome of the research may 
not benefit them and will have no (positive) meaning for them. Thus, they are 
likely  to  become  ‗mere  means‘  of  HPGR.  This  could  lead  to  justice-based 
vulnerability in this situation as they cannot realize they might be exploited by 
others.  Identifying  whether  or  not  researchers  are  in  fact  taking  unfair 
advantage of target groups in HPGR is more complex. The core issue here is to 
assess whether the level of benefit which the researchers or research institutions 
will get is fair or unfair. Exploitation would be identified if benefits are unfair, 
and would not require the existence of actual harm to have occurred. 
In addition, the isolated locations raise another possible source of vulnerability 
for  target  groups  of  HPGR.  They  have  rare  opportunities  to  get  the  offers 
provided  by  HPGR  researchers,  such  as  free  primary  healthcare  services, 
common drugs or trivial amounts of cash. Fewer choices and limited bargaining 
power may exacerbate the justice-based vulnerability of target groups in HPGR. 
For  example,  a  research  institution  affiliated  to  a  university,  such  as  the 
research organization in the Harvard case in China, could offer several summer 
course places to students of ethnic minorities or isolated groups in rural areas in 
developing countries in exchange for 1,000 genetic samples and signed consent 
forms from these groups. Although this offer costs only a trivial amount for the 
research institution, it could be immensely attractive to target groups, because 
without this offer they will have no other such opportunity. Thus, target groups 
probably feel that they have to take this offer. Meanwhile, compared to the risks 
of harm, such as the internal and external harms that may be caused by HPGR 
that  I  have  discussed  in  Chapter  2,  several  summer  course  places  may  be 
perceived as an inadequate benefit. Therefore, target groups of HPGR might be 
considered to have been exploited if they accept this offer.  
On the other hand, some might argue that although from the perspective of a 
neutral  observer,  this  offer  is  inadequate,  nevertheless,  for  target  groups, 
several  summer  course  places  at  a  top  university  could  be  a  reasonable 
recompense for their participation in HPGR. To those target groups, even this 
arguably  unfair  benefit  is  an  option  that  could  let  several  students  of  these 
groups gain further education. Thus, they may  question whether these target 
groups are being exploited. The following example can illustrate why to use the Chapter 3 
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viewpoint of the vulnerable groups as the standard of fairness is problematic. If 
a rich man from a developed country offers an extremely poor man a substantial 
payoff to induce this poor man to be her/his slave, this substantial payoff could 
help the poor man to afford to give his whole family a better life. He has no 
alternative way to gain a better life for his family. However, this substantial 
payoff actually is trivial to the rich man; and to be a slave is a violation  of 
primary human rights. Thus, this is obvious exploitation. Therefore, it requires a 
neutral standard of fairness to be used as a tool for distinguishing between fair 
and unfair benefits, thereby protecting vulnerable parties from exploitation. In 
the context of HPGR, the objective baseline of fairness should be drawn by the 
ethical review committees with the involvement of target group representatives, 
based on the specific economic and cultural context of  certain target groups. 
Without  a  neutral  standard  of  fairness,  target  groups  may  be  vulnerable  to 
exploitation in HPGR. 
The justice-based vulnerability of target groups in HPGR is also relevant to the 
background conditions in the developing countries where the HPGR is conducted. 
The background conditions include lack of effective legal regulations and ethical 
guidelines on human subject protection together with  poor law  enforcement, 
inadequate  experience  of  or  capacity  for  conducting  ethical  and  scientific 
review of proposed research; poor local infrastructure; untrained personnel and 
limited  technical  capacity  for  conducting  the  proposed  research  itself.  Most 
developing  countries  have  no  stringent  rules  on  the  basic  requirements  of 
research involving human subjects, such as informed consent or the welfare of 
human subjects, not to mention effective legal regulations and ethical guidelines 
on human subject research. This situation has led to several troubling examples 
of research trials in developing countries. For example, the Pfizer incident in 
Nigeria during an epidemic of meningitis in children  in 1996  illustrates these 
issues,  although  it  involved  clinical  research,  rather  than  HPGR.  Pfizer,  an 
American  multinational  pharmaceutical  company,  conducted  a  trial  of  an 
antibiotic at the site of the outbreak of a meningitis epidemic in the northern 
state  of  Kano,  where  15,000  people  were  alleged  to  have  died  from  these 
epidemics. Kano is a typical poor area in a developing country, so even the Kano 
Infectious Diseases Hospital, where the trials took place, was reported to be at 
the time a poor, dirty hospital with few beds, poor power supply, and no clean Chapter 3 
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water. Pfizer conducted the clinical trials in Kano to investigate whether the 
oral  form  of  Trovan  was  more  effective  and  efficient  in  treating  children 
infected with meningitis than other existing treatments, including Ceftrixacone, 
the gold standard treatment. Pfizer‘s Trovan had not been previously tested in 
children. However, about 200 infected children participated in the Kano trials. 
100 of the children took Trovan while another 100 were put on Ceftrixacone. 11 
died  in  the  trials,  5  of  whom  were  on  the  experimental  drug,  Trovan,  given 
orally, while the other 6 were on injections of Cetrifaxone.  There were also 
other children involved in the trials who suffered seizures, or became paralysed. 
While  there  is  no  evidence  that  Trovan  was  responsible  for  the  deaths  and 
injuries to children, the trials were conducted within a period of two weeks and 
Pfizer  left  immediately  thereafter.
53  This case was   first publicised by the 
Washington Post in an investigative article on the c onduct of clinical trials by 
developed country researchers in developing countries. According to the report, 
there was no informed consent, no follow-up of the children after conclusion of 
the trial and no parents of the children had been adequately informed about the 
trial.  What is more , there was no approval of the research protocol by an 
independent ethics review committee  - there was no ethics committee in the 
hospital at the time  of the trial.
54 There were no legal regulations or ethical 
guidelines in Nigeria at the time of the trial requiring Pfizer to obtain any such 
approval. When charges of unethical conduct were  made, Pfizer alleged that 
apart from the goals of obtaining information about the efficacy of the drugs, 
‗another  major  reason  for  conducting  the  trials  was  to  provide  humanitarian 
services  to  the  infected  victims  who  were  obviously  in  need  of  medical 
assistance at the time.‘
55  
This case highlights the common situation of lack of effective legislation and 
regulations on biomedical research governance and human subject protection in 
developing  countries.
56 It has been suggested that r esearchers and research 
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institutions  have  all  too  often  defended  their  apparent  double  standards  of 
research ethics in research conducted in developing countries. On the one hand, 
they apply a higher standard of research ethics in their own countries according 
to the relevant legal regulations and ethical guidelines, as well as undertaking 
strict implementation of those rules. On the other hand, these researchers and 
research institutions have proposed and accepted a less demanding standard of 
research  ethics  in  developing  countries,  where  effective  and  adequate  legal 
regulations and ethical guidelines on human subject protection is lacking.
57 They 
may also argue that they have offered participants free physical tests - even free 
treatments such as drugs, - which are needed by these participants and would 
benefit them. However,  it can be argued that  those researchers and research 
institutions take unfair advantage of their richness in economic and social terms. 
Accordingly,  Macklin suggests  that whole communities or countries may be 
vulnerable to exploitation, particularly if ‗investigators or sponsors are from a 
powerful  industrialized  country  or  a  giant  pharmaceutical  company  and  the 
research  is  conducted  in  a  developing  country.‘
58 Therefore,  the  absence  of 
specific regulations and standards for HPGR together with poor law enforcement 
in most developing countries make target groups of HPGR particularly open to 
justice-based vulnerability. 
Consequently, what is significant to note about HPGR in developing countries, is 
that  even  if  the  relational  autonomy  model  is  applied,  which  lets  individual 
participants  take  into  account  the  interests  of  the  group  and  other  group 
members  when  considering  whether  to  consent  to  participate,  given  the 
vulnerability of target groups stated above, it is possible that this would not be 
sufficient to take account of the need to protect all of those who had interests 
at stake. Thus, it is reasonable to suggest that additional protection for target 
groups in HPGR, such as the involvement of the target group as a whole in some 
way, is needed. Nevertheless, it also needs to be  reiterated that arguing for 
group involvement in review of HPGR does not mean advocating group consent 
instead of individual consent. The following section will  nevertheless propose 
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that the target group, or representatives of it, should and could be involved in 
the protection of the group‘s interests. 
3.2 Justifications for Protection of Groups in HPGR 
3.2.1 Critiques of Group Protection in HPGR 
The suggestion that the group as a whole should be protected in HPGR has been 
criticized, since some researchers have doubted that HPGR may lead to potential 
harms for the group as a whole. They have argued that the actual human groups 
under study, human demes, are unidentifiable before research begins,
 since it is 
only when genetic relationships have been established as a result of the HPGR 
study that such a group can be said to exist,
59 thus, there is no group collective 
interest to be harmed in HPGR.  Furthermore, the idea of a group as a rights -
holder has been met with scepticism or outright rejection by  some researchers, 
ethicists, and legal scholars.  The opponents of group protection in HPGR  have 
argued that it is hollow rhetoric to set up a group as an independent entity to be 
protected from the risks of harm in HPGR.
60 Their arguments almost always focus 
on the argument that groups lack moral standing and that seeking to obtain prior 
group permission is not possible in HPGR. 
To explain these criticisms in more detail,  Juengst argues that there are two 
different understandings of a group in HPGR. Firstly, the term ‗target groups‘ in 
HPGR refers to genetic populations or human demes: in his opinion, this type of 
group has no moral standing and cannot be approached for  group consent or 
group permission, since these groups are unidentifiable until the research itself 
has been conducted.
61 Human demes or genetic populations are groups which are 
‗picked  out,  described,  and  compared  in  the  course  of  population-genomics 
research‘;
62 thus, they are not identical with named social groups which might 
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perhaps deserve respect as an independent entity. Since they are the nameless 
demes which are created by researchers of genetic research, as well as  ‗the 
results of mixed lineages that make hash of most of our familial origin stories 
and  social  groupings,‘
63 Juengst  considers  that  these  human  demes  are  ‗not 
autonomous, self-identified human groups, and it would be dangerous to devise 
a system that suggested that demes should be invested with special social value 
or identity.‘
64  Juengst goes on to state that: 
….  given  our  species‘  long  history  of  using  putative  genetic 
relationships  as  the  basis  for  nepotism,  tribalism,  racism,  and 
aggression,  aspiring  to  invest  human  demes  with  special  moral 
standing seems wrong-headed in the first place. If we are right in our 
convictions that our biological roots should be irrelevant to the ways 
in which humans regard each other, promoting our demes as groups 
with interests of their own makes no more sense than reviving old 
eugenic attempts to reify the concepts of ‗race,‘ ‗genetic stock,‘ or 
‗germ plasm.‘
 65  
He concluded that the genetic concept of a human group should just be a tool 
that helps in organizing scientific data in HPGR, but not a way of classifying the 
members of the human species.
66 Thus, if a human deme does indeed mean the 
same as  the target group of HPGR, there is neither moral standing of group 
collective interests, nor would seeking group consent or group approval in HPGR 
be possible or necessary. 
Secondly, even if the group refers to self-identified groups, morally authoritative 
social groups, then in most cases we could approach them for permission ; 
however,  Juen gst  insist s  that  group  permission  in  HPGR  has  its  internal 
limitations. In the first place, the problem of how to define the group still exist s, 
which has also been described as the ‗nesting‘ of local and larger communities. 
The example of the Mohawk,
67 provided by Sharp and Foster, can illustrate this 
problem  well.  I n  the  United  States  and  Canada,  individuals  who  consider 
themselves  Mohawk  may  have  distinct  understanding s  on  what  a  Mohawk 
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community consists of. Some may base this understanding on factors such as 
whether  members  reside  in  a  discrete  local  community,  located  on  a  single 
reservation.  However,  several  of  these  reservation-based  communities  define 
themselves  collectively,  for  example  as  ‗a  part  of  the  League  of  Iroquois,  a 
political and religious organization comprised of six culturally related American 
Indian communities‘.
68 Thus, they argued that nesting all the members of a  self-
identified group is a hard  obstacle. Sharp and Foster warned that ‗the nesting 
problem results from the possibility that the concerns of local communities may 
fail  to  correspond  with  those  of  communities  at  broader  levels  of 
inclusiveness.‘
69 Juengst argues that the practice of nesting local groups within 
larger  social  categories,  as  well  as  cross-cultural  immigration,  would  lead  to 
group consent not having the moral reach to decide for potential participants in 
HPGR.
70 He also points out that there are resource issues if groups are seen as 
the right-holders: 
Accepting  them  [groups  as  right -holders]  would  significantly 
complicate  the  work  of  population  genomicists.  If  groups  have 
interests that require protections like those of individual subjects, a 
layer  of  research  arrangements  would  be  necessary  that  our 
individually-oriented  biomedical  research  ethic  is  ill -prepared  to 
define  or  delimit.  What  would  it  mean  for  a  group‘s  collective 
permission  to  be  ‗informed‘  and  ‗voluntary‘?  If  group  consent  is 
required, are other protections, such as the right to withdraw from 
research, or to confidentiality, also important for groups? How should 
the  ‗researcher-group‘  relationship  be  managed  administratively? 
Moreover,  if  the  logic  behind  the  argument  for  group  rights  in 
population-genomics research is accepted, it is likely to be applied to 
other biomedical spheres as well. 
71 
Sharp and Foster described the costs and demands on researchers when formal 
community approval is required to indicate the same point.
72 They  further 
argued that the practice of group consent is also problematic. They summarized 
this in terms of ‗the dispersion of community‘: 
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A related objection to group consent, one that also can be extended 
to other forms of community review, notes how features of a study 
population‘s  geographical  distribution  can  undermine  the 
effectiveness of involving communities in the review process. It has 
been argued that the dispersion of individual members and the lack of 
frequent social interactions between members of a study population 
combine to limit the effectiveness of community review.
73 
Using these reasons, the opponents of group protection in HPGR have suggested 
that there is no group collective interest that needs to be protected from the 
risks of harm in HPGR, nor could group consent be reasonably obtained and any 
purported group consent would lack moral and legal validity. 
3.2.2 Perspective on Groups as Right-holders 
On the other hand, with respect to target groups of HPGR,  there are several 
scholars who consider that a group should be seen as a right-holder in HPGR. 
First, in HPGR, the effect on individual‘s purely private interests, which are the 
most significant potential risks of harm in other types of genetic research, could 
be protected by anonymising samples. However, the wider risks of harm that 
may arise from HPGR, such as stigmatisation of groups, as has been discussed, 
can  only  threaten  individual  participants‘  welfare  through  their  group 
identities.
74 Thus, the advocates of group protection support their argument 
from the necessity of respect for group identity. For example, Gostin argues that: 
The importance of group identity, a nd of treating social communities 
with dignity and respect, is increasingly well recognized. Human 
beings gain security, happiness, and enjoyment by forming networks 
based  upon  their  special  national  or  sub -national  characteristics. 
Respect  and  beneficence   for  populations  requires  researchers  to 
observe choices made by local communities, and to avoid any activity 
which  stigmatizes,  demeans,  harms,  or  disintegrates  human 
populations, intentionally or inadvertently.
75 
In addition, as ha s been discussed in Chapter 2, members of target groups of 
HPGR tend to identify themselves through and with certain groups to which they 
                                         
73 Ibid., at 47-48. 
74 Foster, M. W., Eisenbraun, A. J., & Carter, T. H. 1997, "Communal discourse as a supplement to 
informed consent for genetic research", Nature Genetics, vol. 17, pp. 277-279. 
75 See supra note 60, at 192. Chapter 3 
Group Protection in Human Population Genetic Research  135 
 
belong, and not as isolated existential individuals. Therefore, members of target 
groups  in  HPGR  are  more  likely  to  largely  accept  their  group‘s  values  and 
priorities  as  their  own,  and  accordingly  they  tend  to  be  protective  of  their 
group‘s interests as reflective of their own interests. This tendency seems to 
support the practice of interests of group as a whole should be considered in 
HPGR by both researchers and ethical review committees. 
Secondly, it has been morally and legally accepted that certain human groups 
can practice collective decision-making. Even those who envision human groups 
as simply free associations of atomistic contractors have to recognize the moral 
authority of many kinds of groups to make collective decisions about the best 
interests of their members.
76 For example, Sanders points out that: 
Group organizations have a particular legitimacy or standing to assert 
rights  on  be half  of  their  members,  which  gives  them  certain 
advantages over individuals seeking redress for rights violations. They 
are the best bodies to seek affirmative action programs, initiate test -
case litigation, handle educational programs, engage with the med ia, 
lobby governments, and choose spokespeople for the group.
77 
In fact, as the proponents of group protection further argue,  the concept of 
autonomy,  or  self -governance,  which  is   widely  accepted  and  adopted  by 
international  human  rights  declarations,  such  as  The  United  Nations 
International Covenant on Civil and Political Rights,
78 in defence of individual 
freedom, has its roots in efforts to protect the ability of particular human groups 
to govern themselves.
79 For example, Michael McDonald supports the community 
as an independent entity of value in this way: 
What the liberal takes as basic and unquestionable is the idea that the 
individual is the measure of everything; hence, the liberal believes 
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that  correct  normative  principles  treat  the  individual  as  the 
fundamental  unit  of  value….Individuals  are  regarded  as  valuable 
because  they  are  choosers  and  have  interests.  But  so  also  do 
communities  make  choices  and  have  values.  Why  not  then  treat 
communities as fundamental units of value...?
80 
Many scholars would agree that if we do not let groups be the entity to make 
decisions on issues related to group identity, it would   undermine both the 
integrity and the autonomy of those groups that enjoy the moral standing to 
make such decisions.
81 For example, Underkuffler poi nts out that on both a 
theoretical and a practical level, the assumed anti -group bias in the Western 
tradition is fraught with weaknesses. She illustrated that  all  of  the negative 
assertions about group collective interests and rights in Western ethics are based 
on the proposition that ‗all moral value is rooted in the well-being of individual 
human  beings.‘
82 Thus,  she  argues  that  if  one  accepts  the  moral  value  of 
distinctly collective interests,  the group  collective interests would have  their 
own moral value as well. On this view, it is normal to entitle a group to be an 
independent  right  holder  to  ‗protect  distinctly  collective  interests,  such  as 
larger  societal  recognition  and  respect  for  the  group‘s  decision-making 
mechanisms, rights, and powers.‘
83 She further argues that:  
From the point of view of what rights do, there is no structural reason 
why legal rights – which guarantee particular states of affairs in law – 
cannot be afforded to groups as well as to individuals. Indeed, the 
idea  that  Western  jurisprudence  shuns  group  rights  is,  itself,  an 
obvious conceptual fallacy. In international law, governments – which 
recognize and enforce individual rights – are themselves groups with 
recognized legal status. In addition, groups of all kinds are recognized 
in a myriad of circumstances. Binding international agreements and 
non-binding  international  declarations  recognize  group  rights  in  the 
contexts  of  cultural  property,  education,  religion,  and  genocide. 
National,  ethnic,  religious,  and  linguistic  minorities,  as  well  as 
indigenous peoples, are afforded group rights.
84 
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Using this argument, the justification for group collective rights in international 
law seems strong. 
3.2.3 Justifications for Protection of Groups in HPGR 
In the first place,  in respect of Juengst‘s first problem, which is  that  target 
groups of HPGR refer either to human demes or social identified groups, it is 
clear that the target groups will already have been identified by the researchers 
in the context of HPGR. As has already been said, they are almost always ethnic 
minorities  or  isolated  groups  in  rural  areas  of  developing  countries,  whose 
members  share  the  same  community  or  group  collective  human  genetic 
information. Even if the result of a particular research project is that the target 
group is not in fact a group given their genetic makeup, this in itself could also 
lead to cultural harms to the target group, as was discussed in Chapter 2. Hence, 
nesting problems cannot be an argument against offering protection to groups in 
HPGR.  
Indeed,  a  great  many  arguments  and  supporting  evidence  can  be  found  to 
provide a justification for group collective rights in international law and human 
rights law. For example, Article 1 of The United Nation International Covenant 
on Civil and Political Rights
85 stated that:  
All peoples have the right of self -determination. By virtue of that 
right they freely determine their political status and freely pursue 
their economic, social and cultural development.
86 
No  matter  how  ‗peoples‘  are  defined,  they  must  be  collectives  consisting  of 
more than one individual. There are also examples, such as the U.N.‘s nation-
building efforts in East Timor and other countries‘ recognition of East Timor as a 
sovereign nation, which can illustrate that the U.N. and other countries regard 
self-determination as a right belonging to an abstract ‗East Timorese people,‘ 
which is a group as a whole.
87 In this case,  self-determination is regarded as a 
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collective right independent of the rights of any individuals who make up this 
group, so the right of self-determination was implemented in good faith for the 
benefit of this abstract group. Since the  right belonged to an abstract group 
above and beyond any of its individual members, the implementation of the self-
determination right was not a matter that was determined by reference to any 
of the individuals, but rather to the abstract group. Thus, although not each 
individual of East Timor voted to be part of a sovereign nation, according to the 
collective ideas of the group, East Timor became a sovereign nation.  
Additionally, in the context of medical law, there are also arguments concerning 
collective human rights to public health which have been used to advance health 
rights in a globalized world. For example, Meier pointed out that although The 
United Nations International Covenant on Economic, Social and Cultural Rights 
(ICESCR)
88 endorsed the right to health and declared the obligation of states to 
provide  the  ‗highest  attainable  standard‘  of  health  for  all,
89  this  highest 
attainable standard is for  each individual, while  the ‗right to health has been 
ineffective in compelling states to address burgeoning inequalities in underlying 
determinants  of  health,  focusing  on  individual  medical  treatments  at  the 
expense of public health systems.‘
90 Distinct from individual human rights that 
need to be enforced by personal action, collective rights operate at a societal 
level, considering the well-being of the whole public, which can only be enjoyed 
by the whole society of people and cannot be fulfilled solely through individual 
rights mechanisms.
91 According to Meier, collective health rights could be a new 
type of independent human right, which would mean that the abstract society or 
state, not each individual, would be the right holder. 
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Thirdly, proponents of group protection also argue that there are real interests 
at stake for human groups in HPGR. This issue has already been addressed, but it 
is  worth  reconsidering  here.  Edlin  has  explained  that  some  genetic 
epidemiological  research  may  lead  to  risks  of  harm  to  participants  and  their 
group  members.  Such  research,  aimed  at  identifying  genes  associated  with 
disease, for example, may find that a certain group carries a relatively greater 
genetic  propensity  for  alcoholism.  This  may  be  interpreted  as  universally 
predictive  for  the  group,  which  could  lead  to  further  harms,  such  as 
discrimination,  stigmatization  and  even  self-stigmatization.
92  What is more, 
Sawyer  and  Hartl  have  argued  that   most  HPGR,  such  as  the  comparative 
genealogical efforts of the molecular anthro pologists, would  pose significant 
risks  to  groups .  According  to  them,  the  genetic  differences  that  most 
contemporary molecular anthropologists use to assess the relatedness of human 
groups consist of medically irrelevant molecular variations in the non -coding 
regions of the DNA, which are then compared to the DNA for functional genes. 
Single mutations are quick to accumulate and can be used quite precisely to 
establish ancestries.
 93 Identifying these genomic hallmarks of particular groups 
would  produce  more  sensitive  gene-based  tools  for  identifying  members  of 
target groups, which may raise the risks of the harm of racism or discrimination. 
Moreover,  Tsosie  also  illustrated  this  point  by  the  example  of  the  Havasupai 
Tribe, referred to earlier: 
...in a case brought by the Havasupai Tribe and its members over the 
use of blood samples, handprints, and genealogy information initially 
taken by researchers at Arizona State University for a diabetes project. 
These materials were then allegedly used by researchers at ASU and 
other institutions for a multitude of unauthorized purposes, including 
research into the frequency of mental health disorders and the origin 
of human populations. Consequently, the affected members sued for 
damages  under  several  legal  theories.  However,  underlying  all  of 
these claims was the allegation that this unauthorized use of genetic 
resources and data not only injured the individuals who gave samples, 
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but  also  caused  a  collective  harm  to  the  Havasupai  Tribe  and  the 
cultural and spiritual beliefs of its members.
94 
She further pointed out that most of the concerns about biotechnology raised by 
indigenous peoples should be regarded as ‗cultural claims‘ that rest on a concept 
of  ‗cultural  rights.‘  Although  the  standard  model  used  to  evaluate  cultural 
claims  suggests  that  ‗such  rights  ought  to  be  adjudicated  within  pluralistic 
societies according to a secular model of rights that respects individual claims to 
autonomy,  equality,  and  liberty,‘  in  certain  situations,  ‗special‘  rights  for 
particular  groups  to  ensure  their  equal  treatment  in  society  can  also  be 
accepted.
95 According to her, HPGR is one of  those special  situations  that 
deserve the recognition of group rights. 
Nevertheless, there remain significant problems in suggesting that target groups 
of HPGR should be deemed to be rights holders in a legal sense. In fact, it would 
be difficult to regard a target group as a rights holder , even if they could be 
identified for a specific HPGR project. As Hartney noted that  
… not all goods (or interest) generate rights ... Goods (or interests) 
may  generate  duties  (e.g.,  of  protection)  but  these  duties  do  not 
correlate with rights, unless there is some specific moral reason for 
protecting  these  good.  There  is  an  importance  deference  here 
between  legal  and  moral  rights.  In  order  to  determine  whether  a 
certain legal rights exists, one determines first whether the law has 
imposed a legal duty on someone, and then whether that duty can be 
interpreted as owed to somebody; since the law can create duties for 
all  sorts  of  reasons,  including  relatively  unimportant,  and  the 
importance of this thing or of the reason for the legal duty do not tell 
us whether there is a right to it. On the other hand, a moral right 
implies  a  good  (or  interest)  sufficiently  important  that  it  warrants 
protection by duties on others. Thus, there are no unimportant moral 
duties, and an estimate of the importance of the good or interest in 
question is central to the determination of the existence of a moral 
right. We have all sorts of legal rights which do not correlate with any 
moral right.
96 
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This statement indicated that there is a difference between recognising a group 
as a legal entity, such as East Timorese mentioned above, and recognising that a 
group have interests that can be harmed. In the context of HPGR, undoubtedly a 
target  group  may  have  interests,  as  they  may  be  harmed,  but  it  does  not 
indicate that target groups should be the right holders. In HPGR, it is difficult to 
argue how a target group could hold rights or enforce them in the context of 
HPGR. Therefore, it can only be suggested that the interests of target groups 
should be taken into account and need protection in HPGR. 
Furthermore, the idea, that a group could be the holder of a legally enforceable 
right to decide whether HPGR  can proceed, would not least face the dilemma of 
creating conflicts between individuals and groups, whether it were to give the 
group  a  right  of  veto  to  research  proceeding,  or  to  allow  group  consent  to 
override individual refusal of consent. Doing so would challenge the baseline of 
respect for fundamental individual rights. Despite this, it is reasonable to argue 
that issues relevant to collective interests should and could be considered in 
HPGR,  even  though  a  group  or  community  approval  of  HPGR  could  not  be  a 
substitute for the decisions made by individual members. Accordingly it needs to 
be emphasized that group consent is not the only way to recognise the concept 
of group/community interests in HPGR. As will be proposed in more detail later, 
the recognition of the possibility of group harms might be achieved in a number 
of alternative ways. These would include group involvement in the design and 
review  of  research  before  individuals  are  asked  to  participate,  taking  group 
collective  views  into  account  by  IRBs/RECs,  asking  representatives  of  target 
groups to be involved in the ethical review process and subsequent monitoring of 
the research and providing them with appropriate training and support to enable 
them to do so effectively.   
3.3 Protection of Groups in HPGR 
3.3.1 Protection of Groups 
At  present,  most  guidelines  for  the  protection  of  groups/communities  in 
research have been drafted for research involving specific indigenous peoples, 
such as American Indians, Alaska Natives, Inuit Peoples, Australian Aborigines, Chapter 3 
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and Maori People. There are three main considerations of these guidelines. First, 
indigenous peoples are often geographically isolated and have their own unique 
histories,  cultures,  beliefs  and  traditions.  The  members  of  these  indigenous 
people often distinguish themselves as a unique and independent group from the 
dominant ones. Second, it has been accepted as a common political aspiration 
by several international political declarations that indigenous peoples have their 
own  rights  to  self-determination  and  autonomy.  There  are  increasingly 
arguments  that  the  responsibility  for  governance  should  belonged  to  the 
groups/communities themselves. For example, Article 3 of the United Nations 
Declaration on the Rights of Indigenous Peoples
97 confers on indigenous peoples 
the right of self-determination and states that ‗by virtue of that right they freely 
determine  their  political  status  and  freely  pursue  their  economic,  social  and 
cultural  development‘.
98 Article  4  of  the  Declaration  also  provides  that  ‗in 
exercising their right to self-determination, indigenous peoples have the right to 
autonomy  or  self-government  in  matters  relating  to  their  internal  and  local 
affairs‘.
99 Third,  indigenous  peoples  are  increasingly  concerned  that  research 
may adversely affect them and their values. 
Therefore,  there  are  several  guidelines  that  have  been  drafted  for  the 
protections  of  indigenous  peoples  in  research.  For  example,  in  Australia,  the 
National Health and Medical Research Council drafted the Guidelines on Ethical 
Matters  in  Aboriginal  and  Torres  Strait  Islander  Research
100 in 1991; and the 
Aboriginal Health Research Ethics Committee of South Australia   drafted the 
Ethical Considerations for Health Related Research Involving Aboriginal People
101 
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in 1998. In the US, the American Indian Law Centre published a Model Tribal 
Research Code
102 in 1999. 
In addition, there are also some  guidelines to protect communities beyond 
indigenous  peoples,  including  the   CIOMS  Guidelines  for   Epidemiological 
Research,
103 and Canada‘s Tri-Council Working Group on Ethics document, Code 
of  Conduct  for  Research  Involving  Humans,
104 which articulate guidelines to 
protect a variety of collective interests of groups. 
According to the reviews of the Australian National Health and Medical Research 
Council
105 and  the  American Indian  Law Centre,
106 the requirements for the 
protection of a group/community can be organized into five themes. I f they are 
to provide adequate protection to a target group/community in HPGR, however, 
there are several shortcomings in each theme, which need to be addressed. 
(1) Consultation in protocol development: a lmost all of the guidelines  require 
that researchers respect the culture of the community , suggesting widespread 
agreement about the need for consultation early in the research developme nt 
process.
107 For example,  Guidelines on Ethical Matters in Aboriginal and Torres 
Strait Islander Health Research noted that  
1. In the preparation of the research proposal, the researcher has 
sought advice not only from State, Territory and Federal Aborigi nal 
and  Torres  Strait  Islander  Health  agencies,  but  also  from  local 
community-controlled  Aboriginal  and  Torres  Strait  Islander  health 
service and agencies. 
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2. The Aboriginal and Torres Strait Islander community, or appropriate 
community  controlled  agency  able  to  represent  the  Aboriginal  and 
Torres Strait Islander group which is the focus or context of research, 
has  indicated  that  the  research  being  proposed  will  be  potentially 
useful to the community in particular or Aboriginal and Torres Strait 
Islanders in general, and will be conducted in a way that is sensitive 
to the cultural and political situation of that community.
108  
However, none of these guidelines provides guidance on how to cope with 
circumstances  when  it  may  be  unclear  who  represent s  a  particula r 
group/community.  In  addition,  none  address es  the  problem  of  oppressed 
individuals within a group/community. 
(2) Consent process and informed consent: most of the research guidelines 
require that informed consent be obtained from individual research subjects and 
from community leaders on behalf of the community. For instance,  Guidelines 
on Ethical Matters in Aboriginal and Torres Strait Islander Health Research , 
which  regulations  on  informed  consent  has  also  been  applied  by  Ethical 
Considerations for Healt h Related Research Involving Aboriginal People   noted 
that  
3. The researcher has obtained w ritten documentation of consent 
from the communities in which it is proposed to conduct research and 
where this has not been possible, the reasons should be documented. 
In such circumstances, informed consent should be shown to have 
involved:  (a)  provision  of  information  in  a  form  accessible  to 
community members and able to be readily understood by them. This 
information should have included details of the collection and analysis 
of data, and the drafting and publication of reports. It should also list 
any potential costs to the community as well as potential benefits; (b) 
face-to-face  discussions  with  community  groups  and  individuals 
concerned wherever possible and wh ere this has not been possible, 
the reasons should be documented;   (c) the allowance of sufficient 
time for the community and the individuals concerned to assimilate 
and  respond  to  the  information  offered;   (d)  demonstration  of  a 
process for obtaining free consent from individuals as well as written 
evidence  of  consent  by  the  community -at-large;  (e)  provision  of 
information to participants that consent may be withdrawn at any 
time.
109 
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However, there is no guideline considering the situation that the target group 
has  the  cultural  tradition  of  collective  decision-making,  thus  no  guideline 
provides for a specific, clear mechanism for obtaining community permission if 
needed. Besides, these guidelines do not address the issue of consent to changes 
in research design. If consent is required for the research to proceed, then it 
would seem logical that major changes in the agreed-upon protocol should also 
be  agreed  to  by  the  community.
110 The same problem occurs  in  respect of 
withdrawal of consent. 
(3) Involvement in  the conduct of  research: some research guidelines suggest 
that community members be trained to help conduct the research, and some 
think  that  they  should  be  employees  of  the  research  and  receive  fair 
compensation for their work.
111 For example,  Guidelines on Ethical Matters in 
Aboriginal and Torres Strait Islander Health Research   stated in  relation to 
community involvement that  
4. Members of the Aboriginal and Torres Strait Islander community 
being studied will be offered the opportunity to assist in the researc h 
and will be paid for the assistance, and the funds to support that 
assistance are included in the res earch budget proposal. Specifically, 
Aboriginal  and  Torres  Strait  Islander  women,  as  advised  by  the 
community, will be involved when research deals with  women‘s and 
children‘s  issues;  and  the  specific  cultural  and  social  needs  of 
Aboriginal  and  Torres  Strait  Islander  men  would  be  similarly 
recognised.
112 
However,  it  is  rare  to  see  the  requirement  that  group/community 
representatives be involved in the conduct and ethical review of research. 
(4) Access to data and samples: because of the historical exploitation and abuse 
suffered by aboriginal communities in  Australia  and  the  US, the need for 
group/community consent for future use of data is urgent.
113 However, current 
guidelines only provide regulations on the secondary use of personal identifiable 
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and sensitive information. For example, Code of Conduct for Research Involving 
Humans, provided by Tri-Council Working Group in Canada, noted that 
Article 3.4 If identifying information is involved, REB approval must be 
sought for secondary uses of data. REB approval is not required for 
access to non-identifying data. 
Article  3.5  Depending  on  the  sensitivity  of  the  information  and  on 
feasibility,  the  REB  may  also  require  that  a  researcher‘s  access  to 
secondary use of data be dependent on: (a) the informed consent of 
those  who  contributed  data;  or  (b)  an  appropriate  strategy  for 
informing the participants; or (c) consultation with a representative 
group of those who contributed data.
114 
There are seldom statements on the related requirement of storage of  research 
samples and data. Such requirements would refer to  the need for researchers 
and communities to discuss where data or samples will be stored, whether or not 
any will be destroyed, and who ultimately controls them after the completion of 
the research.
115 Guidelines are almost all silent on this issue. 
(5) Dissemination and publication of research results: most of   the  guidelines 
require that a draft report be circulated  for comment before publication,  that 
the participation of the community be acknowledged, and that the consent of 
the community be sought concerning whether the community is identified in the 
final report.
116 For example,  Canada‘s  Tri-Council  Working  Group  on  Ethics 
document noted that  
... participants have the right to know whether they will be identified 
directly or indirectly in publications resulting from the research. It is 
important that prospective participants know whether or not they will 
be  given  an  opportunity  to  comment  on  research  findings  prior  to 
publication.  (Affording  participants  an  opportunity  to  review  and 
comment on research results is one way of building a stronger trust 
relationship  between  researchers  and  participants.)  In  some  cases 
(e.g., when there has been a history of alleged misrepresentation), 
individuals or groups may be unwilling to participate unless they are 
guaranteed the right to review research results and even have their 
comments incorporated in resulting publications. Reviewing research 
results  with  participants  may  also  improve  the  quality  of  research 
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(e.g.,  in  terms  of  correcting  mistaken  impressions  on  the  part  of 
researchers or by including a more comprehensive perspective) and 
also help protect the researcher (e.g., against claims of libel).
117 
These requirements point toward  ‗a  tension  between  the  acknowledgement 
requirement and protecting the identity of the community in research where 
confidentiality is a particular concern.‘
118 
While there are therefore, shortcomings in the coverage of individual guidelines, 
their  existence  nevertheless  illustrates  the  possibility  of  taking  into  account 
collective risks posed by HPGR. The need for the involvement of target groups or 
their  representatives  in  identifying  issues  of  concern  to  them  and  reducing 
vulnerability  are  also  highlighted.  The  question  of  vulnerability,  however, 
deserves some further consideration.  
3.3.2 Protection of Vulnerable Groups 
If  we  accept  that  target  groups  of  HPGR  are  vulnerable,  as  I  have  argued 
above,
119 several  influential national legislation and international declarations 
advocate special protection for vulnerable groups  in biomedical research, such 
as the Helsinki Declaration, CIOMS Guidelines and  Universal Declaration on 
Bioethics and Human Rights ; however,  there has not been a specific  approach 
focused on HPGR and group issues . In the US, federal regulations stipulate that 
institutional review boards (IRBs) are charged with the task of protecting human 
research subjects from coercion and unreasonable risk, and assessing a variety of 
scientific and ethical factors in research.
120 IRBs also must  pay attention to the 
emerging interest in the inclusion of vulnerable minority populations in research, 
including the trend of  biomedical research that focuses exclusively on minority 
populations. The confluence of this new emphasis on the role of  vulnerable 
ethnic minorities or isolated groups and some increased willingness on the part 
of these populations to participate in order to obtain healthcare or economic 
benefits,  raises some difficult scientific and ethical questions for IRBs. The 
                                         
117 See supra note 104. 
118 See supra note 107, at 195. 
119 The discussion can be seen in 3.1, at 109 
120 See 45 C.F.R. § 46.101(a). Chapter 3 
Group Protection in Human Population Genetic Research  148 
 
research community should proceed with caution, focusing primarily on human 
subject protections and special protection for vulnerable groups, but IRBs also 
should evaluate questions of protocol design and scientific validity as they affect 
the inclusion of target groups.  
In order to do so it can be proposed that specific regulations to ensure that the 
interests of vulnerable groups in HPGR are properly considered are  essential. 
Hurst has argued that the ‗concept of vulnerability  …serves to identify groups of 
individuals that do, in fact, need and merit this special care in the application of 
criteria  for  ethical  research.‘
121 He  also  argued  that  the  actions  required  for 
special protection would need to be tailored to the sort of risks to be avoided 
and to the source of the specific vulnerability as follows:  
(1) Breach of confidentiality: as researchers or healthcare providers 
may be at greater risk, IRBs should share in the duty of protection, 
and could require specific anonymisation of data to limit colleagues‘ 
access  to  their  personal  information.  (2)  Unfavourable  risk/benefit 
ratio: vulnerable populations are, for example, terminally ill patients, 
so IRBs share in the duty of protection; their risk/benefit ratio should 
be specifically examined by researchers and IRBs rather than assumed 
to  be  the  same  as  for  other  potential  subjects.  (3)  Being  enrolled 
without valid consent: consent is sought at that time only for those 
parts of the protocol that are truly urgent; the remaining problems 
with  consent  at  that  time  can  be  compensated  by  including  a 
requirement that an independent clinician confirm that enrolment is 
not contrary to the potential subject‘s interest. (4) Being denied the 
benefit  of  research:  participants  in  developing  countries  who  lack 
access  to  healthcare  are  excluded  from  an  important  part  of  the 
social  benefits  of  research;  although  IRBs  are  not  alone  in  bearing 
some  responsibility  for  this,  it  is  among  the  points  they  should 
examine in general, and thus also for the purposes of protecting the 
vulnerable;  minimization:  reasonable  availability  aims  to  minimize 
this problem; compensation: fair benefits aim to compensate it [the 
benefit of research].
122  
This approach concentrates on the responsibility of IRBs which have a moral  and 
legal function to protect vulnerable populations.  However, the actual situation 
of HPGR conducted in developing countries is that there are rarely legislation or 
ethical guidelines which require the exis tence of IRBs or ethical committee to 
                                         
121 Hurst, S. A. 2008, "Vulnerability in Research and Health Care: Describing the Elephant in the 
Room", Bioethics, vol. 22, no. 4, pp. 191-202, at 197. 
122 Ibid, at 198. Chapter 3 
Group Protection in Human Population Genetic Research  149 
 
conduct  ethical  review  on  research  involve  human  beings.  Therefore,  it  is 
proposed that  developing countries that do not have IRBs or RECs should set 
them up, governed by appropriate regulations concerning review. Furthermore, 
members  of  target  groups  in  HPGR,  with  proper  training  on  ethical  review, 
should be part of IRBs or RECs in order to provide a level of consideration and 
protection  of  group  interests.  As  a  result,  in  order  to  provide  adequate  and 
appropriate  protections  to  vulnerable  target  groups  of  HPGR  the  existing 
guidance on research involving human beings needs to be reconsidered. 
3.3.3 Attempts to Protect Groups in HPGR 
There have been several attempts to revise the guidelines to protect groups in 
genetic  research.  For  example,  there  has  been  the  suggestion  that  a  fourth 
principle of ‗respect for communities‘ should be added to ‗respect for persons,‘ 
‗beneficence‘  and  ‗justice‘  –  the  three  basic  ethical  principles  which  were 
referred  to  in  the  Belmont  Report.
123  In  addition,  Sharp  and  Foster  have 
developed an account of ‗community review‘ that includes groups‘ interests in 
the research process. Both of these approaches have pointed out some of the 
unique issues of research with groups or communities and the need to devise 
strategies to bring communities into the process and provide insight into the 
risks  that  the  proposed  research  might  pose  to  communities/groups.  The 
following section will analyse these proposals. 
(1)  A fourth ethical principle: ‘respect for communities’ 
Since  existing  ethical  frameworks,  such  as  that  established  by  the  Belmont 
Report,  ignore  the  interests  of  community  in  research,  some  scholars  have 
argued that the basic principles need to be reconsidered. For example, Childress 
has  argued  that  a  new  meaning  of  ‗person‘  in  the  principle  of  ‗respect  for 
persons‘ is necessary. He noted that: 
Any  serviceable  account  of  biomedical  ethics  in  a  liberal  society 
requires  a central place for the principle of respect for autonomy. 
However, its demands are often unclear because of the complexity of 
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personal actions and values, and because it is not the only source of 
moral guidance. In fact, the richest resolutions of debates in bioethics 
presuppose attention to the claims of other ethical principles as well 
as a fuller interpretation of selves in time and community.
124 
What is more,  according  to Weijer, the communitarian  argument  ‗has  been 
successful in establishing two claims:  first, that self-determination is impossible 
unless  we  presuppose  an  individual  located  within  a  community  (otherwise 
choice  can  never  ‗get  off  the  ground‘);  second,  that  the  interests  of  the 
individual may include the continuation of certain communal practices.‘
125 He 
argued that according to these two claims and Childress‘s assertion, it can be 
concluded that the existing framework of ethical principles needs to be enriched. 
He then analysed several attempts which were intended to accomplish this. For 
example, Levine called for a principle of ‗respect for culture,‘ which focused on 
‗Perhaps instead we should recognize the validity of certain forms of cultural 
relativism and have each culture decide how it should show respect for its own 
persons.‘
126 McCarthy suggested that attention should be paid to respect for the 
family and the community of the research subjects, noting that contemporary 
Western principles stress individual liberty and place less emphasis on the rights 
and dignity of the community, while many third world countries have much to 
teach developed nations about community values.
127 
Weijer  then argued for the creation of a new ethical principle:   respect for 
communities. He suggested that there are at least three arguments that support 
the development of this ‗fourth principle‘: 
…First, even if the continuation of some communal practices is in the 
interest  of  the  individual,  community  interests  are  separable  from 
individual interests. Indeed, individual and community interests may 
even conflict…. Second, an ethical principle does not merely serve the 
purpose of capturing existing moral debate; in other words, principles 
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are  not  merely  descriptive.  Ethical  principles  also  serve  to 
acknowledge the moral status of players…. A new ethical principle, 
respect for communities, would similarly accord moral status to the 
community  and  require  that  the  wishes  and  interests  of  the 
community  be  taken seriously….  Third,  the  principle  of  respect  for 
communities can be justified as other ethical principles have been. 
The sorts of justification required to establish a new principle depend 
on just what one thinks ethical principles are…. Concerns about the 
community  in  research,  and  ultimately  moral  rules  regarding  the 
proper treatment of the community, may be loosely collected under 
the  placeholder  ―Be  sure  and  think  about  the  community‖—the 
principle of respect for communities.
128 
According to him, the principle of respect for communities would  ‗obligate 
researchers to respect the values and interests of the community in the research 
and, wherever possible, to protect the community from harms.‘
129  
After making his case for the need for this new principle,  Weijer went on to 
discuss how it would be implemented. He found that ‗clear guidelines exist for 
research  involving  first  nations  communities,  and  the  guidelines  must  be 
respected and ought to be enforced‘,
130 through careful observation of existing 
research  guidelines  for  researchers  working  in  communities,  both  at  the 
international and  the  domestic level. The guidelines include t he Council for 
International Organizations of Medical Sciences (CIOMS)‘s two sets of guidelines: 
International  Ethical  Guidelines  for  Biomedical  Research  Involving  Human 
Subjects,  and  International  Guidelines  for  Ethical  Review  of  Epidemiological 
Studies; the US Department of Health and Human Services regulations pertaining 
to standards for international research; as well as other guidelines for research 
in first nations communities, such as the National Health and Medical Research 
Council  Guidelines  on  Ethical  Matters  in  Aboriginal  and  Torres  Strait  Islander 
Research in Australia, the American Indian Law Centre published Model Tribal 
Research  Code  in  the  US  and  Canada‘s  Tri-Council  Working  Group  on  Ethics 
document, Code of Conduct for Research Involving Humans, However, he also 
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concluded that ‗difficult challenges lay in the way of developing guidelines for 
research on other sorts of communities.‘
131 
One advantage of Weijer‘s proposed fourth principle of respect for communities 
is  that  it  clarifies  the  reasons  why  communities  and  groups  require  separate 
consideration:  since  the  interests  and  potential  risks  for  communities  are 
separate from those potentially posed for each individual within the community. 
Thus,  in  his  revision  of  individualistic  research  ethics,  he  highlighted  the 
significance of community interests. This proposal goes further than simply the 
provision  of  some  special  measures  to  protect  a  community  in  through  the 
process of informed consent. Thus, this revision is targeted at challenging the 
individualism  of  current  research  ethics  through  emphasis  the  interests  of 
community,  not  just  at  making  some  supplementary  adjustments  to  current 
requirements for individual informed consent, though his premise on personhood 
is still  stuck at the isolated individual without consideration of her/his other 
social relationship and context.  
There are, however, some disadvantages. Firstly, he was not able to identify a 
clear pattern of the use of the word ‗community‘. Having investigated existing 
research guidelines he found that there were different ways to use the word 
‗community‘. Moreover, these research guidelines only extended to ‗aboriginal 
communities‘, such as American Indians, Alaska Natives, Inuit Peoples and other 
indigenous  peoples,  but  did  not  comment  on  how  to  protect  other  kinds  of 
communities.  
Secondly, he failed to establish the relationship between the fourth principle 
and the other three principles. Thus, if there is conflict between individual and 
communal choices, for example between the principle of respect for persons and 
respect for communities, he offers no practical approach to resolve it. 
Thirdly,  he  failed  to  provide  a  practical  strategy  for  implementation  of  the 
fourth principle in research. Merely, he says: 
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The  protections  are  arranged  chronologically,  beginning  with  the 
issues  pertaining  to  consultation  with  the  community  on  research 
design  and  ending  with  issues  arising  from  the  dissemination  and 
publication of research findings. The order is as follows: consultation 
in  protocol  development,  consent  process  and  informed  consent, 
involvement  in  research  conduct,  access  to  data  and  samples,  and 
dissemination and publication of research results.
132 
Therefore, having analysed  the gaps  in  research guidelines  in respect of the 
protection of communities , he concluded that  the existing protections are 
incomplete, but failed to provide an effective alternative recommendation. 
(2)  Community review 
Another  attempt  to  revise  current  ethical  framework  to  protect  a 
community/group in HPGR was put forward by Sharp and Foster. They suggested 
that  the  target  group/community  of  HPGR  is  similar  to  other  vulnerable 
populations,  such  as  children,  pregnant  women,  and  prisoners,  which  have 
already been singled out for special protection. Their approach stresses the need 
for members of study populations to be directly involved in the review process, 
particularly when the research aims to identify genetic variations that may be 
unique  to,  or  more  prevalent  among,  members  of  those  populations.    This 
requirement they encapsulated in the principle of ‗community review.‘
133 
Sharp and Foster proposed that the term ‗community review‘ was  ‗a general 
category describing various approaches to involving populations in the evaluation 
of genetic research.‘
134 They argued that the goals of community review are: 
reviewing  research  protocols  considering  the  cultural  sensitivities  of  specific 
target group; identifying and minimizing the risks of harm that may be caused by 
research  to  all  the  involved  parties,  including  individual  participants, 
participating  communities,  and  others  community  members;  promoting 
collaborations and longer partnerships between researchers and target groups, 
through  communicating  interests  and  concerns  with  each  other;  establishing 
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trust between researchers and  target groups through researchers‘ respect for 
the  social  and  cultural  structure  in  place  within  those  communities;  helping 
provide  additional  protection  for  individual  participants  by  assisting  them  in 
assessing the risks and benefits of the research.
135  
Community review takes four forms; each one attempts to achieve the different 
goals described above. Sharp and Foster described them as follows: 
Community dialogue: t his form of review includes both formal and 
informal discussion of a proposed study and its potential implications  
for a socially identifiable group. These discussions may be initiated by 
researchers or arise independently within a  community after contact 
with researchers. Community dialogue is meant to identify collective 
concerns and consider ways of minimizing research-related risks, but 
does not provide a comprehensive review of the research in question 
and often will not engage a representative sample of community  
members. 
Community consultation: in contrast to community dialogue, this type 
of review is more structured. Community consultation documents and 
records the concerns of a socially identifiable group by consulting  a 
representative subset of its individual members   and organizations. 
Other reviewers can then incorporate   these perspectives in their 
assessments of the research. How these perspectives are documented 
will vary, ranging from structured community forums to the creation 
of an independent community review panel. These forums and review 
panels may choose to endorse or oppose the research  in an explicit 
way, but with community consultation, these   evaluations are n ot 
binding on researchers. 
Formal community approval (disapproval) : an even more structured 
type of community review is the  negotiation of a formal contractual 
agreement  between  researchers   and  a  study  population.  This 
arrangement can be   thought of as roug hly analogous to obtaining 
informed consent from individual research participant. In this form of 
review,  members  of  a  study  population  (or  recognized   political 
representatives) are asked to give their collective   permission for a 
research study. That collective decision, however, is not binding on 
individual community members, who still may choose to participate in 
the research (or not to participate). 
Community partnership: the most structured way to involve members 
of a study population in the review process is to make them partners 
in the research. As partners, members of the study population  are 
involved early in the design of the research project  and ‗review‘ the 
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study by helping to define its goals and methodology, and implement 
its experimental design.
136 
It is argued that  these different forms of community review could be used  at 
various stages of a HPGR, as there are subtle differences in emphasis between 
them.  For  example,  community  consultation  could  be  a  way  to  identify 
community concerns in the initial design of a HPGR proposal; while  ‗subsequent 
consideration of these concerns could prompt researchers  to seek community 
approval  at  a  later  stage  in  the  research,  perhaps  in  connection  with  the 
publication of research findings.‘
137 In addition, these four forms of community 
review are highly dependent on each other. For instance, community dialogue 
and consultation both help to ‗convey respect for members of study populations, 
seeking  formal  community  approval  demonstrates  respect  for  the  decision-
making  authority  of  the  constituent  communities.‘
138  Similarly,  community 
partnership  ‗goes  further  and  suggests  a  deeper  sense  of  respect  for  study 
populations by taking note of the unique social and cultural arrangements that 
exist within participating communities.‘
139 
Sharp and Foster also argued that the form of community review adopted should 
be tailored to be appropriate to a given community, or a particular study, and 
depend on the following factors: (1) the frequency of social interaction among 
members of the study population; (2) the extent of shared socio-cultural belief 
and values that are distinctive to the study population.
140 The determination of 
the most appropriate community review form for a particular HPGR for a given 
community should take these two features into account. According to them, and 
as noted before, the risks that may be caused by HPGR are of two distinct types: 
‗external risks‘ which refer to the possible discrimination and stigmatization of 
members  of  the  study  population;  and  ‗internal  risks‘  which  result  from  the 
disruption of interactions among members of the study population. For instance, 
in a population where interactions between members are infrequent, and their 
distinctive  beliefs  few,  the  main  risks  of  HPGR  involve  potential  misuse  of 
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genetic  information  by  others  outside  the  community,  possibly  resulting  in 
discrimination and stigmatization. These risks are not unique to any particular 
group  and  often  can  be  identified  by  individuals  who  are  not  themselves 
members of the population placed at risk. Nevertheless, community dialogue or 
consultation  can  still  be  helpful  in  identifying  research-  related  risks  and 
assessing how members of the study population view the significance of these 
risks.
141 In contrast, where the frequency of social interaction between members 
of a population is high, and  the distinctive shared socio-cultural beliefs help to 
distinguish members of the population from other communities, HPGR can cause 
additional  risks, such as that  genetic findings could reveal that   their  shared 
socio-cultural belief is mistaken. Therefore, in these communities, the full range 
of community review is essential  to identify the risks that may be caused by 
HPGR.
142 In addition, they also offered a model agreement for genetic research 
in  socially  identifiable  populations,  which  ‗defined  the  scope  of  research, 
provided options for naming the population in publications (including anonymity), 
and addressed the distribution of royalties from intellectual property, the future 
use of archival samples, and specific cultural concerns.‘
143 
There  are  several  advantages  to  Sharp  and  Foster‘s  ‗community  review‘ 
approach to protecting target groups/communities in HPGR. Firstly, they address 
the unique risks that groups/communities may face in HPGR, especially ‗internal 
risks‘ which can probably only be recognized within the group; and suggested 
that these implications should be factored into  the  risk-benefit evaluation of 
proposed  research.
144  Although  IRBs  and  other   review  measures  could  be 
instructed to pay special attention to possible intra-community risks, including 
the  disruption   of  existing  social  arrangements  and  relationships  between  
members of a study population , the active involvement of the  target group in 
community review can help identify  internal risks in populations whose socio-
cultural traditions and structures differ from  those of IRB members. Secondly, 
they illustrated four distinctive forms of community review and their main 
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features,  and  proposed  a  means  to  choose  the  most  appropriate  forms  of 
community  review  for  the  target  group  in  a  specific  HPGR.  Thirdly,  they 
established a model agreement for obtaining community consensus for HPGR in 
an Apache tribe in Oklahoma. The essence of the model is that research should 
be preceded by careful efforts to understand how decisions are made in the 
particular community. This process of reaching communal consensus provides a 
feasible approach to  generating  a general model which may be suitable as a 
standard for evaluation of the collective risks for target groups in HPGR. 
There  are,  however,  also  disadvantages  to  community  review.  Firstly,  its 
feasibility is problematic for two reasons: (1) the nesting of community - there 
are difficulties resulting from the fact that individuals are members of multiple 
communities, many of which are nested within each other. The complexity of 
human population structure poses more than practical difficulties for the notion 
of community review. For example, as has been discussed, Juengst has argued 
that the nesting problem results from the concerns of local communities that 
may  fail  to  correspond  with  those  of  communities  at  broader  levels  of 
inclusiveness; hence, consulting with larger communities may fail to identify the 
unique  cultural  concerns  of  local  communities,  and  correspondingly,  the 
concerns of local communities may fail to reflect those of larger communities.
145 
(2) The  extent of dispersion within communities: it has been argued that the 
dispersion  of individual members and the lack of frequent social   interactions 
between members of a study population combine  to limit the effectiveness of 
community review.
146 In widely dispersed populations, individuals may be viewed 
by outsiders as members  of the same community, though they rarely interact 
with each other socially. 
Secondly, community review is  only one element of  protecting members of a 
community/group if an individualistic approach is taken to consent in  research. 
The community collective interests would be considered by researchers and 
ethical review committees throu gh group involvement. Nevertheless, the final 
decision of  an  individual on HPGR participation  might  still  be  based on the 
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information on potential effects on him or her, rather than taking into account 
the need for information disclosure to include potential group harms.  
Thirdly,  the  inappropriate  use  of  community  review  may  harm  the  target 
group/community in HPGR. As Juengst noted, ‗acting as if social groups were the 
groups under study suggests that they are reducible to the demes we construct 
around them, setting the stage for new forms of scientific racism and providing 
new tools for discrimination; moreover, geneticists expect that the biological 
populations  they  pick  out  will  ultimately  ―correct,‖  rather  than  respect,  the 
indigenous  beliefs  that  they  were  ostensibly  commissioned  to  celebrate.‘
147 
Hence,  researchers  implementing  a  community  review  approach  to  socially 
identified groups without fully cultural sensitivity consultation might harm them 
by reifying race, ethnicity, and other socially constructed categories, since it 
might reinforce the idea that biological differences underlie social differences 
between communities. 
Therefore,  although  the  application  of  both  ‗respect  for  community‘  and 
‗community review‘ would offer some help for group protection in HPGR, since 
both  of  them  have  some  weaknesses,  neither  of  them  alone  would  provide 
sufficient protection to the interests of target groups in HPGR.  
In summary, a target group may be vulnerable in the context of HPGR, especially 
where  the  HPGR  is  conducted  in  developing  countries.  Target  groups,  are 
vulnerable  to  all  three  types  of  vulnerability:  consent-based,  risk-based,  and 
justice-based  because  of  low  education  levels,  difficulties  in  correct 
understanding  of  the  risks  of  HPGR,  or  undue  inducement.  These  common 
characteristics of target groups all make them more likely to accept risks that 
are either not understood or appreciated, or that are unfair. Target groups of 
HPGR are thought to be vulnerable to exploitation, because the researchers or 
research institutions of HPGR, who are mostly research institutions or companies 
from developed countries,  may be more likely to take unfair advantage of their 
inadequate  economic  and  social  resources  by  offering  target  groups  unfair 
‗benefits‘  in  exchange  for  their  participation.  If  HPGR  relies  on  individual 
consent to enrol participants who are vulnerable, target groups may not be able 
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to protect their own interests properly. Furthermore, the absence of effective 
and  adequate  legal  regulations  and  ethical  guidelines  in  most  developing 
countries, as well as poor law enforcement, also exacerbate the vulnerability of 
target groups in HPGR. Therefore, the target group and its members need to be 
protected as vulnerable groups in HPGR by specific legal and ethical regulations, 
regarding the specific situations and cultural sensitivities of target groups.  In 
addition to information disclosure on group harms to potential participants to 
enable  individuals  to  consider  such  issues  as  part  of  their  own  risk-benefit 
assessment  before  they  are  asked  to  consent,  the  collective  ideas  of  target 
groups on issues relevant to group collective interests should also be considered. 
It  can  be  suggested  the  target  group  involvement  in  HPGR  is  needed.  An 
alternative model of group protection in HPGR, with the consideration of both 
appropriate  information  disclosure  and  group  involvement,  will  be  offered  in 
Chapter 5 in the context of the PRC. In order to explain the particular context of 
HPGR in the PRC, the next chapter will consider  the social and legal factors 
relevant to such research. Chapter 4 – People’s Republic of China: A Mother 
Lode of Genes? 
4.1 Current Legal Regulations and Ethical Guidelines on 
HPGR in the People’s Republic of China 
It has been indicated that, in this thesis, the People‘s Republic of China will be 
used  as  a  model  to  demonstrate  the  difficulties  associated  with  HPGR  in 
developing countries.  For that reason, this chapter will provide a description of 
the current legal system in China and will evaluate the relevant law/guidelines 
currently  in  place  in  respect  of  human  subject  research,  with  particular 
consideration of their relevance and adequacy in respect of HPGR. 
4.1.1 Brief Introduction of Chinese Legal System 
The People's Republic of China (PRC) is a socialist State. Since the Third Plenary 
Session  of  the  Eleventh  Central  Committee  of  the  Communist  Party  of  China 
(CPC) in 1978, China has attached more importance to the role of law in State 
administration and social life by strengthening the legislative framework. It has 
sought  to  steadily  improve  legislative  procedures,  laying  stress  on  legislative 
techniques and the quality of legislation. At present, ‗ruling the country by law‘ 
is the fundamental guideline to administer the state and manage society under 
the leadership of the CPC, and this was written into the Constitution of the PRC
1 
in 1999. The PRC has been actively building and seeking to improve its legal 
system since its foundation. As a result, a socialist legal system ,  with the 
Constitution as its core and with Chinese characteristics, has taken shape.
2  
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text of the Constitution can be seen on the official website of Chinese government (in Chinese), 
available on http://www.gov.cn/ziliao/flfg/2005-06/14/content_6310_4.htm, last visited on 2011-
01-26.  
2 The introduction of China‘s legal system and legal structure is based on the information provided 
by official website of Ministry of Justice of the PRC, available on http://www.legalinfo.gov.cn/, 
last visited on 2010-05-05.  Chapter 4 
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The Chinese legal system is similar to the civil law systems of Japan, France and 
Germany.
3 The primary sources of law in  PRC are written legislation. The PRC‘s 
legal system contains branches as follows: constitutional and related law, civil 
and commercial law, economic law, administrative law, social law, criminal law, 
litigation  and  non-litigation  procedural  law.
4 Cases cannot be cited as legal 
sources in Chinese courts.  
According to the Constitution, Chin a implements a unified legislative system, 
which is to say that there is only one legislative system, albeit of multiple levels, 
in the country. The Constitution stipulates that the  National People‘s Congress 
(NPC) and its Standing Committees exercise the legislative power of the State to 
enact laws. The State Council formulates administrative regulations according to 
the  Constitution  and  laws.  The  National  People‘s  Congress  and  its  Standing 
Committee of each province, autonomous region or municipality directly under 
the Central Government formulate local regulations, which must not contravene 
the Constitution, laws or administrative regulations. The People‘s Congress of 
each  national  autonomous  area  has  the  power  to  enact  regulations  on  the 
exercise  of  autonomy
5 and separate regulations in the light of the political, 
economic and cultural characteristics of the nationality or nationalities in the 
area concerned. Departments of, and agencies with, administrative functions 
directly under the State Council form ulate rules according to the laws and 
administrative  regulations  of  the  State  Council .  In  addition,  the  people‘s 
government of each province, autonomous region or municipality, as well as the 
people‘s  government  of  the  city  where  a  province  or  autonomous  region  is 
located, and of the city where a special economic zone is located or larger cities 
designated  by  the  State  Council,  may  formulate  rules.  As  to  a  special 
administrative region, which refers to Hong Kong and Macao, according to the 
principle of ‗one country, two systems‘
6 and the provisions of Article 31 of the 
                                         
3  For China‘s legal system, see, Chow, D. 2003, The Legal System of the People's Republic of 
China in A Nutshell St. Paul, MN: West Group. See also, Hsu, C. 2003, Understanding China's 
Legal System, New York: New York University Press. 
4 These branches are divided by Ministry of Justice of PRC, see supra note 2. 
5 The detailed practical system and functions of ethnic minority autonomy will be addressed in 4.3.2. 
6 The Constitution stipulates that the State may, when necessary, establish special administrative 
regions and the systems to be instituted in special administrative regions shall be provided by 
law enacted by the National People's Congress in the light of specific conditions. This is the 
embodiment of the concept of "one country, two systems" in the Constitution. While upholding 
the sovereignty, unity and integrity of the country and that a special administrative region is an Chapter 4 
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Constitution,  the  system  (including  the  legislative  system)  in  a  special 
administrative region shall be stipulated by law enacted by the National People‘s 
Congress.
7  The  sources  of  Chinese  law   include  the  Constitution,  laws, 
administrative regulations, local regulations, regulations of national autonomous 
areas,  regulations  of  special  economic  zones,  rules,  basic  laws  of  special 
administrative regions, international treaties and practices.
8 
The  Legislation  Law  of  the  People‘s  Republic  of  China  (hereinafter  the 
Legislation Law 2000) lays down the general rules of the hierarchy of Chinese 
law.
9 Under the Legislation Law 2000, legislation can be divided into at least 
seven  different  categories:  the   Chinese  Constitution  1982 ;  basic  laws  and 
national law; administrative regulations; local regulations, autonomy regulations, 
separate regulations; administrative rules and local rules (including provincial, 
autonomous and municipal rules, and decrees by major cities). The chart below 
shows the Hierarchy of the Chinese Legal System. The Chinese Constitution 1982 
has the highest legal authority.
10 National law is enacted by NPC  or its Standing 
Committee. It can be divided into two sub -categories: basic laws a nd others. 
There is no clear definition of what laws can be basic laws. The Legislation Law 
2000 does not clearly provide that basic laws are higher than other national laws. 
In practice, however, basic laws are generally considered more important than 
other national laws. Administrative rules are issued by the ‗various ministries, 
                                                                                                                             
inalienable part of the People's Republic of China, such a region is allowed to implement 
economic, social, political and legal systems different from those for other regions of the country, 
that is, its current capitalist system and way of life may remain  unchanged for years. 
7 The Basic Law of Special Administrative Region is adopted by National People's Congress.  
According to the basic laws of special administrative regions, the special administrative regions 
exercise a high degree of autonomy and, except that the foreign affairs and defence remain 
under the power of the Central People's Government, enjoy executive, legislative and 
independent judicial power including that of final adjudication, with their existing legal system 
remaining basically unchanged  as do their existing social and economic systems and ways of 
life.. 
8 The introduction of Chinese legislative system is also based on the information provided by the 
Ministry of Justice of PRC, see supra note 2. 
9  See, Chapter Five Scope of Application and Filing of the Legislation Law of People’s Republic of 
China which was adopted by the 3rd Session of the 9th NPC in 2000. An English translation is 
available at http://www.novexcn.com/legislat_law_00.html (last visited 22-09-2009). 
10  The Legislation Law 2000, Article 78. Chapter 4 
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commissions,  the  People‘s  Bank  of  China,  the  Auditing  Agency,  and  a  body 
directly under the State Council exercising a regulatory function‘.
11  
 
Figure 4-1 The Hierarchy of the Chinese Legal System 
                                         
11  See, Chapter Five Scope of Application and Filing of the Legislation Law of People‘s Republic of 
China which was adopted by the 3rd Session of the 9th NPC in 2000. An English translation is 
available at http://www.novexcn.com/legislat_law_00.html. (Last visited 22-09-2009) Chapter 4 
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4.1.2 Legal Regulations and Ethical Guidelines on HPGR in the 
PRC 
The main legal regulations and ethical guidelines on biomedical research in the 
PRC include ‗Measures for the Ethical Review of Biomedical Research Involving 
Human  Subjects,‘
12 and  ‗Interim  Measures  for  the  Administration  of  Human 
Genetic  Resources.‘
13  Both  of  these  documents  are  formulated  by  various 
ministries of State Council, so they are administrative rules in the hierarchy of 
the Chinese legal system. 
1)  Measures for the Ethical Review of Biomedical Research Involving Human 
Subjects (Measures 2007) 
‗Measures  for  the  Ethical  Review  of  Biomedical  Research  Involving  Human 
Subjects‘  (Measures  2007)  is  the  most  substantial  legal  regulation  on 
biomedical research involving human subjects in the PRC. It was promulgated 
by the Ministry of Public Health of the PRC on Jan. 11
th 2007.  
The  targets  of  the  Measures  2007  are  regulating  biomedical  research 
involving  human  subjects,  protecting  human  life  and  human  health, 
safeguarding human dignity, as well as respecting and protecting the legal 
rights  and  interests  of  human  subjects  of  biomedical  research.
14 Measures 
2007 contains thirty articles and is divided into five sections. I n respect of 
biomedical research involving human subjects, i t essentially sets regulations 
for  the principles of ethical review including   the establishment of   ethics 
committees, measures and procedures  for  ethical review, as well as the 
administration and supervision of such review. In Measures 2007, ‗biomedical 
research  involving  human  subjects  and  the  application  of  its  relevant 
                                         
12 She Ji Ren de Sheng Wu Yi Xue Yan Jiu Lun Li Shen Cha Ban Fa (Shi Xing) [Measures for the 
Ethical Review of Biomedical Research Involving Human Subjects] (in Chinese), available on 
the official website of the Ministry of Health of the PRC: 
http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohbgt/pw10702/200804/18816.htm, last 
visited on 2010-05-06. 
13 Ren Lei Yi Chuan Zi Yuan Guan Li Zhan Xing Ban Fa [Interim Measures for the Administration of 
Human Genetic Resources] (in Chinese), available on the official website of the Ministry of 
Science and Technology of the PRC: 
http://www.most.gov.cn/fggw/xzfg/200811/t20081106_64877.htm, last visited on 2010-05-06. 
14 See supra note 12, Article 1. Chapter 4 
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techniques‘ are defined as research activities on human subjects, adopting 
modern  physical,  chemical  and  medical  methods,  which  focus  on  human 
physiological  and  pathological  phenomena,  as  well  as  the  diagnosis, 
prevention  and  treatment  of  diseases  and  trial  application  activities  of 
medical health techniques or products on human subjects through biomedical 
research.
15 From the perspective of protecting human subjects‘ interests and 
dignity, Measures 2007 highlights that ethical review shall abide by state laws, 
regulations, relevant rules and well-known bioethical principles. Furthermore, 
the  process  of  ethical  review  should  be  independent,  objective,  fair  and 
transparent.
16 
In Measures 2007, the ethical review principles include: 
(1) Respect for and protection of a human subject‘s self-determination and 
right  to  decide  whether  or  not  to  participate  in  certain  research,  strict 
requirements for informed consent, avoiding any improper approach, such as 
deception,  coercion  or  bribery,  to  gain  a  human  subject‘s  consent  and 
allowing a human subject‘s withdrawal from any process of research;
 17  
(2)  The  security,  health  and  interests  of  human  subjects  are  absolutely 
superior to the consideration of scientific and social interests; to endeavour 
to enable the human subject to be benefited to the greatest degree and to 
avoid harm as much as possible;
18  
(3) To reduce or exempt the human subjects‘ financial losses to enable him 
or her to benefit from research;
19 
 (4) To respect and protect the privacy of  the human subject, inform  the 
human subject  about the storage and use of his/her private data and  the 
security measures to protect such data;
20  
                                         
15 See supra note 12, Article 3. 
16 See supra note 12, Article 4. 
17 See supra note 12, Article 14. 
18 Ibid. 
19 Ibid. Chapter 4 
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(5) To ensure timely treatment and appropriate compensation for the human 
subject, if he/she is injured in research;
21  
(6) To provide special protection to vulnerable groups, such as children, 
pregnant  women,  persons   with  learning  disabilities ,  mental  patients , 
prisoners and persons in poor and less-educated positions.
22 
Measures 2007 clarif ies  the role and responsibilities of institutional ethics 
committees, as well as their establishment, membership composition and 
powers  of  examination  and  approval.
23  Meanwhile,  Measures  2007  a lso 
proposes that, according to need,  the Ministry of Health and the provincial 
administrative  departments  of  public  health  should  establish an  ethical 
review guidance and counselling organization , which  will discuss significant 
ethical issues, offer consultations for the drafting of regulations, provisions 
and  policy  measures ,  organize  ethical  review  on  some  major  research 
projects, and guide and supervise the ethical review by institutional ethical 
committees.
24 
In addition, Measures 2007 stresses the role  of government in ethical review 
of biomedical research involving human subjects. In order to ensure the 
quality  of  ethical  review,  the  Ministry  of  Health  and  the  provincial 
administrative departments of public health will supervise the multiple levels 
of  ethical review committees, including the  establishment  of institutional 
ethical committees, ensure compliance with principles for ethical review and 
monitor results.
25 Foreign  researchers or research institutions who conduct 
biomedical research involving hu man subjects inside the PRC should  obtain 
approval from the relevant Chinese   ethical committees and review their 
                                                                                                                             
20 Ibid. 
21 Ibid. 
22 Ibid. 
23 See supra note 12, Article 6-13. 
24 Ibid., Article 5. 
25 Ibid., Article 24. Chapter 4 
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research projects according to Measures 2007, regardless of whether or not 
their research projects have been reviewed in their own countries.
26 
2)  Interim  Measures  for  the  Administration  of  Human  Genetic  Resources 
(HGR Measures 1998) 
‗Interim Measures for the Administration of Human Genetic Resources‘ was 
drafted by the Ministry of Health and the Ministry of Science and Technology, 
and  promulgated  by  the  General  Office  of  the  State  Council  upon  the 
approval of the State Council of the PRC on Jun. 10
th 1998.  
The  primary  targets  of  HGR  Measures  1998  are  efficiently  protecting  and 
rationally  utilizing  human  genetic  resources  in  the  PRC,  strengthening  the 
research  and  development  of  human  gene  technology  and  promoting 
international co-operation and exchange on the basis of equality and mutual 
benefits.
27 In HGR Measures 1998,  ‗human genetic resources‘ are defined as 
materials such as human organs, tissues, cells, blood specimens, preparations 
of  any  types  or  recombinant  DNA  constructs  which  contain  the  human 
genome, genes or gene products. They also include information related to 
such genetic material.
28 HGR Measures 1998 mainly regulates  such activities 
in  the  PRC  as  sampling,  collecting,  researching,  developing,  trading  or 
exporting human genetic resources outside the territory of the  PRC.
29 It has 
six sections and twenty-six articles and contains detailed regulations on the 
administration of human genetic r esources and also the  examination and 
approval  of research on human genetic resource s  in  the PRC. It includes 
provisions concerning benefit-sharing of intellectual property rights, as well 
as rewards and penalties in respect of such research. 
In  general,  in  accordance  with  HGR  Measures  1998,  the  PRC   adopts  a 
reporting and registration system. Any institution or individual who discovers 
or holds important pedigrees and genetic resources in specified regions shall 
                                         
26 Ibid., Article 26. 
27 See supra note 13, Article 1. 
28 Ibid., Article 2. 
29 Ibid., Article 3. Chapter 4 
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immediately report to the Human Genetic Resources Administration of China 
(HGRAC). No institution or individual may sample, collect, trade or export 
human  genetic  resources,  including  both  physical  samples  and  relevant 
genetic  information,  or  take  them  outside  the  territory  of  the  PRC,  or 
provide them to other countries in any form without permission.
30 The State 
adopts a unified review and approval system, regulated at different levels, 
over human genetic resources. The Administrative Department of Science and 
Technology and the Administrative Departm ent of Public Health under the 
State Council are jointly in charge of the administration of the human genetic 
resources of China at national level and had responsibility for establishing the 
Human Genetic Resources Administration of China (hereinafter referred to as 
the HGRAC) to carry out routine duties.
31 
The HGRAC has the following responsibilities: 
(1) To draft the relevant rules and implementing documents; to promulgate 
such  rules  for  entering  into  force  upon  approval  and  to  ensure  the 
enforcement of the Measures through co-ordination and supervision;
 32 
(2) To be in charge of the registration and administration of the important 
pedigrees and genetic resources in the specified regions;
33 
(3)  To  review  and  examine  international  collaborative  projects  involving 
human genetic resources in China;
34 
(4)  To  review  and  approve  applications  for  export  of  human  genetic 
resources,  and  thereafter  to  issue  Export  Permits  for  Human  Genetic 
Materials and;
35 
                                         
30 Ibid., Article 4. 
31 Ibid., Article 6 and 7. 
32 Ibid., Article 8. 
33 Ibid. 
34 Ibid. 
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(5)  Other duties related to the administration of human genetic resources in 
China.
36 
Where human genetic resources from China are involved in any international 
collaborative project, the Chinese collaborating party is responsible for going 
through the appropriate formalities of application for approval. Institutions 
directly  under  the  Ce ntral  Government  must  apply  to  the  relevant 
administrative department under the State Council and local institutions or 
institutions without a specific supervisory department must apply to the local 
administrative departments.  Upon receiving the approval o f the relevant 
departments, the Chinese collaborating party must apply to the HGRAC for 
examination and approval prior to entering into an official contract.
37 In 
addition,  r elevant  departments  under  the  State  Council  and  local 
administrative departments, i n reviewing any application for international 
collaborative  projects,  will  consult  the  relevant  local  administrative 
departments  of  the  region  where  human  genetic  materials  are  to  be 
collected. 
In terms of the intellectual property rights of human genetic  resources, HGR 
Measures  1998  provides  that  t he  Chinese  research  and  development 
institution shall have priority  in  accessing information about the human 
genetic  resources  within  the  territory  of  the  People‘s  Republic  of  China, 
particularly the important pedigrees and genetic resources in the specified 
regions and the relevant data. Providing information and specimens and any 
transfer of such human genetic resources to other institutions are prohibited 
without permission. No foreign collaborating institution or individual who has 
access to the above mentioned information may publicize, publish, apply for 
patent rights or disclose it by any other means without permission.
38 What is 
more, international collaborative projects involving human genetic resources 
must  follow  the  principles  of  mutual  benefits ,  credit  and  trust ,  joint 
participation and sharing of achievements. All of the rights and obligations of 
                                         
36 Ibid. 
37 See supra note 13, Article 11. 
38 Ibid., Article 17. Chapter 4 
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each party should be set out in advance, in order to fully and effectively 
protect their own respective intellectual property rights.
39  
According to HGR Measures 1998, if any Chinese institution or individual, in 
violation of the provisions stipulated in  HGR Measures 1998, exports human 
genetic materials without authorization by any means, the human genetic 
materials will be confiscated by Chinese Customs and the institution or 
individual will be punished. Punishment ranges from administrative sanctions 
to prosecution by the judicial department, according to the seriousness of 
the circumstances.
40 If anyone, in violation of the provisions stipulated in the 
Measures,  provides  human  genetic  materials  to  foreign  institutions  or 
individuals  without  permission,  the  human  genetic  materials  will  be 
confiscated  and  the  institution  or  individual  will  be  fined .  I f  the 
circumstances are serious, he will be investigated for liability according to 
Chinese law.
41 
4.1.3 Critical Evaluation of Existing Legal Regulations and Ethical 
Guidelines on HPGR in the PRC 
While it might seem that the PRC has confronted the issues involved in human 
subject  research  and  particularly  genetic  research  in  a  serious  manner,  on 
reflection  these  regulations  are  not  well  suited  to  HPGR  and  do  not  provide 
adequate protection for participants in such research. The deficiencies can be 
described as follows: 
1)  The  current  rules  are  still  essentially  reactive.  This  means  that  when 
certain  cases  cause  risks  or  harms  to  certain  individuals  or  groups, 
legislation or ethical guidelines will be promulgated, designed to avoid 
the recurrence of similar cases. For example, HGR Measures 1998 was the 
reactive legislation to a number of scandals,
42 such as the Harvard case, 
                                         
39 Ibid., Article 18. 
40 Ibid., Article 21. 
41 Ibid., Article 22. 
42 Doring, O. 2003, "China's Struggle for Practical Regulations in Medical Ethics", Nature Reviews: 
Genetics, vol. 4, pp. 233-239, at 234-235. Chapter 4 
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which has been described above. At that time, in order to reserve the 
benefits relevant to genetic resource and avoid similar genetic resource 
loss cases, China stipulates in HGR Measures 1998 that reserves claims for 
all benefits derived from international biomedical research using Chinese 
biological sources. Hence, as a reactive legislation, the otherwise puzzling 
focus on the interests of the State in genetic research and the absence of 
protection  to  human  subject  and  target  group  in  HGR  Measures  1998  
becomes  understandable.  Accordingly,  these  reactive  legal  regulations 
lack the full anticipation of possible scenarios and are not reviewed in the 
light of the development of biomedical technology. Furthermore, they are 
not at the highest level of the hierarchy of the Chinese legal system. In 
fact,  as  measures  which  legislated  by  the  ministries  of  State  Council, 
Measures 2007 and HGR Measures 1998 only have the lowest legal effect in 
national legislation. If conflicted with other higher level legislation, those 
higher  level  legislation  shall  prevail.  Thus,  Measures  2007  and  HGR 
Measures 1998 are not powerful enough.  
2)  The starting points of these legal regulations and ethical guidelines are 
the State administrative system; hence, they concern the interests of the 
State more than the interests of the individuals or groups who are the 
targets  of  biomedical  research.  Thus,  the  core  regulations  of  HGR 
Measures  1998  provide  for  reporting  and  registration  systems  for 
important pedigrees and genetic resource, as well as the regulations of 
export and intellectual property of human genetic resources in the PRC. 
Nevertheless,  Measure  2007  made  some  positive  efforts  toward  human 
subject  protection.  For  example,  it  clearly  confirmed  that  informed 
consent  should  be  an  essential  requirement  which  needs  to  be strictly 
reviewed  by  ethical  committees.    It  also  stipulates  that  information 
disclosure when seeking consent should be expressed by simple words; in 
minority areas, it can be expressed in local languages to seek to ensure 
that the potential participants have a proper understanding of what is 
involved.
43 When the research  is to be  conducted in minority areas, the 
membership  of  et hical  review  committees  should  consider  i ncluding 
                                         
43 See supra note 12, Article 17 of Measures for the Ethical Review of Biomedical Research 
Involving Human Subjects. Chapter 4 
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members  from  ethnic  minorities  in  advance.
44  However,  these 
considerations remained based on an individualistic model of autonomy, 
and were  lacked reference to   protection  of  the interests of group   or 
information disclosure on group risks. 
3)  Given that these legal regulations and ethical guidelines are essentially 
reactive, they lack unified ethical or legislative principles and have not 
developed  a  complete  set  of  general  rules  that  can  guide  the  ethical 
conduct  of  biomedical  research  and  ensure  the  interests  of  human 
subjects.  
For example, despite the requirement for informed consent by research 
subjects  set  out  in  Measures  2007,  this  Measure  only  gives  limited 
guidance  to  ethics  committees  on  how  to  conduct  ethical  review  of 
biomedical research involving human subjects. There is little specification 
of the method and standards required for the conduct of the informed 
consent process other than the need for information to be provided in 
understandable language. This means that there is no legal requirement 
as to the scope and standard of information disclosure by researchers, nor 
as to other elements of seeking consent from participants in biomedical 
research involving human subjects in the PRC.  
There are some legal requirements relevant to informed consent in the 
PRC in ‗Guidelines for the Moral Principles in Human Embryonic Stem Cell 
Research‘
  45  (HESCR  Guidelines  2004).  This  was  promulgated  by  the 
Ministry of Health and the Ministry of Science and Technology of the PRC 
on Jan. 14
th 2004, and contains twelve articles. It stipulated the principle 
of  informed  consent  and  the  need  for  approval  of  research  by  ethics 
committees.  In Article 8 of HESCR Guidelines 2004,  it  is noted  that to 
protect the privacy of the subjects, research on human embryonic stem 
cells must be conducted in earnest pursuance of the principles of consent 
                                         
44 Ibid., Article 7. 
45 Ren Pei Tai Gan Xi Bao Yan Jiu Lun Li Zhi Dao Yuan Ze [Guidelines for the Moral Principles in 
Human Embryonic Stem Cell Research] (in Chinese), available on the official website of the 
Ministry of Science and Technology of the PRC: 
http://www.most.gov.cn/fggw/zfwj/zfwj2003/200512/t20051214_54948.htm, last visited on 2010-
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and agreement provided on the basis of full knowledge of all facts on the 
part of the subject. A letter of consent must be properly signed recording 
this.
46 For consent to be properly obtained, the researchers must have 
advised  the  gamete  providers  as  to  the  aims  and  the  possible 
consequences and risks of the research in accurate, clear and common 
language.
47 According to the HESCR Guidelines 2004, an ethics committee 
must be set up within a research unit conducting research with human 
embryonic stem cells, consisting of research and managerial staff from 
biology, medical sciences, law or sociology etc. The duty of the ethic s 
committee is to exerci se comprehensive inspection, consultation and 
supervision as to the underlying principles and scientific aims and conduct 
of human embryonic stem cell research.
48 However, the applicable scope 
of the  HESCR Guidelines 2004 is  limited to  human embryonic stem cell 
research, which does not include HPGR or any other biomedical research 
involving human subjects. 
Apart from HESCR Guidelines 2004, there are some other l aws in the PRC 
which  contain  articles  that  may  be  relevant   to  informed  consent, 
including ‗Law of Licensed Doctors of the People‘s Republic of China‘
49 
and  ‗Managerial  Regulation  of  the  Medical  Institutions  of  the  People‘s 
Republic  of  China‘.
50 Article 26 of Law of Licensed Doctors of the PRC 
stipulates  that doctors who wish to conduct any experimental c linical 
treatment shall obtain the approval of the hospital authorities and the 
consent of the patient himself or his relatives.
51 Although this law is at the 
level  of  other  national  laws,  and  was promulgated by  the  Standing 
Committee of the NPC, it  only  stipulates some simple regulations on 
                                         
46 Ibid., Article 8. 
47 Ibid. 
48 Ibid., Article 9. 
49 Zhong Hua Ren Min Gong He Guo Zhi Ye Yi Shi Fa [Law of Licensed Doctors of the People’s 
Republic of China] (in Chinese), available on the official website of the Ministry of Health of the 
PRC: http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohzcfgs/s3576/200804/18250.htm, 
last visited on 2010-05-06. 
50 Yi Liao Ji Gou Guan Li Tiao Li [Managerial Regulation of the Medical Institutions of the People’s 
Republic of China] (in Chinese), available on the official website of the Ministry of Health of the 
PRC: www.moh.gov.cn/uploadfile/200591152042127.doc, last visited on 2010-05-10. 
51 See supra note 49, Article 26. Chapter 4 
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patients‘ consent,  not concerns  specifically relating  to the interests of 
human  subjects  in  biomedical  research.  Article  33  of  Managerial 
Regulation of the Medical Institutions of the PRC also stipulates that the 
medical institution shall obtain the consent of the patient himself, and 
shall  also  obtain  written  consent  from  his  family  members  or  other 
relatives,  before  conducting  any  operation,  special  testing  or  special 
treatment, though this does not provide a clear mechanism to deal with 
the possible conflicts between patient and her/his family.
52 However, the 
applicable  scope of this Regulation is innovative treatment rather than 
biomedical research involving human subjects. 
Therefore, although the Measures 2007 has clea rly  established  general 
principles for biomedical research involving human subjects, such as  the 
need to obtain  informed consent,  which are widely accepted by both 
international  guidelines  and  most  Western  countries,  the  legislative 
framework of the PRC on ly provides broad principles, not more specific 
regulation to protect the interests of individuals  and groups who may be 
asked to participate in HPGR. 
4)  These  legal  regulations,  such  as  they  are,  are  not  designed  to  fit  the 
particular position of China.  They are based on Western principles that 
focus on individual autonomy and in many cases are copied word for word 
from  Western  regulations.  For  example,  the  rules  of  Measure  2007  on 
informed consent are almost directly transplanted from the relevant rules 
of  the  CIOMS  Guidelines  and  the  Helsinki  Declaration.  The  following 
section will argue that the cultural tradition of bioethics in the PRC is not 
entirely  the  same  as  in  Western  countries.  Thus,  it  is  reasonable  to 
suppose that these transplanted regulations may not work effectively or 
be  culturally  appropriate  in  the  PRC,  where  the  traditional  ethic 
emphasises social harmony over individual interests.  
Having  discussed  the  deficiencies  of  current  Chinese  legal  regulations,  it  is 
important to stress once again that current dominant Western legal regulations 
and ethical guidelines, which are still grounded in an individualistic autonomy 
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model, are also ill-suited to take account of the particular concerns surrounding 
group/community collective genetic information and the vulnerability of target 
groups in HPGR. Effective regulation of HPGR in the PRC will need to consider 
these matters.  
4.2 HPGR in the PRC 
It has been argued here that the current legal legislation and rules which relate 
to human subject research in the PRC cannot provide adequate and systematic 
protection for research subjects of HPGR. This is problematic, not least because 
the PRC, which has rich human genetic resources, seems to be an ideal mother 
lode for human population genetic research.  
4.2.1 Brief Introduction of HPGR in the PRC 
Facing the new era of genetics, the PRC has its own ambitions and problems. 
HPGR projects in the PRC, especially those conducted by foreign researchers, 
are highly controversial.  
On the one hand, The PRC‘s active participation in the Human Genome Project 
and its completion of the sequencing of the rice genome indicated that China is 
seeking  an advanced place  in  genetics  and  genomics.
53 In the area of human 
population genetics, HPGR has also been encouraged and supported by the  
government. China began its own HPGR , the Chinese Human Genome Diversity 
Project (CHGDP) in November 1993, which still continues on a large scale. It was 
designed to ‗collect the cell lines of the 56 official ethnic groups in China in the 
National Cell Line Repository in the Kunming Institute of Medical Biology (part of 
the  Chinese  Academic  of  Medical  Sciences)  and  Beijing  Institute  of  Genetics 
(part of the Chinese Academic of Sciences).‘
54 According to a paper by Chu et 
al.,
55 CHGDP has collected genetic information and cell-lines from the official 
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ethnic groups and has tested their DNA.
56 The project was also concerned with 
determining the types and incidences of genetic diseases and preserving each 
ethnic group‘s genetic information.
57 Along with the rapid d evelopment of the 
Chinese economy, transport between different areas in PRC bec ame easier and 
faster, which has led to an increase in intermarriage  between different people 
from different areas, and it  may  also  lead to the dilution of the unique 
population genetic information of China‘s minority ethnic groups. The Chinese 
HPGR proposed to collect the DNA samples of ethnic minorities and store the 
collections in gene banks, especially those of some of the rural populations and 
ethnic groups of Central and Southwest China. For example, a large gene bank 
for ethnic minorities in Yunnan Province, which aims to study the diversification 
of inheritance and inherited diseases of the ethnic minorities, has stored 1,250 
men‘s DNA from 25 ethnic groups.
58 Given that the participants  in this project 
live in isolated rural areas in Yunnan, they are thought to have  ‗no history of 
marrying other ethnic peoples, and every man has the same ethnic origin for at 
least three generations in succession,‘
59 so their genetic information is deemed 
to have high purity. So far this is the largest data bank of its kind in the world.
60 
This type of HPGR project is thought to be helpful to ‗reconstruct the history of 
populations  by  studying  genetic  variation  to  determine  patterns  of  human 
migration.‘
61 Hence, some scholar even noted that ‗the leaders of the People‘s 
Republic hope that the biotech revolution — now shaking the formerly isolated 
communist  nation  —  will  have  similar  effects  to  those  induced  by  the  Soviet 
Union‘s legendary Sputnik space programme, bringing the country to the world‘s 
attention.‘
62 
The  encouraging  attitude  of  Chinese  government  toward  genetic  research, 
arguably combined with a considerable lower level of standards in biomedical 
regulation, or a weakness in enforcing the related guidelines, has promoted a 
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number of foreign researchers to conduct HPGR in China. For example, a French 
company,  Genset,  sent  a  letter  to  the  Chinese  Academy  of  Medical  Science 
(CAMS) seeking research co-operation. The plan was to employ some of CAMS‘s 
researchers  to  collect  DNA  and  diagnose  genetic  conditions.  Genset  and  its 
partner,  the  French  trading  company  Tang  Frère  International,  would  then 
analyze  these  DNA  samples  in  France,  using  gene-sequencing  machines,  to 
develop new diagnostic methods and new drugs. In this letter, they declared 
that ‗[w]e view gene research as extremely important for Chinese health care in 
the  21st  Century  and  we  are  convinced  that  our  joint  effort  will  lead  to 
fundamental discoveries which will benefit not just China but the rest of the 
world.‘
63 The Harvard study is also a typical HPGR project. A newspaper report 
described the Harvard case as following: 
The  China  project  was  hatched  in  the  office  of  Geoffrey  Duyk,  a 
Harvard geneticist who had one foot out the door to industry. At the 
time, 1994, genetics seemed the next big thing in American medicine. 
Among  those  enamored  was  Scott  Weiss,  a  prominent  Harvard 
respiratory  epidemiologist.  Weiss  had  come  to  Duyk  for  help  in 
launching a study into genetic causes of asthma and similar illnesses. 
Duyk  perked  up  when  Weiss  said  he  had  a  line  on  an  unusually 
homogeneous  population  of  62  million  people  in  Anhui  province,  a 
region  isolated  by  geography  and  poverty  for  2,000  years….The 
research required thousands of volunteers, nearly impossible to obtain 
in such a remote place without an experienced guide. Weiss had just 
the person -- he had mentored a post-doctoral fellow, Xu Xiping, who 
came  from  Anhui  and  had  conducted  several  public  health  studies 
there. Xu was an epidemiologist with no real expertise in genetics, 
but he had hometown connections and a proven aptitude for getting 
things done in China. 
64 
Therefore, the appeal of the PRC as  a  HPGR sample lode has been widely 
acknowledged. 
On the other hand, along with the breakou t of scandals associated with HPGR, 
such as the  Harvard study, a sensitive debate on HPGR  has also been raised  in 
the PRC.
65 Advocates have argued that HPGR in China could help to discover 
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more about the diversity of human genetic information and the causes of some 
diseases, which could benefit the progress of medical research both in China and 
elsewhere.
66 Opponents have argued that HPGR  conducted by foreign research 
institutions in the PRC could result in risks of harm to both  the interests of the 
target groups and  the national security of the PRC. According to Yang, HPGR 
conducted by foreign countries in the PRC could lead to the collection of Chinese 
genetic information by  foreign organisations to produce medicine  which could 
then be sold to China at a high cost,
67 as well as potentially being used to create 
genetic weapons  targeted at  Chinese people.
68 Furthermore, some bioethical 
scholars, such as  Sleeboom, are concerned that it also could be used to ‗make 
claims  on  disputed  territory,  resources,  and  self-determination.‘
69 Meanwhile, 
given  the  absence  of  relevant ethical  and  legal  regulations  on  HPGR  in  PRC, 
HPGR may also lead to the violation of the interests of both target groups and 
individual participants.
70 In the Harvard study, the blood and genetic samp les of 
200 million Chinese people were taken to the US. If there are no effective legal 
regulations or  policies, these samples will be analyzed in foreign counties and 
potentially be developed into new diagnostic methods and new drugs, without 
ensuring the interests of the Chinese  target groups and individual  participants 
who provided their population‘s genetic information. 
4.2.2 Attractions of Conducting HPGR in the PRC 
Although some points have been outlined above and in Chapter 1, the special 
advantages of the PRC as a research target of HPGR should be reinforced and 
explored in more details: 
1)  Due to size, geographic diversity, and social traditions and customs, there 
are a great many isolated populations within China.  
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The  population  size  makes  it  possible  to  recruit  a  large  number  of 
participants for HPGR.
71 To be accurate, according to the China Statistical 
Yearbook (2008) of the National Bureau of Statistics of China, by the end of 
2007, the total population of China was 1,321,290,000 persons; what is 
more, the rural population consists of 727,500,000 persons.
72 
In addition, the Chinese people have remained relatively isolated in the 
past,  which  has  preserved  the  relative  genetic  homogeneity  of  the 
population in many regions, especially in the areas where the mi norities 
are living, for reasons such as that little modern transportation exists in 
rural China, or that there is a tradition for most members of Chinese 
families to live together.  Therefore, China contains rich genetic resources 
and several isolated areas which have idiographic cultures. The tradition of 
Chinese populations, which are relatively stable, with relatives tending to 
live in the same area, makes it easier to study certain groups/communities 
and carry out long -term follow-up. Furthermore, divorce is rare in rural 
China; thus, the households are stable. This facilitates the collection of 
comparative data. 
2)  It is very cost-beneficial to conduct HPGR in China. The current per-capita 
income of rural China is still very low. According to data from the National 
Bureau of Statistics of China, by the end of 2007, the per capita annual 
income  of  rural  household  was  4140.4
73 yuan.
74 Medical services in rural 
China do not work well; a large number of people there cannot be provided 
with basic medical care. Hen ce, research institutions and researchers can 
recruit large number s  of participants by providing simple free physical 
examinations or providing some cheap standing drugs, such as vitamins and 
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hypotensors. The story of poor farmer Chu in the Harvard case,
 75 which has 
been mentioned previously, illustrates this well. His family provided several 
blood samples, but only received a little amount of money and some simple 
food. 
76 The difficulties in ensuring that participants are not exploited but 
at the same time are not subjected to undue influence have been discussed 
in Chapter 3. 
3)  Conducting  collaborative  HPGR  in  China  seems  to  be  relatively  easy. 
China‘s ambitions in genetics and Chinese genetic researchers‘ desire to 
collaborate HPGR projects with foreign research institutions with advanced 
technology and wide experience also contribute to it. Before the Harvard 
case,  there  were  few  legal  regulations  or  government  policies  on 
conducting  HPGR,  even  HPGR  conducted  by  foreign  researchers  or 
institutions. For example, according to Xiong et al‘s reports, in 1996, a new 
co-operative medical centre was set up in Yuexi district sponsored by Xu 
Xiping, from which more than 1,400 genetic samples were taken.
77 After 
this case,  since 1998,  researcher s  or research institution s  need  State 
permission for HPGR and also permission to take samples abroad. However, 
researchers or research institutions can conduct HPGR by running their own 
laboratories  or  through  jointly  operated  laboratories  with  Chinese 
researchers in China. Some C hinese researchers prefer to conduct these 
kinds of co-operative projects in HPGR. For example, Fang Zhi -an, head of 
the  committee  for  health  and  education  of  the  Anqing  City‘s  Peoples‘ 
Congress‘ Standing Committee, was satisfied with his co-operation with Xu 
Xiping, who is an associate professor at Harvard University, and the Harvard 
project. He believes that it has initiated the development of local hygiene 
work and has trained both Chinese talents locally, in Anqing, and nationally. 
What  is  more,  Fang  and  Xu  have  co-authored  more  than  10  articles  in 
international  academic  journals.
78 However,  some  foreign  researchers‘ 
Chinese partners felt that the collaborations were not balanced and that 
Chinese academic interests have been frustrated. For example, Liu Jianhui, 
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the  vice-director  of  science  research  management  of  Anhui  Medical 
University, who is the other partner of Xu Xiping in the Harvard studies, 
complained  that  the  Chinese  should  receive  more  information  on  the 
outcome of the research.
79  
In summary, due to the large size of the population, the unique genetic history, 
geographical  diversity,  high  participation   rates,  low cost  and  stable  social 
traditions and customs, China is an  ideal research target of HPGR. Hence, not 
only  Chinese,  but  also  foreign ,  researchers  and  research  institutions  are 
enthusiastic about conducting HPGR which target s certain groups/communities 
here. 
4.3 Target Group Protection in HPGR in the PRC 
Given the substantial number of ethnic minorities and isolated groups in rural 
areas, in the foreseeable future there are likely to be more domestic Chinese 
and foreign researchers or research institutions intending to conduct HPGR in the 
PRC. Nevertheless, these ethnic minorities and isolated groups in the PRC have 
their own cultural sensitivities, which are distinct from Western ones. The PRC 
has its own specific legislation and policies on ethnic minority protection, which 
will be evaluated in the following section in the light of these sensitivities.  
4.3.1 Cultural Sensitivity of Target Groups in HPGR in the PRC 
As  has  been  demonstrated  in  previous  chapters,  conducting  HPGR  without 
understanding the cultural sensitivities of the target group may lead to harms to 
target groups. 
(1)  A Brief Introduction to Bioethics in the PRC 
Although  bioethics  as  a  discipline  does  not  formally  exist  within  traditional 
Chinese  culture,  undoubtedly  China  has  its  own  unique  bioethical  traditions 
which are distinct from Western bioethics. For example, Bowman and Hui have 
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explained  that  in  traditional  Chinese  medicine  the  view  of  illness  is  entirely 
different from Western views. They note that in Chinese traditional medicine, 
the  body,  soul  and  spirit  are  viewed  as  an  integrated  whole.  Furthermore, 
because human beings are considered products of nature, humankind and the 
natural environment are seen to be inseparably and interdependently related; 
protecting  the  integrity  of  the  human–nature  dyad  is  thus  fundamental  to 
health.
80 
In the context of ethical discussion, in the traditional Chinese medical view it is 
commonly acknowledged that Confucianism dominated medical ethics   in pre-
modern China. Generally speaking, Confucianism is an ethic that teaches people 
how to be human. Different from Western individual-oriented political and social 
philosophy,  Confucianism  focuses  on  the  co llective  interests  of  family, 
community, society, even nation. Qiu describes Confucian teaching and its basis 
as follows: 
For Confucians, demarcation between a human and an animal lies in 
whether you care for others or you care only yourself. The basic 
concept of Confucianism is ren, which means  ‗loving  people‘.  The 
golden rules of Confucianism are: ‗you should not do to others what 
you don‘t want to do to yourself,‘ and ‗after establishing yourself, you 
should help others to establish themselves; after you develop yourself, 
you should help others to develop.‘… One reason is that Chinese hold 
a  different  concept  of  the  ‗person‘  from  the  Westerners.  For  the 
Chinese, a person is not as independent as some Westerners presume. 
No person can survive without support from others; so a person is a 
relational person or a person in relation. Metaphorically, a person is 
an atom in the west, but a person is a drop of sea water in China. For 
some Westerners, if an individual person does not exist, the whole 
world  becomes  meaningless.  But  for  Chinese  a  drop  of  water 
evaporates,  but  the  sea  will  still  exist.  So  the  collective  is  more 
important  than  the  individual  in  China.  If  there  is  any  conflict  of 
interest between the individual and the collective, the former should 
be subordinated to the latter.
81   
However, in order to fully understand traditional Chinese medical morality, one 
must take  into account the influence of Taoism and Buddhism, as well as 
Confucianism. In Confucian teaching, death is seen as a type of accomplishment 
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in this world, such as the fulfilment of ‗ren‘. ‗Ren‘ denotes ‗the cultivation of 
positive  human  attributes  such  as  humaneness,  charity  and  beneficence.‘
82 
Hence, one‘s death can be a ‗good‘ one, which is to say worthy and acceptable, 
for the person has fulfilled his/her moral duties in life. If a patient has been 
cured, it means that he/she has unfinished business, which is worth the ‗Tian‘
83 
extending  his/her  life  to  complete  unfinished  tasks  or  fulfil  moral  duties. 
Another significant position is based in Taoism, which ‗teaches the post mortem 
survival of the whole bodily person and an afterlife of torture and suffering in 
endless Hell.‘
84 Hence, Taoism teaches people to pursue maintaining youth and 
attaining  longevity  and  immortality.  However,  philosophical  Taoism  has  a 
radically different perspective, which is reflected in the phrase, ‗Man comes into 
life  and  goes  out  to death.‘
85 Thus,  one  should  view  death  calmly.  Buddhism 
provides a more unpredictable response to the suffering of dying and the event 
of death. This philosophy claims that ‗if the person maintains his or her belief in 
the impermanence and cyclical nature of life, he or she may be easily resigned 
to death; but if the person sees the suffering of the dying event as an occasion 
to  ‗work  out‘  his  or her  karma (which  may  include  suffering  from  one‘s  bad 
deeds)  in  this  lifetime,  then  the  person  may  not  welcome  death  quite  so 
readily.‘
86 The views of Chinese traditional medicine were deeply influenced by 
each of these three philosophical traditions.  
In  addition,  Chinese  bioethical  perception  is  not  influenced  by  a  single 
theoretical  perspective.  From  1949,  when  the  PRC  was  established, 
communitarian  ethics  gradually  became  the  dominant  paradigm;  especially 
during the Cultural Revolution.
87 Traditional Chinese moral norms were officially 
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attacked as the ‗pernicious influence of feudalism,‘ and ideas from the West, 
except Marxism, were censured as the ‗bourgeois fallacy.‘
88 However, traditional 
Chinese values never completely disappeared; along with the new policies of 
openness and reform, traditional medical ethics started to revive. Thus, as Fox 
and  Swazey
89 have pointed out,  contemporary Chinese medical morality is an 
unbalanced  combination of Maoism -Marxism-Leninism, Confucianism, Taoism, 
and Chinese Buddhism.
90 Despite this, many Chinese scholars also hold that there 
exists a characteristic Chinese way of thinking about  and acting in public and 
private life, interpersonal interactions, and moral issues in medical practice. For 
example, Qiu, who is cur rently a leading bioethical scholar in the PRC, argued 
that  although   there  is  an  ‗awakening  of  the  rights  sense,  especially  in 
intellectuals,  university  students,  and  the  young,  along  with  the  advance  of 
modernization,‘
91 however, he summarized the common Chinese view of Chinese 
medical ethics as follows: 
A  quasi-holistic  socio-political  philosophy  has  been  developed  from 
Chinese cultural tradition. It is based on two thousand years of power-
centralized,  autocratic  monarchy—one  that  has  lacked  any  rights-
oriented,  individualistic,  liberal  democratic  tradition.  In  recent 
decades, Marxism—rather, a mixture of Russian and Chinese versions 
of Marxism—has become the dominant ideology. The historicism and 
social holism of this system, inter woven with traditional ideas, puts 
the greatest emphasis on nation, society, and country rather than on 
individuals.
92 
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Along  with  China‘s  Economic  Reform  and  Open  Policy  published  in  1978,
93 a 
significant number of Western ideas flooded into the PRC. Some Chinese scholars 
who favour Western bioethics have used this to illustrate the theoretical blind -
spots and practical   deficiency of Chinese medical ethics and to stress the 
importance of learning from the developed Western countries.
94 Currently, most 
of the medical institutes in the PRC have set up bioethics courses and conduct 
educational bioethics activities based on  internationally acknowledged ethical 
norms such as the Nuremberg   Code,
95 the Declaration of Helsinki
96 and the 
International Standards of Ethical Examination of Biomedical Research Involving 
Human Subjects.
9798 Meanwhile, ethics committees have been established in most 
large-scale hospitals in the PRC, with responsibilities for ethics education and  
ethical review consultation for medical professionals on how to implement  the 
principles of bioethics.
99 Hence, medical professionals and  the highly-educated 
populations in the PRC are mostly influenced by, and accept, Western bioethics.  
Therefore, Nie has argued that ‗[I]n today‘s China, one can easily find in the way 
people actually live, and even in official State publications, the co-existence of 
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traditional Confucianism, Taoism, and Buddhism along with sinonized Western 
Marxism  and  communism;  the  conceptions  of  filial  piety  and  loyalty  to  the 
country along with the ideals of individual happiness, self-fulfilment, and self-
perfection.‘
100 For  example,  Chinese  people‘s  unique  view  on  truth-telling  in 
health  care  can  illustrate  that  although  almost  Chinese  people  believe  the 
combined  ideology  of  Maoism-Marxism-Leninism,  Confucianism,  Buddhism  and 
Western  bioethics,  their  moral  experience  and  practices,  when  ill,  are  very 
unlikely to reach the same answer.
101 
With regard to truth -telling in health care, there is not a single  
distinctive  Chinese  approach —e.g.,  toward  either  disclosing  or 
concealing the diagnosis of terminal disease. For the sake of patients‘ 
well-being,  many  contemporary  Mainland  Chinese  physicians,  along 
with family members and friends, do not directly tell the whole truth 
to patients who are suffering terminal diseases. But this is far from 
standard practice in traditional China. Partly (and only partly) due to 
Western influence, more and more physicians prefer to discuss frankly 
and openly all the related medical issues with their patients. Many 
patients know the nature of their disease from other sources as well, 
including the ward in which they are hospitalized, the department in 
which the doctor works,  and the gestures of people in and around 
their family. It is not uncommon, however, for a patient who knows 
the truth to pretend otherwise to his or her loved ones in order to 
reduce  their  suffering.  For  the  physician  to  speak  directly  to  the 
patient is just one way of telling the truth.
102 
As a result, in general, contemporary Chinese bioethics is indeed a mixture of a 
great number of values and beliefs—ancient and modern, Western and Eastern. 
(2)  Cultural Sensitivity of Target Groups of HPGR in the PRC 
Given that the target groups in HPGR are ethnic minorities and isolated groups in 
rural areas in the PRC, their bioethical conceptions, decision-making processes 
and  cultural  sensitivities  are  more  likely  to  be  influenced  by  traditional 
Confucianism  and  Marxism.  Therefore,  the bioethical background of  the most 
likely target groups of HPGR in China needs to be explored in more detail. 
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Almost every scholar who is interested in Chinese bioethics would notice the 
specific view of Chinese people on autonomy or informed consent. For example, 
Bowman and Hui described this issue as follows: 
The  concept  of  autonomy  best  highlights  the  contrast  between 
Western and Chinese cultures. In the West, the principle of autonomy 
implies that every person has the right to self-determination. In the 
context of healthcare, this means that the patient is the best person 
to make healthcare decisions. Within Chinese culture, however, the 
person  is  viewed  as  a  ‗relational  self‘  –  a  self  for  whom  social 
relationships,  rather than  rationality  and  individualism,  provide  the 
basis for moral judgement.  From this perspective,  an insistence on 
self-determination  erodes  the  value  placed  on  personal 
interconnectedness  and  the  social  and  moral  meaning  of  such 
relationships. In traditional Chinese society, the influences of which 
still endure, the family is based on an extended or clan structure and 
plays a central role in an individual‘s life…. All major decisions made 
by the family are thus informed by these hierarchical structures… In 
Chinese culture, the family functions as collective decision maker and 
also as a powerful conduit for moral, religious, and social norms. The 
family‘s role in self-determination is, therefore, integral to any notion 
of Chinese bioethics.
103 
What is more, they also  argued that respect for an individual‘s right to self-
determination  is  not  prominent  in  traditional  Chinese  culture,  because  ‗the 
Confucian concept of relational personhood challenges the assumption that the 
patient should be given the diagnosis and prognosis and the opportunity to make 
his or her own medical decisions,‘ as well as the fact that ‗social and moral 
meaning  rests  in  interdependence,  which  overrides  self-determination.‘
104 
Consequently,  before making decision,  many Chinese patients, by contrast to 
Western  ones,  would  consider  not  only  the  influence  to  her/him,  but  also 
disclose  relevant  information  to  who  are  important  to  her/him  and  consult 
opinion of them. When making decision, they would also take account to the 
potential affects to her/his family or community as well as potential influence to 
her/him. Sometimes, they would also like to regard family or community ideas 
as her/his decision, even when they themselves are competent.  
Currently, Chinese culture is characterized by strong communal values and an 
emphasis  on  social  harmony.  As  Fan  has  pointed  out,  ‗[s]ince,  compared  to 
                                         
103 See supra note 80, at 397-398. 
104 Ibid., at 400. Chapter 4 
People‘s Republic of China: A Mother Lode of Genes?  188 
 
Western societies, East Asian states are still homogeneous in their conceptions of 
the  good,  a  set  of  values  relating  to  clinical  decision  making  is  generally 
accepted by various communities, families and individuals, thus serving as an 
objective or impersonal conception of the good.‘
105 For example, in the clinical 
context, this feature can be reflected by  the following example: if a patient 
refuses treatment because he judges his life is no longer worth living, when the 
relevant others do not agree in terms of the objective conception of the good, 
the  patient‘s  wishes  would  not  be  followed,  whether  or  not  the  patient  is 
competent.
106  
Another example is provided by Fan, a bioethics scholar who  labelled the East 
Asian principle of autonomy   as  ‗a  family-determination-oriented  principle.‘
107 
She offered a description of the principle of autonomy in East Asia, which is that 
‗[p]ositively: every agent should be able to make his or her decisions and actions 
harmoniously  in  cooperation  with  other  relevant  persons;  and  negatively:  no 
harmoniously  made  decisions  and  actions  should  be  subjected  to  controlling 
constraints  by  others.‘
108  She  also  provided  a  clinical  care  decision-making 
process in East Asia to illustrate the distinction between the understanding of 
Western and East Asia on autonomy as following: 
For instance, when a patient requests or refuses a treatment while a 
relevant  family  member  holds  an  opposite  opinion,  the  physician 
generally should not simply follow the patient‘s wish as in the West, 
even  if  the  patient  is  evidently  competent.  Instead,  the  physician 
should  tell  the  patient  and  the  family  members  to  negotiate  and 
provide an agreement to him before he can undertake a medical act. 
Indeed, on the one hand, East Asian people make a clear distinction 
between intra-familial and extra-familial authority. On the other hand, 
it is not a sick family member him/herself but the entire family that 
has real authority in clinical decision making. Western people might 
be  concerned  about  this  claim  of  the  family-sovereignty.  But  the 
family under this notion can be viewed as an autonomous social unit 
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from  the  physician  and  the  state,  analogous  to  the  autonomous 
individual in the West.
109 
She  also  pointed  out  that  the  basis  for  this  distinction  is  the  Confucian 
understanding of the nature of the family and individuals. In Confucianism, it is 
the arrangement of Heaven (tian) that every individual is born to a family; hence, 
there are special relations that exist between family members and one‘s life is 
lived inseparably from the family. Familial relationships  are three of the five 
basic human relations in Confucianism. Thus, Confucian morality requires that 
one should consider one‘s family as an autonomous unit from the rest of society, 
flourishing or suffering as a whole.
110 Although her argument  emphasized only 
one of the Chinese traditional moral ideologies  - Confucianism - which centred 
on the family, Fan has pointed out an essential characteristic of Chinese ethical 
understanding on autonomy; which is a decision should not be taken in isolation 
based on the individual‘s own interests. In Western countries, some groups also 
have similar relational perspectives.
111 However, in the West, in most cases, if 
possible, a competent patient generally has the final word regarding medical 
decisions about his or her care,  while  in  China  both the patient and family 
members tend to reach an agreement before a clinical decision can be made . 
This tendency makes China in a better position to adopt  a relational autonomy 
model in HPGR. 
Therefore, the major value advocated by Chinese cultur e can be described as 
‗harmonious  dependence.‘
112  According  to  Chinese  people‘s  understanding, 
individuals  are  not  only  independent  persons,  but  also  members  of  certain 
families, groups/communities; thus, their decisions, especially medical decisions, 
require a full range consideration of the interests of all relevant parties who 
would  be  affected  by  this  decision.  This  feature  means  that,  whatever  the 
relevant guidelines say, the Chinese may not apply the individualised Western 
bioethical  standard  directly.  For  example,  Engelhardt,  through  analysis  of 
difficult  cases  on  medical  consent,  concluded  that  when  making  a  medical 
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decision on a patient, even the patient is competence, the family would play an 
important role in securing patient consent and others, such as community and 
fellow-work  would  also  be  involved,  rather  than  the  patient  make  it 
independently.
113 Hence, it is reasonable to agree with some Chinese  scholars 
who consider that transplanting Western medical morality would be practically 
impossible and  also dangerous in theory .
 114 It  needs  to  be  clarified  that  this 
assertion  does  not  means  that  it  is  useless  to  seek  informed  consent  from 
participants of HPGR in the PRC, but is intended to highlight the significance of 
seeking informed consent through a mechanism which is suitable to the specific 
situation and is sensitive to cultural values.  
There  may  also  be  difficulties  posed  by  the  background  and  experience  of 
potential  research  participants.  For  example,  a  study  on  informed  consent 
strategies, which was conducted in three areas south-west of Shanghai, in an 
epidemiological project approved by the regional research ethics committees in 
Sweden and China
115 found that although informed consent was adopted in the 
epidemiological project, even  where  the  informed consent procedures   in  the 
PRC were sought to be conducted to the same standard enforced in the Western 
countries, it was not always easy to convey information and obtain real consent, 
since  the educational  level  and  background knowledge of  these subjects of 
biomedical research were not the same as those in the West. Furthermore, the 
study was conducted in Shanghai, which is the most modernized city in the PRC, 
where the average educational level is higher than the average level of the PRC. 
Due to the ge nerally low level of  education of large populations in the rural 
areas of mainland China,  and the influence of traditional cultural sensitivities, 
more problems could emerge in the practice of informed consent  in HPGR. For 
example, in 2005, the well-known scientific journal ‗Nature‘ published a story of 
the unethical conduct of a clinical trial for a drug called VGV-1 on HIV-positive 
farmers from Henan province by a collaborate research project of Beijing‘s Ditan 
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Hospital  and  Viral  Genetics  of  Azusa  which  is  a  US  drug  company.
116 In this 
research project, participants said that they had been told that they would be 
injected with a new drug which  would keep them in good health for 20 years 
without further treatment and were not notified that there were also associated 
risks.
117 The known risks of harm of this drug tri al  were  not disclosed to the 
participants,  but  participants  then  ‗signed  informed-consent  forms  that  they 
could not understand and that doctors made no effort to explain.‘
118 The other 
inappropriate issues in the trial included that ‗copies of the forms had to be paid 
for; expenses were not covered as agreed; participants weren‘t informed of the 
trial‘s results, despite asking.‘
119 The potential participants in HPGR are more 
vulnerable to failing to understand the relevant information and  making poor 
decisions even than the participants in the study above. The use of language 
with adequate accuracy and articulation, easily understood by people with a low 
level  of  education,  and  with  respect  for  cultural  sensitivities  is  crucially 
important for appropriate information disclosure and consent; it is particularly 
important when the researchers come from other countries.  
Therefore,  in the context of HPGR in the PRC, rather than applying Western 
frameworks slavishly, in order to protect the interests of target group it would 
be  better  to  consider  and  give  respect  to  the  specific  needs  and  cultural 
sensitivities  of  target  groups  in  the  PRC,  which  are  highly  influenced  by  the 
traditional  Chinese  Confucian  moral  order.  The  need  for  cultural  sensitivity 
makes Chinese target groups in HPGR more appropriately considered under a 
relational  autonomy  model,  rather  than  a  purely  individualistic  model.  The 
following three examples can illustrate this viewpoint: 
Firstly, possible risks of harm that may be posed by HPGR to both individual 
participants and target groups should be disclosed to the potential participants. 
In  some  communities  or  groups  according  to  traditional  customs,  individuals 
would be likely to wish to consider both the interests of their group/community 
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as well as their own private interests. Evaluating the interests and preferences 
of the group/community before decision-making is their cultural approach. 
Secondly,  where  decisions  may  be  relevant  to  the  interests  of  a 
group/community, individuals‘ may seek or rely on group/community leaders‘ 
opinions in forming their own decisions. Again, this may be part of the cultural 
norms of members of a group, so that seeking or accepting such views cannot be 
regarded as being undue influence.  This suggests that community/group leaders 
should be consulted where HPGR is proposed. 
Thirdly,  in  some  Chinese  groups/communities,  if  issues  are  relevant  to  the 
interests of the group/community as a whole, there is a cultural tradition and 
expectation of group consultation and involvement. This custom would suggest 
the  involvement  of  members  of  target  group  in  research  design  and  at  the 
ethical review stage to help  to correctly identify and avoid potential risks of 
harm. This might take the form of the involvement of community leaders or a 
wider range of people from the target group, depending on the scope of the 
study and cultural norms within the target group. 
In  this  vein,  target  groups  in  HPGR  from  the  PRC  are  quite  suitable  to  be 
considered  in  terms  of  relational  autonomy.  Unfortunately,  current  legal 
regulations  and  ethical  guidelines  in  the  PRC  do  not  take  this  approach. 
Nevertheless,  the  protection  of  minorities  is  seen  as  an  important  concern, 
which suggests that extension of consideration to the protection of target groups 
would not be such a substantial leap. 
4.3.2 Legal Regulations and Public Policies on Ethnic Minorities 
Developing legal regulation and public policies concerning ethnic minorities is 
one  of  the  basic  principles  of  the  legal  system  in  the  PRC.  The  Government 
white paper ‗China‘s Ethnic Policy and Common Prosperity and Development of 
All Ethnic Groups‘
120 noted in its preface that 
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China is a unified multi-ethnic country jointly created by the people 
of  all  its  ethnic  groups.  In  the  long  course  of  historical  evolution 
people of all ethnic groups in China have maintained close contacts, 
developed  interdependently,  communicated  and  fused  with  one 
another, and stood together through weal and woe, forming today‘s 
unified multi-ethnic Chinese nation, and promoting the development 
of the nation and social progress.
121 
It also describes the current make-up of ethnic minorities in the PRC as follows: 
Over the past 60 years, the total population of the ethnic minorities 
has been on  a constant increase, comprising a rising proportion in 
China's total population. The five national censuses that have been 
conducted show that the total population of ethnic minorities was 
35.32 million in 1953, 6.06 percent of the total population; 40.02 
million in 1964, 5.76 percent of the total; 67.30 million in 1982, 6.68 
percent of the total; 91.20 million in 1990, 8.04 percent of the total; 
and 106.43 million in 2000, 8.41 percent of the total. The populations 
of the ethnic groups vary greatly from on e to another. For example, 
the Zhuang has a population of 17 million, far more than that of the 
Hezhe, numbering only some 4,000.
122 
The Constitution provides that China practises a certain degree of regional 
autonomy, which may have an ethnic basis. Regiona l autonomy is exercised and 
organs  of  self -government  are  established  in  areas  where  various  ethnic 
minorities  live  in  compact  communities.   National  autonomous  areas  are 
classified into autonomous regions, autonomous prefectures and autonomous 
counties.  There  are  in  total  five  autonomous  regions  (the  Inner  Mongolia 
Autonomous Region, the Xinjiang Uygur Autonomous Region, the Guangxi Zhuang 
Autonomous  Region,  the  Ningxia  Hui  Autonomous  Region  and  the  Tibet 
Autonomous Region), 30 autonomous prefectures, 116 a utonomous counties and 
three autonomous banners   in the whole country.
123 All national autonomous 
areas are integral parts of the People‘s Republic of China. According to statistics 
revealed in the fifth national census, conducted in 2000, of the country‘s 55 
ethnic minorities, 44 had their own autonomous areas. The population of ethnic 
minorities practising regional autonomy accounted for 71 percent of the total 
population of ethnic minorities, and the area where such regional autonomy was 
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practised accounted for 64 percent of the entire territory of China. In addition, 
China has established 1,100 ethnic townships, as a supplement to the system of 
regional ethnic autonomy.
124 
The PRC has its unique regional national autonomy system; and regional national 
autonomy policy is also a basic policy, which the PRC adopts to handle problems 
among its ethnic groups, as well as a fundamental political system for this 
country.  The  establishment  of  the  regional  national  autonomy  system  is 
determined by the relationships amon g its local ethnic groups, the economic 
development of the locality, and its historical background: First, as far as history 
and traditions are concerned, the long -term existence of a unified multi -ethnic 
country  is  the  historical  background  for  implementi ng  regional  ethnic 
autonomy.
125 The white paper on Chinese ethnic minorities noted that ‗[a]s early 
as in the pre-Qin Dynasty times before 221 BC the concepts of ‗country‘ and 
‗unification‘ had taken shape in the minds of the Chinese people.‘
126 Second, as 
far as ethnic relationships are concerned, the Chinese people consist of multi-
ethnic groups, and the close and extensive ties among them are the economic 
and cultural base for the implementation of regional ethnic autonomy.
127 Third, 
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the distribution of ethnic groups plays a large part in determining the scope of 
regional  autonomy.  Some  of  China‘s  ethnic  groups  inhabit  vast  areas,  while 
others live in individual compact communities in small areas or live in a mixture 
of  each.
128 Fourthly, as far as economic devel opments are concerned,  the 
previous and current economic conditions of ethnic minorities  led to the policy 
of regional ethnic autonomy to deal with poverty, which is still the key issue in 
ethnic minority areas.
129 Hence, ethnic minorities  are believed to  need special 
policies and support from the State. 
Therefore, in 2001, in consideration of the actual conditions when the socialist 
market economy was established, the Standing Committee of the NPC made 
revisions  to  the  Law  on  Regional  Ethnic  Autonomy.
130  Subsequently,  the 
Provisions of the State Council on Implementation of the Law of the People‘s 
Republic of China on Regional Ethnic Autonomy,
131 issued by the State Council in 
2005, defined the duties of governments at higher levels to support and help the 
organs  of self-government in ethnic autonomous areas.
132 The organs of self -
government  of  national  autonomous  areas  are  the  People‘s  Congresses  and 
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People‘s  Governments  of  autonomous  regions,  autonomous  prefectures  and 
autonomous counties.
133  
In addition to the fun ctions and powers of other ordinary local organs of the 
State, the organs of self-government of national autonomous areas exercise the 
power of autonomy in accordance with the law and implement the laws and 
policies of the State in the light of existing lo cal conditions.
134 The  people‘s 
congresses of national autonomous areas have the power to enact regulations on 
the  exercise  of  autonomy  and  separate  regulations  in  light  of  the  political, 
economic and cultural characteristics of the nationality or nationalities in the 
areas concerned.
135 The organs of self -government of the national autonomous 
areas independently arrange for and administer local economic development 
under the guidance of State plans; the organs of self-government of the national 
autonomous areas have the power of autonomy in administering the finances of 
their areas. The organs of self -government of the national autonomous areas 
independently administer educational, scientific, cultural, public health and 
physical culture affairs in their respective areas.
 136 
What is more, the State is responsible for promoting the development of ethnic 
minorities.  In  exploiting  natural  resources  and  building  enterprises  in  the 
national autonomous areas, the State gives due consideration to the interests of 
those areas; the State provides financial, material and technical assistance to 
the  minority  nationalities  to  accelerate  their  economic  and  cultural 
development; the State helps the national autonomous areas train large number 
of  cadres  at  various  levels  and  specialised  personnel  and  skilled  workers  of 
                                         
133 According to this law, among the chairmen and vice-chairmen of the standing committee of 
these governing bodies should be one or more citizens of the nationality exercising regional 
autonomy in the area. The chairman of an autonomous region, the prefect of an autonomous 
prefecture or the head of an autonomous county should be a citizen of the nationality exercising 
regional autonomy in the area concerned. 
134 Article 19 of Law on Regional Ethnic Autonomy of the PRC, see supra note 130. 
135 If a resolution, decision, order or instruction of a State organ at a higher level does not suit the 
conditions in a national autonomous area, the organ of self-government of the area may either 
implement it with certain alterations or cease implementing it after reporting to and receiving the 
approval of the State organ at the higher level. 
136 Article 20-45 of Law on Regional Ethnic Autonomy of the PRC, see supra note 130. Chapter 4 
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various  professions  and  trades  from  among  the  nationality  or  nationalities  in 
those areas.
137 
Although these specific regional powers and laws  may provide some protection 
to ethnic minorities in the PRC, it cannot be   said that there  is adequate 
protection for the target groups in HPGR in the PRC for the following reasons: 
1)  All such laws are focused on the interests of official ethnic minorities, 
which cannot include all the target groups of HPGR.  
HPGR  researchers  hope  that  identifying  differences  in  genetic  sequences 
between peoples will help to determine what makes certain groups of people 
different  from  others.  In  fact,  there  are  a  number  of  factors  that  are 
relevant to the delineation of populations for HPGR. These criteria need a 
balance  between  linguistic  and  genetic  development,  or  environmental 
isolation  and  genetic  development.  Hence,  Cavalli-Sforza  states  that  the 
methods  used  by  HPGR  researchers  to  identify  target  populations  include 
genealogical  records  and  linguistics.  The  use  of  these  methods,  however, 
leads to research problems closely related to history and culture, which do 
not assume languages to be static: languages migrate and change, and are 
not necessarily aligned with the biological make-up of genetic groups.
138 This 
means that  the target subjects that  the Chinese legislation and policies on 
ethnic minority intend to protect  are not necessarily the same as the target 
groups in HPGR. 
In the PRC, t he official  definition of ‗ethnic minorities‘ was created in the 
1950s  by  a  political  decision.
139 The  specific standards for the division   of 
                                         
137 Article 54-72 of Law on Regional Ethnic Autonomy of the PRC, see supra note 130. 
138 Cavalli-Sforza, L. L. 2000, Genes, Peoples and Languages, London: Penguin Books. 
139 The definition of ethnic minorities has had a tortuous history: in the 1950s, China began to 
adhere to the Stalinist definition of a nation, according to which a nation is a historically formed 
stable community of people arising on the basis of common language, common territory, 
common economic life and a typical cast of mind manifested in a common culture.  Ironically, 
after 1954 and in the 1960s, the concept of nation lost its meaning through the rejection of the 
idea that minorities and their territories were distinctive. In its paradoxical efforts to accelerate 
the evolutionary process leading to a class-less and nation-less communist society, the Chinese 
Communist Party (CCP) encouraged class struggle and assimilation with the Han majority. All 
agencies for the minorities (for instance, nationality commissions, institutes, schools, etc.) were 
disbanded. The minorities were to be treated as the Han, and all special privileges were 
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ethnic minorities include not only the genetic make-up of peoples, but also 
other factors, such as their living environment and traditional customs. Thus, 
Sleeboom-Faulkner claims that ‗[i]deas about genetic particularity in the PRC 
have roots in ethnic and socio-biological views about national minorities and 
mountainous  populations  in  remote  areas...‘
140  Hence,  national  ethnic 
minorities share characteristics that make them important as genetic targets 
to  researchers,  thus,  some  ethnic  minorities  could  be  the  research target 
groups  in  HPGR.  Meanwhile,  except  ethnic  minorities,  some  genetic 
populations  from  remote,  mountainous  and  isolated  areas  also  have  those 
characteristics  and  could  be  excellent  research  targets  of  HPGR. 
Unfortunately, those isolated groups are not protected by the legislation on 
ethnic minorities. For example, the Harvard study involved HPGR conducted 
on  the  people  of  Anhui  rural  areas,  who  are  Han  people,  not  an  ethnic 
minority. 
As  suggested  above,  the  research  subjects  of  HPGR  are  not  only  official 
ethnic minorities, but also other rural and isolated group in the PRC: thus, 
the special legislation on ethnic minorities cannot provide protection for all 
the research subjects of the HPGR in the PRC. 
2)  The  majority  of  the  regulations  or  legislation  on  ethnic  minority 
protection in the PRC are on a macro level, and most of them focus on 
political rights. This means that they do not pay any attention to ethnic 
minorities‘  interests  and  rights  as  groups  concerning  issues  such  as 
participation in biomedical research.  
The legislative purpose of the Law of the People‘s Republic of China on 
Regional  Ethnic  Autonomy,  clearly  stated  in  its  Preface,  is  ‗critical  to 
enhancing the relationship of equality, unity and mutual assistance among 
different  ethnic  groups,  to  upholding  national  unification,  and  to 
accelerating  the  development  of  places  where  regional  autonomy  is 
                                                                                                                             
was recognized. After the Deng-ist reforms in 1978, however, the special nature of the national 
minorities was gradually recognized. See supra note 140, at 407.  
140 Sleeboom-Faulkner, M. 2006, "How to Define a Population: Cultural Politics and Population 
Genetics in the People's Republic of China and the Republic of China", BioSocieties, vol. 1, pp. 
399-419, at 404. Chapter 4 
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practiced and promoting their progress.‘
141 Therefore, it can be seen as a 
law  which  is  used  to  construct  an  essential  part  of  the  basic  political 
system of the PRC. It is not difficult to understand why it concentrated on 
regulations on how to build a regional autonomous government and its 
functions.  However,  there  was  a  lack  of  regulation  on  how  to  provide 
adequate  protection  to  ethnic  minorities  and  their  interests  in  other 
aspects of their lives. Thus, in the context of HPGR in the PRC, although 
some ethnic minorities would likely be involved as target groups,  their 
interests, which might be harmed in HPGR, cannot be protected by the 
legal regulations on ethnic minorities. 
In summary, According to the analysis above, although there are special  laws 
and rules which aim to provide protections to ethnic minorities and regulate the 
ethical  conduct  of  biomedical  research  involving  human  subjects  in  the  PRC, 
they  all  have  some  deficiencies  and  therefore  fail  to  provide  adequate 
protections  to  research  subjects  of  the  HPGR.  At  the  same  time,  given  the 
practical situation and the distinctive cultural sensitivities of target groups in 
the PRC, the values of Western bioethical principles and guidelines may not all 
work  well  in  the  PRC.  Nonetheless,  the  PRC,  which  has  rich  human  genetic 
resources,  seems  to  be  an  ideal  mother  lode  of  human  genes  for  HPGR. 
Therefore, to further the goals of the ethical conduct of HPGR and enhance the 
protection of target groups and individual participants in the PRC, it is essential 
to  continue  to  clarify  how  legal  and  ethical  frameworks  can  be  amended  to 
adapt to the Chinese situation. 
 
                                         
141 See supra note 130, Preface. Chapter 5 – Conclusion 
In  the  thirteenth  century,  the  English  philosopher  Roger  Bacon  had  already 
pointed out that developments in medicine would never be the same as in the 
natural sciences because scientists could ‗multiply their experiments till they 
get rid of deficiency and errors.‘ On the other hand, the physician was unable to 
do  this  ‗because  of  the  nobility  of  the  material  in  which  he  works.‘
1 This 
assertion  illustrates  that  issues  concerning  the  ethics  of  research  involving 
human beings have been raised for centuries. In the absence of effective ethical 
and  legal  regulations  on the  conduct  of biomedical  research involving  human 
subjects, the welfare of human subjects could be harmed or ignored. Therefore, 
all  of  the  existing  international  declarations,  ethical  guidelines  and  national 
legislation  on  biomedical  research  are  dedicated  to  the  development  and 
improvement  of  human  subject  protection  in  an  effort  to  avoid  or  minimize 
harms  to  their  interests.  With  the  development  of  genetic  science  and 
technology,  research  on  the  human  genome  and  the  collection  and  use  of 
genetic information are the new ‗hotspots‘ of biomedical research. Unlike the 
Human Genome Project (HGP) which focused on completing the ‗map‘ of the 
‗common‘ human genome,
2 human population genetic research (HPGR) projects‘ 
main purpose of is to identify the diversity and variation of the human genome 
and how human group and individual genetic diversity has developed. However, 
concerns  have  arisen  about  the  application  of  the  current  dominant  Western 
ethical and legal frameworks on human subject protection to HPGR. This has 
been the focus of this thesis. It has discussed target group protection in HPGR 
and  examined  it  in  the  context  of  developing  countries,  specifically,  the 
People‘s Republic of China. 
In  order  to  identify  the  difficulties  of  applying  Western  standards  to  HPGR, 
Chapter  2  of  this  thesis  firstly  adopted  a  theoretical  analysis  approach  to 
                                         
1 Rothman, D. J. 1998, "The Nuremberg Code in Light of Previous Principles and Practice in 
Human Experimentation", in Ulrich Trohler and Stella ReiterTheeil in cooperation with Eckhard 
Herych (eds), Ethics Codes in Medicine: Foundations and Achievements of Codification Since 
1947, Ashgate: Aldershot, at 50.  
2 The HGP aimed to determine the sequences of the 3 billion chemical base pairs that make up 
human DNA. This sequence reflects the average sequence of human genome. The goals of 
HGP can be found on its official website, available at: 
http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml, last visited on 
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evaluate the current individual autonomy model and challenges posed to it by a 
relational autonomy model. It was followed by the discussion on the role and 
general rules of consent in the medical context, as well as the specific rules of 
consent  to  medical  research  involving  human  subjects,  including  ethical  and 
professional guidance and legal principles. It then addressed risks that human 
subjects might be exposed to as a result of participation in medical research, 
and introduced the legal regulations and ethical guidelines on the well-being of 
human  subjects  from  an  international  perspective.  It  came  to the  conclusion 
that  currently,  according  to  these  international  declarations  and  ethical 
guidelines,  there  are  two  basic  values  that  are  central  to  Western  legal  and 
ethical frameworks on biomedical research involving human subjects: namely, 
the autonomy of the human subject and the well-being of the human subject. In 
order to protect the autonomy and well-being of human subjects, there are two 
critical steps in determining whether biomedical research involving them can be 
conducted  in  an  ethical  manner:  obtaining  individual  potential  subjects‘ 
informed consent and assessing risks and potential benefits to them. These two 
steps work  at two different levels.  At one level,  individual research subjects 
should be fully informed about the nature, scope, and risks of the research, and 
consent to participation should be informed and voluntary. This requirement is 
based on the basic ethical principle of ‗respect for autonomy‘ or ‗respect for 
persons‘. It focuses on the liberty and free choice of the individual. At another 
level, existing regulations require researchers to submit proposals for research 
involving  human  subjects  to  expert  committees,  which  must  judge  those 
proposals  based  on  their  adherence  to  current  legal  regulations  and  ethical 
guidelines for the protection of human subjects, as well as ensuring the validity 
of the process of information disclosure and consent. However, current Western 
dominant frameworks are highly focused on the individual participant and fail to 
give  adequate  consideration  to  the  interests  of  other  relevant  parties  and 
relevant  groups,  or  to  the  interests  of  individuals  in  taking  account  of  the 
interests of others in their own decision-making. In current Western dominant 
research ethics, there is a strong common moral conviction that every individual 
has a fundamental right to self-determination with respect to his or her body.
3 
Thus, in biomedical research ethics,  individual consent is a significant element. 
                                         
3 Childress, J. F. & Fletcher, J. C. 1994, "Respect for Autonomy", Hastings Centre Report, vol. 24, 
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It  is,  therefore,  clear  that  current  Western  dominated  ethical  and  legal 
frameworks on human subject protection are based on individualised informed 
consent  and  ethical  review  of  the  risk-benefit  analysis  of  the  interests  of 
individual human subjects. Since the subject of the protection provided by the 
Western ethical and legal frameworks on biomedical research is the individual 
participant,  the  interests  of  other  parties,  such  as  groups  which  might  be 
affected,  however  indirectly,  by  some  types  of  biomedical  research,  are 
generally not addressed by these standards.
4  
This thesis, then,  concentrated  on the specific concerns raised by genetic 
research, which be come  even more prominent   in HPGR. It  was argued    that 
genetic information has some unique qualities when compared with other health 
information, in the sense that  certain types  of genetic  information, such as 
group collective genetic information, can be gained from any individual, but may 
reveal the collective information of  a certain family; even a group/community. 
Hence, the main risks of harm in genetic research  are primarily related to the 
disclosure of information and research results that could lead to discrimination, 
social stigmatization, familial disruption, or psychological distress  to the human 
subject and her/ his family  or community  members.
5  For example,  genetic 
research might lead to risks of harm including ‗inadvertent disclosure of painful 
facts  about  family  relationships  (such  as  non-paternity);  stigmatization 
associated with having a genetic abnormality; and intra-familial discord.‘
6 The 
inappropriate publication or misuse of an individual‘s genetic information would 
violate  not  only  her/his  interests  but  also  the  interests  of  his/her  family 
members,  even  group/community  members.  In  the  context  of  HPGR,  the 
concerns or interests of groups become important. Since HPGR focuses on the 
collective genetic information of specific target groups/communities rather than 
individual  human  subjects,  the  information  collected  by  HPGR  is 
                                         
4 Laurie, G. T. 2001, "Challenging Medical-Legal Norms: The Role of Autonomy, Confidentiality, 
and Privacy in Protecting Individual and Familial Group Rights in Genetic Information", Journal 
of Legal Medicine, vol. 22, pp. 1-54. 
5 Beskow, L. M., Burke, W., Merz, J. F., Barr, P. A., Terry, S., Penchaszadeh, V. B., Gostin, L. O., 
Gwinn, M., & Khoury, M. J. 2001, "Informed Consent for Population-Based Research Involving 
Genetics", Journal Of the American Medical Association, vol. 286, no. 18, pp. 2315-2321, at 
2318. 
6 Green, R. M. & Thomas, A. M. 1998, "DNA: Five Distinguishing Features for Policy Analysis", 
Harvard Journal of Law and Technology, vol. 11, pp. 571-591, at 573. Chapter 5 
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group/community collective genetic information. Hence, this thesis then turned 
to a discussion of potential harms to target groups in HPGR. 
A detailed explanation was given of the potential risks of harm that the target 
group as a whole  might be exposed to upon the disclosure of information or 
research results of HPGR. Such harms might be external harms, such as genetic 
discrimination and stigmatization of the whole target group, as well as threats to 
national security and the survival of certain groups/communities. There might 
also be internal harms, which may occur inside the target group of HPGR, such 
as  harm  to  the  constitution  of  the  group  itself,  and  challenges  to  or 
disparagement  of  target  groups‘  spiritual  traditions,  historical  narratives,  or 
traditional  beliefs.    It  was  contended  that  the  application  of  current  legal 
regulations  and  ethical  guidelines  is  problematic,  since  they  do  not  provide 
protections against these types of risk of harms.  
In Chapter 3, discussion concentrated on the target groups in HPGR, who are 
frequently  ethnic  minorities  and  isolated  groups  in  rural  areas  of  developing 
countries. Give the common features of these target groups, such as poverty, 
low-educational  level  and  lack  of  social  and  medical  resources,  this  thesis 
argued that they have three different kinds of vulnerabilities in HPGR. In this 
chapter, the concept of human vulnerability and its relationship to HPGR was 
addressed.  It  was  argued  that  vulnerability  should  be  examined  from  three 
distinct  perspectives  —  consent-based,  risk-based,  and  justice-based.
7  In 
addition, in developing countries, it is common  that there is a lack of effective 
legislation  and  regulations  on  biomedical  research  governance  and  human 
subject protection. This situation, together with poor law enforcement in most 
developing countries,  makes target groups of HPGR more vulnerable. Hence, 
target groups in HPGR should be treated as vulnerable group s and they need 
specific protection to eliminate or reduce their vulnerabilities.  
However, through the analysis, this thesis concluded  that the vulnerability of 
target groups  in HPGR cannot be eliminate d  or reduced  by current ethical 
frameworks.  Currently ,  most  guidelines  for  the  protection  of 
                                         
7 Coleman, C. H. 2009, "Vulnerability as a Regulatory Category in Human Subject Research", 
Journal of Law, Medicine and Ethics, vol. 37, no. 1, pp. 12-18, at 15. Chapter 5 
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groups/communities  in  research  have  been  drafted  for  research  involving 
specific indigenous peoples, such as American Indians. Although almost all of the 
guidelines require that researchers respect the culture of the community, none 
of these guidelines provides guidance on how to cope with circumstances when 
it may be unclear who represents a particular group/community. There is no 
guideline  that  provides  for  a  specific,  clear  guidance  and  standard  for 
group/community  involvement.  It  is  also  rare  to  see  any  requirement  that 
group/community representatives be involved in the conduct and ethical review 
of research. Therefore, it is concluded that these guidelines are inadequate to 
protect the special vulnerabilities of the target groups in HPGR.  
There  are  a  great  many  arguments  and  supporting  evidence  to  provide  a 
justification for group collective rights in international law, human rights law 
and even medical law itself. For example, as has been illustrated in Chapter 3, 
in the context of medical law, there are arguments concerning collective human 
rights to public health in order to advance health rights in a globalized world. 
While, this thesis then, argued that although viewing target groups as holders of 
legally  enforceable  rights  in  respect  of  HPGR  is  not  feasible  under  current 
dominant (Western) legal and ethical regulations, it can surely be agreed that 
their interests should and could be protected in other ways. 
In Chapter 4, the PRC has been used as an example to examine whether or not 
current  legal  and  ethical  frameworks  could  provide  adequate  protections  to 
vulnerable  target  groups,  with  specific  consideration  of  relevant  cultural 
sensitivities. In China, target groups in HPGR are more likely to be influenced by 
traditional Confucianism and Marxism. According to these traditions, individuals 
would  not  only  take  their  own  interests  into  account  when  making  decisions 
about issues relevant to the interests of their group/community, but would also 
be likely to wish  to consider these wider interests. In some groups, individuals 
would also wish to rely on the views of group or community leaders. It is part of 
their cultural traditions which ought to be respected and should not be seen as 
undue influence. However, under current ethical frameworks, researchers and 
IRBs/RECs from Western countries may not appreciate these facets of decision-
making.  Therefore,  although  individual  informed  consent  has  its  own 
justification in bioethics, even if the informed consent procedures in developing Chapter 5 
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countries were conducted to the same standards that are enforced in Western 
countries, the simple application of individualised informed consent may not fit 
into  the  cultural  context  of  decision-making  in  the  PRC,  particularly  in  the 
context of HPGR. 
Following  the  above  discussion,  it  became  necessary  to  propose  some 
recommendations on how to reconstruct a legal and ethical framework in HPGR. 
As has been argued in Chapter 2,
8 it would be appropriate to adopt the relational 
autonomy model in HPGR. It needs to be highlighted that the adoption of  this 
model does not means that obtaining group consent instead of individual consent 
from participants  should be a legal obligation in HPGR. Rather, relational 
autonomy  requires  that  the  interests  of  all  relevant  parties  need  to  be 
considered during the  design of research, ethical review, the  consent process 
and the conduct and monitoring of research.  In order to protect the interests of 
target  group  in  HPGR,  both  researchers  and  IRBs  or  RECs   need  to  take 
responsibility  for  ensuring  adequate  target  group  protection.  To  provide 
adequate protections for human subjects in HPGR, this thesis suggests that high 
level legislation needs to play an active role in the protection of participants and 
that the basic protections offered by the international guidelines need to be 
reconstructed into a form which is appropriate to  the specific situation  in any 
developing country in which this kind of research is undertaken or proposed.  
While this thesis specifically focused on HPGR in the context of the P RC, it is 
evident  from  examples  provided  of  HPGR  conducted  in  other  developing 
countries that the same   kinds of concerns would arise more widely ,
9 it is 
therefore proposed that t he following approaches  should be  adopted by both 
international ethical guidelines and domestic legal regulations on target group 
protection in all HPGR: 
1)  Enhancing researchers‘ responsibilities for group protection 
The general obligations of researchers in HPGR should include the following. 
                                         
8 See 2.2.3(2). 
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Firstly, researchers in HPGR should undertake consultation with target groups 
about relevant cultural issues at the stage of research design. There are several 
obstacles that can interfere with HPGR being conducted in an ethical way by 
researchers from developed countries. These are caused by distinctions between 
researchers and target groups in HPGR, such as marked inequality of power and 
resources  and  a  lack  of  cultural  sensitivity  regarding  decision-making.  In  the 
context of HPGR, target groups should be involved in the development, design 
and conduct  of  the  research,  since the  process  of  consultation  could  offer a 
potential mechanism to protect communities against exploitation. Consultation 
on research design should be a necessary prerequisite to ensuring that the HPGR 
is  undertaken  in  a  way  that  respects  the  cultural  norms  of  the  target 
group/community and alerts the group/community to the possibility of harms 
arising from the research questions or findings. The content of the researchers‘ 
consultation  in  all  HPGR  projects  should  include  the  following  three  main 
aspects:  
a)  In  order  to  establish  a  proper  research  protocol,  researchers  should 
investigate  the  basic  social,  economic  and  average  educational 
background of the target group.  
b)  To identify the possible external and internal harms relevant to HPGR, 
social and cultural concerns should also be investigated by researchers 
intending  to  conduct  HPGR.  These  may  include  harms  including 
discrimination and stigmatisation and disruption of the group‘s common 
beliefs,  traditions  or  narratives.  The  bioethical  background  of  the 
target group, which may be very different from the Western standard 
of research ethics, should be investigated and taken into account of by 
researchers.  
c)  Researchers  in  HPGR  also  have  an  obligation  to  investigate  the 
culturally appropriate form of decision-making. In addition, in order to 
ensure the quality of group consultation, researchers in HPGR ought to 
collaborate  with  the  group/community  to  define  how  the  research 
problem might be approached and explained to participants and, where Chapter 5 
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relevant, oral traditions and other sources of group collective beliefs or 
common culture ought to be used in a respectful manner. 
Secondly, researchers should obtain a collective permission from a target group 
leader or recognized authority for HPGR, if the target group has the cultural 
tradition  of  collective  decision-making.  The  mechanism  of  group  approval  in 
HPGR should respect the cultural sensitivities or customs in collective decision- 
making,  which  should  be  based  on  the  results  of  group  consultation.  Target 
groups in HPGR may have their own specific means of collective decision-making. 
If there is a community authority or community leader who can represent the 
target group to make collective formal and explicit approval or disapproval, such 
as in the case of the Apache Business Committee which represents the Apache 
Tribe  of  Oklahoma  when  making  fundamental  collective  decisions,
10  group 
approval or disapproval should be  sought from these community authorities or 
community leaders. Similarly, in developing countries like the PRC, most of the 
target groups have their own group leaders or authoritie s which should be the 
agent to provide group approval/disapproval. While such collective approval or 
disapproval would not obviate the need to obtain consent from individual 
participants, it would be a highly relevant factor in determining whether the 
study should proceed  –  and  if  there  is  collective  disapproval,  this  should  be 
regarded  as  determinative.  Potential  participants  may  wish  to  rely  upon  the 
views of community leaders in making their own decisions and information about 
them should be made available to them.  
Thirdly, in order to eliminate or reduce the vulnerabilities of members of target 
groups in HPGR, at the stage of individual information disclosure, researchers 
should consider the  potential participants‘  cultural traditions and educational 
level. Researchers should pay careful attention to the method of communication 
with  individuals.  Researchers  should  use  communication  measures  which  are 
appropriate  giving  adequate  time  to  potential  participants  to  ask  questions 
about  the  HPGR,  and  providing  adequate  time  for  consideration  of  their 
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decisions.  Information  should  be  provided  in  language  and  concepts  that  are 
understandable to them and which enable a meaningful consent to be given.  
2)  Considering the Interests of Groups in Ethical Review 
In  the  context  of  HPGR  in  developing  countries,  ethical  review  committees 
should accept additional responsibilities to ensure the interests of target groups 
are safeguarded and avoid the risk of exploitation. The ethical review should be 
conducted by an independent ethical review committee including members from 
target groups, rather than simply an institutional ethical review committee.  
In order to consider the interests of the group, the following measures should be 
included in domestic legislation on ethical review for all HPGR projects:   
Firstly, ethical review committees in HPGR should include  members from the 
target  group  with  varying  genders,  age  groups  and  educational  levels.  The 
number  of  representatives  should  be  decided  by  the  population  size  of  the 
target  group.  If  there  are  group  leaders  or  recognized  authorities  in  target 
groups, they must be included in ethical review committees. If there is no group 
leader or group recognized authorities, the representatives should include the 
most affected members, the most educated members and some other random 
members.  Some  would  argue  that  it  can  never  be  certain  that  the 
representatives  will  really  voice  the  real  opinion  of  the  target  group  they 
represent. However, these selective representatives are members of the target 
group  and  may  be  expected  to  share  common  traditions  and  beliefs.  It  is 
reasonable to expect that their opinions could reflect the views of the target 
group members and their participation would also help to examine whether or 
not certain HPGR may lead to potential risks of harm that research participants 
and other members of the target group view as important. 
Secondly,  those  responsible  for  administering  RECs  should  provide  proper 
training to members from target groups to assure the competence and quality of 
their  ethical  review  participation.  The  training  for  review  of  HPGR  should 
emphasize  the  development  of  the  ability  of  members  from  target  group  to 
evaluate scientific issues in HPGR and to make complex risk-benefit assessments. Chapter 5 
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The training should at least include the following content: background scientific 
knowledge  of  HPGR,  potential  risks  of  harm  of  HPGR,  appropriate  harm 
minimization measures, general research ethical principles, and standard ethical 
review procedures in a way that is understandable to target group members.  
Thirdly,  in  addition  to  risk-benefit  assessments  concerning  individual  human 
subjects,  risk-benefit  evaluations  on  the  interests  of  target  groups  of  the 
proposed HPGR should also be conducted, with emphasis on the assessment of 
potential collective risks of harm related to HPGR and awareness of the specific 
cultural  sensitivities  of  target  groups.  It  should  identify  how  various  social, 
religious, economic, cultural, and political communities/groups view the risks 
related to the proposed HPGR. The standard of ethical review of group risks of 
harm in HPGR should include the following factors: (a) the group risks of harm 
related to HPGR must be minimized, to the extent that doing so is consistent 
with sound scientific design. (b) The group risks of harm posed by HPGR must be 
reasonable in relation to the knowledge that is expected to be gained from the 
study.  (c)  The  group  risks  of  harms  of  HPGR  must  be no  more  than  a  minor 
increase over the minimal group risks of daily life for the identified group. 
Fourthly, ethical review committees should be responsible for determining any 
proposed  compensation  or  payment  based  on  the  degree  of  risk  and  other 
burdens of HPGR in developing countries. Given the different levels of economic 
development between researchers from developed countries and target groups 
in HPGR from developing countries, there may be a dilemma for researchers in 
offering  compensation  or  payment  to  target  groups:  offer  too  little  and  the 
participants are exploited, offer too much and their participation may be unduly 
influenced. Independent ethical review committees with members from target 
groups are more capable of identifying the appropriate level of compensation or 
payment which fits into the specific economic development levels of the target 
groups.  
3)  Highlighting the involvement of target groups at all stages of the research Chapter 5 
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In  addition  to  representatives  from  target  groups  being  included  in  ethical 
review  committees,  target  groups  should  also  be  involved  in  other  stages  of 
HPGR. 
a)  At the stage of research design in HPGR, how to deal with the research 
data  and  samples  should  also  be  discussed  by  the  researchers  and 
target groups, including where data or samples will be stored, whether 
or not any will be destroyed, and who ultimately controls them after 
the completion of the research. 
b)  At the stage of publication of the HPGR results, the opinion of target 
groups should be respected. Before publication, group representatives 
should be carefully informed  of the potential contents‘ relevance to 
the  target group and their potential  implications and any objections 
noted. A consultation to avoid harms caused by publication should be 
made between researchers and target group. 
c)  The  mechanism  of  choosing  group  representatives  to  consider  such 
issues should follow the rules of group representatives involved in the 
ethical review committees.  
As Western developed countries gain economic and technological ascendance, 
they need human population genetic resources which some developing countries 
have  in  abundance;  accordingly,  most  HPGR  will  likely  be  conducted  by 
researchers from developed countries in developing countries. Some developing 
countries,  such  as  China,  which  is  both  engaged  in  HPGR  and  contains 
groups/communities with specific cultural sensitivities, have realized the need 
for specific protection in HPGR and made some legislative attempts to do so. 
However, after a critical analysis of these documents, it became clear that such 
regulations as do exist have borrowed their terminology and conceptual basis 
directly  from  Western  ideologies,  despite  different  cultural  and  philosophical 
traditions. Yet, as has been argued above, Western ethical and legal frameworks, 
which focus on individual autonomy and the welfare of individual participants, 
do not provide adequate protection for target groups in HPGR. Therefore, these 
legal  regulations,  copied  word  by  word  from  Western  frameworks,  are  not Chapter 5 
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culturally appropriately in China, where the traditional ethic emphasises social 
harmony  over  individual  interests.  Although  there  are  special  legislation  and 
rules  which  aim  to  provide  protections  to  ethnic  minorities  and  regulate  the 
ethical  conduct  of  biomedical  research  involving  human  subjects  in  the  PRC, 
they  all  have  some  deficiencies  and  therefore  fail  to  provide  adequate 
protections  to  research  subjects  of  the  HPGR.  In  addition,  of  the  laws  and 
regulations related to human subject protection which were analyzed in detail in 
Chapter  4,  most  turn  out not  to  be  promulgated by  the  highest  level  of  the 
legislature, which in the PRC is the Chinese Congress and Its Standing Committee. 
They are, therefore, not powerful enough. In the context of PRC, human subject 
and target group protection need a firm foundation in high level legislation if 
they  are  to  be  effective  and  sensitive  to  cultural  practices  and  norms.  In 
addition, the concept of vulnerable group protection should also be introduced 
in Chinese high level legislation on human subject protection. Therefore, this 
thesis suggests that the PRC should establish a comprehensive legislation relating 
specifically  to  HPGR,  which  highlights  vulnerable  population  protection.  This 
legislation  should  be  formulated  by  the  Chinese  Country  Legislature  –  the 
Chinese Congress and Its Standing Committee. 
According to the analysis presented in this thesis, in order to provide adequate 
protections  for  target  groups  in  HPGR,  it  has  been  argued  that  developing 
countries need to play an active role in the protection of the target group, and 
that  the  protections  offered  need  to  be  reconstructed  into  a  form  which  is 
appropriate to the specific situation and cultural context of that country. This 
thesis has analyzed the specific situation of China; thus, it is suggested that the 
following  two  aspects  of  regulation  should  be  developed  in  the  proposed 
domestic legislation on human subject protection in China. However, a noted, it 
can be further proposed that in order to eliminate or reduce the vulnerabilities 
of target groups in other developing countries where similar concerns are likely 
to  arise,  these  two  aspects  of  regulation  should  also  be  adopted  by  all 
developing countries.  
1)  Double Review in International Collaborative HPGR Chapter 5 
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In order to ensure the welfare and interests of vulnerable target groups in HPGR, 
international collaborative HPGR must be regulated by both Western frameworks 
and legislation of host developing countries. This proposed legislation would, for 
example, require that foreign researchers or research institutions who conduct 
HPGR in China, no matter whether or not it has been reviewed according to the 
legal  regulations  or  ethical  guidelines  of  their  own  countries,  also  obtain 
approval  from  ethical  review  committees  which  are  in  conformity  with  the 
standard required by relevant laws, regulations and rules on biomedical research 
of the PRC, which would be more aware of the cultural sensitivities of target 
groups in HPGR and be able to take account of their vulnerabilities. This double 
review principle would play the role of preventing researchers from developed 
countries from taking advantage of loopholes in their own countries‘ regulations 
to exploit target groups in the  host country. Significantly, if the approach to 
ethical review I have advocated is adopted, such double review would in fact 
provide  additional  protections  for  participants  and  target  groups  to  those 
currently existing in the Western research ethics framework. 
2)  Supervision  of HPGR by Developing Countries  
In consideration of the vulnerability of target groups in HPGR, it is reasonable to 
doubt  that  representatives  from  vulnerable  target  groups  in  HPGR  in  ethical 
review committees established by researchers  have appropriate knowledge of 
regulations governing biomedical research involving human subjects. Therefore, 
using the example of the PRC, local government should play a supervisory role in 
the whole process of HPGR. The best way to achieve the supervision is to require 
that  the  ethical  review  committees  of  HPGR  should  be  established  by  local 
government.  Since  the  ethical  review  committees  would  be  set  up  by  local 
government,  it  would  be  helpful  to  deal  with  the  issues  relevant  to  group 
consideration,  such  as  correctly  identify  the  extent  of  dispersion  within 
communities and avoid the inappropriate use of ethical review which may harm 
the target group/community. These committees need a firm foundation in law 
specific to biomedical research. Ensuring the independence and legitimacy of 
these  committees  requires  that  they  operate  within  the  proposed  high  level 
legislation on human subject protection, not merely national ethical guidelines 
although  the  latter  have  the  advantage  of  ease  of  amendment.  These Chapter 5 
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committees would supervise the whole process of HPGR, including the selection 
of  target  groups,  group  consultation,  information  disclosure,  group  approval, 
research results publication and further use of research samples.  
As proposed earlier, their supervision should include consideration of the wide 
range  of issues  which  ethics  review  committees  may  have  to  consider  in  the 
context of the socio-economic factors operating in specific situations and certain 
areas.  These  committees  should  also  consider  the  issues  specific  to  the 
particular target groups and the particular research; for instance, determining 
whether HPGR will be harmful to a target group given the specific needs of that 
community. If these committees find that the intended HPGR fails to meet any 
legal requirement stipulated in the proposed special law on biomedical research 
relevant to HPGR, they should report this to the local government. The local 
government should then require the researchers to stop the project immediately. 
The proposed general  model for additional protections for groups in HPGR in 
China is summarized in Figure 5-1. Chapter 5 
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Figure 5-1 General Model for Additional Protections to Groups in HPGR 
The growth of international research has given rise to increasing concern that 
international  researchers  may  benefit  excessively  from  conducting  biomedical 
research in the developing world, and thus exploit the vulnerability of potential Chapter 5 
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participants  and  their  communities.
11 Thus, attention has now turned to the 
question of how to provide adequate protection to vulnerable populations in 
developing countries with respect to their specific  cultural sensitivities. This 
change makes studies on the legal and ethical protection in biomedical research 
involving human subjects in developing countries more significant than before.  
Although this thesis was intended to examine the need for an alternative model 
for group protection in HPGR in the specific situation of China,  it has a broader 
application in that it throws some light on general issues of group protection in 
HPGR  by examining the existing Western ethical and legal frameworks on 
biomedical research. This thesis has illustrated that in addition to risks of harm 
to individual participants, HPGR may expose target groups and other members of 
certain groups who are not directly involved to additional risks of harm. Current 
Western ethical and l egal frameworks on biomedical research cannot provide 
adequate protection of the interests of target groups in HPGR. There  is a need 
for  additional  protections  which  can  take  specific  account  of  the  special 
interests of target groups and their cultural sensitivities, such as group approval 
and  community  review  conducted  by  target  groups  and  ethical  review 
committees involving target group representatives. Given the common situations 
of poverty, isolat ion, low-educational  level and lack of social and economi c 
resources, target groups in HPGR are vulnerable groups. Target groups may have 
their own traditions of decision-making which do not fit into the Western pattern. 
This thesis has sought to help  legislators and policy makers to understand in a 
precise  way  the  inadequacies  of  current  ethical  and  legal  frameworks  on 
biomedical research in group protection in HPGR, with  specific consideration of 
the vulnerabilities and cultural sensitivities of target groups in developing 
countries. 
Although there are some stu dies that highlight concerns about the interests of 
the third  parties  in  biomedical  research,
12  they  are  mostly  still  based  on 
                                         
11 Ballantyne, A. 2008, ""Fair Benefits" Accounts of Exploitation Required A Normative Principle of 
Fairness: Response to Gbadegesin and Wendler, and Emanuel et al.", Bioethics, vol. 22, no. 4, 
pp. 239-244, at 240. 
12 See Resnik, D. B. & Sharp, R. R. 2006, "Protecting Third Parties in Human Subjects Research", 
IRB: Ethics and Human Research, vol. 28, no. 4, pp. 1-7. Also see Kimmelman, J. 2005, 
"Medical Research, Risk, and Bystanders", IRB: Ethics and Human Research, vol. 27, no. 4, pp. 
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individualised  autonomy  or  only  consider  the  issues  of  indigenous  people  in 
developed countries. One of the reasons why there is a lack of studies in this 
area  could  be  the  influence  of  Western  individualism  that  dominates  in 
biomedical research; namely, respect for (individual) persons. This can lead to 
the interests of groups being ignored. What is more, there are few scholars with 
the awareness of cultural distinctions between different cultures. Thus, it is far 
from  easy  for  researchers  in  developed  countries  to  discuss  vulnerable  group 
protection  in  biomedical  research  conducted  in  developing  countries.  Despite 
this  difficulty,  this  thesis  has  demonstrated  that  studies  in  this  area  can  be 
carried out by examining vulnerable target group protection in HPGR in the PRC. 
Meanwhile,  the  People‘s  Republic  of  China,  as  an  example  of  a  developing 
country, is rich in genetic resources which lend themselves to the conduct of 
HPGR. This thesis has provided recommendations on how to reconstruct a legal 
and ethical framework for HPGR in China to ensure protection of the interests of 
target  groups  and  eliminate  or  reduce  their  vulnerabilities,  with  specific 
awareness of the cultural sensitivity of target groups in China. For developing 
countries  which  have  not  adopted  legal  regulations  or  ethical  guidelines  on 
human  subject  protection,  or  are  in  the  process  of  formulating  national 
regulations,  although  they  may  not  have  the  same  legal  system  or  cultural 
sensitivity as China, this thesis could raise the awareness of the need for target 
group  protection  with  due  consideration  of  their  special  vulnerabilities  and 
group interests. For those developing countries which have already adopted legal 
regulations and ethical guidelines on human subject protection, this thesis can 
also serve to remind regulators that the existing regulations and guidelines may 
need  to  be  amended  to  provide  adequate  protection  to  target  groups.  In 
addition, this thesis could raise the awareness of group protection in biomedical 
research  conducted  in  developing  countries,  which  could  contribute  to  the 
amendment  of  international  declarations  and  ethical  guidelines,  with  specific 
consideration of the vulnerability and cultural sensitivities of target groups. 217 
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WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
Ethical Principles for Medical Research Involving Human Subjects 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added) 
59th WMA General Assembly, Seoul, October 2008 
A. INTRODUCTION 
1.  The  World  Medical  Association  (WMA)  has  developed  the  Declaration  of 
Helsinki  as  a  statement  of  ethical  principles  for  medical  research  involving 
human subjects, including research on identifiable human material and data. 
The Declaration is intended to be read as a whole and each of its constituent 
paragraphs  should  not  be  applied  without  consideration  of  all  other  relevant 
paragraphs. 
2.  Although  the  Declaration  is  addressed  primarily  to  physicians,  the  WMA 
encourages other participants in medical research involving human subjects to 
adopt these principles. 218 
3. It is the duty of the physician to promote and safeguard the health of patients, 
including those who are involved in medical research. The physician's knowledge 
and conscience are dedicated to the fulfilment of this duty. 
4. The Declaration of Geneva of the WMA binds the physician with the words, 
―The health of my patient will be my first consideration,‖ and the International 
Code of Medical Ethics declares that, ―A physician shall act in the patient's best 
interest when providing medical care.‖ 
5. Medical progress is based on research that ultimately must include studies 
involving  human  subjects.  Populations  that  are  underrepresented  in  medical 
research should be provided appropriate access to participation in research. 
6. In medical research involving human subjects, the well-being of the individual 
research subject must take precedence over all other interests. 
7.  The  primary  purpose  of  medical  research  involving  human  subjects  is  to 
understand  the  causes,  development  and  effects  of  diseases  and  improve 
preventive, diagnostic and therapeutic interventions (methods, procedures and 
treatments). Even the best current interventions must be evaluated continually 
through  research  for  their  safety,  effectiveness,  efficiency,  accessibility  and 
quality. 
8. In medical practice and in medical research, most interventions involve risks 
and burdens. 
9. Medical research is subject to ethical standards that promote respect for all 
human subjects and protect their health and rights. Some research populations 
are particularly vulnerable and need special protection. These include those who 
cannot give or refuse consent for themselves and those who may be vulnerable 
to coercion or undue influence. 
10.  Physicians  should  consider  the  ethical,  legal  and  regulatory  norms  and 
standards for research involving human subjects in their own countries as well as 
applicable  international  norms  and  standards.  No  national  or  international 219 
ethical, legal or regulatory requirement should reduce or eliminate any of the 
protections for research subjects set forth in this Declaration. 
B. PRINCIPLES FOR ALL MEDICAL RESEARCH 
11. It is the duty of physicians who participate in medical research to protect 
the  life,  health,  dignity,  integrity,  right  to  self-determination,  privacy,  and 
confidentiality of personal information of research subjects. 
12.  Medical  research  involving  human  subjects  must  conform  to  generally 
accepted  scientific  principles,  be  based  on  a  thorough  knowledge  of  the 
scientific  literature,  other  relevant  sources  of  information,  and  adequate 
laboratory and, as appropriate, animal experimentation. The welfare of animals 
used for research must be respected. 
13. Appropriate caution must be exercised in the conduct of medical research 
that may harm the environment. 
14. The design and performance of each research study involving human subjects 
must be clearly described in a research protocol. The protocol should contain a 
statement of the ethical considerations involved and should indicate how the 
principles in this Declaration have been addressed. The protocol should include 
information regarding funding, sponsors, institutional affiliations, other potential 
conflicts of interest, incentives for subjects and provisions for treating and/or 
compensating subjects who are harmed as a consequence of participation in the 
research study. The protocol should describe arrangements for post-study access 
by study subjects to interventions identified as beneficial in the study or access 
to other appropriate care or benefits. 
15.  The  research  protocol  must  be  submitted  for  consideration,  comment, 
guidance and approval to a research ethics committee before the study begins. 
This committee must be independent of the researcher, the sponsor and any 
other undue influence. It must take into consideration the laws and regulations 
of the country or countries in which the research is to be performed as well as 
applicable international norms and standards but these must not be allowed to 
reduce or eliminate any of the protections for research subjects set forth in this 220 
Declaration. The committee must have the right to monitor ongoing studies. The 
researcher  must  provide  monitoring  information  to  the  committee,  especially 
information about any serious adverse events. No change to the protocol may be 
made without consideration and approval by the committee. 
16.  Medical  research  involving  human  subjects  must  be  conducted  only  by 
individuals with the appropriate scientific training and qualifications. Research 
on patients or healthy volunteers requires the supervision of a competent and 
appropriately  qualified  physician  or  other  health  care  professional.  The 
responsibility for the protection of research subjects must always rest with the 
physician  or  other  health  care  professional  and  never  the  research  subjects, 
even though they have given consent. 
17.  Medical  research  involving  a  disadvantaged  or  vulnerable  population  or 
community is only justified if the research is responsive to the health needs and 
priorities of this population or community and if there is a reasonable likelihood 
that  this  population  or  community  stands  to  benefit  from  the  results  of  the 
research. 
18. Every medical research study involving human subjects must be preceded by 
careful  assessment  of  predictable  risks  and  burdens  to  the  individuals  and 
communities involved in the research in comparison with foreseeable benefits to 
them and to other individuals or communities affected by the condition under 
investigation. 
19.  Every  clinical  trial  must  be  registered  in  a  publicly  accessible  database 
before recruitment of the first subject. 
20. Physicians may not participate in a research study involving human subjects 
unless they are confident that the risks involved have been adequately assessed 
and can be satisfactorily managed.  Physicians must immediately stop a study 
when the risks are found to outweigh the potential benefits or when there is 
conclusive proof of positive and beneficial results. 221 
21.  Medical  research involving  human  subjects  may  only  be  conducted  if  the 
importance of the objective outweighs the inherent risks and burdens to the 
research subjects. 
22. Participation by competent individuals as subjects in medical research must 
be  voluntary.  Although  it  may  be  appropriate  to  consult  family  members  or 
community leaders, no competent individual may be enrolled in a research study 
unless he or she freely agrees. 
23. Every precaution must be taken to protect the privacy of research subjects 
and the confidentiality of their personal information and to minimize the impact 
of the study on their physical, mental and social integrity. 
24.  In  medical  research  involving  competent  human  subjects,  each  potential 
subject must be adequately informed of the aims, methods, sources of funding, 
any possible conflicts of interest, institutional affiliations of the researcher, the 
anticipated benefits and potential risks of the study and the discomfort it may 
entail, and any other relevant aspects of the study. The potential subject must 
be informed of the right to refuse to participate in the study or to withdraw 
consent to participate at any time without reprisal. Special attention should be 
given to the specific information needs of individual potential subjects as well as 
to the methods used to deliver the information. After ensuring that the potential 
subject has understood the information, the physician or another appropriately 
qualified individual must then seek the potential subject‘s freely-given informed 
consent, preferably in writing. If the consent cannot be expressed in writing, the 
non-written consent must be formally documented and witnessed. 
25. For medical research using identifiable human material or data, physicians 
must normally seek consent for the collection, analysis, storage and/or reuse. 
There may be situations where consent would be impossible or impractical to 
obtain for such research or would pose a threat to the validity of the research. 
In  such  situations  the  research  may  be  done  only  after  consideration  and 
approval of a research ethics committee. 
26.  When  seeking  informed  consent  for  participation  in  a  research  study  the 
physician  should  be  particularly  cautious  if  the  potential  subject  is  in  a 222 
dependent relationship with the physician or may consent under duress. In such 
situations the informed consent should be sought by an appropriately qualified 
individual who is completely independent of this relationship. 
27.  For  a  potential  research  subject  who is  incompetent,  the physician  must 
seek  informed  consent  from  the  legally  authorized  representative.  These 
individuals must not be included in a research study that has no likelihood of 
benefit for them unless it is intended to promote the health of the population 
represented by the potential subject, the research cannot instead be performed 
with competent persons, and the research entails only minimal risk and minimal 
burden. 
28. When a potential research subject who is deemed incompetent is able to 
give assent to decisions about participation in research, the physician must seek 
that assent in addition to the consent of the legally authorized representative. 
The potential subject‘s dissent should be respected. 
29.  Research  involving  subjects  who  are  physically  or  mentally  incapable  of 
giving  consent,  for  example,  unconscious  patients,  may  be  done  only  if  the 
physical  or  mental  condition  that  prevents  giving  informed  consent  is  a 
necessary characteristic of the research population. In such circumstances the 
physician  should  seek  informed  consent  from  the  legally  authorized 
representative. If no such representative is available and if the research cannot 
be delayed, the study may proceed without informed consent provided that the 
specific reasons for involving subjects with a condition that renders them unable 
to  give  informed  consent  have  been  stated  in  the  research  protocol  and  the 
study has been approved by a research ethics committee. Consent to remain in 
the research should be obtained as soon as possible from the subject or a legally 
authorized representative. 
30. Authors, editors and publishers all have ethical obligations with regard to the 
publication  of  the  results  of  research.  Authors  have  a  duty  to  make  publicly 
available the results of their research on human subjects and are accountable 
for  the  completeness  and  accuracy  of  their  reports.  They  should  adhere  to 
accepted guidelines for ethical reporting. Negative and inconclusive as well as 
positive  results  should  be  published  or  otherwise  made  publicly  available. 223 
Sources of funding, institutional affiliations and conflicts of interest should be 
declared  in  the  publication.  Reports  of  research  not  in  accordance  with  the 
principles of this Declaration should not be accepted for publication. 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
31. The physician may combine medical research with medical care only to the 
extent that the research is justified by its potential preventive, diagnostic or 
therapeutic  value  and  if  the  physician  has  good  reason  to  believe  that 
participation in the research study will not adversely affect the health of the 
patients who serve as research subjects. 
32. The benefits, risks, burdens and effectiveness of a new intervention must be 
tested  against  those  of  the  best  current  proven  intervention,  except  in  the 
following circumstances: 
• The use of placebo, or no treatment, is acceptable in studies where no current 
proven intervention exists; or 
• Where for compelling and scientifically sound methodological reasons the use 
of placebo is necessary to determine the efficacy or safety of an intervention 
and the patients who receive placebo or no treatment will not be subject to any 
risk of serious or irreversible harm. Extreme care must be taken to avoid abuse 
of this option. 
33. At the conclusion of the study, patients entered into the study are entitled 
to be informed about the outcome of the study and to share any benefits that 
result from it, for example, access to interventions identified as beneficial in 
the study or to other appropriate care or benefits. 
34. The physician must fully inform the patient which aspects of the care are 
related to the research. The refusal of a patient to participate in a study or the 
patient‘s  decision  to withdraw  from  the  study  must  never  interfere  with  the 
patient-physician relationship. 224 
35. In the treatment of a patient, where proven interventions do not exist or 
have been ineffective, the physician, after seeking expert advice, with informed 
consent  from  the  patient  or  a  legally  authorized  representative,  may  use  an 
unproven intervention if in the physician's judgement it offers hope of saving life, 
re-establishing health or alleviating suffering. Where possible, this intervention 
should  be  made  the  object  of  research,  designed  to  evaluate  its  safety  and 
efficacy.  In  all  cases,  new  information  should  be  recorded  and,  where 
appropriate, made publicly available. 
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Amendments to Chinese Provisions of Human subject Protection 
 
1)  Better Chinese High Level Legislation on Human Subject Protection 
Of the laws and regulations related to human subject protection which  were 
analyzed in detail in Chapter 4,  most turn out not to be promulgated by the 
highest level of the legislature, which in the PRC is the Chinese Congress and Its 
Standing  Committee.  They  are,  therefore,  not  powerful  enough.  To  provide 
adequate  protections  for  human  subjects  in  biomedical  research,  this  thesis 
suggests that high level legislation needs to play an active role in the protection 
of  participants  and  that  the  basic  protections  offered  by  the  international 
guidelines  need  to  be  reconstructed  into  a  form  which  is  appropriate  to  the 
specific  situation  in  that country. In  the context  of PRC,  human  subject and 
target group protection need a firm foundation in high level legislation if they 
are to be effective and sensitive to cultural practices and norms. In addition, the 
concept of vulnerable group protection should also be introduced in Chinese high 
level legislation on human subject protection. It is suggested that the legislation 
on human subject protection, which highlights vulnerable population protection 
in the PR China should be formulated by the Chinese Country Legislature – the 
Chinese Congress and Its Standing Committee. 
There is evidence that vulnerable groups, such as ethnic minorities and isolated 
groups  in  rural  areas,  tend  to  be  underrepresented  in  biomedical  research.
1 
However, some international declarations and ethical guidelines on human 
subject  protection  do  pay  specific  attention  to  the  issues  raised  by  the 
participation of minorities in research. For example, the CIOMS guidelines make 
reference to this issue as follows: 
Members of vulnerable groups also have the same entitlement to 
access  to  the  benefits  of   investigational  interventions  that  show 
promise of therapeutic benefit as persons not  considered vulnerable, 
                                         
1 For discussion, see Sheikh, A. 2006, "Are Racial and Ethnic Minorities Less Willing to Participate 
in Health Research?", PLOS Medicine, vol. 3, no. 2, pp. 0166-0167.  226 
particularly when no superior or equivalent approaches to therapy are 
available.
2 
This statement  acknowledges the dilemma  that, on the one hand, it is unjust 
selectively to recruit vulnerable populations to serve as research subjects simply 
because they may be more easily induced to participate in exchange for  small 
payments;  on  the  other  hand,  such  vulnerable  populations  should  not  be 
categorically excluded from   research protocols. The concerns of v ulnerable 
population protection and  the benefits of  participation should be considered 
together to  seek  to an appropriate  balance. In  the  clinical trial setting,  this 
dilemma also exists. Some countries have realized this situation and  introduced 
relevant  policies  to  promote  the  participation  of  minorities  in  potential ly 
beneficial clinical research. For example, Noah illustrated this situation in the 
US as follows: 
Evidence  suggests….that  racial  and  ethnic  minorities  have  less 
opportunity to participate in potentially beneficial clinical research. 
For reasons of scientific and practical convenience, minority groups 
were  commonly  excluded  from  clinical  trials  until  the  mid-1990s.  
More recently, in recognition of the fact that minority participation in 
medical  research  enhances  scientific  understanding  of  variations  in 
disease and treatment response among races and out of concern for 
healthcare justice, the government has instituted policies designed to 
encourage the inclusion of minorities in clinical trials. Even so, the 
research  community  must  proceed  with  caution  in  any  efforts  to 
equalize participation, both because of the inherent risks of medical 
research to individual participants and because some efforts at racial 
inclusion may have unintended negative consequences.
3 
Therefore, it need s  to be highlighted that special protections  for  vulnerable 
populations in biomedical research involving human subject in the PRC  should 
not deliberately prohibit vulnerable populations from being the subject of those 
research projects. 
                                         
2 International Ethical Guidelines for Biomedical Research Involving Human Subjects was prepared 
by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with 
the WHO, Geneva, 2002. The full text of CIOMS Guidelines can be seen on the official website 
of World Heath Organization (WHO) on 
http://whqlibdoc.who.int/emro/2004/9290213639_annex2.pdf, last visited on 2010-07-27, 
Commentary and reference to Guideline 12. 
3 Noah, B. A. 2003, "The Participation of Underrepresented Minorities in Clinical Research", 
American Journal of Law and Medicine , vol. 29, no. 2-3, pp. 221-245, at 224. 227 
However, it needs to be noted that the situation of HPGR should be treated as a 
special  case.  Most  HPGR  projects  are  designed  simply  to  improve  scientific 
understanding and are unlikely to offer direct benefit to participating groups. 
Thus, since the target groups of HPGR are vulnerable groups, and some HPGR 
protocols pose potential risks to those groups, participation in HPGR should not 
be promoted. Meanwhile, if target groups have decided to participate in certain 
HPGR,  their  interests  should  be  ensured  by  the  provision  of  systematic  and 
effective  protection  to  vulnerable  target  groups  and  their  members,  while 
guarding against the imposition of unfair burdens or risks for any one group of 
participants.  
2)  Amendment to Provisions of Researchers’ Responsibilities 
As discussed in Chapter 3, most HPGR projects are conducted by researchers 
from developed countries, while the target groups in HPGR are almost always 
isolated groups or ethnic minorities in rural areas of developing countries, such 
as PR China; thus, target groups in HPGR are almost vulnerable groups with their 
own  cultural  sensitivities  and  need  additional  protections.  Researchers,  who 
have advantages in power and resources, must accept a series of obligations to 
mitigate the vulnerabilities of target groups in the whole process of HPGR. 
(1) Group Consultation 
There are several obstacles that can interfere with HPGR being conducted in an 
ethical  way  by  researchers  from  developed  countries.  These  are  caused  by 
distinctions  between researchers  and  target  groups  in  HPGR,  such  as  marked 
inequality of power and resources and a lack of cultural sensitivity regarding 
decision-making. In the context of HPGR, target groups should be involved in the 
development,  design  and  conduct  of  the  research,  since  the  process  of 
consultation could offer a potential mechanism to protect communities against 
exploitation. Consultation on research design should be a necessary prerequisite 
to  ensuring  that the  HPGR  is  undertaken in  a  way that  respects  the cultural 
sensitivity of target group/community and alerts the group/community to the 
possibility of harms arising from the research questions or findings.  228 
The content of the researchers‘ consultation in HPGR in the PRC should include 
the following three main aspects: 
A.  In  order  to  establish  a  proper  research  protocol,  researchers  should 
investigate the basic social, economic and average education background 
of the target group. Since target groups in HPGR are usually impoverished 
people, who are highly susceptible to prospects of financial rewards, even 
small financial payments can act as a coercive force, compelling the poor 
to do what the rich would be reluctant to consider. They may be unable 
to give unqualified consent to HPGR, when confronted with compensation 
for  research  participation.  What  is  more,  non-financial  incentives  that 
could  improve  the  living  standard  of  target  groups  may  also  be  overly 
coercive.  These  offers  might  include  food,  clothing,  basic  medical 
treatment and drugs. The limits of the economic and social resources in 
developing  countries  can  transform  these  simple  rewards  or  basic 
resources into forceful incentives for target groups in HPGR. Researchers 
conducting  HPGR  must  not  assume  that  the  incentive  level  should  be 
based on their own standards. Any incentive level researchers offer should 
be tailored to the level of social and economic development of the target 
group. It is the obligation of researchers to identify the proper way of 
providing  compensation  or  rewards  to  ensure  that  the  human  subjects 
make their own decisions on whether or not to participate without the 
pressure  of  undue  incentives.  In  addition,  the  average  educational 
background of  the  target group should be related to the expression of 
information disclosure, which should be clear and understandable. 
B.  To identify the possible internal harms relevant to certain HPGR, cultural 
sensitivity  which  may  be  harmed  by  certain  HPGR,  such  as  a  group‘s 
common belief, specific group traditions or group narratives, should also 
be investigated by researchers of HPGR. The cultural sensitivity such as 
bioethical  background,  which  would  be  opposite  to  the  application  of 
Western  standard  of  research  ethics,  should  be  investigated  by 
researchers  in  HPGR.  For  example,  for  individuals  in  non-Western 
societies, perspectives on the nature of disease, the subject-investigator 
relationship, and the doctor-patient relationship may be entirely different 229 
from those in Western societies.
4 The meaning of ‗person‘ may also be 
different between Western and non-Western societies. It has been argued 
that  ‗the  majority  viewpoint  manifest  in  most  other  societies,  both 
technologically  developing  (e.g.,  Central  Africa)  and  technologically 
developed  (e.g.,  Japan),  does  not  reflect  the  American  perspective  of 
radical individualism.‘
5 As De Craemer puts it: 
  The American notion of person has still other characteristic 
features.   It  is  markedly  rational,  and  also  legalistic-
prototypically expressed in   the  language  of  rights,  and 
central not only to our Declaration of   Independence  and 
Constitution, but to a very wide range of issues   that  find 
their way into our courts and our legislatures. 
  In turn, these rational-legal aspects of our cultural outlook on 
  personhood  are  associated  with  the  voluntary,  functionally 
specific,   contractual model of social relations that has a 
predominant place in   our  society,  particularly  in 
economic and political spheres.... 
  The  American  view  of  the  human  person  is  pervaded  by 
logical-rational dichotomies. This view sharply opposes body 
and mind,   thought  and  feeling,  the  conscious  and 
unconscious, self and other, reality and nonreality (imagining, 
dreaming, and hearing voices, for example are not ―real‖).
6 
He further argues in his summary statement that the ‗American way of 
thinking  about  the  person  represents  the  way  men  and  women  of  all 
societies and cultures should and do think about personhood when they 
are being supremely rational and moral.‘
7 In the PRC, as was discussed in 
Chapter  4,  however,  the  culture  of  isolated  groups  in  rural  areas  is 
characterised by communal values and highlights social harmony. In both 
Confucianism  and  Marxism/communism,  a  person  cannot  be  seen  in 
isolation. Instead, they are at the centre of relationships. A person exists 
in a social context in order to fulfil their social responsibilities, and a 
                                         
4 Clinton, R. N. 1990, "Rights of Indigenous Peoples as Collective Group Rights", Arizona Law 
Review, vol. 32, no. 4, pp. 739-748 
5 Levine, R. J. 1991, " Informed Consent: Some Challenges to the Universal Validity of the Western 
Model", Journal of Law, Medicine and Ethics, vol. 19, pp. 207-213, at. 209. 
6 De Craemer, W. 1983, "A Cross-Cultural Perspective on Personhood ", The Milbank Memorial 
Fund Quarterly: Health and Society, vol. 61, no. 1, pp. 19-34, at 21. 
7 Ibid., at 34. 230 
person‘s nature manifests itself only through human relatedness. As has 
been  said,  ‗[t]he  Chinese  believe  in  the  importance  of  individual 
autonomy, but they also believe that this right of autonomy is guided by 
social  needs.‘
8 These  bioethical  backgrounds  should  be  considered  by 
researchers to ethically conduct certain HPGR, with acknowledgement of, 
and respect for, target groups‘ cultural sensitivities. 
C.  Researchers in HPGR also have an obligation to investigate the cultural 
sensitivity  regarding  decision-making.  According  to  the  result  of  group 
consultation on cultural sensitivity regarding decision-making, researchers 
could decide whether or not group approval/disapproval is needed. If the 
cultural sensitivity on decision-making is individual as final decision maker, 
the process of group approval/disapproval does not need to be conducted. 
If  certain  target  group  have  the  cultural  sensitivity  on  group  decision-
making  or  used  to  follow  the  decision  of  group  leader,  then,  group 
approval/disapproval should be conducted. It need to be highlighted, the 
requirement on group approval/disapproval do not means the complete 
abandon of individual informed consent. It means that the result of this 
group approval/disapproval should be the precondition of whether or not 
certain  HPGR  could  be  conducted.  If  group  approved,  the  individual 
informed consent should also be conducted before collect samples from 
individual  participants.  Rather,  when  conducting  individual  informed 
consent, the group approval should be provided to individual participants. 
For  example,  according  to  Confucianism,  which  is  a  traditional  and 
influential culture in the PRC, especially in isolated rural areas, the family 
is not only a means for human flourishing, but also has its own status in 
decision-making. One‘s family members sustain an element of one‘s own 
being. This leads to the belief that one‘s choices have a profound effect 
on both the individual and the family as a whole. This understanding of 
the  family  is  reflected  in  the  Confucian  approach  to  making  medical 
decisions,  assessing  medical  technology,  and  financing  health  care. 
Medical  decision-making  involves  the  whole  family,  since  the  whole 
family‘s interests as well as the individual‘s are at stake. The interests of 
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Genetics, vol. 4, pp. 233-239, at 236. 231 
the  family  must  also  be  taken  into  account  when  assessing  medical 
technology.  This does not mean that individual interests should always 
give way to family interests when conflicts occur. However, in most cases 
of target groups in HPGR in the PRC, the opinion of community leaders or 
senior  family  members  (or  community  leaders)  would  be  a  significant 
reference for members of target groups. This opinion from a community 
leader or senior family member, which would  be likely to influence the 
decision of potential participants, is a part of the social context of an 
individual‘s decision-making; thus, it is not undue influence at least in 
this  culture.  Accordingly,  in  most  cases  of  HPGR  in  the  PRC,  group 
approval/  disapproval  should  be  considered.  Therefore,  the  cultural 
sensitivities of target groups, which will influence their decision-making, 
should be identified and understood by the researcher in HPGR before the 
research design stage. 
In  recognition  of  these  issues,  there  should  be  a  basic  legal  requirement  on 
researchers  in  HPGR  to  conduct  precise  consultation  about  relevant  cultural 
sensitivity issues at the stage of research design in the PRC.  
In order to ensure the quality of group consultation, researchers in HPGR ought 
to collaborate with the group/community to define how the research problem 
might be approached and, where relevant, oral tradition and other sources of 
group  collective  beliefs  or  common  culture  ought  to  be  used  in  a  respectful 
manner.  The  consultation  process  should  include:  (a)  researchers  survey  and 
communication with group representatives on the cultural sensitivity of certain 
groups, for example, asking community/group leaders, affected and unaffected 
persons a series of questions about how they recognize and make decisions about 
illness; (b) dialogue or communication between researchers and group members. 
The contents of consultation should include questions regarding whom they ask 
for advice in medical decision-making, who may have assisted them in seeking 
care, who may have provided care for them, and their social relationships to 
those  persons,  whether  there  is  there  any  group  common  belief  or  cultural 
sensitivity concerning disease, health and life. If necessary, social scientists with 
working  experience  of  the  target  groups,  as  well  as  prominent  community 
members, could be consulted to interpret these answers. 232 
In addition, the final consultation should also be submitted to both supervision 
authorities of local government in the PRC and IRBs or RECs, for the purposes of 
scrutiny. 
(2) Group Approval /Disapproval 
The term ‗group approval / disapproval‘ is ambiguous and proponents of group 
approval do not always make clear what precisely they mean by it. In  group 
approval  as  it  is  understood  here,  researchers  should  obtain  a  collective 
permission from a target group leader or recognized authority for HPGR, only if 
target group has the cultural tradition of collective decision-making. It needs to 
be highlighted that the collective decision, group approval / disapproval, is not 
binding  on  individual  members  who  may  choose  to  consent  or  refuse  to 
participate in HPGR. The results of group approval/disapproval here would be 
one  piece  of  necessary  relevant  information  which  would  be  provided  to 
potential individual participants as a reference to help them to make their own 
decision on whether or not to participate in certain HPGR, according to their 
decision-making patterns.  
Since the main criticisms of group approval focused on giving a target group the 
authority to veto proposed HPGR involving their members,
9 it is important to 
stress  that  the group approval/disapproval discussed here   is not intended to 
extend a ‗veto power‘ to the target group in HPGR. Rather, in the context of the 
PRC, as has been discussed above, likely target groups have a culture of group 
decision making, or acceptance that the group leader has the right to decide. If 
researchers intend to achieve genuine consent from individual members of such 
target  groups  with  cultural  sensitivity  regarding  group  decision-making, 
researchers  in  HPGR  should  obtain  and  provide  the  opinions  of  their  group 
leaders  or  recognized  authorities  on  the  proposed  research  in  order  to  help 
individual members to make their own decisions.  
The  mechanism  of  group  approval  in  HPGR  should  respect  the  cultural 
sensitivities or customs in collective decision- making, which should based on the 
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results of group consultation. Target groups in HPGR may have their own specific 
means  of  collective  decision-making.  If  there  is  a  community  authority  or 
community leader who can represent the target group to make collective formal 
and explicit approval or disapproval, such as in the case of the Apache Business 
Committee  which  represents  the  Apache  Tribe  of  Oklahoma  when  making 
fundamental  collective  decisions,
10 group approval or disapproval should be 
sought from these community authorities or community leaders. Similarly, in the 
PRC, most of the target groups have their own group leaders or authorities, 
which should be the agent to provide group approval/disapproval.  
Therefore, if researchers obtain group approval for a particular HPGR, it implies 
that  researchers can conduct this HPGR,  only when it is  based on informed 
consent from individual group members. If the target group considers that HPGR 
might lead to harms and does not approve it , in the context of the PR China, 
certain HPGR would not be conducted, since researchers would be unlikely to be 
able to recruit sufficient numbers of participants from target groups where the 
decision of community leaders is generally  accepted as definitive. Meanwhile, 
group disapproval was  also likely to lead to the project not being approved at 
ethical review and hence not proceeding. 
The legal requirement o f group approval/disapproval  needs to respect to the 
changes  or  withdrawal of  group approval  by  target group  in  HPGR.  If  group 
approval is required for the research study to  proceed, then major changes in 
the agreed-upon protocol should also be examined by the target group.  
In addition to being provided to potential individual par ticipants in HPGR as 
necessary information for decision-making, the written result of group decision 
should also be submitted to both supervision authorities of local government in 
the PRC and IRBs or RECs. 
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(3) Individual Informed Consent  
The  information that  must  be  disclosed  to  a  potential  human subject  who is 
considering participating in biomedical research, which he/she in turn must have 
the opportunity to evaluate (a process that includes having access to a member 
of  the  research  team),  is  listed  in  various  research  guidelines  and  legal 
regulations.  In  general,  this  information  includes  a  broad  description  of  the 
nature of the study (including what part is experimental and how long the study 
will  last),  a  description  of  reasonably  foreseeable  risks,  a  description  of  any 
potential  benefits  to  the  subject,  a  statement  of  how  the  confidentiality  of 
records will be maintained, a statement of whether there will be compensation 
for injury, a designation of a contact person who is a member of the research 
team,  and  a  declaration  that  participation  is  voluntary  and  that  there  is  no 
penalty  for  withdrawal.  In addition to information  has  been  listed in current 
research guidelines, given there are additional risks of harm that may be caused 
by HPGR to the target group as a whole as discussed in Chapter 2, the special 
rules on HPGR in the PRC should require the following two additional contents: 
(a) potential benefits and risks of harm to the interests of target group in HPGR, 
which is similar to the list of information concerning disclosure with potential 
participants  about  anticipated  benefits  and  potential  risks  to  individual 
participant; (b) if has the cultural sensitivity on group decision-making, group 
decision  made  by  group  leader  or  group  recognized  authority  should  also  be 
disclosed to potential individual participants as a reference to make their own 
decisions. 
The disclosure standard applied in HPGR in the PRC should require disclosure of 
whatever it can reasonably be concluded potential participants would consider 
significantly  in  their  decision-making.  Since  target  groups  in  HPGR  may  be 
vulnerable,  the  standard  would  require  researchers  to  disclose  to  potential 
participants all  of the relevant information  that any qualified individual of  a 
target group would reasonably need to know to make a decision on whether or 
not participate in the HPGR. This standard is similar to the reasonable patient 235 
rule which has been used as a standard of disclosure in legal cases about medical 
treatment decisions in some countries.
11 
In order to eliminate or reduce the vulnerabilities of target groups in HPGR, the 
new legal requirement in the PRC should be stipulated to a more appropriate 
way which could fit into the specific situations of target groups. The detailed 
measures include:  
A.  The conduct of information disclosure needs to be undertaken in a clear 
and intelligible manner, such as using local languages where necessary. As 
O‘Neill pointed out, a normal person ‗may find that being confronted with 
the  full  detail  of  research  protocols  provides  excess,  inassimilable 
information, to which they can hardly hope to give genuinely  informed 
consent.‘
12 Given that the target groups in HPGR in the PRC are vulnerable 
groups with low-educated level, the situation of confusing by a thick stack 
of papers which lists of complex questions described by difficult medical 
terms would be even worse. Therefore, in order to ensure the quality of 
information  disclosure,  the  new  legal  requirement  also  should  require 
that  researchers  should  provide  information  in  the  language  of  the 
potential participants and at a level appropriate to their reading level, 
where providing written information is likely to be of practical value. It 
should also provide an emphasis on process rather than mere agreement 
or signing a consent form.  
B.  Considering the cultural sensitivity and educational level of the members 
of target groups in HPGR, during the process of information disclosure, 
researchers should pay attention to the method of communication with 
group members. In order to ensure the fullest possible understanding of 
relevant information, the new guideline should suggest that researchers 
use  specific  group  communication  measures  which  are  appropriate  to 
certain  target  groups,  such  as  face-to-face  meetings  between 
communities  and  researchers,  giving  adequate  time  to  potential 
                                         
11 The discussion on ‗reasonable patient standard‘ can be seen in Chapter 2. 
12 O'Neill, O. 2002, Autonomy and Trust in Bioethics, Cambridge University Press, at 157. 236 
participants  to  ask  questions  about  the  HPGR,  and  providing  adequate 
time for consideration of their decision. 
C.  The new legal requirement should require researchers to clearly inform 
potential participants of the right to refuse to take part in HPGR or to 
withdraw consent to participate at any time without reprisal, as well as 
provide easy procedure to exercise the decision of refuse or withdrawal. 
As  O‘Neill  suggested,  ethically  acceptable  consent  should  meet  the 
standard that ‗the possibility of refusal should be made as clear and as 
easy to exercise as the possibility of consent.‘
13 
The written informed consent forms from individual participants in HPGR should 
be submitted to both supervision authorities of local government in the PRC and 
ethical review committees. The process of individual informed consent should be 
fully reviewed by ethical review committees, and be supervised by supervision 
authorities of local government in the PRC. 
3)  Amendment to Provisions of Ethical Review 
In  order  to  ensure  the  welfare  and  well-being  of  human  subjects,  all 
international  declarations  and  conventions,  research  guidelines,  and  some 
national  regulations  propose  that  research  ethics  committees  (REC)  or 
institutional  review  boards  (IRB)
14 should undertake a risk -benefit assessment 
and risk management of biomedical research involving human subjects. Without 
the approval of RECs or IRBs, no biomedical research can be ethically conducted, 
no matter whether or not  a person consents to participate in  it. RECs or IRBs  
allow biomedical researchers and bioethical experts with varying backgrounds to 
promote  adequate  review  of  research  activities   and  weigh  the  merits  of 
proposed biomedical research and its potential impact on the rights, safety, and 
welfare of human subjects from their own viewpoints. In general, ethical review 
committees provide ethical advice to researchers so as to assist decision -making 
on the adequacy of proposed research projects, with respect to the protection 
of potential and actual human subjects. Ethical review committees may function 
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at the institutional, local, regional, or national level, and in some cases at the 
international level. For example, ethical review committees play a major part in 
the  Declaration  of  Helsinki.
15  Article  15  of  the  Declaration  highlights  the 
requirements  of  ethical  review  in  the  whole  process  of   the  design  and 
performance of each experimental procedure involving human subjects.
16 
In the context of HPGR in developing countries like th e PRC, due to the 
vulnerabilities of target groups caused by poverty, low -educational  level and 
lack of social and medical resources, ethical review committees should  accept 
additional responsibilities to ensure the interests of target groups and avoid  the 
risk of exploitation. Therefore, this type of ethical review should be conducted 
without the researcher, the sponsor or any kind of undue influence. The Chinese 
provision in HPGR should require the ethical review in HPGR must be conducted 
by an independen t ethical review committee including members from target 
groups; rather than institutional ethical review committee. 
(1) Membership and Composition of Ethical Review Committees in HPGR 
As discussed in Chapter 2, in HPGR, in addition to the potential risks of harm to 
individual human subjects, there are potential risks of harm to the target group 
as a whole. However, one important difficulty for ethical review committees is 
that members who are outsiders often struggle to identify intra-community risks, 
such as the disruption of existing social arrangements and relationships between 
members of a target group. Therefore, in the PRC, it is proposed that ethical 
review  committees  including  members  from  the  target  group  with  varying 
genders,  age  groups  and  educational  backgrounds  should  be  an  essential 
requirement  of  ethical  review  of  IRBs  or  RECs  in  HPGR.  The  number  of 
representatives  should  be  decided  by  the  population  size  of  target  group.  If 
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http://www.wma.net/en/30publications/10policies/b3/index.html, last visited on 2010-07-27. 
16 Ibid., Article 15. 238 
there are group leaders or group recognized authorities of target groups, they 
must be included in ethical review committees. If there is no group leader or 
group  recognized  authorities,  the  representatives  should  include  the  most 
affected  members,  the  most  educated  members  and  some  other  random 
members.  
Some  would  argue  that  it  can  never  be  certain  that  the  representatives  will 
really voice the real opinion of the target group they represent. However, these 
selective representatives are members of  the target group and have common 
traditions and beliefs with members of target group. They should therefore be 
capable  of  making  reasonable  decisions  on  the  basis  of  understanding  the 
information relevant to the HPGR; their opinions could partly reflect the views 
of the target group members and would also help to examine whether or not 
certain HPGR may lead to potential risks of harm that research participants and 
other members of the target group view as important. If they are concerned that 
HPGR  could  potentially  harm  their  internal  or  external  interests,  such  as 
disrupting existing social arrangements or harming their common beliefs, then 
these risks of harm are something that ought to be taken into consideration in 
the ethical review process of the research. 
(2) Additional Assessment Contents in HPGR 
In  order  to  provide  adequate  protection  to  target  groups  and  reduce  their 
vulnerabilities, in addition to risk-benefit assessment on individual and group-
based  human  subjects,  the  provisions  on  ethical  review  should  include  the 
following two additional factors: 
A.  It should require risk-benefit evaluations on the interests of target groups 
of  the  proposed  HPGR.  It  should  highlight  the  assessment  of  potential 
group  collective  risks  of  harm  related  to  certain  HPGR,  with  the 
awareness of the specific cultural sensitivities of target groups. As Sharp 
and Forster have pointed out:  
Presently,  little  is  known  about  how  members  of  various 
underserved  or  marginalized  communities  weigh  individual 
research risks against group risks, how salient collective risks 
are in relation to other risks encountered in daily life, or how 239 
individuals attempt to reconcile potential conflicts that may 
exist between personal interests in research participation and 
collective  opposition  to  proposed  research.  Because  not  all 
collective harms carry the same weight—that is, some group 
harms  are  more  significant  than  others—it  is  important  to 
assess how members of historically underserved communities 
evaluate collective research-related harms. Moreover, without 
such information it will be difficult, if not impossible, to tailor 
oversight processes to specific communities.
17 
Thus, in order to identify how various social, religious, economic, cultural, 
and political communities/group view risks  related to certain HPGR, in 
the PRC, the special rules on HPGR should require an additiona l risk-
benefit assessment on the interests of the target group as a whole. 
The standard of ethical review o f group risks of harm in HPGR should fit 
the three ethical requirements which are required in all ethical reviews of 
non-therapeutic procedures.
18 First, the  group  risks  of harm related to  
HPGR must be minimized, to the extent that doing so is consistent with 
sound scientific design. This can involve avoiding unnecessary procedures, 
identifying less risky ways of testing a study hypothesis,   or excluding 
participants who are at increased risk of being harmed. Second, the group 
risks  of harm  posed  by  HPGR  must be reasonable in relation to the 
knowledge that is expected to   be gained from the study. Third,  since 
target groups in HPGR  may be vulnerable populations, the group risks of 
harms of HPGR must be no more than a minor  increase over the minimal 
group risks of daily life for the identified group in question. 
B.  Ethical review committees should also be responsible for determining the 
proposed compensation or payment based on the degree of risk and other 
burdens in HPGR. In some literature on ethical conduction of biomedical 
research  in  developing  countries,  it  has  been  argued  that  there  was  a 
tendency to exaggerate the risk of undue inducement, which would lead 
to restricting payments to participants on the grounds of potential undue 
                                         
17 Sharp, R. R. & Foster, M. W. 2002, "Community Involvement in the Ethical Review of Genetic 
Research: Lessons from American Indian and Alaska Native Populations", Environmental 
Health Perspectives, vol. 110, pp. 145-148, at 147. 
18 Weijer, C. 2000, "The Ethical Analysis of Risk", Journal of Law, Medicine and Ethics, vol. 28, pp. 
344-361. 240 
inducement.
19 This situation would provide decreasing costs of researchers, 
while reducing the financial welfare of the participants. Therefore, it has 
been  suggested  that  ethical  review  c ommittees  should  undertake 
assessment of compensation, such as  required infrastructure charge, as 
part of their  general assessment  of the  acceptable standard  of the 
research protocol.
20 Given the different levels of economic development 
between researchers from developed countries and target groups in HPGR 
from developing countries, there would be a dilemma for researchers  in 
offering compensation or payment to target groups: o ffer too little and 
they are exploited, offer too much and their participation may be unduly 
influenced. Independent ethical review committees with members from 
target groups are more capable  of  identifying  the appropriate level of 
compensation  or  payment  which  fit s  into  the  specific  economic 
development levels of target groups.  Therefore, an additional review on 
proposed compensation or payment by researchers would be helpful to 
eliminate or reduce the vulnerabilities of target groups in HPGR in the 
PRC. 
(3) Double Review in International Collaborate HPGR 
As Western developed countries gain economic and technological ascendance, 
they need human population genetic resources which some developing countries 
like the PRC have in abundance; accordingly, most HPGR will likely be conducted 
by  researchers  from  developed  countries  in  developing  countries.  Due  to  the 
conflict of interests between developed and developing countries in HPGR, the 
legal regulations and ethical guidelines on biomedical research would have some 
differentiated  standards  on  ethical  review.    Therefore,  the  Declaration  of 
Helsinki emphasized that independent committees should act in conformity with 
the laws and regulations of the country in which the research is performed.
 21 
Article 15 also stipulated that the committee has the right to monitor ongoing 
trials. According to these provisions, the researcher has the obligation to provide 
                                         
19 Ballantyne, A. 2008, "Benefits to Research Subjects in International Trials: Do They Reduce 
Exploitation or Increase Undue Inducement?", Developing World Bioethics, vol. 8, no. 3, pp. 
178-191. 
20 Ibid., at 190. 
21 See supra note 15, Article 15. 241 
information to the committee, especially about any serious adverse events. The 
ethical committee is still there for consideration, comment and guidance, but it 
has to be told about conflicts of interests. If there is any serious adverse event, 
the ethical committee has to be notified.
 22  
Therefore,  in  order  to  ensure  the  welfare  and  interests  of  vulnerable  target 
groups in HPGR and decrease the practical burden of ethical review committees, 
the provision of ethical review in the PRC must require double review of HPGR. 
It should require that foreign researchers or research institutions who conduct 
HPGR inside the PRC, no matter whether or not it has been reviewed according 
to the legal regulations or ethical guidelines of their own countries, it should 
obtain approval from ethical review committees, which are in conformity with 
the  provisions  of  relevant  Chinese  laws,  regulations  and  rules  on  biomedical 
research.  This  double  review  principle  would  play  the  role  of  preventing 
researchers from developing countries take advantage of the legitimate loophole 
of their own countries to exploit target groups in the PRC. 
4)  Amendment  to  Provisions  of  Supervision  of  Local  Government  in 
HPGR 
At present,  many  developing countries,  such as the PRC,  lack comprehensive 
legal frameworks relating specifically to research involving humans in HPGR, for 
example  in    terms  of  adequate  training  or  low  educational  standards.  It  is 
reasonable to doubt that representatives from vulnerable target groups in HPGR 
in  ethical  review  committees  have  appropriate  knowledge  of  regulations 
governing biomedical research involving human subjects. Therefore, this thesis 
suggests,  in  addition  to  independent  ethical  review  committees,  local 
government of the PRC should also undertake the responsibility of supervision on 
all HPGR conducted in the PRC. The detailed rules should include  a provision 
that  every  HPGR  conducted  in  the  PRC  must  be  registered  with  the  local 
government before it is conducted, and the whole process of HPGR should be 
recorded and supervised by local governments. 
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In particular, in the context of international HPGR conducted in the PRC, local 
government in the PRC should play a supervisory role in the whole process of 
ethical review, as an additional protection to vulnerable target groups and  to 
ensure  the  ethical  conduct  of  HPGR  in  the  PRC.  The  approach  of  local 
government supervision in international HPGR could be to establish independent 
local ethical review committees. These committees need a firm foundation in 
special law on biomedical research to carry out their functions effectively, in 
the absence of which they would operate from a weak and dependent position. 
Ensuring  the  independence  and  legitimacy  of  these  committees  requires  that 
they operate within a legal framework, not merely national ethical guidelines 
although  they  have the  advantage of  ease  of  amendment.  These  committees 
would supervise the whole process of ethical review, including the selection of 
target  groups,  group  consultation,  information  disclosure,  group  approval, 
ethical review, research results publication and further use of research samples. 
Their supervision should include consideration of the wide range of issues which 
ethics  review  committees  may  have  to  consider  in  the  context  of  the  socio-
economic  factors  operating  in  specific  situations  and  certain  areas.  These 
committees should also consider the specific issues of the target groups and the 
particular research; for instance, determining whether a particular HPGR will be 
harmful to a particular target group, given the specific needs of that community. 
If these committees find that certain HPGR fails to meet any legal requirement 
stipulated in the proposed special law on biomedical research relevant to HPGR, 
they should report this to the local government. The local government should 
then request the researchers to stop the project immediately.   
Therefore, in order to protect target groups and reduce their vulnerabilities in 
HPGR, new approaches to regulation are needed in the PRC.  243 
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